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SUMMARY
A novel fluorometric method for measurement of glycated serum albumin 
has been automated on a Cobas Bio centrifugal analyser. The method has 
been standardised, optimised and adapted to enable analysis of untreated 
serum samples and at a consumable cost of 25p per sample (including 
correction for serum albumin levels), 50-60 samples can be assayed in 1 
hour. Between-batch imprecision was found to range from a CV of 5.8% to 
11.4%, with a borderline diabetic/non-diabetic CV of 9.6%.
Analysis of samples from a diabetic (n=8 6 ) and a non-diabetic (n=75) 
population produced a mean diabetic value 2 -fold higher than the mean non­
diabetic value and the assay results were shown to correlate well with an 
aminophenylboronate affinity chromatography method for glycated albumin 
(r=0.842). Optimum conditions for sample and reagent storage have been 
established and the effects of several possible interferents upon analysis and 
on in vitro glycation of albumin as detected by the fluorometric method 
have been investigated. Various chemical modifications of serum albumin 
have been performed in order to try and elucidate the chemical 
characteristics of this assay, and studies are described which suggest that 
glycated albumin is measured specifically.
Together with affinity chromatography techniques for measuring glycated 
albumin and glycated total protein, and the established ‘fructosamine’ test, 
the new method has been assessed in various clinical situations. Components 
of biological variation have been determined for all these assays and the 
clinical utility of the fluorometric assay has been compared for monitoring 
both acute and chronic changes in glycaemia as well as diabetic pregnancy. 
The sensitivity of the new method as a screening test for diabetes/impaired 
glucose tolerance has been investigated and the suitability of the assay to a 
routine clinical chemistry laboratory has been established.
ACKNOWLEDGEMENTS
The work described in this thesis was funded by a locally organised research 
scheme grant, awarded by the South West Thames Regional Health 
Authority. Without this grant and the valuable advice and guidance 1 have 
received from Dr Barry Gould, my supervisor at the University of Surrey, 
this work would not have been possible. 1  would therefore like to thank 
Barry for this, and also Dr William Alston, for his continual encouragement 
and for enabling me to perform the majority of the practical work at the 
Biochemistry Department, Frimley Park Hospital.
1 am indebted to all my colleagues in the Biochemistry and Haematology 
Departments at Frimley Park Hospital for their assistance in the processing 
of clinical samples, particularly Miss Pat Frampton for phlebotomy, and Mr 
Tony Bateman for performing HbA^g analyses at such a competitive price! 
1 am grateful to Dr David Donaldson, Dr Sarah Davie and Miss Sue Marr 
for access to specific blood samples, and also to the staff and patients of 
Upper Gordon Road Surgery, Camberley, for recruitment of volunteers to 
various clinical studies. In this respect 1 would particularly like to thank Mrs 
Maggie Harris and Mrs Olive Attwell as well as Mrs Andrea Clench, 
diabetic liaison nurse at Frimley Park Hospital, for her help with recruitment 
of diabetic patients.
1 must also thank Mrs Paulette Cusick and Dr Ian Fry for their assistance 
in the preparation of this manuscript, and in particular my long-suffering 
husband Tim, who has had to cope as a single parent throughout the writing 
up of this thesis.
ABBREVIATIONS
AGE
Alb
AMP
AP
APBA
Bicine
BCG
CAPD
CV
CVa
C V g
CV,
Dansyl (Dns) 
DENS 
DETAPAC 
DP
Dns (dansyl) 
Dns-PBA
DMF
DMSO
DNA
EDTA
EPPS
FAF-HSA
FN
FP
GA
GSH
GTP
Hb
HEPES
HLA
HMF
HPLC
HSA
IDDM
IFCC
X
LDL
Advanced glycosylation end-products.
Albumin.
2 -amino-2 -methyl- 1 -propanol.
Amadori product.
Aminophenylboronic acid. 
N,N-bis(2-hydroxyethyl)-glycine.
Bromocresol green.
Continual ambulatory peritoneal dialysis.
Coefficient of variance.
Analytical coefficient of variance.
Between-subject coefficient of variance. 
Within-subject coefficient of variance.
5-dimethylaminonaphthalene-1 -sulphonyl.
Data evaluation of non-linear standard curves. 
Diethylenetriaminepenta-acetic acid.
Delta fluorescence.
5-dimethylaminonaphthalene-1 -sulphonyl. 
N -(5 -d im ethy lam inonaph thalene-l-su lphony l)-3 - 
aminophenylboronic acid.
1 -deoxy- 1 -morpholino fructose.
Dimethyl sulphoxide.
Deoxyribonucleic acid.
Ethylenediaminetetra-acetic acid.
N-(2-hydroxyethyl)piperazine-N’-3-propanesulphonic
acid.
Fatty acid free-human serum albumin 
False negative.
False positive.
Glycated albumin.
Glutathione.
Glycated total serum (or plasma) protein. 
Haemoglobin.
N-2-hydroxyethylpiperazine-N’ -2-ethanesulphonic acid. 
Human leucocyte antigen.
5-hydroxymethyl-2-furfuraldehyde.
High performance liquid chromatography.
Human serum albumin.
Insulin-dependent diabetes mellitus.
International federation of clinical chemistry. 
Wavelength.
Low density lipoprotein.
MES
Mansyl
Mansyl-PBA
2-(N-morpholino)ethanesulphonic acid.
6-(N-methylanilino)naphthalene-2-sulphonyl.
6 -(N -m ethy lan ilino )naph tha lene-2 -su lphony l-3 - 
aminophenylboronic acid.
NBT 
N control
NIDDM 
OGTT 
PBS 
PCMB 
P control
PLP
PM
PVN
PVP
QC
r
RPM
SD
TBA
TEA
TN
TP
UV
V
Va
Vg
V.
WHO
Nitroblue tétrazolium.
Roche ‘normal’ control, marketed for use with the 
fructosamine assay.
Non insulin-dependent diabetes mellitus.
Oral glucose tolerance test.
Phosphate buffered saline.
Parachloromercuribenzoic acid.
Roche ‘pathological’ control, marketed for use with the 
fructosamine assay.
Pyridoxal-5’-phosphate.
Photomultiplier.
Predictive value negative.
Predictive value positive.
Quality control.
Regression coefficient.
Revolutions per minute.
Standard deviation.
Thiobarbituric acid.
Triethanolamine.
True negative.
Total protein or true positive.
Ultra violet.
Variance.
Analytical variance.
Between-subject variance.
Within-subject variance.
World Health Organisation.
Haemoglobin Classification.
HbA Major class of normal human haemoglobin (0 C2,p2).
HbAi HbAi_.
HbAja Hb glycated by glucose-6 -phosphate or fructose bis phosphate
at p-chain N-terminal.
HbAib Probably deamidated HbA at p-chain N-terminal.
HbAjc Adduct of glucose attached at p-chain terminal valine residue
by ketoamine linkage.
HbC G lu^L ys at p 6  of HbA (oCz^ Pi)-
HbF Fetal Hb (0 2 ,7 2)-
HbS Glu->Val at p 6  of HbA (0 C2,p2).
Units.
mol mole,
mmol millimole.
|Limol micromole,
nmol nanomole.
1 litre,
ml millilitre.
\il microlitre.
kg kilogram,
g gram,
mg milligram.
|ig microgram.
nm nanometre.
INDEX
CONTENTS PAGE
TITLE PAGE 1
SUMMARY 2
ACKNOWLEDGEMENTS 3
ABBREVIATIONS 4
INDEX 7
CHAPTER 1. GENERAL INTRODUCTION. 15
1.1. THE HISTORICAL BACKGROUND OF
DIABETES MELLITUS. 16
1.2. DIABETES MELLITUS. 17
1.2.1. Classification and aetiology of diabetes mellitus. 17
1.2.1.1. Primary diabetes. 17
1.2.1.2. Secondary diabetes. 19
1.2.2. The histopathology of diabetes mellitus. 20
1.2.3. The chemical pathology of diabetes mellitus. 21
1.2.4. Treatment of diabetes mellitus. 22
1.2.5. Complications of diabetes mellitus. 23
1.2.6. Monitoring diabetic control. 25
1.3. NON-ENZYMIC PROTEIN GLYCATION. 27
1.3.1. Protein glycation sites and reaction kinetics. 29
1.3.2. Advanced glycosylation end-products and the
pathology of protein glycation. 31
1.4. PLASMA PROTEIN AND HAEMOGLOBIN
METABOLISM IN HEALTH AND DISEASE. 35
1.4.1. Haemoglobin. 35
1.4.2. Plasma proteins. 36
1.5. CURRENT METHODOLOGY FOR
GLYCATED PROTEIN MEASUREMENT. 38
1.5.1. Methods based on charge differences. 39
1.5.1.1. Cation-exchange chromatography. 39
1.5.1.2. Electrophoretic techniques. 41
1.5.2. Methods based on chemical reactivity. 42
1.5.2.1. Weak acid hydrolysis. 42
1.5.2.2. Strong acid hydrolysis. 44
1.5.2.3. Reaction with phenylhydrazine. 45
1.5.2.4. Sodium borohydride reduction. 45
1.5.2.5. Periodate oxidation. 48
1.5.2.6. Reduction of nitroblue tétrazolium -
‘Fructosamine assay’. 49
1.5.3. Methods based on structural differences. 55
1.5.3.1. Immunoassay. 55
1.5.3.2. Affinity chromatography. 56
1.5.3.3. Boronate ester formation in solution. 59
1.6. INVESTIGATION OF SUITABLE 
FLUORESCENT PROBES FOR DETECTION
OF GLYCATED SERUM PROTEIN. 62
1.6.1. Basic probe requirements. 62
1.6.2. Selection of a probe. 63
AIMS OF THIS THESIS. 6 8
CHAPTER 2. OPTim SA TlON OF THE FLUOROMETRIC 
ASSAY. 69
Introduction. 70
Materials. 71
2.1. THE SYNTHESIS AND SPECTRAL
CHARACTERISTICS OF DANSYL-PBA. 73
2.1.1. Synthesis and purification of Dns-PBA. 73
2.1.2. In vitro glycation of human albumin. 73
2.1.3. Fluorescence spectra of Dns-PBA. 74
2.2. VARIATION OF EXPERIMENTAL CONDITIONS. 77
2.2.1. Automation of the Dns-PBA assay using the
Cobas Bio. 77
2.2.2. Buffer selection, concentration and pH. 78
2.2.2.1. The effect of pH on Dns-PBA fluorescence. 78
2.2.2.2. HEPES buffer. 79
2.2.2.3. Bicine buffer. 79
2 2 2 A. EPPS buffer. 82
2.2.2.5. MES buffer. 82
2.2.2.6. AMP buffer. 82
222.1, Buffer comparisons at optimum pH. 85
2.2.2.S. Bicine concentration and analysis of
undiluted serum. 91
2.2.3. Dns-PBA concentration. 91
2.2.4. The effect of heat on Dns-PBA reagents. 93
2.2.5. Boric acid concentration. 95
2.2.6. Cobas Bio emission filter assessment. 95
2.2.6.1. Adaptation of the assay for the 470 ± 20 nm
emission filter. 98
2.2.6.2. Comparison of assay imprecision using the
90 nm and 40 nm bandwidth emission filters. 100
2.2.6.3. Comparison of assay accuracy and 
sensitivity using the 90 nm and 40 nm
bandwidth emission filters. 1 0 2
2.2.6.4. Selection of Cobas Bio excitation wavelength
and fluorescence emission filter. 1 0 2
2.2.7. The time course of the fluorometric assay. 104
2.2.8. Summary of optimised Dns-PBA fluorometric
assay parameters. 107
2.3. LINEARITY, CALIBRATION AND
STANDARDISATION OF THE 
DANSYL-PBA ASSAY. 108
2.3.1. In vitro glycation of human citrated plasma
and preparation of assay standards. 108
2.3.2. Quality control material. 109
2.3.3. Calibration of the Dns-PBA assay using the 
reducing properties of glycated albumin on
nitroblue tétrazolium. 1 1 0
2.3.4. Linearity studies for the optimised
Dns-PBA assay. 110
2.3.5. Standardisation of the Dns-PBA assay. I l l
2.3.6. Limit of detection and assay sensitivity. 115
2.3.7. Control of the Dns-PBA assay. 116
2.4. REAGENT AND SAMPLE STABILITY. 116
2.4.1. Reagent stability. 116
2.4.1.1. Linearity check. 119
2.4.1.2. Quality control results. 119
2.4.2. Sample stability. 123
2.4.3. The effect of repeated freezing and thawing
on serum samples for fluorometric analysis. 126
2.5. ASSAY IMPRECISION AND COMPARISON
OF REFERENCE RANGES FOR DIABETIC 
AND NON-DIABETIC POPULATIONS. 127
2.5.1. Assay imprecision. 127
2.5.1.1. Within-batch imprecision. 127
2.5.1.2. Between-batch imprecision. 129
2.5.2. Dns-PBA assay reference ranges. 129
2.5.2.1. Non-diabetic reference range. 129
2.5.2.2. Diabetic range of results. 131
DISCUSSION. 134
CHAPTER 3. EVALUATION OF THE DANSYL-PBA ASSAY. 144
Introduction. 145
Materials. 147
3.1. COMPARISON OF DANSYL-PBA 
FLUORESCENCE ASSAY RESULTS WITH 
AFFINITY CHROMATOGRAPHY RESULTS FOR 
GLYCATED ALBUMIN AND TOTAL PROTEIN. 148
3.1.1. Affinity chromatography procedure. 148
3.1.1.1. Glycated albumin measurement by
affinity chromatography. 149
3 .1 .1 .2 . Glycated total protein measurement by
affinity chromatography. 150
3.1.2. Reference ranges and imprecision of
affinity chromatography results. 151
3.1.3. Correlation of Dns-PBA fluorescence 
assay results with affinity
chromatography values. 152
3.2. THE INVESTIGATION OF POSSIBLE
ANALYTICAL INTERFERENCES WITH
THE DANSYL-PBA ASSAY. 157
3.2.1. The effect of anticoagulant. 157
3.2.1.1. Lithium heparin anticoagulant. 157
3.2.1.2. K-EDTA anticoagulant. 158
3.2.1.3. Fluoride oxalate anticoagulant. 158
3.2.2. Schiff base interference. 158
3.2.3. Free glucose interference. 160
3.2.4. Haemoglobin interference. 160
3.2.5. Lipaemia interference. 162
10
3.2.6. Bilirubin interference. 162
3.2.7. Urea interference. 163
3.2.8. Salicylate interference. 163
3.2.9. Ibuprofen interference. 165
3.2.10. Ascorbate interference. 165
3.2.11. Pyridoxal phosphate interference. 166
3.2.12. a-tocopherol interference. 166
3.3. THE INVESTIGATION OF POSSIBLE
INTERFERING FACTORS IN THE BINDING 
OF GLUCOSE TO SERUM ALBUMIN, AS 
MEASURED BY THE DANSYL-PBA 
FLUORESCENCE ASSAY. 168
3.3.1. In vitro studies. 168
3.3.1.1. The in vitro effect of urea on glycation
of human serum albumin. 170
3.3.1.2. The in vitro effect of bilirubin on
glycation of human serum albumin. 170
3.3.1.3. The in vitro effect of salicylic acid on
glycation of human serum albumin. 170
3.3.1.4. The in vitro effect of ibuprofen on
glycation of human serum albumin. 173
3.3.1.5. The in vitro effect of ascorbic acid on
glycation of human serum albumin. 173
3.3.1.6. The in vitro effect of pyridoxal phosphate
on glycation of human serum albumin. 173
3.3.1.7. The in vitro effect of a-tocopherol on
glycation of human serum albumin. 175
3.3.2. In vivo studies. 175
3.3.2.1. The in vivo effect of ascorbic acid on
Dns-PBA assay results. 175
3.3.2.2. The in vivo effect of pyridoxine
hydrochloride on Dns-PBA assay results. 177
3.4. INVESTIGATION OF THE SPECIFICITY OF
THE DANSYL-PBA ASSAY. 180
3.4.1. Dns-PBA fluorescence analysis of in vitro 
glycated albumin, a , p and y globulin
fraction proteins. ISO
3.4.1.1 . Preparation of protein fractions. 180
3.4.1.2. In vitro glycation and sample analysis. 181
3.4.2. Comparison of affinity chromatography,
Fructosamine Plus and Dns-PBA assay
specificities. 181
11
3.4.3. The effect of sorbitol on Dns-PBA binding. 183
3.4.4. The influence of thiol groups on Dns-PBA binding. 186
3.4.4.I. The effect of p-chloromercuribenzoic acid on
Dns-PBA binding. 186
3.4.4.2. The effect of glutathione on Dns-PBA binding. 188
3.4.5. In vivo and in vitro glycation studies on
albumin Redhill. 188
3.4.6. The effect of chemical modification of glyco
groups on the Dns-PBA assay results. 193
3.4.6.1. Borohydride reduction. 193
3.4.6.2. Periodate oxidation. 194
DISCUSSION. 198
CHAPTER 4. EXAMINATION OF THE EFFECTS OF
METHODOLOGICAL AND BIOLOGICAL VARIATION ON
GLYCATED PROTEIN VALUES. 214
Introduction. 215
Materials. 216
4.1. METHODS. 217
4.1.1. Patients and specimens. 217
4.1.2. Statistical evaluation of the data. 218
4.2. RESULTS. 2 2 2
4.2.1. Weekly glycated protein profiles. 2 2 2
4.2.2. Daily glycated protein profiles. 233
DISCUSSION. 246
CHAPTER 5. APPLICATION OF THE DANSYL-PBA
FLUOROMETRIC ASSAY TO THE DIAGNOSIS AND
MONITORING OF DIABETIC PATIENTS. 254
Introduction. 255
Materials. 258
5.1. APPLICATION OF THE DANSYL-PBA ASSAY
TO SCREENING FOR IMPAIRED GLUCOSE
TOLERANCE AND DIABETES. 258
5.1.1. Methods. 258
1 2
5.1.2. Results. 260
5.I.2 .I. Use of receiver operating characteristic
(ROC) curves. 260
5.2. COMPARISON OF GLYCATED PROTEIN
METHODS FOR MONITORING ACUTE AND
CHRONIC CHANGES IN GLYCAEMIC
CONTROL. 268
5.2.1. Monitoring chronic changes in glycaemia. 268
5.2.1.1. Methods. 268
5.2.1.2. Results. 269
5.2.2. Monitoring acute changes in glycaemia. 272
5.2.2.I. Investigation of possible analytical
interferences in ketoacidotic serum. 274
5.2.2.2. Patients and methods. 276
5.2.2.3. Results. 277
DISCUSSION. 287
CHAPTER 6 . GLYCATED PROTEIN LEVELS IN DIABETIC
AND NON-DIABETIC PREGNANCY. 296
Introduction. 297
Materials. 308
6 .1 . METHODS. 308
6 .1 .1 . Monitoring non-diabetic pregnancy. 308
6 .1 .2 . Monitoring insulin-dependent diabetic pregnancy. 309
6 .2 . RESULTS. 310
6 .2 .1 . Monitoring non-diabetic pregnancy. 310
6 .2 .2 . Monitoring insulin-dependent diabetic pregnancy. 312
DISCUSSION. 318
13
CHAPTER 7. GENERAL DISCUSSION. 323
7.1 THE DANSYL-PBA ASSAY. 324
7.2 COMPARISON OF DANSYL-PBA ASSAY 
RESULTS TO AFFINITY CHROMATOGRAPHY. 327
7.3 DANSYL-PBA ASSAY INTERFERENCES. 329
7.4 CLINICAL STUDIES. 331
7.5 THE IDEAL ROUTINE METHOD
FOR GLYCATED PROTEIN. 334
BIBLIOGRAPHY. 337
14
CHAPTER 1.
GENERAL INTRODUCTION.
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SECTION 1. THE HISTORICAL BACKGROUND OF DIABETES 
MELLITUS.
The word ‘diabetes’ is of Greek origin (literally meaning ‘passer through’) 
and is used to describe any disorder characterised by excessive urine 
excretion. The word ‘mellitus’ is Latin for honey and distinguishes the 
polyuric disorder of glucose metabolism with production of a sweet tasting 
urine, from that of diabetes insipidus in which a deficiency of antidiuretic 
hormone (or lack of renal tubular response to this hormone) results in over 
production of an insipid tasting urine.
In the second century A.D., Galen proposed that diabetes mellitus was the 
result of a weakness of the kidneys which attracted fluid and could not hold 
it back. This idea was perpetuated for at least 1,500 years in Western 
medicine despite a suggestion by Aricenna (A.D. 980-1037) that a 
disturbance of liver function could be the primary fault. Medieval writers 
were quick to blame immoderate use of alcohol, poor diet, worry and 
nervous ailments for the condition and Richard Mead (1673-1754) was the 
first in modem times to consider diabetes mellitus a disease of the liver. At 
the beginning of the nineteenth century a German chemist, Claude Bernard 
(1813-1878), observed that the liver was capable of producing sugar which 
entered the circulation, and that any excess was excreted by the kidneys. 
However, Claude Bernard also found that puncture of the floor of the fourth 
ventricle of the brain caused glycosuria, a discovery which fuelled the belief 
that diabetes mellitus was a disease of the nervous system. Following the 
observations by Langerhans in 1869, of previously unreported cell stmctures 
in the pancreas. Von Mering and Minowski (1889) showed that diabetes 
mellitus could be produced by removing the pancreas and the idea was bom 
of preparing a pancreatic extract which would replace the unknown missing 
substance. In 1922, Banting and Best finally succeeded in isolating the 
active secretion of the islets of Langerhans in a pure enough form for
16
diabetic patients to be able to tolerate it without ill effect. The name of 
‘insuline’ was adopted for this secretion, as had been previously proposed 
by De Meyer (1909) and Schafer (1916), following the suggestion by 
Laguesse (1893) that the islets secreted a substance into the ‘mileu 
intérieur’. These references have been cited by Malins (1968).
With the discovery of insulin, the central position of the pancreas in the 
pathogenesis of diabetes mellitus was established.
SECTION 2. DIABETES MELLITUS.
The clinical syndrome of diabetes mellitus is characterised by 
hyperglycaemia, due to deficiency or diminished effectiveness of insulin. 
Lack of insulin, whether absolute or relative, affects the metabolism of 
carbohydrate, protein, fat, water and electrolytes and if left uncontrolled can 
be fatal. This condition is the most common of the endocrine disorders, 
affecting over 1 % of the population (approximately 800,000 individuals) in 
Great Britain.
1.2.1. Classification and aetiology of diabetes mellitus.
On the basis of aetiology, 2 main categories of diabetes are recognised: 
primary and secondary diabetes.
1.2.1.1. Primary diabetes.
Most cases belong to this group which consists of 2 main clinical types: 
insulin dependent diabetes mellitus (IDDM or type I) which is most frequent 
in individuals less than 50 years old, and non-insulin dependent diabetes 
mellitus (NIDDM or type II) occurring mainly in the middle-aged and 
elderly. Although the precise aetiology of the disease is still uncertain, in 
both types it is the susceptibility to diabetes, rather than the diabetes itself
17
which is inherited. Hereditary and environmental factors seem to interact to 
determine which of those with a genetic predisposition will actually develop 
the clinical syndrome, as well as the time of its onset.
Insulin dependent diabetes mellitus.
IDDM is a chronic irreversible disease whose incidence is believed to be 
rising in many Northern European countries with a rate equivalent to a 
doubling time of 20-30 years in some places (Court, 1991). It has been 
argued that changes in genetic susceptibility of the population cannot alone 
account for this increase, even when recognising that children with diabetes 
have been surviving to have families of their own and successful diabetic 
pregnancies are now the rule. Many environmental factors have been 
implicated in the increased incidence, including more refined diets, stress, 
affluence, food additives and viral infections. However, despite an immense 
research effort, direct evidence of environmental factors in the aetiology of 
IDDM in humans has proved to be elusive. Although a number of viruses 
such as mumps, coxsackie virus types B4 and B5, cytomegalovirus, 
reoviruses and rubella have been implicated in the pathogenesis of IDDM, 
their precise role remains obscure.
Over the past 20 years evidence has accumulated that establishes 
autoimmune mechanisms, directed at the islets of Langerhans, as important 
in the development of IDDM. This includes the identification of specific 
circulating antibodies to islet cells, the demonstration of abnormalities of 
cell mediated immune function with the development of beta cell destruction 
and the association of IDDM with other immunologically mediated 
disorders (Vardi et al, 1987).
Complex associations of type I diabetes with the human leucocyte antigen 
(HLA) system suggests that genetic susceptibility is determined by genes 
near the DR locus. The strongest positive association exists with HLA-DR3 
and DR4, and there is some support for the concept of different clinical
18
presentations being associated with specific HLA patterns eg. the presence 
of HLA-DR4 has been linked with a younger age of onset (Eberhardt, 
1985).
Non-insulin dependent diabetes mellitus.
NIDDM is not HLA linked and there is no evidence that autoimmunity or 
viral infections are involved in its development. Family studies have shown 
that genetic factors are more important in the development of type II 
diabetes than in type I but problems in relation to the definition and 
ascertainment of the condition have hampered progress in this field. Simple 
deficiency of insulin cannot entirely account for the diabetic syndrome in 
NIDDM as increased hepatic production of glucose and resistance to the 
action of insulin are characteristic of this type of diabetes. Most evidence 
supports the view that obesity is diabetogenic in those genetically 
predisposed to the disorder although this cannot account for all cases of 
insulin resistance which is also found in non-obese patients. The insulin 
resistance observed in NIDDM could be due to an abnormal insulin 
molecule, an excessive amount of circulating antagonists or most commonly 
to target tissue defects. These defects can be due to a decreased number of 
cellular insulin receptors or a post-receptor defect in the action of insulin. 
Although the absolute insulin level in patients with only mild NIDDM may 
be normal, a delay in the insulin response to an oral glucose tolerance test 
is commonly seen. This defect appears to be selective for glucose as the 
response to other stimuli such as amino acids and sulphonylurea drugs is 
normal, hereby implying some form of beta cell abnormality, either in its 
sensitivity or due to an intrinsic structural or metabolic change.
I.2.I.2. Secondary diabetes.
A minority of cases of diabetes occur as a result of a recognisable 
pathological process or secondary to the treatment of another condition. 
Diseases such as pancreatitis, haemochromatosis and carcinoma causing
19
destruction of the pancreas will all lead to impaired secretion and release of 
insulin. Abnormal circulating concentrations of hormones antagonistic to the 
action of insulin can also precipitate diabetes as occurs with excesses of 
growth hormone in acromegaly. Many patients with Cushing’s syndrome 
show abnormal glucose tolerance due to raised adrenocortical hormones, as 
do patients with phaeochromocytoma tumours which release adrenaline 
causing increased breakdown of liver glycogen to glucose. Excesses of 
thyroid hormones can also aggravate the diabetic state, as can pregnancy in 
susceptible individuals where there is an increased demand for insulin which 
cannot be met by a slightly failing pancreas. Liver disease, notably cirrhosis 
and hepatitis, can also be associated with impaired glucose tolerance and in 
those predisposed to the condition, diabetes may be precipitated 
iatrogenically by administration of corticosteroids or thiazide diuretics.
Although this classification of diabetes developed by the National Diabetes 
Data Group (1979) was adopted by the World Health Organisation, in the 
light of current knowledge it has limitations being based on clinical 
characteristics. Sims and Calles-Escandon (1990) have therefore suggested 
that a task force of experts could be assembled to develop minimal 
standards for characterisation of diabetic patients, and at least to further 
classify the subtypes on the basis of pathogenesis rather than phenotypes.
1.2.2. The histopathology of diabetes mellitus.
In IDDM there is degeneration of pancreatic islet tissue, from which the 
beta cells have largely disappeared leaving behind a variable number of 
alpha cells and a majority of small undifferentiated cells. Any remaining 
beta cells show evidence of excessive activity and this appearance is 
consistent with the extremely low plasma insulin levels found in these 
patients. In NIDDM, although there is a moderate reduction in the total
20
mass of islet tissue this is not generally sufficient to account for the diabetes 
(Cardell, 1968). In many cases the beta cells fail to develop cytological 
signs of hyperactivity despite prolonged hyperglycaemia, which suggests that 
these cells may be relatively insensitive to the stimulus of an elevated blood 
glucose.
1.2.3. The chemical pathology of diabetes mellitus.
The hyperglycaemia characteristic of diabetes mellitus arises from 2 main 
sources. There is a reduced rate of removal of glucose from the body by 
peripheral tissues, as insulin is necessary to promote the entry of glucose 
into cells, and an increased rate of release of glucose from the liver into the 
circulation.
When the glucose concentration in the blood exceeds the capacity of the 
renal tubules to reabsorb it (usually at around 1 0  mmol/1) glycosuria occurs. 
This sets up an osmotic diuresis preventing reabsorption of water, causing 
polyuria and polydipsia. Severe depletion of water and electrolytes may then 
ensue and impaired utilisation of carbohydrate results in a sense of fatigue, 
causing 2 main compensatory mechanisms to come into operation. Increased 
glycogenolysis, and gluconeogenesis from non-carbohydrate precursors such 
as glycerol, lactate and amino-acids serve to increase blood glucose levels 
further and increased lipolysis attempts to provide an alternative metabolic 
substrate to cells, with both effects leading to loss of body tissue or 
‘wasting’. The extent to which increased lipolysis occurs is proportional to 
the degree of insulin deficiency, which if marked will cause the non- 
esterified fatty-acid concentration in the blood to become persistently 
elevated. The fatty-acids are taken up by the liver and degraded to release 
acetyl coenzyme A, which would normally be taken into the citric acid cycle 
by condensation with oxaloacetic acid, but in diabetes excessive production 
of acetyl coenzyme A results in its conversion to acetoacetic acid which
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may be reduced to p-hydroxybutyric acid or decarboxylated to acetone. 
Small amounts of these ketone bodies can be oxidised and used as metabolic 
fuel but surpluses accumulate in the blood increasing plasma osmolality and 
causing withdrawal of water from the cells. These excess acids will also 
readily dissociate to release hydrogen ions, causing a fall in blood pH which 
is partly buffered by bicarbonate. When severe this condition therefore 
results in ketoacidosis, which can lead to coma, although the extent to which 
the clinical features of dehydration and ketoacidosis are seen depends on the 
speed at which the condition develops, the patient’s increased fluid intake 
and the degree of insulin deficiency present (Davidson, 1984).
1.2.4. Treatment of diabetes mellitus.
There are 3 methods of treatment in diabetes mellitus. This may be by diet 
alone, diet and oral hypoglycaemic drugs or diet and insulin. It is generally 
the younger patients which will require insulin although individuals may 
pass from one group to another, either temporarily or permanently. The 
treatment of all diabetic patients involves some dietary restrictions if control 
is to be satisfactory but it is not impossible for an intelligent, well informed 
individual to adjust their insulin regime in order to accommodate slight 
dietary variations. Only those patients showing very mild diabetes can be 
successfully treated on diet alone and these individuals need to maintain a 
fixed daily intake, as any increase in calorific value can have a cumulative 
effect on their blood glucose levels over a number of days. Oral 
hypoglycaemic drugs include the sulphonylureas (eg tolbutamide, 
glibenclamide, chlorpropamide) and the biguanides such as metformin. 
Approximately 20% of diabetic patients are managed with these drugs and 
although their mechanisms of action are different, both groups depend upon 
a supply of endogenous insulin so it is not possible to control IDDM with 
these compounds. However, with one or more of the insulin preparations
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now available it is usually possible to keep the blood glucose levels of an 
IDDM patient within reasonable, although not necessarily physiological, 
limits throughout the day and night without undue risk of hypoglycaemia.
1.2.5. Complications of diabetes mellitus.
Despite the successful treatment of diabetes, the risk of ketoacidosis in these 
patients is still present, particularly if the disease and its treatment is poorly 
understood by the patient, or if additional illness (such as infection) 
increases the individual’s insulin requirement. Similarly, for patients on oral 
hypoglycaemics or insulin therapy, a risk of hypoglycaemia is introduced 
which must be appreciated by the patient.
Although the successful treatment of diabetes has dramatically reduced the 
mortality and morbidity of diabetics due to coma, administration of insulin 
or oral hypoglycaemic agents neither prevents nor corrects the multiple 
tissue defects of the disease. Now that diabetics live longer these 
complications are seen more often and provide the biggest challenge to 
therapy. Vascular disease; arterial, arteriolar and capillary is the largest and 
most intractable problem in clinical diabetes, accounting for most diabetic 
deaths over the age of 50 years. Atherosclerosis occurs commonly and 
extensively in diabetes, at a much earlier age than in non-diabetics, 
predisposing patients to myocardial infarcts and hypertension.
Diabetic nephropathy is also well documented, with a specific type of renal 
lesion occurring as a result of changes in the basement membrane of the 
glomerular capillaries (diabetic glomerulosclerosis). Thickening of this 
membrane may be diffuse (generalised) or nodular whereby rounded masses 
of hyaline material are superimposed on the diffuse lesion. Once these 
lesions become clinically apparent as proteinuria there is no way of 
preventing or modifying the progression of nephropathy and chronic renal 
disease inevitably follows.
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Diabetic retinopathy is the commonest long-term complication of diabetes 
and although in many cases it may cause no symptoms, it has become the 
most common form of blindness in the middle-aged population. Different 
aspects of retinopathy occur in different patients although microaneurysms 
are the earliest clinical abnormality detected, with venous abnormalities, 
haemorrhages, soft and hard exudates and formation of new vessels arising 
later. As with nephropathy, the duration of diabetes is the most important 
factor influencing the occurrence of retinopathy and at least one 
microaneurysm can be seen in the fundi of over 60% of diabetics who have 
had the condition for 30 years. If diagnosed early, diabetic retinopathy is 
now a treatable condition, hence the importance of regular eye examinations 
in the diabetic patient.
Mononeuropathy, generalised neuropathy and autonomic neuropathy are also 
frequent complications of diabetes at any stage, and often involve segmental 
demyelination. Involvement of the autonomic nervous system can result in 
an impaired sympathetic response to hypoglycaemia whereby the patient no 
longer receives the classical warning symptoms of this condition.
It is a subject of controversy as to whether these later complications of 
diabetes (discussed at length by Keen and Jarrett, 1982) are a direct 
consequence of the resulting hyperglycaemia or whether they represent a 
separate facet of the disease. Much clinical and biochemical information has 
suggested hyperglycaemia as the single metabolic effect of insufficient 
insulin action most responsible, but there are several negative arguments 
(West, 1982) including the inconsistency of the relationship of complications 
to blood glucose levels in those with typical IDDM. As found for the 
aetiology of diabetes mellitus itself, there appear to be strong genetic and 
environmental influences on an individual’s susceptibility to complications 
arising from this disease, with the likelihood that the specific complications 
all have their own particular causes.
However, in the light of current knowledge, blood glucose levels are one
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factor which the diabetic patient is now able to control and would therefore 
be advised to do so to their best ability, if only for their immediate well 
being, in the knowledge that they may also be reducing their chances of 
developing further complications.
1.2.6. Monitoring diabetic control.
Diabetic control can only be easily and practically monitored in terms of 
glycaemic control, whereas the absolute stabilisation of a diabetic would be 
defined as normalisation of all the metabolic disturbances posing an 
immediate or long-term threat to their health. Glycaemic control is easily 
assessed for the immediate situation by measurement of a blood glucose 
level which can be performed by the physician, nurse or the patient 
themselves using dry reagent chemistry techniques, with or without the aid 
of a reflectance meter. Due to the simplicity and convenience of this type 
of analysis, routine urine testing for the presence of glucose, reducing sugars 
and ketones has become much less important once the condition of diabetes 
has been diagnosed, although urine testing was fundamental to the discovery 
of diabetes and is still a useful qualitative test in screening procedures. 
Although the diabetic patient is instructed in the art of routine urine testing 
and advised to aim for negative results, any information obtained from the 
analysis is retrospective and therefore not as relevent as the blood glucose 
level. Similarly, when presenting at the diabetic clinic with a urine sample, 
it is not uncommon practice for the patient to have previously tested the 
urine and diluted it accordingly to obtain the desired result! However, 
capillary blood glucose testing in the diabetic chnic does not necessarily 
give a good indication of a patient’s general glycaemic control as many will 
make a conscious effort to please on the day of attendance. Also, for those 
patients performing home blood glucose measurements, their own records 
of results can be unreliable, either due to fictitious entries or problems with
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quality control.
Identification of glycated haemoglobin by Rahbar in 1968 was therefore the 
first stage in the realisation that a true indication of integrated blood glucose 
control could be obtained from a single blood sample, and progress in this 
area is now such that glycated haemoglobin analysis can also be performed 
by the clinician within a matter of minutes. This measurement is now an 
established means of assessing diabetic patients’ blood glucose control over 
the preceeding 4-6 weeks, and measurement of glycated serum proteins are 
also proving useful when an indication of control over the preceeding 2-3 
weeks is required. This is particularly relevant to the monitoring of diabetic 
pregnancies.
The clinical utility of glycated haemoglobin analysis has been established 
in several studies (Nathan et al, 1984; Larsen et al, 1990) which conclude 
that the technique provides information about the degree of long-term 
glucose control that is not otherwise obtainable in the usual clinical setting, 
and that when measured regularly it can encourage an improvement of 
metabolic control as indicated by a lowering of the values. In comparisons 
of the clinical utility of glycated haemoglobin vs glycated serum protein 
measurement, opinion has been split as to whether one shows any real 
advantage over the other. Fisken et al (1990) and Jemtorp et al (1988) both 
found serum glycated proteins (as measured by a Tructosamine’ assay) to 
be a less reliable marker of glycaemic control in clinical practice than 
glycated haemoglobin. Watts et al (1991), Ziel & Davidson (1987) and 
Allgrove & Cockrill (1988) concluded that each measurement had its own 
optimum situation and that neither assay was necessarily more advantageous 
than the other, whereas Hindle et al (1985, 1986) suggest that serum 
fructosamine measurement is a useful and reliable alternative to glycated 
haemoglobin. There may therefore be a case for having both forms of 
analysis available to the clinician.
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SECTION 3. NON-ENZYMIC PROTEIN GLYCATION.
The chemical reaction referred to as protein glycation involves formation of 
a linkage between a reducing sugar and a receptive amino-acid. This 
reaction was first described in relation to food proteins by Maillard (1912) 
who noticed that proteins heated or stored in the presence of sugars formed 
brown fluorescent pigments. Following the separation of 3 negatively 
charged minor components of normal adult haemoglobin (Hb), designated 
HbAia, HbAjb and HbA^c (or collectively H bA J by Allen et al (1958), other 
workers were able to demonstrate that HbAj and in particular the HbAjj, 
fraction was elevated in diabetic patients. In 1968 Bookchin and Gallop 
demonstrated that HbAjj, had a glucose adduct linked to the amino terminal 
valine residue on the p-chain via an aldimine (Schiff base) linkage, which 
then underwent an Amadori rearrangement to form the more stable 
ketoamine product. This process is summarised in Figure 1.3.1 and is 
applicable to glycation of any susceptible protein. By 1976, Fliickiger and 
Winterhalter had shown that HbAi^ could be formed in vitro from both 
whole blood or purified haemoglobin when incubated with glucose, hereby 
suggesting that the glycation reaction was not enzyme-mediated. The 
hypothesis therefore soon developed that in diabetes, the level of glycated 
haemoglobin would be proportional to the integrated blood glucose level 
over the preceeding 4-6 weeks, a period slightly less than the half-life of the 
average red blood cell (60 days) as the glycated protein actually reaches 
equilibrium in 21-28 days (Cerami, 1985). Clinical studies were able to 
confirm this hypothesis so that by the early 1980s many diabetic clinics had 
started to include measurement of glycated haemoglobin in their repertoire 
of tests for regular diabetic monitoring. The possibility of spuriously 
elevated results due to interference by the labile aldimine fraction was 
realised early on and steps were therefore taken to eliminate this fraction 
prior to analysis. By this time, investigations into the formation and clinical
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Figure 1.3.1. Proposed reaction scheme for the formation of glucose 
adducts on a susceptible protein.
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utility of glycated serum proteins were also underway (Day et al,1979; 
Guthrow et al, 1979).
1.3.1. Protein glycation sites and reaction kinetics.
Reducing sugars in solution exist in both their open and ring (pyranose or 
furanose) forms. It is only the free aldehyde group of the open forms which 
can react with the uncharged amino groups of protein so it follows that the 
reactivity of a sugar depends on the proportion of the open form present in 
solution. In this respect, glucose is a relatively slow reactant as when in 
solution only 0.001% is in the open form (Bunn & Higgins, 1981). This 
percentage is much higher for fructose and pentoses as well as for glucose-
6-phosphate. Although the length of exposure of proteins to glucose is an 
important determinant of the extent of glycation, it has been upheld that 
theoretically, ambient glucose concentration provides the rate limiting step 
in the glycation reaction (Staley, 1987) as in a physiological situation 
available lysine residues (the main source of amino groups) will always be 
in excess of reactive open chain glucose molecules, even if the glucose 
rapidly isomerises to the open chain form in order to maintain its 
equilibrium.
Apart from the e-amino groups of lysine residues, N-terminal a-amino 
groups are also susceptible to glycation, and their generally lower pK^ 
values would suggest that at physiological pH Schiff base formation here 
would be more favourable. However, glycation of the N-terminal valine 
residue on the p-chains of haemoglobin appears to be the exception rather 
than the rule although a small proportion of HbAp is also glycated at several 
other possible sites, including the N-terminal of the a-chains as well as more 
extensively in vivo at p-66, p-17 and p-61 lysine residues (Shapiro et al,
1980). Glycation of the a-chain N-terminus is minimal despite its low pK^ 
(«7.2) so the pK of the reactive amino group is clearly not the sole
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determinant of susceptibility to non-enzymic glycation. In vitro glycation of 
purified HbAo by this group produced additional glycation sites at a - 16, a-7 
and P-120 lysine residues. Obviously the accessibility of amino groups to 
glucose is important, a fact which is particularly relevent to glycation of 
serum albumin, one of whose main physiological roles is as a carrier for 
other smaller molecules. Also, the Amadori rearrangement from aldimine to 
ketoamine is known to be accelerated by acid catalysis (Isbell & Frush, 
1958; Feeney et al, 1975) which may be provided by adjacent side groups 
of acidic amino-acid residues, which are particularly prevalent in albumin. 
Nearby basic groups can also be influençai as is catalysis by anions such as 
inorganic phosphate, bicarbonate and diphosphoglycerate.
Human albumin has been shown to be susceptible to non-enzymic glycation 
at its N-terminal aspartate residue (Robb et al, 1989) although e-amino 
glycation was found to be 8 times more prevalent. The main site of in vivo 
glycation of human serum albumin was originally demonstrated by Garlick 
and Mazer (1983) as lysine-525 where almost 50% of glycation occurs. 
These researchers have also suggested that human albumin is glycated 
approximately 9 times faster than haemoglobin, and that in vitro, lys-199 is 
also susceptible to a significant amount of glycation. Day et al (1979) have 
also implicated lys-189 as a candidate for in vitro glycation.
The in vitro reaction kinetics for non-enzymic glycation of human serum 
albumin have been investigated by Baynes et al (1984) who were able to 
show that glucose is rapidly incorporated into the aldimine intermediate 
within a 2 hour period, followed by a slower rearrangement to the Amadori 
product. This group have also shown the amount of aldimine and ketoamine 
formed to be dependent on protein concentration. Dissociation of the 
aldimine adduct demonstrated a half-life at 37 °C of 1.8 hours but the 
ketoamine adduct had an estimated minimum half-life of 3 weeks, after 
which time the study was not pursued. For glycated serum albumin in vivo, 
reversal of this reaction is therefore not physiologically relevant as the half­
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life of albumin is also approximately 3 weeks. A comparison of this work 
on human serum albumin to previously obtained data on haemoglobin 
indicates that glycation of albumin is 4-5 times faster than haemoglobin due 
to a more rapid conversion of the aldimine to the ketoamine despite similar 
equilibrium constants for formation of the labile Schiff base, which were 
approximately proportional to the relative lysine content of the 2 proteins. 
Olufemi et al (1987) have also produced data to support the higher glycation 
rate of albumin over haemoglobin.
Although serum albumin generally comprises over 50% of the circulating 
plasma proteins, other serum proteins can also become glycated, at levels 
reflecting the chemical characteristics of the protein and the half-life, as well 
as the time-averaged blood glucose concentrations to which they are 
exposed. Whereas glycated haemoglobin is representative of a patients 
glycaemic control over the preceeding 4-6 weeks, glycated albumin reflects 
the more recent short-term control over the preceeding 2-3 weeks due to its 
half-life of approximately 20 days. Plasma fibrinogen however, has an even 
shorter half-life of 4 days and can therefore respond even more quickly to 
changes in glycaemic control. This protein is present in plasma at a 
concentration of approximately 4 g/1, one tenth the concentration of albumin. 
Austin et al (1987) have studied the non-enzymic glycation of several major 
plasma proteins and found that the immunoglobulins showed the greatest 
proportion of glycation in vivo, followed in descending order by albumin, 
complement Q , fibrinogen, transferrin, haptoglobin and aj-antitrypsin. In 
general this trend reflects the decreasing half-lives of the group of proteins.
1.3.2. Advanced glvcosvlation end-products and the pathology of protein 
glycation.
In vivo, Amadori products reach an equilibrium within 14-20 days (Bunn 
et al, 1976; Mortensen & Christophersen, 1983) which results in their
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accumulation on both short-lived and long-lived proteins. However, in 
contrast to proteins whose turnover time is equal to or less than the time 
required to reach equilibrium, proteins that turnover at a much slower rate 
such as crystallins, collagen, elastin and myelin will continue to accumulate 
irreversible post-Amadori non-enzymatic glycation end-products. These 
advanced glycosylation end-products, or AGEs, form very slowly from the 
Amadori products over a number of years following spontaneous 
fragmentation of the Amadori product to form reactive dicarbonyl 
compounds called deoxyglucosones. These compounds, in particular 3- 
deoxyglucosone, may then themselves react with amino groups of proteins 
to form intraprotein cross-links hereby producing AGEs (Igaki et al, 1990). 
It is also likely that AGEs can form by condensation of 2 Amadori products 
or of the deoxyglucosone with Amadori product (Dominiczak, 1991) 
although the chemistry is still very uncertain. Most AGEs so formed are 
fluorescent, with the degree of fluorescence being related to the amount of 
cross-linking present. The continued presence of hyperglycaemia is not 
necessary for production of these compounds once the Maillard reaction has 
been initiated and in diabetic vascular tissues the level of these products can 
exceed 4 times that found in non-diabetic specimens, because the rate of 
AGE formation is approximately second order with respect to glucose 
(Tanaka et al, 1988).
The three main consequences of AGE formation in diabetics have recently 
been reviewed by Brownlee (1991). These are the cross-linking of 
extracellular proteins, altered cell-matrix interactions and modification of 
DNA structure and function. Cross-linking of extracellular proteins can 
cause expansion of extracellular matrix components resulting in 
characteristic basement membrane thickening. This can impair renal function 
(Makita et al, 1991) and contribute to the progressive occlusion of blood 
vessels. When matrix proteins are modified by AGEs, their associated cell 
functions are pathologically altered, for example, high affinity AGE
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receptors have been identified on macrophages which upon binding release 
various factors that stimulate glomerular synthesis of collagen and 
proliferation of endothelial, mesangial and smooth muscle cells. 
Modification of DNA structure and function by the presence of AGEs has 
been suggested as a persistent biochemical lesion that could cause 
complications to develop even in the absence of continued hyperglycaemia. 
Recent data produced by W olff and Dean (1987) has implicated the 
involvement of cumulative oxidative stress, caused by glucose autoxidation, 
in non-enzymic glycation. Autoxidation of glucose in vitro yields hydrogen 
peroxide and reactive dicarbonyls, and generates hydroxyl radicals. These 
workers have found that the transition metal chelator, diethylenetriamine- 
penta-acetic acid (DETAPAC) is capable of inhibiting glucose incorporation 
into proteins hereby supporting their theory, as monosaccharide autoxidation 
requires the presence of a transition metal. The contribution of this process 
to non-enzymic glycation is possibly reduced at high glucose concentrations 
(Lee & Dominiczak, 1990). It has also been suggested by Jones et al (1987) 
that the actual ketoamine is able to generate a superoxide free radical by 
autoxidation of its eneaminol form, another possible contributor to long-term 
tissue damage.
Elucidation of the effects of AGEs has prompted pharmacological studies 
in an attempt to inhibit their formation. Aminoguanidine hydrochloride, 
selected for study by Brownlee et al (1988), has been shown to effectively 
block reactive carbonyl groups on AGE precursors (Igaki et al, 1990) and 
has been used successfully in the treatment of animal models (Nicholls & 
Mandel, 1989). Although AGEs have therefore been implicated in 
development of the long term complications of diabetes, the presence of 
excessive amounts of the Amadori product is also implicated in the more 
immediate metabolic derangements seen in this disease. The effect of 
diabetes induced hyperglycaemia on levels of Amadori products in various 
tissue proteins is very similar to its effect on haemoglobin and sei*um
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albumin, with approximately a 2-fold increase seen in diabetic samples when 
compared to non-diabetics. The pathology of this form of glycation has been 
reviewed by Brownlee et al (1984), highlighting its effect on enzyme 
activity, binding of regulatory molecules, susceptibility to proteolysis, 
nucleic acid function, macromolecular recognition and endocytosis as well 
as immunogenicity. An aspect proving to be of particular interest in this area 
is whether non-enzymic glycation of low-density lipoproteins (LDL) 
contributes to the increased prevalence of hyperlipaemia and atherosclerosis 
in diabetic patients. It has been shown that glycation of LDL from diabetic 
subjects does exceed that of non-diabetic individuals (Schleicher et al, 
1981), although the absolute level of glycation is relatively small due to 
their short half-lives. This may explain why, despite contrary findings for 
in vitro hyperglycated LDL, limited non-enzymic glycation of LDL was not 
found to alter its catabolism in tissue culture (Schleicher et al, 1985) despite 
suggestions that decreased uptake of LDL could be responsible for raised 
plasma cholesterol.
Shaklai et al (1984) have however demonstrated that glycation of serum 
albumin is able to alter its conformation and function and Dolhofer- 
Bliesener and Gerbitz (1990) have shown that glycation of immunoglobulin 
G causes marked changes in functional properties of the fragment. 
Another mechanism by which hyperglycaemia has been proposed to lead to 
diabetic complications is the alteration of steady-state levels of intracellular 
metabolites, particularly in relation to the polyol pathway. When blood 
glucose levels exceed the capabilities of the glycolytic pathway in insulin- 
independent cells, the excess glucose is metabolised to fructose by the 
polyol pathway with concurrent production of sorbitol which cannot readily 
permeate cell membranes. The intracellular accumulation of sorbitol is 
proposed to initiate various metabolic abnormalities leading to functional 
and structural abnormalities in susceptible tissue (ie retina, nerve, 
glomerulus and ocular lens).
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It is more than likely that several factors lead to the pathogenesis of long­
term diabetic complications, with certain aspects predominating over others 
depending on the susceptibility of the individual. However, one constant 
association which appears regularly in hypotheses is that of hyperglycaemia 
which fortunately can now be recognised retrospectively by measurement of 
glycated blood proteins, and used by both the clinician and the patient to try 
and stabilise the diabetic condition.
SECTION 4. PLASMA PROTEIN AND HAEMOGLOBIN METABOLISM 
IN HEALTH AND DISEASE.
Although the measurement of glycated haemoglobin and plasma proteins for 
monitoring diabetic control can provide useful clinical information, the 
limitations of these analyses with respect to the physiological variation and 
metabolism of the particular protein must be taken into consideration.
1.4.1. Haemoglobin.
Useful measurement of glycated haemoglobin as HbA^g or HbA^ is based 
upon the 120 day life-span of a typical erythrocyte, containing haemoglobin 
with 2 a  and 2 p globin chains. Any alteration in the survival time of the 
erythrocytes, such as may occur in states of anaemia, will change the type 
of information obtained from a glycated haemoglobin assay. In general, the 
cause of an anaemia may be one or more of the following processes: Loss 
of blood (either acute or chronic), inadequate production of normal red 
blood cells by the bone marrow or excessive destruction of red blood cells. 
Factors contributing to anaemia due to inadequate production of red blood 
cells are often particularly relevent to diabetic patients eg. inflammatory 
disease (infective and non-infectivè), renal failure, drugs and thyroid 
abnormalities. A reduction in the percentage of newly formed red blood
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cells can then give rise to falsely elevated glycated haemoglobin results, 
whereas excessive destruction of these cells can affect the results by 
reflecting more recent glycaemic control than the established range of 4-6 
weeks.
Complications for the interpretation of glycated haemoglobin results in 
patients with haemoglobinopathies (eg HbS, HbC) can also arise, even when 
the method of analysis is not interfered with by these variants. Such patients 
can have periodic episodes of haemolysis which will obscure their true 
results, and may also have a hereditary persistence of foetal haemoglobin 
(Hb, 0 C2 7 2) which will produce falsely low percentage HbAi^ values. 
Diabetic control in these patients can therefore be more effectively assessed 
by measurement of glycated plasma proteins.
Results from glycated haemoglobin analysis should also be treated with 
caution when monitoring patients throughout pregnancy, because although 
the physiological anaemia of pregnancy is generally considered to be an 
effect of haemodilution, this is due to an increase in total red cell volume 
(approximately 17%) being accompanied by an even larger increase in 
plasma volume (approximately 35%) with very wide inter-individual 
variation.
1.4.2. Plasma proteins.
Plasma contains a mixture of proteins which differ in origin, function and 
half-life. Albumin normally makes the largest single contribution to plasma 
total protein and hypoproteinaemia is almost always due to 
hypoalbuminaemia. An appreciable rise in the concentration, but not the 
actual amount, of protein can occur if excessive amounts of protein-free 
fluid are lost from the vascular compartment, either due to dehydration or 
to stasis during venepuncture. Total protein levels can often be misleading 
and may appear to be normal in the face of quite marked changes in the 
constituent proteins. For example, a fall in albumin may be approximately
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balanced by a rise in immunoglobulin levels and is quite a common 
occurrence. Also, because most of the individual proteins make a relatively 
small contribution to the total value, a quite large percentage change in the 
concentration of one of them may not be detectable as a change in total 
protein value.
As diabetic patients have increased susceptibility to infection and 
autoimmune disease, increases in the ‘acute phase’ proteins are not 
uncommon and this may or may not be accompanied by increases in 
immunoglobulin levels. The inherent variability in concentration and half- 
life of the many different plasma proteins can therefore have the effect of 
obscuring information obtained from analysis of glycated plasma proteins, 
whereas measurement of glycation in only one selected plasma protein gives 
more well defined information. However, specific measurement of glycated 
albumin can also be misrepresentative of glycaemic control when albumin 
synthesis is decreased (as in cirrhosis of the liver) or when there is increased 
albumin catabolism or loss, as found in the nephrotic syndrome which is not 
uncommon in diabetics.
During pregnancy, plasma protein concentrations (particularly albumin) can 
fall considerably, due to the increased circulating blood volume, so under 
these circumstances glycated albumin levels are best expressed as a 
percentage value or corrected to plasma albumin levels. Correction of results 
in this way will not however, produce meaningful absolute values when 
albumin synthesis or degradation is deranged although results could still be 
useful for monitoring if the patient is in a steady state.
A more complex issue which may also affect the reliability of glycated 
albumin results, particularly in individuals with wide fluctuations in 
glycaemic control, is that of whether glycated albumin is catabolised at the 
same rate as non-glycated albumin. From studies with rabbits, Kallner 
(1990) has suggested that the half-life of glycated albumin is shorter than 
that of the unmodified protein due to its preferential degradation although
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Johnson et al (1991), using rat models, were unable to confirm this except 
in the presence of hyperglycaemia. This group have therefore concluded that 
the effect is insignificant in relation to the degree of glycation occurring. 
From an alternative angle. De Feo et al (1991) have provided evidence that 
albumin synthesis in humans is an insulin sensitive process and is therefore 
decreased upon insulin withdrawal. Similarly, altered renal handling of 
glycated and non-glycated albumin could affect the reliability of plasma 
glycated albumin results, depending on the degree of proteinuria in each 
individual patient. All these concepts could partly explain the large within 
and between-individual variation seen in glycated plasma protein levels in 
diabetics, and emphasise the clinical importance of treating the patient rather 
than the glycated protein result.
SECTION 5. CURRENT METHODOLOGY FOR GLYCATED PROTEIN 
MEASUREMENT.
Despite the great potential of glycated protein analysis in medicine, and a 
variety of different techniques which have been proposed and evaluated, 
accurate measurement of this entity is still difficult to perform. Although the 
wide choice of possible methods available has facilitated investigations into 
the chemical structure of glycated proteins, it has also produced the 
insurmountable problem of standardising all these assays together. Each 
form of analysis involves its own reference material, upon which a specific 
population of glycated protein is measured, or relies upon expression of 
results as a percentage.
Not all techniques for glycated protein analysis are applicable to both 
haemoglobin and plasma proteins, but they can be broadly classified into 3 
main groups: methods based on charge differences, chemical reactivity or 
structural differences. Most of these methods have been summarised in a 
number of articles and reviews (Goldstein et al, 1986; Bunn, 1981; Miedema
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& Caspari, 1984; Furth, 1988; Schleicher & Wieland, 1989).
1.5.1. Methods based on charge differences.
These methods are commonly applied to measurement of glycated 
haemoglobin (either as HbAj or H bA iJ and are dependent upon the marked 
drop in pK which occurs when amino groups are converted to a Schiff base 
or Amadori product. As a-amino group pKs occur at the non-denaturing pH 
of 6-7, the glycation of haemoglobin occurring at the N-terminal valine of 
the p-chain (as HbAj or HbA^J can be isolated on the basis of charge, 
although the full extent of haemoglobin glycation is underestimated as 
protein glycated at e-lysine amino groups with higher pKs (10-11) migrates 
with the unglycated fraction. Glycated albumin can be separated by charge 
dependent methods but the drop in isoelectric point upon glycation is not 
very dramatic so separation can be difficult.
1.5.1.1. Cation exchange chromatography.
This is the most widely used method in clinical laboratories for quantitation 
of glycated haemoglobin. Procedures range from disposable microcolumns 
to automated high performance liquid chromatography (HPLC) systems and 
may result in the separation of either HbAj or HbA^g from the total 
haemoglobin. A small volume of haemolysate is applied to a column of 
negatively charged exchange resin and the less positively charged minor 
haemoglobin components (HbAj^, HbA^y and H bA iJ elute in a buffer at 
approximately pH 6.6 before the main HbAg fraction, which elutes with a 
lower pH buffer. Haemoglobin can then be detected spectrophotometrically 
in both eluates and the results expressed as a percentage of the total 
haemoglobin result. Two buffers can also be used to separate HbA^c from 
HbAi leaving HbAg on the column and necessitating determination of the 
total haemoglobin absorbance prior to its application. Several companies
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now market HPLC equipment totally dedicated to HbAjj. analysis (based on 
the method of Cole et al, 1978) which is fully automated, hereby producing 
excellent precision and requiring minimum hands on technician time, 
although good laboratory technique is necessary for maintaining optimal 
results. Samples are injected onto the HPLC system and 3 phosphate elution 
buffers of increasing ionic strength are pumped, one at a time, through the 
system. The separated fractions pass through a spectrophotometer, this 
produces a chromatogram and an integrator calculates the area under each 
peak. This area is corrected with respect to a HbA^c reference standard and 
the percentage HbAjj. is calculated. Temperature is strictly controlled by 
placing the ion-exchange column in a temperature controlled column heater 
at 30 °C.
Assay factors that can effect these test results include variations in 
temperature, column size, pH and ionic strength of buffers. Most of these 
factors are controlled for the automated HPLC analysis although users are 
dependent on manufacturers maintaining the quality of reagents. The manual 
mini-column techniques are obviously prone to more fluctuations but this 
low pressure chromatography has also been automated which does improve 
performance. It is essential for both methods that the labile Schiff base 
intermediate (pre-HbA^g) is removed prior to analysis as this co­
chromatographs with the HbAjc fraction and can falsely elevate results 
dependent on the prevailing blood glucose level of the sample. Haemolysis 
reagents supplied by kit manufacturers are commonly made up in borate 
buffer which, following a 30 minute incubation at 37 °C, binds to the 
vicinal diols of glucose hereby promoting the dissociation of Schiff base. 
One other advantage of the HPLC version of this technique is that 
haemoglobin variants can be identified (eg. HbF, HbS and HbC). This is 
important, as in the minicolumn techniques with poorer resolution, HbF co­
chromatographs with the glycated haemoglobins and the unidentified 
presence of HbS or HbC will falsely lower HbA^ percentage results, as
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glycated HbS and HbC do not elute with HbAi^ (Engbaek et al, 1990). 
Similarly, non-glucose adducts of haemoglobin such as acetylated or 
carbamylated haemoglobin can also increase test results but once again, 
suspicions are aroused by the abnormal chromatographic pattern produced 
using the HPLC method. Although automated HPLC equipment for HbAjj. 
analysis is expensive to purchase, for a laboratory with a high workload the 
cost can soon level out to that of the disposable mini-column system.
1.5.1.2, Electrophoretic techniques.
Two electrophoretic methods have been adapted for measuring glycated Hb. 
Isoelectric focusing on thin slabs of polyacrylamide gel with non-linear 
amphoteric pH gradients, is able to separate HbA^g from HbAg by virtue of 
their different isoelectric points, but a relatively expensive high quality 
densitometer is necessary for quantitation and the technical skill can be 
demanding if the poorly defined bands have to be cut from the gel and the 
Hb eluted. Under optimum conditions separation of pre-HbAjj. can also be 
achieved, and haemoglobinopathies do not interfere. Despite acceptable 
assay precision, the isoelectric focusing method is probably best suited to 
research purposes rather than the throughput of a high volume of routine 
clinical samples.
Due to an electro-endosmotic flow of buffer, electrophoresis of haemoglobin 
on agar gel at pH 6.5 provides a much wider separation than that obtained 
by isoelectric focusing hereby making quantitation easier. Unglycated 
haemoglobin is preferentially retarded by negatively charged groups on the 
support medium but only the total HbAj fraction can be separated from 
HbAo. A specialised densitometer is required to read the gels but many 
samples can be assayed in each batch. Schiff base must be removed prior 
to analysis of samples and once again HbF interferes with the results. HbS 
and HbC do not interfere but between batch precision has been reported to 
be not quite as good as for the manual column ion-exchange method (Hayes
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et al, 1981). However, agar gel electrophoresis is much less pH and 
temperature dependent than ion exchange and is therefore an attractive 
alternative in the routine laboratory.
1.5.2. Methods based on chemical reactivity.
Chemical methods for analysis of non-enzymically glycated protein can 
either be performed following hydrolysis of the Amadori product, or on the 
intact protein-sugar adduct, providing that enzymically glycosylated proteins 
do not interfere.
15.2.1. Weak acid hydrolysis.
Gottschalk, in 1952, was the first to report that treatment of fructose-amino 
acids with dilute or weak acids could yield 5-hydroxymethyl-2- 
furfuraldehyde (HMF) by hydrolysis and dehydration of the carbohydrate 
adduct. The HMF so formed can then be separated by HPLC and quantitated 
spectrophotometrically at 280 nm or by fluorescence (Flückiger & Gallop, 
1984). However, HMF will also condense with thiobarbituric acid (TEA) to 
form a chromophore as shown in Figure 1.5.1, which can be detected at 443 
nm, and following its introduction in 1976 by Fliickiger and Winterhalter for 
quantitation of glycated haemoglobin, this form of colorimetric detection 
became very important in much of the early literature. Boiling oxalic acid 
is commonly used to release the hexose sugars from protein, which is then 
precipitated out with trichloroacetic acid, but any sugar with 6  or more 
carbons will produce HMF, so free sugars and glycoproteins do interfere 
although Schiff base, haemoglobinopathies and non-glucose adducts do not. 
This method is applicable to both plasma proteins and haemoglobin analysis, 
upon which it will measure all sugar adducts on e-lysine or valine and N- 
terminal a-amino groups. Serum or plasma samples can be assayed if 
sodium borohydride blanks are run for each sample, as this reduces the
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Figure 1.5.1. The formation of a chromophore in the HMF-TBA method
for glycated proteins.
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Weak acid hydrolysis releases the 5-hydroxymethyl-2-furfuraldehyde (HMF) 
from the Amadori product (AP). The HMF then condenses with 
thiobarbituric acid (TBA) to produce a chromophore which can be detected 
at 443 nm. (Adapted from Furth, 1988)
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ketoamine derivatives to non-reactive deoxyglucitol-protein adducts, hereby 
enabling non-specific interferences to be eliminated. The assay can be 
standardised using pure fructose which, like the Amadori product, reacts 
particularly fast, or results can be expressed as nmol HMF/mg protein using 
purified HMF or glycated protein as a standard. These different forms of 
standardisation can create confusion and make it difficult to compare results 
between laboratories. Also, HMF itself is acid labile and although over 80% 
of protein bound radiolabelled glucose can be released as HMF (Ney et al,
1981), in practice yields are often less than 10% so the TBA method is 
generally better for comparative than for absolute determinations. Despite 
modification of the original method by McFarland et al in 1979, Dolhofer 
and Wieland (1981) have suggested that several critical areas still need 
addressing, such as the optimum concentration of borohydride for 
preparation of blanks, the amount of protein in each sample, dialysis for 
removal of glucose and borohydride prior to assay, and increasing the yield 
of HMF by more appropriate hydrolysis conditions. Also, Garlick et al 
(1983) have shown that the colour yield from ketoamine linked glucose with 
TBA depends markedly upon the site of attachment, with a-N H 2 valine 
linked glucose producing about 8  times as much colour as E-NH2 lysine 
linked glucose. This assay can also be very laborious and despite semi­
automation is still not suited to a high routine clinical workload.
I.5.2.2. Strong acid hydrolysis.
By boiling glycated proteins in 6 N HCl for 18 hours the glucose-lysine 
adducts can be isolated and assayed independently of other components. If 
glycated proteins are hydrolysed without prior reduction, approximately 30% 
of the Amadori product is converted to furosine (e-N-(2-furoylmethyl)-L- 
lysine) by cyclization between C3 and Cg of the sugar adduct. Although 50% 
of the lysine adduct reverts to lysine, a minor cyclization product is 
pyridosine whereby Cg attaches to the e-amino group as shown in Figure
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1.5.2. The furosine can be separated by HPLC and detected directly by its 
absorbance at 280 nm. As furosine is not formed from the Schiff base or 
from enzymically bound sugar this method is specific for lysine bound 
ketoamine derivatives. Simultaneous UV detection of tyrosine at 254 nm 
allows internal standardisation for protein content, and human serum 
albumin (calibrated with synthetic fructose-lysine) can be used for 
calibration. This system can also be used to quantitate HbA^g by hydrolysis 
of fructose-valine residues.
Following the introduction of the furosine method by Schleicher and 
Wieland in 1981 it was modified by Drexel et al (1987) who increased the 
furosine yield and shortened the assay time, still claiming excellent 
sensitivity and resolution. Although this method therefore meets the 
requirements of precision, specificity and sensitivity of a laboratory test it 
is still quite laborious and not well suited to routine work.
1.5.2.3. Reaction with phenylhydrazine.
Synthetic ketoamines on haemoglobin, and glycated albumin from diabetics 
have been shown to react with phenylhydrazine to form a phenylhydrazone 
adduct with an absorbance maximum at 350 nm (Acharya and Manning, 
1980; Ghiggeri et al, 1986). However, this approach does not appear to have 
been developed further.
1.5.2.4. Sodium borohydride (NaBH )^ reduction.
Borohydride reduction provides a very sensitive assay for measuring non- 
enzymic glycation, particularly with tritiated borohydride reagent. Reduction 
takes place across the C=N bond of the aldimine and the C = 0  bond of the 
ketoamine adduct to produce acid stable deoxyaminohexitol compounds as 
shown in Figure 1.5.3. As NaBH^ is only stable under alkaline conditions 
and glycosidic bonds are alkali-labile, hydrolysis of mixtures containing 
glycoproteins must be under very mild conditions to prevent the release of
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Figure 1.5.2. Formation of furosine from fructose-lysine adducts.
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Following strong acid hydrolysis, 50% of the fructose-lysine adduct reverts 
to lysine, 30% is converted to furosine and pyridosine is a minor product. 
(From Furth, 1988)
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Figure 1.5.3. Borohydride reduction of glycated proteins.
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Schiffs base and Amadori product are reduced to deoxyaminosorbitol and 
deoxyaminomannitol derivatives. Asterisks represent the site of tritium 
labelling. (From Furth, 1988).
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reactive reducing groups from these enzymically glycated species although 
non-glycoproteins such as albumin can withstand more rigourous conditions. 
Following reduction, the aldimine adducts are converted to the 
deoxyaminohexitols of sorbitol whereas the ketoamines give the deoxyamino 
derivatives of sorbitol and mannitol. As these compounds are stable to 
strong acid hydrolysis this can be performed with boiling 6N HCl to destroy 
the excess borohydride, then amino acid analysis can be used to identify 
these products of both e-amino and a-amino glycation.
If tritiated borohydride is used for reduction, it is necessary to obtain values 
for non-specific labelling by removing all reducible sugar groups first with 
periodate in order to obtain a sample blank. Obviously neither of these 
methods is suitable for routine use although a slightly simplified procedure 
involving NaBH^ reduction has been described by Kumar et al (1988). This 
procedure exploits the finding that very low concentrations of NaBH^ are 
capable of reducing free glucose and fructose in solutions of glycated 
proteins whose sugar-protein adducts are only reduced at much higher 
NaBH^ concentrations. Serum glycated protein values have therefore been 
derived by this group by reducing samples with both concentrations of 
borohydride and measuring the difference in their responses to a phenol- 
sulphuric acid method for carbohydrate. This group found a good correlation 
of their results with the HMF-TBA assay previously described but once 
again it has proved to be too laborious to become commonplace in routine 
laboratories.
1.5.2 5. Periodate oxidation.
Periodate oxidation is able to cleave cis-diol or cis-aminol groups on carbon 
atoms as well as the corresponding ketol or ketoamine compounds. The C-N 
bondings linking sugar to protein can also be broken, hereby liberating 
unglycated protein. Although most carbons are released from the sugar 
adduct as formic acid, a minority are released as formaldehyde as shown
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in Figure 1.5.4 and it is this compound that gives an indication of non- 
enzymic protein glycation. As formaldehyde can only be released from the 
terminal carbons on the sugar chain which are adjacent to carbons carrying 
a hydroxyl or carbonyl group, pyranosyl rings in glycosidic linkage are not 
susceptible. Formaldehyde is released from the ketoamine adducts in both 
straight chain and ring form but not at all from on the aldimine adduct. 
Formaldehyde is however, released at Q  on both types of straight chain 
arrangement, but if the Schiff base is dissociated before analysis an 
additional step of reducing the ketoamine with NaBH^ prior to periodate 
oxidation breaks the ketoamine ring structures cleaving all the Q  
formaldehydes hereby doubling their production. This is a useful procedure 
for establishing whether contaminating substances are present. 
Formaldehyde produced by this assay is generally detected fluorometrically 
after conversion to diacetyldihydrolutidine, although this conjugate can also 
be measured spectrophotometrically. Control of reaction conditions in this 
assay needs to be fairly strict, as prolonged exposure to light and to 
periodate itself can cause the formaldehyde to break down by overoxidation. 
When combined with borohydride reduction the analysis shows good 
specificity, but removal of Schiff base is necessary and it is not ideal for 
processing large numbers of samples. When used for analysis of glycated 
haemoglobin, the globin fraction must be prepared prior to assay (Gallop et 
al, 1981) hereby extending the procedure further.
I.5.2.6. Reduction of nitroblue tétrazolium - ‘Fructosamine assay’.
In 1982, Johnson, Metcalf and Baker published details of a novel manual 
method designed to measure glycated serum proteins as an index of diabetic 
control. They proposed the name of ‘fructosamine’ as a general term for 
non-enzymically glycated protein but throughout this thesis this term has 
been used only in relation to this specific form of analysis. The actual assay 
exploits the reducing activity of complex ketones, such as the Amadori
49
Figure 1.5.4. Periodate oxidation of glycated proteins.
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product, which in strong alkali rapidly enolizes to form an eneaminol. It is 
possible that this eneaminol then dehydrates to release the protein and a 
strongly reducing enediol, which can be quantitated by its ability to reduce 
nitroblue tétrazolium (NET) to a blue formazan dye. However, the exact 
mechanism by which glycated proteins do reduce NET is still unknown 
although Jones et al (1987) have suggested that there is a superoxide 
intermediate in the reaction (based on the ability of superoxide dismutase to 
inhibit this reduction of NET), a theory supported by Sakurai and Tsuchiya 
(1988,1989) who have shown that it is necessary for the NET to bind to the 
protein prior to its reduction. Einding of NET to albumin was shown by 
these workers to be much more favourable than binding of NET to a 
polylysine substrate, whether glycated or not.
As only straight chain sugars can enolize, and at alkaline pH ketoses do so 
much faster than aldoses, neither Schiff base nor free glucose should 
significantly interfere with the fructosamine reaction. Enzymically 
glycosylated protein would also not be expected to interfere unless the 
terminal contained a ketose group.
In order to perform the fructosamine assay, serum or plasma is added to 
carbonate buffer at pH 10.35 containing NET which is reduced, and the 
absorbance of the formazan product is measured 10 and 15 minutes later. 
The pH of the carbonate buffer was originally the object of some argument 
as it was first reported to have an optimum of 10.8 (Johnson et al, 1982). 
Although several evaluations of the fructosamine assay were performed 
using this pH (Lloyd & Marples, 1984; Hindle et al, 1985), correspondence 
between authors was later able to establish that the pH of 10.8 was incorrect 
(Eaker & Johnson, 1985). The fructosamine assay was soon automated on a 
variety of analysers, all commonplace in clinical laboratories (Lloyd & 
Marples, 1984), which gave excellent precision and was therefore produced 
in kit form by Hoffman-La Roche, Easle, Switzerland. Initially this assay 
therefore appeared to be ideally suited to the fast analysis of large numbers
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of untreated serum samples, with no interference from Schiff base, 
glycoproteins or free glucose. A 10 minute pre-incubation period was 
proposed to eliminate interference due to fast reacting reducing substances 
in the samples, such as ascorbate, glutathione and uric acid. However, it 
soon became evident that standardisation of the assay could be a problem, 
as this was originally performed using a synthetic ketoamine (1-deoxy-l- 
morpholinofructose, DMF) in a 40 g/1 solution of human serum albumin. 
The changing response of this DMF standard in different preparations of 
albumin, as well as to slight changes in assay pH, was found to be 
substantial (Hindle et al, 1985) and was one cause of poor between- 
laboratory agreement on fructosamine reference ranges (Hill, 1988) which 
was probably due to different absorbtion maxima for serum and DMF 
(Rowbury et al, 1989). San-Gil et al (1985) found that preparation of 
standards in human serum resulted in a different standard curve again 
although they found this to improve the accuracy of their assay. In 1986, 
Johnson and Baker found that the actual reducing activity of protein 
ketoamines was approximately 5-times greater than an equivalent amount of 
DMF, possibly due to lack of binding of NET to DMF as found for 
polylysine by Sakurai and Tsuchiya (1989), and that as such, glycated 
protein results expressed as DMF equivalents were not physiologically 
representative of their true levels. Following extensive controversy over the 
use of DMF as calibrant, secondary standards of glycated bovine albumin 
were suggested by Eaker et al (1985). These proved to be less variable with 
changes in reaction conditions, giving greater accuracy and reproducibility. 
Another potential problem for the fructosamine assay is that of establishing 
exactly what it is measuring within a serum or plasma sample. The inherent 
simplicity of the assay has facilitated its investigation so the literature on 
this subject is vast. Schleicher et al (1988) performed a comparison of the 
fructosamine assay with the furosine method (see section 1.5.2.2) and found 
purified human serum albumin glycation to be measured correctly. However,
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analysis of diabetic and non-diabetic sera indicated that up to 50% of the 
reducing activity present was non-specific, was independent of the level of 
albumin glycation and was not reducible by NaBH^. This could partly 
explain why the means of typical ranges of diabetic results are only 
approximately 1.5-times higher than a non-diabetic group (Cefalu et al, 
1991) whereas with other methods of glycated protein analysis there is 
usually a 2-fold difference (Gould et al, 1984). In an attempt to overcome 
this problem Kricka et al (1991) have proposed that a blank is assayed for 
each sample in the presence of m-aminophenylboronic acid which 
complexes with the cis-diol groups on the ketoamine hereby preventing it 
from reducing the NET. The clinical impact of this blank correction has not 
yet been assessed.
Winocour et al (1987) have also concluded that glycated albumin (as 
measured by affinity chromatography) and fructosamine levels reflect 
varying glycaemic levels to a different degree although several studies have 
been able to demonstrate the clinical usefulness of the fructosamine assay, 
albeit in conjunction with glycated haemoglobin analysis (Dominiczak et al, 
1988; Hindle et al, 1985; Mosca et al, 1987; Lloyd & Marples, 1984). 
Potential interferences in the fructosamine assay were originally investigated 
by Eaker et al (1985), on a particular autoanalyser, showing that increased 
bilirubin, EDTA, heparin, cysteine and urate could interfere with analysis. 
However, Elair et al (1987) found the actual effects of these contaminants 
to vary dependent on the analyser used, possibly due to different allowable 
incubation times on different instruments. Other than interfering reducing 
substances, lipaemia and haemolysis can also interfere with the fructosamine 
assay. In order to facilitate analysis of lipaemic samples (lipaemia being 
fairly common in type 11 diabetes) the addition of detergent to the assay 
reagent was proposed (Philipou et al, 1988) which solved the problem of 
lipaemia but was observed to increase the interference from urate (Kallner, 
1989). Addition of uricase was successful in overcoming this hurdle
53
although Kallner concludes that the modifications do not necessarily 
improve the performance of the original method.
The latest kit form of this test produced by Roche Diagnostics ( Wellwyn 
Garden City, Herts, UK) is named ‘Fructosamine Plus’ and incorporates 
both these modifications. The calibrator supplied with this kit is a stabilised 
solution of in vitro glycated human serum, calibrated against glycated 
polylysine and human albumin glycated with '^‘C-glucose. However, none 
of these modifications alter the fact that this assay measures total glycated 
serum proteins which has its own inherent difficulties (as discussed in 
sections 1.3.1 and 1.4.2). In addition to possible changes in protein profiles, 
it has also not yet been established whether NET reacts equally well with 
different plasma proteins and, i f  binding of NET to protein is necessary for 
reduction to occur, this could significantly affect results. Rodriguez-Segade 
et al (1989) have suggested that immunoglobulin A may be highly reactive 
with respect to NET as this was the only individual serum protein found to 
be dependently related to serum fructosamine levels out of a total of 9 
possible proteins (including albumin) in the study of a large number of 
subjects.
One other major analytical concern with the fructosamine assay is the effect 
of serum protein (notably albumin) concentration on the results. It has been 
reported that serum fructosamine concentration is independent of albumin 
or total protein levels (Johnson & Eaker, 1987) particularly if the albumin 
is > 35 g/1 (Lloyd & Marples, 1984). Van Diejen-Visser et al (1986) suggest 
that this does not hold, as do McCance et al (1987), and some workers have 
proposed the use of a correcting algorithm (Howey et al 1987). This issue 
therefore remains a subject of debate whereby some laboratories do correct 
for albumin or total protein levels and others do not. It is obviously 
important to realise that the condition giving rise to low albumin levels may 
invalidate the fructosamine results anyway by altering the normal protein 
metabolism.
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An alternative use of NET reduction by glycated protein has been in the 
application of this assay to glycated haemoglobin. First described by Somani 
et al (1989), Hill (1990) has partly automated the assay which involves 
extraction of haem prior to assay of the glycated globin with NET. Results 
obtained correlated well with other methods, giving a 2-fold increase in 
mean results for diabetics compared to non-diabetics, and with further 
development this form of analysis may prove to make more informative use 
of the production of formazan fron NET.
1.5.3. Methods based on structural differences.
i.5.3.1. Immunoassay.
Advances in this area have recently been dramatic, since 1978 when Javid 
et al succeeded in the production of antibodies with a low affinity for 
HbAic, which cross-reacted with HbAi^ and HbAn,. Immunoassays have 
been described for glycated haemoglobin which recognise glucitol-lysine 
residues, necessitating prior reduction of samples with NaEH^, as the 
reduced compounds have proved to be more immunogenic (Makita et al, 
1991) than the native glycated proteins. However, Novo Nordisk Diagnostics 
Ltd (Cambridge, UK) have now succeeded in producing an enzyme 
immunoassay for HbAi^ using a monoclonal antibody which specifically 
detects the glycated heptapeptide at the N-terminus of the p-chain. This 
antibody will therefore not recognise HbS and HbC which vary at p-chain 
position 6, or HbF which possesses y-chains instead of p. There is reported 
to be no cross-reactivity within the HbA^ group and no interference from 
lipaemia, hyperbilirubinaemia or from non-glucose adducts. Precision of this 
form of analysis is traditionally very good and this particular assay will take 
approximately 2 hours to run a batch of up to 88 samples. Good correlations 
have been obtained for this method against electroendosmosis and affinity 
chromatography, but at the moment the analysis is relatively expensive,
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particularly for a laboratory not already running other enzyme 
immunoassays. Bayer Diagnostics (Basingstoke, UK) have recently applied 
the same technology to a discrete portable HbA^c analyser which can assay 
individual capillary blood samples at the clinic or surgery within minutes. 
Although some initial outlay is necessary on this equipment, the cost of 
reagents and consumables is currently very competitive.
Technology for immunological measurement of glycated serum proteins is 
slightly behind that for glycated haemoglobin, but similar approaches have 
been taken in the production of antibodies towards glucitol-lysine (Ohe et 
al, 1987). Cohen and Hud (1989) were the first to raise a monoclonal 
antibody against unreduced glycated albumin, and they used this to develop 
an enzyme linked immunosorbent assay (Hud and Cohen, 1989) with an 
enzyme conjugated second antibody directed against human albumin. This 
method was also found to provide clinically relevant results, with acceptable 
precision, indicating that the future of glycated protein analysis within the 
routine clinical laboratory could definitely lie in immunoassay.
1.5.3.2. Affinity chromatography.
The ability of boronic acid to form complexes with compounds containing 
coplanar cis hydroxyl groups represents another reaction principle for the 
detection and determination of glycated amino acids, peptides and proteins. 
This principle was first exploited by Brownlee et al (1980) who immobilised 
aminophenylboronic acid (APBA) on a column and used it to measure 
glycated amino acids in urine of diabetic patients. However, the supporting 
matrix for this analysis was only suitable for separation of small molecules 
so that anything as large as haemoglobin would be excluded. Mallia et al 
(1981) therefore adapted the column by producing a cross-linked agarose gel 
activated with carbonyl diimidazole, which was then complexed to APBA 
to form an affinity matrix suitable for analysis of larger glycated proteins. 
By applying a sample of haemolysate onto a column of gel, equilibrated
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with an alkaline buffer, non-glycated material could be washed through in 
this buffer and collected. Removal of the bound glycated fraction was 
achieved by displacement with a sorbitol buffer. Absorbances of the 
separated haemoglobin fractions were measured at 414 nm in order to 
calculate the percentage of bound, or glycated material.
The interaction of glycated protein with the affinity gel involves the 
formation of a 5 membered ring complex with boronic acid as shown in 
Figure 1.5.5. It is essential for the boronate to be negatively charged during 
the chromatography hence the requirement for an alkaline buffer.
As demonstrated by Mallia et al (1981) and Klenk et al (1982) this 
technique for estimation of glycated haemoglobin does not only measure 
HbAig, but also detects e-amino group glycation products. Several groups 
have evaluated the performance of this assay (Gould et al, 1982; Klenk et 
al, 1982; Middle et al, 1983), finding good correlations with other 
methodologies. The analysis is less pH and temperature dependent than ion- 
exchange procedures and is not affected by the presence of HbF, HbS or 
HbC (Abraham et al, 1983). Good within and between batch precision has 
also been demonstrated but there must be good agreement between different 
batches of gel, in the degree of derivatisation with the affinity ligand. 
Although the affinity columns can be reused, the gel is susceptible to 
oxidation and should be kept in the dark. Affinity chromatography is also 
applicable to analysis of glycated plasma proteins, either as a total quantity 
or for the individual proteins, as once the glycated and non-glycated 
fractions have been separated only the protein of interest needs to be 
assayed in the wash fractions. In 1984, Gould et al found that the amount 
of protein applied to each affinity column was critical to achieving optimum 
results as the columns could easily be overloaded. The low applications of 
protein required necessitated the use of a sensitive procedure for detection 
of protein in the wash fractions (Bradford, 1976) hereby resulting in slightly 
higher imprecision than that achievable for glycated haemoglobin analysis.
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Figure 1.5.5. The binding of glycated protein to a 
m-aminophenylb oronate agarose affinity gel.
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This diagram has been simplified by presentation of the glycated proteins 
in their open chain forms.
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Quantitation of glycated albumin by this technique is possible using 
immunoassay procedures for estimation of albumin in the wash fractions. 
This has been performed successfully by Reed et al (1986) using 
immunoturbidimetry, John and Jones (1985) using rocket 
immunoelectrophoresis and Woo et al (1987) using radioimmunoassay. 
Shima et al (1988) have taken an alternative approach and separated 
albumin from serum by HPLC ion-exchange prior to affinity 
chromatography. This eliminated problems of column overloading and 
enabled easier spectrophotometric quantitation of the eluants.
For successful measurement of glycated total protein in plasma it was 
relevant to identify whether glycoproteins would also bind to the affinity 
matrix. This was shown not to occur by Gould and Hall (1987), possibly 
due to steric hind ranees from highly branched glycoprotein chains or to 
effects of modified groups on these sugars.
Affinity chromatography is therefore a viable method of assessing glycaemic 
control, which is easier to perform than the manual ion-exchange procedure. 
However, it does require some technical experience in order to achieve good 
precision and even with batch analysis it is not feasible to assay many more 
than 50 samples per day.
I.5.3.3. Boronate ester formation in solution.
In 1980, Burnett et al succeeded in attaching a 5-dimethylaminonaphthalene- 
1-sulphonyl (dansyl) group to aminophenylboronic acid, the affinity ligand 
for analysis of glycated proteins. Although this group were interested in 
using the compound to detect cis-diol groups on bacterial cell walls, Hayashi 
and Makino (1985) later demonstrated its effectiveness as a possible 
fluorescent marker for non-enzymic glycation of human serum albumin. The 
structure of dansylated phenylboronic acid (Dns-PBA or N-(5-dimethyl 
amino-l-naphthalenesulphonyl)-3-aminobenzene boronic acid) is shown in 
Figure 1.5.6. Hayashi and Makino (1985) developed an assay with this
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Figure 1.5.6. The chemical structure of N-(5-dimethyI amino-1- 
naphthalenesuIphonyl)-3-aminobenzene boronic acid (Dansylated 
phenylboronic acid or Dns-PBA).
H3C CH.
\ /
N
I
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B
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fluorophore which involved the addition of a micromolar solution of Dns- 
PBA to a diluted human serum sample. By performing fluorescence scans 
of the Dns-PBA solution both in the absence and the presence of human 
serum albumin with an excitation wavelength of 330 nm, the Dns-PBA 
emission peak was found to shift from 530 nm to 490 nm, with an 
appreciable increase in fluorescence intensity. By altering the concentration 
of Dns-PBA in the reaction, Hayashi and Makino were able to demonstrate 
that there were at least 2 different interactions between the Dns-PBA and 
human serum albumin which caused this change in fluorescence spectrum. 
At low concentrations of Dns-PBA there was a steep increase in 
fluorescence emission intensity with increasing concentration, but the 
gradient decreased above approximately 0.2 p,mol/l Dns-PBA. Addition of 
50 mmol/1 boric acid was found to abolish the steep slope component, which 
was then shown to increase with increasing Dns-PBA concentrations until 
saturation. By separating free Dns-PBA from that bound to albumin (by gel 
filtration) the fluorescence of the Dns-PB A-albumin complex at 490 nm was 
shown to coincide with the fluorescence intensity that could be inhibited by 
addition of boric acid. These workers have therefore proposed that the Dns- 
PBA is capable of binding to ai gi^cose/ adduct, or adducts, on glycated 
albumin specifically through a borate cis-diol linkage. Interaction of the 
Dns-PBA within a hydrophobic site on the protein could then alter its 
fluorescence characteristics, and non-specific binding can be eliminated by 
obtaining a sample blank in the presence of boric acid. A good correlation 
of these results with a column affinity chromatography method was 
demonstrated as well as an apparent lack of interference from other serum 
proteins.
Other than one publication by Hayashi et al in 1990, which involves 
application of the Dns-PBA assay to analysis of glycated albumin in urine, 
this assay has not come into general use although Schleicher and Wieland 
(1989) have investigated the possibility of using a diazophenylboronic acid
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conjugate in the same way, as the UV-visible absorption spectra of this 
compound was also found to alter upon binding to glycated albumin. As 
fluorescence is a much more sensitive technique than UV-visible 
spectrophotometry, the method of Hayashi and Makino is presumably more 
promising, and the reason that it has not been more extensively investigated 
may be due to the general unreliability of some manual fluorescence 
techniques which can be subject to considerable interferences.
SECTION 6. INVESTIGATION OF SUITABLE FLUORESCENT PROBES 
FOR DETECTION OF GLYCATED SERUM PROTEIN.
1.6.1. Basic probe requirements.
If a fluorescent probe is to be used in any serum assay system, several 
points must be considered in order to produce the optimum assay. The probe 
should have a high fluorescence intensity and the fluorescence must be 
clearly distinguishable from background. The intensity of the fluorescence 
depends on both the absorption of excitation by the probe and on the 
quantum yield of the emission. The molar absorbance of the probe should 
be as great as possible (>10"^  1 cm'^ mol*^) and the quantum yield in an 
appropriate solvent should approach unity.
The background fluorescence found in serum has an excitation maximum 
around 340 nm and an emission maximum around 470 nm. This often 
precludes the use of dansyl chloride as a probe for serum analysis because 
its excitation and emission maxima fall within this same region.
The high protein content of serum can cause strong scattering due to the 
short excitation and emission wavelengths of various proteins (Soini & 
Hemmila, 1979), but a probe with a large Stoke's shift (>100 nm) can 
reduce this effect and make possible the use of filters as an efficient means
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of discriminating between excitation and emission wavelengths. In order to 
eliminate background interference in serum, an emission wavelength 
between 500 nm and 700 nm is preferable.
Additional criteria must then be satisfied for a probe to fit the requirements 
of the glycated protein assay:
The chosen probe needs amine selective reactivity in order to conjugate with 
the amino group on aminophenylboronic acid. This final conjugate must be 
water soluble and be sensitive to environmental changes, i.e. based on the 
assumptions of Hayashi and Makino (1985) that there is a specific binding 
site for the dansyl group, this must be a hydrophobic interaction.
1.6.2. Selection of a probe.
Most fluorescent amine reagents are either ‘activated’ derivatives of 
carboxylic or sulphonic acids, or halogen derivatives of reactive aromatic 
compounds and dichlorotriazines.
Based on data published by Haughland (1985), 13 appropriate groups of 
amine selective fluorescent probes were chosen and comparisons were made 
between the fluorescence characteristics of various compounds within these 
groups.
Table 1.6.1. lists examples of compounds within the groups and highlights 
those characteristics which do not meet the basic probe requirements as 
outlined in section 1.6.1. Unless specific data on the characteristics of probe 
conjugates was given, it was assumed that the properties of a conjugate 
would be similar to those of the native probe.
Although quantum yield values have been given in Table 1.6.1, this data 
will vary considerably depending on the solvent employed and on the final 
probe environment. The quantum yield was therefore considered to be of 
minimal importance except in the case of 4-chloro-7-nitrobenz-2-oxa-1,3- 
diazole. Here, substituents on the amino group that restrict electron
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conjugation with the benzoxadiazole nucleus (eg. the phenyl group on 
aminophenylboronic acid) cause a drastic loss of fluorescence (Ghosh and 
Whitehouse, 1968) making the compound totally unsuitable in this instance. 
The probes in groups 1-5 of Table 1.6.1 all have high absorbance maxima, 
and emission wavelengths greater than 500 nm. However, they all have a 
Stoke’s shift less than 40 nm. Groups 7-12 also have a relatively low 
Stoke’s shift, coupled with the disadvantage of emission wavelengths less 
than 500 nm.
The naphthalene amine selective group (number 13, table 1.6.1) contains 
more than one compound with a Stoke’s shift greater than 100 nm, all of 
which are particularly environmentally sensitive. The most suitable probes 
here appear to be dansyl chloride and mansyl chloride which each have only 
one drawback; dansyl chloride has a relatively low extinction 
coefficient,whilst mansyl chloride has a maximum emission wavelength of 
less than the ideal 500 nm.
The emission wavelength data for Dns-PBA / Dns-Cl from Burnett et al 
(1980), Hayashi and Makino (1985) and from Table 1.6.1 of this chapter 
indicates a shorter maximum emission wavelength for Dns-PBA than for 
Dns-Cl. It is therefore very likely that the maximum fluorescence emission 
wavelength of mansyl-PBA would be lower than that for mansyl chloride, 
resulting in increased background interference and possibly a Stoke’s shift 
of less than 100 nm. The emission wavelength maximum may then be even 
further reduced upon binding to albumin (c.f. Dns-PBA) hereby 
compounding the problem.
One other disadvantage of mansyl chloride over dansyl chloride is that it is 
100 times more expensive, so although the Molar absorbance of dansyl 
chloride is less than lO'^  1 cm'^ m ol'\ it has a very high Stoke’s shift and 
appears to be the probe most suited to conjugation with APBA for the 
determination of glycated serum protein.
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AIMS OF TfflS THESIS.
Based on the work described by Hayashi and Makino (1985) and on the 
information detailed in section 6 of this chapter, it was the aim of this thesis 
to automate the fluorometric analysis of glycated albumin in serum, to 
evaluate, optimise and standardise the analytical conditions of the assay and 
to investigate possible interfering factors. The anticipated intention was to 
produce a precise, simple, inexpensive assay, capable of processing a high 
workload of samples with the minimum of manual labour. The utility of this 
analysis for monitoring diabetic control was to be assessed by application 
to a number of different clinical situations and by comparison to established 
methodologies.
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CHAPTER 2
OPTIM ISATION OF THE FLUO ROM ETRIC ASSAY.
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Introduction
Luminescence techniques have become increasingly popular for use in 
clinical laboratories, particularly in areas where radioisotopes have been 
widely used. Although very high sensitivity can be acheived with isotopic 
analyses, the radiation involved can constitute a health risk and a special 
permit is required in order to receive the reagents. A designated area or 
laboratory is necessary to perform the analyses and the instrumentation and 
reagents are relatively expensive.
Comparable sensitivity can be acheived with luminescence measurements, 
by virtue of the fact that the emitted light is of a different wavelength to the 
incident light. In uv/visible spectrophotometry a ratio of the emitted lincident 
light is being measured and the actual assay result is derived from a small 
difference between these two large values. With luminescence techniques 
(eg. fluorescence, chemiluminescence) the emitted light is distinguishable 
from a zero baseline, hereby enhancing any small deviations and improving 
sensitivity by several orders of magnitude over conventional 
spectrophotometry. It is this level of sensitivity which has promoted the use 
of luminescence in the analysis of low levels of compounds in biological 
tissues and fluids.
Many organic compounds are intrinsically fluorescent and may be assayed 
directly, or induced to fluoresce by a slight alteration in assay conditions. 
Alternatively, fluorescent probes can be synthesised. This is relatively 
inexpensive and non-hazardous, and enables the sensitivity of fluorescence 
to be combined with the specificity of other techniques such as 
immunoassay.
The main disadvantage to the clinical application of fluorescent probes over 
radioisotopes is the background fluorescence, present in variable amounts in 
body fluids and tissues. The intensity of this background is affected by the 
many fluorescing compounds present in biological samples, particularly
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proteins. As well as fluorescing, proteins will increase the amount of light 
scattering hereby reducing sensitivity.
Spurious fluorescence can also be attributed to contamination of the sample 
by impurities in the reagents or to dirty equipment. Careful attention must 
therefore be paid to sample and reagent preparation for fluorescence 
analysis.
The high sensitivity of this technique makes it an ideal contender for 
automation as relatively minor variations in manual assay technique could 
grossly affect the final results.
Automation of the Dns-PBA assay in this chapter has facilitated the 
optimisation and full evaluation of the method which has not yet been 
established by its original instigators. The assay has been adapted in order 
to accomodate analysis of undiluted serum samples; an important 
consideration for an assay being run in a busy routine laboratory.
All possible variables within the assay have been optimised and 
investigations into the linearity, calibration, standardisation, sensitivity and 
precision of the assay have been carried out. A different approach to 
standardisation has been taken to that of Hayashi et al (1990) who have 
based their most recent results on the fluorescence intensity of the Raman 
line of water.
Standardisation of the assay has enabled reference ranges for diabetic and 
non-diabetic populations to be derived, which are essential if the Dns-PBA 
assay results are to be clinically useful.
Suitable reagent and sample storage conditions have also been established 
in this chapter, hereby helping to ensure the quality of results in later 
clinical studies.
Materials.
Equipm ent :
LS-5 Perkin Elmer Luminescence spectrometer with Perkin Elmer 561
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recorder.
Cobas Bio centrifugal analyser with fluorometric attatchment. (Roche 
Products, Welwyn Garden City, Herts.)
Edwards freeze dryer modulyo, Pirani 501.
Helena Super Z electrophoresis system (Helena Laboratories, Beaumont, 
Texas).
Elgastat Spectrum water purification system (Elga Ltd. High Wycombe 
Bucks).
Consumables :
The following blood collection tubes were obtained from Sherwood Medical, 
Crawley, West Sussex:
10ml plain glass tubes 
10ml lithium heparin tubes 
5ml fluoride oxalate tubes 
5ml potassium EDTA tubes
Dialysis tubing (29mm diameter) with a relative molecular mass cut off of 
12-14,000 Daltons was obtained from Medicell International Ltd., London.
Reagents:
All reagents were obtained from British Drug Houses Ltd, Poole, Dorset and 
were of Analar grade, unless stated otherwise.
‘Fructosamine’ Calibrator, N control (normal), and P control (pathological) 
are human based lyophilised materials with standardised levels of glycated 
protein, marketed by Roche Products (Welwyn Garden City) for use with 
the ‘Fructosamine Plus’ assay.
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SECTION 1. THE SYNTHESIS AND SPECTRAL CHARACTERISTICS 
OF DANSYL-PBA.
2.1.1. Synthesis and purification of Dns-PBA
Dns-PBA was prepared as described by Burnett, Peebles and Hagemann 
(1980):
A 3 mmol/1 solution of m-aminophenylboronic acid (Sigma Chemical Co.) 
in 70 ml of 0.75M phosphate buffer (Na2HP0 4  /  KH2PO4) pH 6.5, was 
mixed with a 3.7 mmol/1 solution of dansyl chloride (Aldrich Chemical Co.) 
in 90 ml of acetone. This mixture was incubated at 30 °C for 2 hours, after 
which time 30 mmoles of mannitol were added and the pH was adjusted to 
9.9 with Molar sodium hydroxide.
Acetone was removed by means of a rotatory evaporator, and the clear 
aqueous solution was extracted with four 30 ml portions of diethyl ether 
which were then discarded.
The aqueous layer was acidified with molar hydrochloric acid to pH 4.1 
and the resultant cloudy solution extracted with four more 30 ml portions 
of diethyl ether. These ether extracts were pooled and washed with four 20 
ml portions of deionised water. Thé ether was removed with a rotatory 
evaporator . In order to produce an amorphous green powder as described, 
the resultant green slurry was freeze dried.
A small amount of the prepared conjugate was dissolved in acetone and thin 
layer chromatography was performed on a silica gel plate (Merck, silica gel 
6 O254) in 50% aqueous acetone. This produced a single fluorescent spot when 
observed under ultra violet light.
2.1.2 In vitro glycation of human albumin.
‘Globulin-free’ albumin was obtained from Sigma Chemical Co. (Poole,
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Dorset). The purity of this albumin was confirmed using cellulose acetate 
protein electrophoresis.
A 50 mmol/1 solution of D-glucose was prepared in deionised water with 
approximately 2 mg of sodium azide, and 5 ml of this solution was added 
to 200 mg of the globulin-free albumin (40 g/1). The albumin solution was 
incubated at 37 °C for 3 days then dialysed against 2 changes of 0.9% saline 
(250 ml) over 7 hours at 4 °C. Following dialysis, less than 1.0 mmol/1 
glucose remained in the glycated albumin solution.
2.1.3. Fluorescence spectra of Dns-PBA
Reagents were prepared as described by Hayashi and Makino (1985):
Reagent A: 0.6 p.mol/1 Dns-PBA (Sigma Chemical Co. or synthesised 
c o n j u g a t e )  p r e p a r e d  i n  5 0  m m o l /  ) H E P E S  
(hydroxyethylpiperazineethanesulphonic acid, (Sigma Chemical Co.) , pH
8.5.
Reagent B: 50 mmol/1 boric acid, prepared in reagent A, pH 8.5.
pH adjustments to 8.5 were made using 5M sodium hydroxide.
Reagents A and B were prepared from both Dns-PBA purchased from 
Sigma, and from that synthesised in the laboratory. Each reagent was 
scanned for maximum excitation and emission wavelengths between 300 and 
700 nm, using a scanning spectrofluorometer.
Additional scans were performed following a 4 minute incubation at 20 °C 
with 1.7 p.mol/1 in vitro glycated albumin in the final solution.
Fig 2.1.1 shows the emission spectra obtained using the synthesized Dns- 
PBA with excitation at 330 nm. The addition of glycated albumin caused an 
emission shift from 510 nm to 470 nm being reduced with reagent B.
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A
Figure 2.1.1. Dns-PBA assay fluorescence emission spectra.
I
f
•tIcI0
1  
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660 470510 330
Emission wavelength (nm)
Fluorescence spectra of a) 1.7 |xmol/l human serum albumin plus reagent A, 
b) 1.7 jimol/l human serum albumin plus reagent B, c) reagent A or reagent 
B with no additions. Excitation was at 330 nm.
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Additional peaks observed at 350 and 370 nm did not alter throughout and 
were due to fluorescence of free APBA in the solution which has a 
maximum excitation wavelength of 340 nm. The peak observed at 330 nm 
is due to Tyndall and Rayleigh scattering of the excitation wavelength. 
Identical profiles were obtained using the Dns-PBA purchased from Sigma 
Chemical Company but the fluorescence intensities of the 510 nm and 470 
nm emission peaks were lower than those for synthesised Dns-PBA and the 
peaks observed at 350 and 370 nm were higher. This indicates a higher 
degree of contamination with APBA in the Sigma compound, and may be 
reflecting the breakdown of Dns-PBA with time as the synthesised Dns-PBA 
had been freshly prepared.
The fluorescence emission at 510 nm, of an equivalent concentration of 
Dns-PBA prepared in acetone was approximately double that observed in 
the aqueous environment, hereby confirming the possibility of a hydrophobic 
interaction being responsible for the change in fluorescence intensity in the 
glycated albumin assay.
A fresh supply of Dns-PBA was purchased from Sigma and used throughout 
this thesis for the preparation of reagents A and B, unless stated otherwise.
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SECTION 2. VARIATION OF EXPERIMENTAL CONDITIONS.
2.2.1 Automation of the Dns-PBA assay using the Cobas Bio.
The assay described by Hayashi and MaJdno (1985) was automated on a 
Cobas Bio centrifugal analyser with fluorometric attachment, using a simple 
end-point type of analysis. The photomultiplier voltage was set using a high 
response sample.
All serum samples were diluted 1:4 in HEPES buffer (50 mmol/1, pH 8.5) 
prior to analysis using the following parameters:
1. Units OWN
2. Calculation factor 1000
3. Standard 1 concentration 0
4. Standard 2 concentration 0
5. Standard 3 concentration 0
6. Limit 0
7. Temperature °C 25
8. Type of analysis 1
9. Wavelength (excitation) nm 330
(emission) filter position 2 (490nm)
10. Sample volume p-1 3
11. Diluent volume jiil 22
12. Reagent volume ill 370
13. Incubation time sec. 0
14. Start reagent volume 0
15. Time of first reading sec. 0.5
16. Time interval sec. 30
17. Number of readings 7
18. Blanking mode 0
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19. Printout mode 1
Use of the multi run facility on the Cobas Bio enabled each sample to be 
assayed twice within each run; once with reagent A and once with reagent 
B. The reagents were exchanged manually at the pertinent time and DF 
results (reagent A - reagent B results) were calculated from these values. 
The emission filter pre-fitted to the analyser covered the wavelengths of 450 
+ 45 nm.
2.2.2 Buffer selection, concentration and pH.
A change in the pH of a solution can lead to a change in the ionisation of 
a compound’s substituent groups, thereby modifying its fluorescence 
characteristics. The effect of altering pH on the Dns-PBA assay was 
therefore investigated. In order to cover a wide pH range, 5 different 
buffers were studied. The effect of pH on Dns-PBA in water was also 
investigated, to try and characterise any ionizations which may have been 
occurring.
All buffer pH adjustments were made with 6 mol/1 HCl or 5 mol/1 NaOH. 
Solutions prepared in water were adjusted with 0.05 mol/1 HCl or 0.05 mol/1 
NaOH.
2.2.2.I. The effect of pH on Dns-PBA fluorescence.
A 2.5 iimol/1 solution of Dns-PBA was prepared from a 50 iimol/1 stock 
solution , in deionised water. Aliquots of this solution were adjusted to a 
range of pH values between 5.5 and 10.5 and were analysed in duplicate on 
the Cobas Bio as the assay reagent, with deionised water in the sample cups. 
This experiment was then repeated with the addition of 50 mmol/1 boric acid 
to each reagent. The pH values were readjusted to the same range.
Both sets of reagents (with and without boric acid) were also used for
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duplicate analyses of an in vitro glycated albumin solution. Results of these 
4 runs are shown graphically in Figure 2.2.1. This shows a peak in 
fluorescence emission of Dns-PBA at pH 9.0, which is unaffected by the 
presence of boric acid. On addition of glycated albumin, the fluorescence 
response for both reagents is increased, with a peak at pH 9.0 in the absence 
of boric acid.
Fluorescence scans performed on each aliquot of reagent using a manual 
spectrofluorometer, were able to confirm that shifts in emission maxima 
with varying pH were not responsible for the observed peak of Dns-PBA 
fluorescence on the Cobas Bio.
2 .2 .2 .2 , H E PE S  b u ffe r  (N -2 -h y d ro x y e th y Ip ip e ra z in e -N ’-2- 
ethanesulphonic acid).
pKa = 7.5, useful pH range 6.8 - 8.2.
A stock solution of Dns-PBA (60 |imol/l) was prepared in HEPES buffer 
(50 mmol/1) at pH 7.0. Reagents A and B (0.6 iimol/1 Dns-PBA) were 
prepared by diluting this stock in HEPES and adjusting the pH to give a 
range between 7.0 and 8.5.
A solution of in vitro glycated albumin was assayed on the Cobas Bio, in 
duplicate, at each pH.
Results shown in Figure 2.2.2 indicate an optimum pH of 8.3 for this buffer 
and show a high degree of pH dependence: adjustment of the pH from 7.9 
to 8.3 results in over a 30% increase in DF value.
2.2.2.3. Bicine buffer (N,N,-bis[2-Hydroxyethyl]glycine). 
pKa = 8.3, useful pH range 7.6 - 9.0.
Reagents were prepared as in 2.2.2.2, substituting bicine buffer (Sigma 
Chemical Co.) for HEPES, to produce a pH range from 7.6 to 9.0. Analysis
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FIG. 2.2.1: The effect of pH on Dns-PBA 
fluorescence in water, in the presence 
and absence of glycated albumin (GA).
1200 n
Î 900 -
II
300 -I
~S- -GA -Boric -GA +Boric -©- +GA -Boric +GA +Boric
Samples of deionised water, or an in vitro glycated albumin solution, were 
assayed using i S  jiimol/l Dns-PBA, prepared in water ± 50 mmol/1 boric 
acid. Points represent the mean values of duplicate analyses.
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FIG.2.2.2: pH profile of DF results for
glycated albumin, assayed in HEPES
buffer.
400-1
6  300-
3
200
8.0 8.5 8.0
pH
FIG.2.2.3: pH profile of DF results for 
glycated albumin, assayed in bicine 
buffer.
i
Q
100
8.0 9.0
pH
Points represent mean values of duplicate results obtained with 0.6 jimol/l 
Dns-PBA, 50 mmol/1 boric acid.
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of in vitro glycated albumin as in the previous paragraph gave the results 
shown in Figure 2.2.3.
These results showed much less pH dependency than those for HEPES 
buffer, the general trend being towards decreasing DF values with increasing 
pH.
2.2.2A  EPPS buffer (N-[2-HydroxyethyI]-piperazine-N’[3-
propanesulphonic acid]).
pKa = 8.0, useful pH range 7.3 - 8.7.
Reagents were prepared as in 22.2.2, substituting EPPS buffer (Sigma 
Chemical Co.) for HEPES, to produce a pH range from 7.3 to 8.7. Analysis 
of in vitro glycated albumin gave the results shown in Figure 2.2.4. As with 
the HEPES results, a small change in pH here could cause a large difference 
in DF values.
2,22,5. MES buffer (2-[N-Morpholino]ethanesuIphonic acid). 
pKa = 6.1, useful pH range 5.5 - 6.7.
Reagents were prepared as in 2.2.2.2, substituting MES buffer (Sigma 
Chemical Co.) for HEPES, to produce a pH range from 5.5 to 6.7. Analysis 
of in vitro glycated albumin gave the results shown in Figure 2.2.5. There 
was very little change in DF response at any pH below 6.5.
2.2.2.6. AM P buffer (2-amino-2-methyl-l-propanoI). 
pKa = 9.7, useful pH range 9.0 - 10.5.
Reagents were prepared as in 2.2.2.2, substituting AMP buffer (Sigma 
Chemical Co.) for HEPES, to produce a pH range from 9.2 to 10.4. 
Analysis of in vitro glycated albumin gave the results shown in Figure 2.2.6.
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FIG.2.2.4: pH profile of DF results for
glycated albumin, assayed in EPPS
buffer.
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FIG.2.2.5: pH profile of DF results for 
glycated albumin, assayed in MBS buffer.
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Points represent mean values of duplicate results obtained with 0.6 p,mol/l 
Dns-PBA, 50 mmol/1 boric acid.
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FIG.2.2.6: pH profile of DF results for
glycated albumin assayed in AMP buffer.
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FIG.2.2.7: Comparison of patient serum 
& in vitro glycated albumin DF response 
in various buffers at optimum pH.
II
Q
e.S 7.0 7 J S  8.0 8.5 9
Optimum pH (various buffers)
•  Glycated albumin ■ Serum
9.5
Points represent mean values of duplicate results obtained with 0.6 p.mol/1 
Dns-PBA, 50 mmol/1 boric acid.
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The most obvious pH effect with this buffer appears to be at its pKa, with 
pHs above 9.7 giving lower DF values than those below pH 9.7.
2.2.2.7. Buffer comparisons at optimum pH.
The pH optima for the 5 buffers, based on maximum DF values, were 
judged to be as follows:
HEPES pH 8.4
Bicine pH 7.8
EPPS pH 8.0
MES pH 6.7
AMP pH 9.2
A 60 p-mol/1 stock solution of Dns-PBA was prepared in deionised water. 
Reagents A and B (0.6 pimol/1 Dns-PBA) were prepared from this stock in 
each of the 5 buffers (50 mmol/1). Each set of reagents was then adjusted 
to its own optimum buffer pH. Reagent B contained 50 mmol/1 boric acid 
in all cases.
All 5 buffers were incorporated into one run on the Cobas Bio for the 
analysis of a patient’s serum sample and the in vitro glycated albumin 
solution.
Figure 2.2.7 demonstrates the equivalent response of human serum to that 
of in vitro glycated albumin when assayed in the different buffers. 
Fluorescence emission scans of human serum were performed using the 
manual fluorometer for a comparison of responses in each buffer. The serum 
emission peaks are summarised in Table 2.2.1 and no additional peaks were 
observed. From Table 2.2.1 it can be seen that analysis of samples in AMP 
buffer (pH 9.2) gave the lowest, and MES buffer (pH 6.7) gave the highest 
wavelength emission maxima. These two buffers are at either extreme of the
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Table 2.2.1. Serum emission peaks of the Dns-PBA assay in various 
buffers at optimal pH.
BUFFER BUFFER MAXIMUM EMISSION WAVELENGTHtnm)
pH Reagent A Reagent A Reagent B Reagent B
+ serum + serum
AMP 9.2 506 462 504 462
BICINE 7.8 526 470 526 466
EPPS 8.0 510 472 510 470
HEPES 8.4 510 470 512 470
MES 6.7 530 486 530 482
Results were obtained from a scanning spectrofluorometer:
Serum (20 p,l) was added to 3 ml assay reagent and incubated for 4 minutes 
at 20 °C prior to excitation at 330 nm.
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pH range studied and the results are suggestive of changes in ionisation of 
the Dns-PBA.
A comparison of the various buffer DF results when samples were assayed 
on the Cobas Bio, is shown in Table 2.2.2. The percentage specific binding 
to albumin was calculated from the following formula:
Reagent A result - Reagent B result x 100 
Reagent A result
This parameter shows the most specific binding detected in the presence of 
AMP buffer for both the patient sample and the in vitro glycated albumin, 
although the highest emission intensities were found with HEPES buffer. 
The high specific binding results for AMP buffer and the low results for 
MES buffer can be explained by the differences in emission maxima: Figure 
2.2.8 shows the appearance of a typical emission spectrum (emission max. 
= 470 nm) within the window defined by the Cobas Bio emission filter. It 
can be seen that as the maximum emission wavelength decreases (as with 
AMP) more light passes through the filter, including the wavelength 
frequencies where the maximum difference between reagent A and reagent 
B results occur. Similarly, the increase in emission wavelength observed 
with MES buffer results in the peaks moving out of the filter window.
The advantages and disadvantages of each buffer system, for use in the Dns- 
PBA fluorescence assay, are set out in Table 2.2.3. From this information, 
either AMP or bicine buffer would appear to be most suitable. Bicine buffer 
was finally selected in preference to AMP as the bicine showed less pH 
dependence around its pKa, where it would give the most effective buffering 
capacity. pH 8.0 was chosen as the overall optimum for this buffer, 
providing a compromise between the slightly higher DF values obtained at 
lower pH and the pKa of 8.3.
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Table 2.2.2. Fluorescence results and specific binding of Dns-PBA for 
analysis of in vitro glycated albumin and a patient sample in various 
buffers.
BUFFER FLUORESCENCE VALUES DF SPECIFIC
Reagent A Reagent B BINDING
{ AMP 811 661 150 18%
Patient { BICINE 805 716 89 11%
Sample { EPPS 912 835 77 8%
{ HEPES 988 898 90 9%
{ MES 786 762 24 3%
{ AMP 1006 714 292 29%
Glycated { BICINE 974 767 207 21%
Albumin { EPPS 1118 926 192 17%
{ HEPES 1179 965 214 18%
{ MES 688 570 118 17%
Results were obtained from the Cobas Bio analyser.
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Figure 2.2.8. Dns-PBA assay emission spectra within the 450 ± 45 nm 
filter window.
§
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Emission peaks obtained by fluorometric analysis of serum using reagents 
A and B (0.6 |xmol/l Dns-PBA, 50 mmol/1 boric acid).
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Table 2.2.3. Advantages and disadvantages of various buffer systems for 
the Dns-PBA assay on the Cobas Bio.
BUFFER ADVANTAGES DISADVANTAGES
AMP High DF values. pH optimum at limit of 
buffer capacity.
BICINE Good DF values, 
pH optimum within 
buffering capacity, 
pH is robust.
EPPS Reasonable DF values. pH not robust.
HEPES Good DF values. pH optimum out of 
effective buffering 
range.
pH not robust.
MES pH optimum at limit of 
buffering capacity, 
poor DF values.
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2.2.2.S. Bicine concentration and analysis of undiluted serum.
In the original Dns-PBA assay (Hayashi and Makino, 1985) HEPES buffer 
was used at a concentration of 50 mmol/1.
The buffer concentration used needs to be sufficient to buffer the addition 
of a small volume of human serum whilst causing as little as possible 
interference to the ensuing chemical reaction. A buffer concentration of 25 - 
100 mmol/1 is normally sufficient in such a system.
A 1 mol/1 solution of bicine was prepared in deionised water. This stock 
solution was diluted as appropriate to give 6 bicine solutions of 0, 25, 50, 
100, 200, 500 and 1000 mmol/1, all adjusted to pH 8.0. Solutions of Dns- 
PBA (2.4 limol/1) were prepared in all 6 buffers as reagent A. Reagent B 
contained 50 mmol/1 boric acid.
A sample of ‘Fructosamine’ P control was assayed in duplicate, undiluted, 
with all 6 buffer concentrations. The results shown in Figure 2.2.9 
demonstrate that an increase in bicine concentration causes a decrease in the 
fluorescence intensity for reagents A and B. The DF value (reagent A - 
reagent B) appears to plateau between 25 and 200 mmol/1 bicine so the 
concentration being used in the previous assays (50 mmol/1) should be 
adequate to produce a robust assay, without causing unnecessary 
interference. It is unlikely that more buffering capacity will be required 
when serum of pH 7.4 (approx.) is added in this 1:130 dilution.
During this study, serum was assayed undiluted and the Dns-PBA 
concentration was increased accordingly from 0.6 pmol/1 to 2.4 p.mol/1.
2.2.3. Dns-PBA concentration.
Reagents A and B were prepared from a 60 p.mol/1 stock solution of Dns- 
PBA in 50 mmol/1 bicine buffer pH 8.0. Reagent B contained 50 mmol/1 
boric acid.
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FIG. 2.2.9: The effect of varying bicine
concentration on fluorescence results.
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Points represent mean values of duplicate results for fructosamine P (high) 
control, assayed with 2.4 [imol/l Dns-PBA.
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‘Fructosamine’ P control was assayed undiluted for DF, in triplicate, with 
varying Dns-PBA concentrations between 0.0 and 3.0 [imol/1. Results are 
shown in Figure 2.2.10 and are in accordance with those found by Hayashi 
and Makino (1985) assaying serum albumin in HEPES. From Figure 2.2.10, 
a Dns-PBA concentration of 2.5 |xmol/l was deemed to be sufficient for the 
analysis of undiluted patient samples.
2.2.4. The effect of heat on Dns-PBA reagents.
In order to completely dissolve Dns-PBA in aqueous buffer, it was found 
necessary to heat the solution in a water bath at 80 °C. Although the 
compound would generally dissolve within 5 minutes when immersed at this 
temperature, the effect of continued heating on the Dns-PBA fluorescence 
intensity was examined in order to determine how precisely this procedure 
needed to be performed.
Dns-PBA (1.85 mg) was added to 100 ml bicine buffer (50 mmol/1, pH 8.0) 
and placed in an 80 °C water bath until completely dissolved. (50 p^mol/1 
Dns-PBA). An aliquot of this stock solution was removed at intervals and 
diluted 1:20 to produce 2.5 [imol/1 Dns-PBA as reagent A. Reagent B was 
prepared from this solution by the addition of 50 mmol/1 boric acid. Each 
reagent so prepared was used for duplicate analysis of a blank buffer 
sample, and a diabetic patient’s serum sample with a high glycated protein 
level.
Although the blank results did not alter throughout the study, the results 
shown in Fig. 2.2.11 indicate that due to a decrease in total binding of Dns- 
PBA in the serum sample (reagent A results), the DF result starts to 
decrease after 15 minutes at 80 °C. This may be due to breakdown of the 
Dns-PBA to a level below that required to assay the diabetic sample.
The procedure of dissolving the Dns-PBA at 80 °C was therefore 
standardised at 5 minutes for all future preparations.
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FIG. 2.2.10: The effect of varying
Dns-PBA concentration on DF results.
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Points represent mean values of triplicate results obtained using 
fructosamine P (high) control.
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2.2.5. Boric acid concentration.
Having increased both the serum volume and the Dns-PBA concentration for 
the fluorometric assay, it was necessary to establish the boric acid 
concentration required, to produce a reliable assay blank from reagent B. 
Reagent A (2.5 p-mol/1 Dns-PBA) was prepared in bicine (50 mmol/1, pH
8.0) and used to prepare reagent B containing 100 mmol/1 boric acid (pH
8.0). These 2 reagents were then combined to produce a range of 10 boric 
acid concentrations from 10 -1 0 0  mmol/1. Samples of ‘Fructosamine’ N 
control and P control were assayed undiluted , using each concentration of 
reagent B to give the results shown in Figure 2.2.12.
For both the high and low levels of glycated proteins, 50 mmol/1 boric acid 
was still sufficient to block the specific binding of Dns-PBA . This 
concentration was therefore used in all future assays.
2.2.6. Cobas Bio emission filter assessment.
When the Cobas Bio centrifugal analyser is fitted with the fluorescence 
option a 90 nm bandwidth emission filter is prefitted to the analyser, which 
is compatible for use with many commercial kit assays, enabling 
measurement of a variety of analytes.
This emission filter covers the range of 405 - 495 nm wavelengths and has 
therefore been suitable in this study for the detection of wavelength maxima 
at 470 nm. The position of the relevant emission peaks within this window 
for the Dns-PBA assay are shown in Figure 2.2.8. From this figure it can be 
seen that there is a substantial amount of overlap of the 2 peaks (reagent A 
and reagent B) being detected below 435 nm. Use of a narrower bandwidth 
emission filter could therefore eliminate this possible cause of error, and by 
increasing the ratio of specific to non-specific Dns-PBA binding hereby 
improve the sensitivity and the precision of the assay.
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FIG 2.2.11: The effect of prolonged 
heat on preparation of Dns-PBA reagents 
for assay of samples.
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Points represent mean values of duplicate results obtained for a high 
response diabetic sample, assayed with 2.5 jxmol/l Dns-PBA.
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FIG. 2.2.12: The effect of varying boric
acid concentration on reagent B results.
700-1
I
1 600 -
8I
500
0 20 40 60 80 100 120
[Boric acid] mmol/1 
P control N control
Points represent results obtained for fructosamine N (low) and P (high) 
control, assayed with 2.5 jxmol/l Dns-PBA.
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To this end, a range of 16 diabetic and non-diabetic patient serum samples 
were scanned for their emission maxima under the predetermined assay 
conditions. The results gave a mean value ± standard deviation (mean ± SD) 
of 470 ± 4 nm, hereby confirming earlier results.
An emission filter to the specification of 470 ± 20 nm was purchased from 
Roche Diagnostics and fitted to the Cobas Bio in order to perform a 
comparison with the original filter.
2.2.6.I. Adaptation of the assay for the 470 ± 20 nm emission filter.
Initial investigations with the 470 ± 20 nm filter, using the predetermined 
assay conditions, showed that the narrower emission bandwidth reduced the 
detected fluorescence emission by over 90% when compared to the 450 ± 
45 nm filter. This necessitated individual adjustments to the photomultiplier 
(PM) voltage on the Cobas Bio, for each filter.
Assay sensitivity was investigated with each filter by analysing double 
dilutions of a diabetic serum sample in saline. The DF results shown in 
Figure 2.2.13 indicate a lack of sensitivity being shown with the narrow 
emission filter, implying that the higher PM voltage was unable to 
compensate for the large decrease in emitted light reaching the 
photomultiplier.
An alternative approach was taken in order to increase the amount of light 
reaching the photomultiplier via the 470 ± 20 nm filter:
Dns-PBA concentration and serum volume were both increased 10 fold to 
give 25 [imol/1 Dns-PBA and 30 p.1 serum per assay. A range of boric acid 
concentrations from 50 - 500 mmol/1 were prepared in this reagent A and 
analysis of a diabetic patient’s serum indicated that 300 mmol/1 boric acid 
was adequate to estimate non-specific binding, although use of this 
concentration resulted in a positive saline blank of approximately 17 DF 
units.
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FIG. 2.2.13: Comparison of DF results 
using 2 different bandwidth emission 
filters on the Cobas Bio.
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Points represent results obtained for a diabetic sample assayed with 2.5 
(xmol/I Dns-PBA. The regression line is fitted to the results for the 450 ± 45 
nm filter (y = 87.3x + 0.6, r = 0.997).
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Using these revised conditions, the PM voltage on the Cobas Bio could be 
set to a value more comparable to that achieved with the original filter, and 
a linear response was achieved for a serum dilution down to 1:4.
2.2.6.2. Comparison of assay imprecision using the 90 nm and 40 nm 
bandwidth emission filters.
Within batch precision of DF results was assessed by the analysis of 3 
samples with a wide range of glycated protein levels.
Each sample was assayed 14 times within one run on the Cobas Bio using 
either:
Test no. 1:- 450 ± 45 nm filter
2.5 p.mol/1 Dns-PBA 
50 mmol/1 boric acid 
3 p,l plasma 
OR
Test no. 2:- 470 ± 20 nm filter
25 p.mol/1 Dns-PBA 
300 mmol/1 boric acid 
30 p.1 plasma
The results shown in Table 2.2.4 indicate very little difference in precision 
between the 2 assays, particularly at the borderline diabetic /  non-diabetic 
intermediate level.
Serum albumin levels were measured on samples using a bromocresol green 
dye binding method (Rodkey, 1965) automated on the Cobas Bio. DF results 
were divided by serum albumin levels (g/1) to give corrected results of 
DF/g/1.
100
Table 2.2.4. Comparison of witbin-batcb imprecision at 3 levels, using 
2 different emission filters on tbe Cobas Bio.
450 ± 45nm filter 470 ± 20nm filter
Mean ± SD %CV Mean ± SD %CV
{ Reagent A 629 ± 5 0.8 714 + 7 0.9
Low { Reagent B 559 ± 6 1.2 648 + 6 1.0
{ DF 70 + 8 11.6 66 ± 6 9.0
{ DF/g/1 2.05 ± 0.25 12.1 1.93 ± 0.20 10.4
{ Reagent A 725 ± 6 0.8 804 + 4 05
Med { Reagent B 602 ± 4 0.6 675 + 7 1.1
{ DF 123 + 7 5.7 129 ± 7 5.6
{ DF/g/1 3.38 + 0.25 7.4 3.53 + 0.25 7.1
{ Reagent A 939 ± 6 0.6 1042 ±  9 0.9
High { Reagent B 717 ± 4 0.6 794 + 10 12
{ DF 222 + 7 3.3 249 + 7 3.0
{ DF/g/1 6.04 ± 0.18 2.9 6.76 + 0.32 4.8
n=14, at each level: Low, Medium (Med) and High.
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2.2.6.3. Comparison of assay accuracy and sensitivity using the 90 nm 
and 40 nm bandwidth emission filters.
Using established affinity chromatography techniques described in chapter 
3 of this thesis, 17 serum samples (from both diabetic and non-diabetic 
patients) were assayed for % glycated albumin (%GA) and % glycated total 
protein (%GTP). The same samples were also analysed by the fluorometric 
method using both emission filters and their associated assay conditions. 
DF/g/1 results were correlated with both %GA and %GTP results by linear 
regression.
The results shown in Table 2.2.5 indicate a better correlation of results with 
both %GA and %GTP for DF/g/1 values obtained using the wider bandwidth 
filter. The higher y intercept values observed with the narrow bandwidth 
filter are reflecting the positive blank values obtained with the more 
concentrated boric acid in reagent B.
The 17 samples assayed using both emission filters were divided into 
diabetic (n=8) and non-diabetic (n=8) groups. One sample, from a pregnant 
diabetic, was excluded. A mean DF/g/1 value was calculated for each group 
using each filter. Results obtained using the 450 ± 45 nm filter gave a 
diabetic mean 1.9 times higher than the non-diabetic mean, whereas results 
obtained using the 470 ± 20 nm filter gave a diabetic mean only 1.6 times 
higher than the corresponding non-diabetic mean.
The narrower bandwidth emission filter therefore has no beneficial effect on 
the discriminating power of the fluorometric assay.
2.2.6.4. Selection of Cobas Bio excitation wavelength and fluorescence 
emission filter.
From the investigations described in this section, the narrower bandwidth 
emission filter shows no advantages over the wider one. Selection of the
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Table 2.2.5. Correlation of DF/g/1 results (using 2 different emission 
filters) with affinity chrom atography data.
Test no. 1 Test no. 2
450 + 45nm filter 470 ± 20nm filter
DF/g/1 vs %GA y = 0.38% + 0.54 y = 0.32% + 0.71
r  = 0.955 r  = 0.881
DF/g/1 vs %GTP y = 0.39% - 0.42 y = 0.32% - 0.07
r  = 0.972 r  = 0.897
%GA = % glycated albumin (affinity chromatography) 
%GTP = % glycated total protein (affinity chromatography) 
n = 17.
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narrow filter would also involve additional expense in setting up the 
fluorometric assay on this particular analyser.
All further studies were therefore performed using the prefitted 450 ± 45 nm 
filter.
Using the optimised assay conditions, fluorometric scans were performed on 
reagents A and B, both with and without the addition of diabetic serum. 
Serum (2 p.1) was added to 3 ml reagent, mixed and incubated at 20 °C for 
4 minutes prior to scanning. Results of the excitation and emission maxima 
are shown in Table 2.2.6.
These results indicate a shift in the maximum excitation wavelength as well 
as the maximum emission wavelength on addition of serum. The shift in 
excitation wavelength warranted further investigation on the Cobas Bio:
A group of 24 serum samples were analysed using the optimised assay on 
the Cobas Bio, once with an excitation wavelength of 330 nm and once at 
355 nm. There was no statistically significant difference between reagent A 
values, reagent B values or DF results using the two different wavelengths 
although they all showed a slight mean increase with the 355 nm filter. 
Subsequent assays were performed with an excitation wavelength of 330 nm 
in order to give a larger Stoke’s shift.
2.2.7. The time course of the fluorom etric assay.
Parameters on the Cobas Bio were reset to take 20 readings at 30 second 
intervals over a period of 10 minutes.
A diabetic serum sample and a non-diabetic sample were assayed using 
reagent A and reagent B. Results of the reaction time course are shown in 
Figure 2.2.14 for the diabetic sample.
This figure shows that although a slight increase in fluorescence is still 
occurring after 180 seconds (the end-point taken for all previous studies), 
this increase is parallel for reagents A and B, hereby cancelling out any
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Table 2.2.6. Excitation and émission maxima for the optimised Dns-PBA 
assay.
Excitation Emission
maximum (nm) maximum (nm)
Reagent A 
Reagent B 
Reagent A + serum 
Reagent B + serum
340
340
355
355
524
526
470
470
Results were obtained from a scanning spectrofluorometer:
Reagents (3 ml) were scanned with and without the addition of 20 p-1 serum.
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FIG. 2.2.14: Dns-PBA fluorescence assay 
time course for a diabetic serum sample.
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Points represent results obtained for a diabetic sample assayed with 2.5 
ILimolA Dns-PBA.
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effect on DF.
Analysis of 14 different patient samples using data taken from the 180 
second reading and the 570 second reading gave results that were not 
significantly different by Student’s paired t-test.
The end-point of 180 seconds was therefore judged to be adequate for all 
future analyses.
2.2.8. Sum m ary of optimised Dns-PBA fluorom etric assay param eters.
For automation on the Cobas Bio centrifugal analyser, the parameter listing 
remains as it appeared earlier in this chapter (section 2.2.1).
Reagents, prepared as follows, are stored in brown glass bottles at 4 °C:
Reagent A:- 2.5 |imol/l Dns-PBA prepared in 50 mmol/1 bicine, pH 8.0. 
Reagent B:- 50 mmol/1 boric acid prepared in reagent A, pH 8.0.
Undiluted serum is assayed by both reagent A and reagent B on the same 
run. Reagent B results are subtracted from reagent A results to give a DF 
value. DF is divided by the serum albumin result in g/1 to give DF/g/1. 
The emission filter fitted to the Cobas Bio in position 2 is 450 ± 45 nm. 
Unless stated otherwise, these conditions have been used throughout the 
remainder of this thesis for the determination of DF and DF/g/1 results.
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SECTION 3. LINEARITY. CALIBRATION AND STANDARDISATION 
OF THE DANSYL-PBA ASSAY.
2.3.1. In vitro glvcation of human citrated plasma and preparation of 
assay standards.
In order to standardise results from the Dns-PBA assay between runs, 2 
assay standards were prepared.
Commercially produced materials in use for standardisation of other routine 
biochemical analyses were not suitable as glycated serum protein levels are 
not commonly catered for. Although materials produced specifically for use 
in glycated protein assays are expensive, calibration and control sera 
produced by Roche Diagnostics for use in the ‘Fructosamine Plus’ test were 
originally assessed for their suitability in the Dns-PBA assay. These samples 
did prove to be compatible with the fluorescence assay but they were not 
incorporated as assay standards due to the frequency with which the 
manufacturers changed sample batches and lot numbers.
Fresh frozen plasma (200 ml) was obtained from the National Blood 
Transfusion Service (Tooting, London). This human plasma had been treated 
with citrate as an anticoagulant.
The plasma was allowed to defrost at room temperature and sodium azide 
(0.04g) was added. The plasma was then divided into 2 aliquots of 100 mis, 
to one of which was added D-glucose to a concentration of 50 mmol/1. This 
sample was incubated at 37 °C for 3 days in order to produce a high 
glycated protein standard. The remaining 100 ml of plasma was stored at 4 
°C, to be used as a low glycated protein standard.
Following these incubations, the aliquots of plasma were dialysed separately, 
each against 3 changes of 0.9% saline (1 litre) over 24 hours at 4 °C. This 
ensured removal of citrate (anticoagulant), azide and glucose.
The resultant glucose concentrations in the dialysates were measured using
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a glucose dehydrogenase method (Banauch et al, 1974) on the Cobas Bio 
analyser. Glucose levels of the dialysates were 1.7 mmol/1 for the high 
standard and less than 1.0 mmol/1 for the low standard.
These 2 standard solutions were vortex mixed and centrifuged at 3,000 rpm 
for 10 minutes, prior to being put into 5 ml glass vials in aliquots of 2 ml. 
These samples were freeze-dried and sealed with plastic bungs, whilst still 
under vacuum.
The resultant high and low glycated protein standard materials were stored 
at 4 °C and reconstituted with 2 ml of deionised water when required. Once 
reconstituted, samples were stored at 4 °C and used for up to 5 days.
2.3.2. Quality control material.
Quality control (QC) material was prepared in-house, due to the expense of 
commercial preparations.
Serum obtained from 10 healthy, non-diabetic laboratory staff was pooled 
to produce approximately 90 ml of a low glycated protein QC. A volume 
of 75 ml was also obtained by pooling serum from diabetic patients with 
particularly poor glycaemic control, for use as a high glycated protein QC. 
A 35 ml aliquot from the diabetic pool was added to 25 ml from the non­
diabetic pool to produce a medium level glycated protein QC.
After thorough mixing, each control pool (normal, medium and diabetic) 
was pipetted into 5 ml glass vials in T m l aliquots and freeze-dried. The 
vials were sealed with plastic bungs whilst still under vacuum.
The resultant control materials were stored at 4 °C and reconstituted with 
1 ml deionised water when required. Due to the short supply of these 
control materials, each 1 ml sample was reconstituted when required, then 
divided into 6 aliquots of approximately 150 |x l , which were frozen at -20 
°C for use over the following 14 days.
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2.3.3. Calibration of the Dns-PBA assay using the reducing properties 
of glycated albumin on nitroblue tétrazolium.
Although the ‘Fructosamine’ method for the measurement of glycated serum 
proteins has been shown not to be completely reliable (Flückiger et al, 1987; 
Schleicher et al, 1988; Zoppi et al, 1987), the principle of the reaction is 
valid for measurement of isolated proteins, as it is the effect of the serum 
matrix and total protein profiles that can cause variability of results.
If the Dns-PBA assay is truly capable of measuring glycated albumin, it 
should be possible to calibrate the fluorescence assay from the fructosamine 
results when pure glycated albumin is assayed.
The ‘Fructosamine Plus’ assay as marketed by Roche Diagnostics uses a 
human serum calibrator based on glycated albumin results expressed in 
jimol/1. The following experiment confirms the plausibility of this type of 
calibration being applied to the Dns-PBA assay.
Double dilutions of in vitro glycated albumin solution (as prepared in 
section 2.1.2) were made with bicine buffer (50 mmol/1, pH 8.0) down to 
a 1:16 dilution. Each dilution plus a buffer blank was assayed by the 
‘Fructosamine Plus’ method and by the Dns-PBA method, in duplicate. The 
resulting calibration curve is shown in Figure 2.3.1 which indicates very 
well that the same information is being derived from each assay and that if 
the fluorescence method can be shown to be measuring glycated albumin 
alone, when in a serum matrix, this would be a possible means of 
converting DF results into |xmol/l.
2.3.4. Linearity studies for the optimised Dns-PBA assay.
Analysis of the glycated albumin dilutions prepared in 2.3.3, using the 
optimised Dns-PBA assay gave linear results (y=218jc-6, r=0.997).
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In order to investigate the assay linearity in a serum matrix, double dilutions 
of the ‘Fructosamine’ P control were prepared, in both deionised water and 
in ‘Fructosamine’ N control. The mean results for duplicate analyses of each 
sample are shown in Figure 2.3.2 for the aqueous matrix , and in Figure 
2.3.3 for the serum matrix.
Linearity of DF was demonstrated for both the aqueous and the serum 
matrix dilutions. These figures show the effect of the serum matrix in 
maintaining a constant amount of quenching /  inner filter effects, in 
comparison to the aqueous dilutions where these effects have caused a 
curved response. Linearity was also obtained with a diabetic patient’s 
sample in aqueous dilution. (y=149jc+3, r=0.996).
The results of this study therefore confirm the linearity of the method for 
analysis of serum and indicate that any samples found to exceed the top 
limit of the assay (as determined by the photomultiplier voltage) can be 
diluted 1:2 in deionised water to obtain a DF value.
2.3.5. Standardisation of the Dns-PBA assay.
Having established the linearity of the Dns-PBA assay for analysis of 
untreated serum samples, it was feasible to standardise the assay using 3 
linear standards. It was not possible to obtain primary standards for this 
assay as it is not known what the analysis is actually measuring.
By using a saline blank and the 2 assay standards prepared in section 2.3.1, 
the assay could be standardised for use throughout this thesis by assigning 
DF values to each standard. These values were derived from multiple 
between-batch analyses of each material, the results of which are shown in 
Table 2.3.1.
Following the preparation of a new batch of reagent, the PM adjust voltage 
on the Cobas Bio was reset using the high standard. Each Dns-PBA assay
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FIG. 2.3.1: Correlation of ‘Fructosamine
Plus’ & DF results for aqueous dilutions
of in vitro glycated albumin solution.
200 -
150-
S 1 0 0 -
5 0 -
100 150 200
Fructosamine Plus (umol/1)
250 300
Points represent mean values of duplicate results for glycated albumin, 
assayed with 2.5 |imol/l Dns-PBA. y = 0.68% + 0.73, r  = 0.999.
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FIG.2.3.2: Fluorometric analysis of 
Fructosamine P (high) control in aqueous 
dilution.
I
P  200
0 ^  OJ
P control dilution
Reagent A Reagent B ♦ DF
FIG.2.3.3: Fluorometric analysis of 
Fructosamine P (high) control diluted in 
N (low) control.
a 800
3  400H
M.
I Oi) Oj 0.4 0.0P control dilutionReagent A Reagait B 1.0♦ DF
Points represent mean values of duplicate results.
For DF in aqueous dilution (Fig. 2.3.2): y = 121% + 1.5, r  = 0.992.
For DF in a serum matrix dilution (Fig. 2.3.3): y = %% + 61, r  = 0.990.
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Table 2.3.1. Assayed standard values for in vitro glycated plasma.
n DF ± SD
Saline blank 14 0.6 ±  2.0
Low standard 19 63 ± 9
High standard 19 225 ± 23
Results were obtained between-batches, using the optimised Dns-PBA assay 
on the Cobas Bio.
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would then include the high and low glycated protein standards on every run 
and results would be adjusted manually by linear regression analysis to 
conform to the predetermined standard values, including a saline blank. 
Corrected sample results can be easily determined, using a scientific 
calculator.
2.3.6. Limit of detection and assay sensitivity.
The detection limit of an assay is an indication of sensitivity (which itself 
has no numerical value) and is defined as the smallest single result which 
can be distinguished from a suitable blank with 95% confidence (Broughton, 
1978).
In order to determine the limit of detection for the DF results of the 
standardised Dns-PBA assay, 14 saline blanks were analysed, plus 14 
samples of the low standard in a 1:4 dilution and 14 samples of the same 
standard in a 1:8 dilution (prepared in deionised water).
The mean DF results ± SD are shown in Table 2.3.2 which also gives the 
critical values of t obtained by applying Student’s t-test for the difference 
between means of small samples. The critical values of t which must be 
exceeded in order to fulfill the above criteria of detection limit, is 2.05. This 
value is exceeded for the 1:4 dilution of the low standard, which is 
equivalent to a DF level of 14. DF values of less than 14 are therefore 
meaningless and any results around this point will be imprecise and may be 
inaccurate.
These results also indicate that differences in DF results of 14 or less are 
relatively insignificant, which is reflected in both the accuracy and the 
imprecision of the overall assay.
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2.3.7. Control of the Dns-PBA assay.
In order to check the standardisation procedure and maintain quality control 
over the DF results, 2 of the 3 control materials prepared in 2.3.2 were 
included on every run assayed. From 20 results accumulated over a period 
of 2 months, the quality control ranges shown in Table 2.3.3 were derived. 
Any run where either QC result appeared outside the established range after 
standardisation of the assay (as described in 2.3.5) was rejected.
SECTION 4. REAGENT AND SAMPLE STABILITY.
2.4.1. Reagent stability.
As the constituents of reagents A and B are all simple chemicals (Dns-PBA, 
boric acid and bicine buffer), the most obvious cause of any instability will 
be due to degradation of any of these compounds. Dns-PBA is known to be 
light sensitive, so whenever the reagents were not in use they were stored 
in dark brown glass bottles at 4 °C. This temperature was adequate to 
restrict bacterial growth as at no time did the reagents appear cloudy. 
Reagent stability was assessed in 2 ways:
1) By ensuring that DF linearity was maintained for high response samples 
over a defined time period.
2) By ensuring that assay QC results showed no bias throughout the lifespan 
of the reagent.
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Table 2.3.2. Data for determination of the Dns-PBA assay limit of 
detection, on the Cobas Bio.
DF ± SD Critical ratio 
n = 14 t
Saline blank 0 + 2
Low std. 1:8 8 + 4 1.68
Low std. 1:4 14 ± 6 2.37*
Critical value of t is 2.05 at the 95% confidence level.
* Statistically significant difference from the saline blank (p<0.05)
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Table 2.3.3. DF ranges obtained for 3 quality control materials.
n DF ± SD QC range
DF +/- 2SD
Normal QC 20 91 ± 9 73 - 109
Medium QC 20 154 ± 15 124 - 184
Diabetic QC 20 182 ± 15 152 - 212
Results were obtained between-batches, using the standardised Dns-PBA 
assay on the Cobas Bio.
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2.4.1.1. Linearity check.
Any breakdown of Dns-PBA upon storage of reagents A and B, would 
result in decreased DF values for high samples due to exhaustion of the 
relevant fluorophore.
A fresh Dns-PBA stock solution was prepared in bicine buffer (50 mmol/1, 
pH 8.0). Working reagents A and B were prepared from this stock solution 
and immediately used to assay double dilutions of ‘Fructosamine’ P control, 
diluted down to 1:16 in deionised water. This assay was repeated at intervals 
over a period of four months, using the same reagents, (stored at 4 °C) and 
freshly reconstituted P control, or a high response diabetic patient’s sample. 
The results shown in Table 2.4.1 indicate that linearity was maintained 
throughout the whole 4 month period. Student’s paired t-tests on the 
linearity data showed no significant difference between the baseline results 
and those at all other time points. Fresh working reagents were also 
prepared from the original 50 pmol/l Dns-PBA stock solution after 4 weeks 
and 15 weeks storage. Assay linearity was once again maintained.
2.4.1.2. Quality control results.
Figure 2.4.1 shows the normal QC and diabetic QC results for standardised 
DF assays obtained over a 5 month period. There is no obvious bias 
occurring at either of the QC levels over a 4 month period (runs 43-90) in 
which the same Dns-PBA stock solution was used to prepare reagents. 
Student’s t-test between means was applied to establish any difference 
between 2 sets of normal QC values and 2 sets of diabetic QC values 
obtained during the 2 month period either side of the fresh stock solution. 
Results of this test are summarised in Table 2.4.2. No significant difference 
was found for either control. Insufficient data was available to perform this 
test on the medium control.
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Table 2.4.1. The effect of reagent storage on assay linearity: serum  
dilution (%) vs DF results (y).
Age of reagent 
(weeks)
y = mx + c r
0 y = 159% + 1 0.999
2 y = 149% + 3 0.996
4 y = 153% + 6 0.995
6 y = 156% + 5 0.991
8 y = 148% + 10 0.990
15 y = 155% + 3 0.999
18 y = 156% + 8 0.997
Results from double dilutions of P control assayed on the Cobas Bio.
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FIG.2.4.1: Standardised DF results 
obtained for 2 QC materials over a 2 
month period.
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Fresh stock reagent (50 jiimol/l Dns-PBA) and fresh working reagents (2.5 
fimol/l Dns-PBA) were prepared at run numbers 1 and 43. Fresh working 
reagents were also prepared at run numbers 28, 58 and 76.
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Table 2.4.2. Comparison of DF results obtained for QC material 2 
months before and after preparation of fresh assay reagents.
n D F ± S D
Normal { -2 months 40 89 ± 1 2
QC { +2 months 29 90 ± 10 *
Diabetic { -2 months 35 181 ± 13
QC { +2 months 18 179 ± 10 *
* No statistically significant difference.
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The results of both these studies indicate that the Dns-PBA reagents are 
stable upon storage at 4 °C in dark glass bottles for at least 4 months.
2.4.2. Sample stability.
For the Roche ‘Fructosamine test plus’, serum, heparin plasma and EDTA 
plasma are the samples recommended for the assay. Roche quote the 
stability of serum to be 3 days at 15-25 °C, 2 weeks at 2-8 °C and 2 months 
at -20 °C. For the original ‘Fructosamine test’ marketed by this company, 
serum levels were quoted to remain unchanged for up to 3 months at -20 
°C. Sample stability was therefore investigated for serum and lithium 
heparin plasma samples at 4 different temperatures, for measurement by the 
Dns-PBA fluorometric assay.
Fresh serum and heparin plasma samples were obtained from the routine 
workload of the Biochemistry Department, Frimley Park Hospital. A total 
of 20 serum samples were assayed for glucose, DF and albumin, then each 
divided into 4 aliquots of 300 p.1. One set of 20 aliquots was stored at -80 
°C, one set at -20 °C , one set at 4 °C and one set was left at room 
temperature (15-25 °C).
The stored samples were mixed thoroughly and assayed for DF and albumin 
at various intervals over a 3 month period. Any significant differences in 
results were assessed by using Student’s paired t-test. Results obtained are 
shown in Table 2.4.3. The decrease in DF/g/1 vaiu.es after 4 days at room 
temperature was mainly due to a significant decrease in DF results (p<0.01). 
Similarly, the increase in DF values following storage of samples for 2 
months at -20 °C (p<0.01) was primarily responsible for the increased 
DF/g/1 results.
A similar experiment was performed to assess the stability of 8 lithium 
heparin plasma samples. Results from this study are shown in Table 2.4.4.
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Table 2.4.3. Serum  stability study.
Mean baseline result = 1.55 DF/g/1, n = 20.
Storage
time
Mean DF/g/1 Mean (baseline - stored) 
DF/g/1 ± SD
Room { 4 days 1.19 0.36 ± 0.37 ***
temp.
4 °C { 4 days 1.57 -0.03 ± 0.34
{ 7 days 1.54 0.01 ± 0.32
{ 14 days 1.37 0.18 ± 0.47
{ 1 month 1.53 0.01 ± 0.65
-20 °C { 14 days 1.61 -0.06 ± 0.51
{ 1 month 1.74 -0.19 ± 0.49
{ 2 months 1.89 -0.34 ± 0.48 **
{ 3 months 1.56 -0.01 ± 0.51
-80 °C { 1 month 1.49 0.06 ± 0.42
{ 2 months 1.49 0.06 ± 0.42
{ 3 months 1.78 -0.23 ± 0 .59
Serum samples from 20 non-diabetic individuals were stored at 4 different 
temperatures for up to 3 months. The mean blood glucose level (± SD) in 
baseline samples was 5.8 ± 1.7 mmol/1.
Significant difference from baseline, p<0.01 
Significant difference from baseline, p<0.001
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Table 2.4.4. Heparin plasma stability study.
Mean baseline result = 1.06, n = 8.
Storage
time
Mean DF/g/l Mean (baseline - stored) 
DF/g/l ± SD
Room
temp.
{ 4 days 0.38 0.68 + 0.38 **
4 °C { 4 days 1.13 -0.07 ± 0.28
{ 7 days 0.66 0.40 ± 0.23 **
{ 14 days 0.70 0.37 ± 0.43 *
-20 °C { 14 days 1.53 -0.47 ± 0.21 ***
{ 1 month 1.86 -0.80 ± 0.29 ***
-80 °C { 1 month 1.55 -0.49 ± 0.33 **
{ 2 months 1.63 -0.56 ± 0.28 ***
{ 3 months 1.69 -0.63 ± 0.32 ***
Lithium heparin plasma samples from 8 non-diabetic individuals were stored 
at 4 different temperatures for up to 3 months. The mean blood glucose 
level (± SD) in baseline samples was 6.4 ±1 .7  mmol/1.
* Significant difference from baseline, p<0.05 
Significant difference from baseline, p<0.01 
Significant difference from baseline, p<0.001
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As found with the serum samples, DF/g/l results decreased significantly after 
4 days at room temperature. Once again, the decrease in DF/g/l for plasma 
was due to a significant decrease (p<0.001) in DF values with no significant 
change in albumin levels.
The decrease in results seen at 4 °C after 7 days was due to a significant 
decrease in DF (p<0.05) and a significant increase in albumin (p<0.01). 
Increasing DF results seen after freezing at -20 °C and -80 °C were mainly 
due to highly significant increases in DF values (p<0.001).
2.4.3. The effect of repeated freezing and thawing on serum samples for 
fluorometric analysis.
Fresh serum samples ( 1 8 x 2  ml) were divided into 4 aliquots of 500 p.1; A, 
B, C, and D. One set of 20 samples (A) was stored at 4 °C and the other 3 
sets were frozen at -20 °C. After approximately 90 minutes, set B was 
allowed to defrost at room temperature. These samples were vortex mixed 
and refrozen at -20 °C. Approximately 90 minutes later, sets B and C were 
allowed to thaw at room temperature , vortex mixed, and then returned to - 
-20 °C. After a further 90 minutes, all sets of samples (B, C and D) were 
allowed to thaw at room temperature , prior to vortex mixing.
Following overnight storage at 4 °C, all samples were assayed for DF/g/l. 
Samples were arranged so that all 4 aliquots of each sample were assayed 
on the same run.
By applying Student’s paired t-test to the resulting data, there was no 
significant difference in results following 1, 2 or 3 fi-eeze-thaw cycles.
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SECTION 5. ASSAY IMPRECISION AND COMPARISON OF 
REFERENCE RANGES FOR DIABETIC AND NON-DIABETIC 
POPULATIONS.
2.5.1. Assay imprecision.
Imprecision was assessed for the optimised Dns-PBA fluorometric assay, 
both within-batch and between-batch.
2.5.1.1. W ithin-batch imprecision.
The in vitro glycated assay standards prepared in 2.3.1 were used to assess 
within-batch imprecision. The low and high standards were combined in a 
ratio of 10:8 to produce an intermediate level and all 3 samples were 
assayed for DF, 14 times within one run. (This is the maximum number of 
samples that can be assayed on one run). Albumin analyses were also 
performed in 3 batches of the 14 samples.
The results in Table 2.5.1 show the mean ± SD values and coefficient of 
variance (%CV) for reagent A fluorescence, reagent B fluorescence, DF, 
albumin (g/1) and DF/g/l at all 3 levels.
The precision attained by reagents A and B alone is excellent, but because 
the difference between these 2 values is relatively small, the %CV of DF 
increases dramatically. As the serum albumin result is not independent of 
the DF values, the CV of this assay has relatively little effect on the 
imprecision achieved after correction of DF for albumin levels. Within - 
batch imprecision of the DF/g/l assay therefore ranges from a CV of 2.9% 
to 12.1% with a borderline diabetic/non-diabetic CV of 7.4%.
127
Table 2.5.1. Within hatch imprecision of the Dns-PBA assay.
Mean ± SD %cv
{ Reagent A 629 + 5 0.8
Low { Reagent B 559 + 6 1.2
Standard { DF 70 ± 8 11.6
{ Albumin (g/1) 3 4 + 1 2.9
{ DF/g/l 2.05 ± 0.25 12.1
{ Reagent A 725 + 6 0.8
Medium { Reagent B 602 ± 4 0.6
Standard { DF 123 + 7 5.7
{ Albumin (g/1) 37 + 1 2.7
{ DF/g/l 3.38 + 0.25 7.4
{ Reagent A 939 ± 6 0.6
High { Reagent B 717 + 4 0.6
Standard { DF 222 + 7 3.3
{ Albumin (g/1) 3 7 +  1 2.7
{ DF/g/l 6.04 + 0.18 2.9
n = 14, at each level.
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2.5.1.2. Between-batch imprecision.
Between-batch imprecision was assessed using the control sera prepared in
2.3.2. DF results (30) were obtained over a period of approximately 4 
months, necessitating 3 changes of assay reagent during this time. Fewer 
than 30 albumin results were available for correction of the DF values as 
each QC level was only assayed once for albumin each day, even though 
more than one fluorometric assay may have been performed.
Results of this study are shown in Table 2.5.2 where once again, results 
have not been grossly affected by correction for serum albumin levels. 
Between-batch imprecision of the DF/g/l assay therefore ranges from a CV 
of 5.8% to 11.4% with a borderline diabetic/non-diabetic CV of 9.6%.
2.5.2. Dns-PBA assay reference ranges.
2.5.2.I. Non-diahetic reference range.
A non-diabetic reference range for DF/g/l results was compiled by the
standardised assay of serum samples over a 1 year period. Samples were 
obtained from patients giving a normal glucose tolerance test (see Chapter 
5, section 5.1.1), healthy laboratory staff and from routine serum samples 
received in the laboratory from patients with no known diabetes and a 
random blood glucose level of less than 6.5 mmol/1. Pregnant women were 
excluded from the study.
For the 75 non-diabetics studied (35 male, 40 female, age range 18-91 
years), the mean ± SD values of DF/g/l were 1.74 ± 0.35 , which gives a 
reference range (mean ± 2SD) of 1.04 - 2.44.
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Table 2.5.2. Between-batch imprecision of the Dns-PBA assay.
n Mean ± SD %CV
Normal
QC
{ DF 30 90 ± 11
{ Albumin (g/1) 9 48 ± 2.0
{ DF/g/l 30 1.89 ± 0 .22
12.1
4.2
11.4
Medium { DF 30 154 ± 1 4
QC { Albumin (g/1) 11 46 ± 1.5
{ DF/g/l 30 3.35 ± 0.32
9.1
3.3
9.6
Diabetic
QC
{ DF 30 180 ± 10
{ Albumin (g/1) 10 45 ± 1.0
{ DF/g/l 30 4.02 ± 0.23
5.6
2.2
5.8
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This data is presented as a histogram in Figure 2.5.1, together with the 
diabetic results. The non-diabetic data clearly represents a normal 
distribution.
2,5.2,2. Diabetic range of results.
A diabetic range for DF/g/l results was compiled by the standardised assay 
of serum samples, received over a period of 1 year, and assayed in 
conjunction with the non-diabetic samples above. Samples were obtained 
from both insulin dependent and non-insulin dependent diabetics attending 
the diabetic clinic at Frimley Park Hospital as out-patients. Pregnant diabetic 
women were excluded from the study.
For the 86 samples analysed (48 male, 38 female, age range 16-82 years), 
the mean ± SD values of DF/g/l were 3.41 ± 1.18. This data is also shown 
in Figure 2.5.1 which gives a clear indication of the 2 different populations. 
The mean DF/g/l value for the diabetic population is 2.0 times that for the 
non-diabetic population.
The diabetic data can be further divided into non-insulin and insulin 
dependent diabetics as shown in Figure 2.5.2. Although there is no 
significant difference between the means of the 2 groups, the insulin 
dependent patients do show a slightly wider spread of results.
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FIG. 2.5.1: Diabetic and non-diabetic 
reference ranges for DF/g/l results.
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Assay results were obtained over the course of 1 year, for a total of 75 non­
diabetics and 86 diabetic patients.
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FIG. 2.5.2: Non-insulin dependent and 
insulin dependent diabetic ranges for 
DF/g/l results.
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Assay results were obtained over the course of 1 year, for a total of 37 non­
insulin dependent and 49 insulin dependent diabetics.
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DISCUSSION
The decision to use Dns-PBA as the fluorescent probe in this study was 
primarily based on the high Stokes shift obtainable with Dns-Cl (238 nm), 
the availability and low cost of the Dns-PBA conjugate and on the 
promising results of previous studies (Hayashi & Makino, 1985). Although 
the optimum excitation and emission wavelengths of Dns-PBA when 
combined with glycated albumin were found to coincide with the 
background fluorescence found in serum, any interference was eliminated 
from the final result by subtraction of the reagent B from the reagent A 
results. In this way reagent B not only acts as a blank for the glycated 
albumin measurement, but also serves to eliminate spurious fluorescence. 
However, the fact that a blank measurement is necessary for the analysis has 
greatly reduced the assay sensitivity by producing a situation analogous to 
that found with uv/visible spectrophotometry: the final result is derived from 
a small difference between two large variables. This phenomenon is also 
responsible for the relatively high imprecision of the assay.
The binding of Dns-PBA to human serum albumin resulted in a decrease in 
the fluorescence emission wavelength. With most fluorescent compounds, 
the emission wavelength is observed to shorten with decreasing polarity of 
the solvent or of the immediate environment. It is therefore very likely that 
the interaction of Dns-PBA with glycated albumin occurs within a 
hydrophobic site on the albumin molecule (as proposed by Hayashi & 
Makino, 1985). The dansyl group on Dns-PBA is known to be 
environmentally sensitive in this way so a useful experiment would have 
been to conjugate an alternative probe, such as fluorescein isothiocyanate 
which is not environmentally sensitive, to APBA and assess any changes in 
fluorescence characteristics of this compound. However, although the actual 
coupling of fluorescein isothiocyanate to APBA was performed, difficulties 
were encountered in separating the coupled product from the hydrolysed dye
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(results not shown). As the same problem had also been documented by 
other workers (Simpson, 1978; Kawauchi et al, 1969) this line of 
investigation was discontinued.
With regard to the published emission wavelengths for previous studies 
using Dns-PBA, this work has produced some notable differences. Although 
changes in assay buffer may be expected to affect the emission maxima by 
altering associations with the Dns-PBA, identical assay conditions in this 
chapter have produced different results to Burnett et al (1980) and Hayashi 
and Makino (1985). Burnett et al found a maximum emission wavelength 
of 550 nm for Dns-PBA in EPPS buffer whilst Hayashi and Makino quote 
a value of 530 nm with HEPES, shifting to 490 nm in the presence of 
glycated albumin. Throughout this study, an emission maximum of 510 nm 
was obtained for Dns-PBA in either of the above buffer systems, shifting to 
470 nm in the presence of glycated albumin. The actual shift of the peak 
therefore remains unchanged (40 nm) but as none of the wavelengths have 
been corrected for the quantum distribution of the excitation source they 
cannot be directly compared.
Following the decision to continue to use Dns-PBA as the fluorophore in the 
Dns-PBA assay, a fluorescence titration against pH was performed to try 
and establish pK values of the compound. An acid base titration proved to 
be impossible due to the low solubility of Dns-PBA in aqueous solution. 
The peak produced by the fluorescence titration in Fig. 2.2.1 at pH 9.0 was 
not an artefact produced by alterations in the maximum emission wavelength 
with changing pH, as this was checked by scanning the solutions. It is 
therefore possible that this peak is reflecting 2 different ionisations. The 
only positions on the Dns-PBA molecule that are likely to ionise (see 
Chapter 1, Fig. 1.5.6) are the boronic acid moiety, which is known to receive 
a hydroxyl ion and a net negative charge prior to reaction with cis-diol 
groups of glycated proteins, and the secondary amine attached to the phenyl 
group of PB A.
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Foster (1957) has shown that the formation of boron complexes with neutral 
sugars is favoured at alkaline pH. The pK^ of the boronic acid group on 
APBA is 8.8 although when conjugated to Dns-Cl, it is possible that the 
sulphonyl group may be having an electron withdrawing effect in an 
opposing direction, hereby reducing the pK^. In Fig.2.2.1 it is therefore 
likely that this ionisation is represented by the upward slope of the peak at 
pH 9.0, with a point of inflection, or pK^, at around pH 8.2. However, 
instead of reaching a plateau at pH 9.0, the ensuing decrease in fluorescence 
with increasing pH could be attributed to the increased binding of hydrogen 
at the secondary amine. This nitrogen would be a fairly weak base and as 
such, a pKy of approximately 10.0 would not be unexpected.
The fact that the ionisations on the APBA part of the Dns-PBA conjugate 
appear to be affecting the fluorescence of the whole compound, implies that 
there is some interaction between the delocalised electrons of the naphthyl 
group pi electron clouds and the phenyl group pi electron cloud. Such an 
interaction would be diminished by protonation of the secondary amine 
group, hereby reducing fluorescence. Similarly, ^he production of a negative 
charge on the boronic acid moiety would increase delocalisation of electrons 
and enhance fluorescence.
In the presence of glycated albumin, (Fig. 2.2.1) fluorescence results on the 
Cobas Bio were increased by almost 10-fold. This was partly due to the 
shift of the maximum emission wavelength further into the window of the 
emission filter, but also due to enhanced fluorescence upon binding. The 
peak seen at pH 9.0 for Dns-PBA in water with glycated albumin coincides 
with the peak observed without glycated albumin and may therefore be 
attributable to the previously described ionisation effects occurdng with the 
free (unbound) Dns-PBA. This peak was not apparent when boric acid was 
added to the Dns-PBA in the presence of glycated albumin. It is possible 
that the peak has been obscured by the overriding effect of the boric acid 
ionisation on its binding to glycated albumin: Boric acid has a pK^of 9.24
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and will preferentially bind to neutral sugars when ionised (Foster, 1957). 
Once bound to the glycated protein at a specific binding site, the boric acid 
prevents the Dns-PBA from binding and fluorescence enhancement is 
reduced.
Regardless of the presence of boric acid, fluorescence emission intensity 
undergoes a rapid decline at pH values above 9.0. This implies that both the 
specific and the non-specific association of Dns-PBA with the protein is 
being restricted, and is indicative of a hydrophobic reaction as this would 
diminish at high pH (Myohanen et al, 1981). At lower pH values, there is 
a relatively small difference between the fluorescence intensity of Dns-PBA 
with or without boric acid (Fig. 2.2.1) as assayed in water. This suggests 
that very little specific binding is occurring, considering the nature of the 
sample, and implies that the assay buffer may be necessary for participation 
in complex formation.
The DF results for glycated albumin obtained over a similar pH range in the 
presence of MES, HEPES, EPPS and AMP buffers also showed an overall 
trend towards increasing values around pH 9.0. (Figs. 2.2.2 - 2.2.7). This 
effect was not obvious in the presence of bicine buffer, which produced 
remarkably stable results.
It is interesting to note that Myohanen et al (1981) found that in the 
presence of triethanolamine (TEA) buffer at pH 8.5, binding of a - 
glucosidase to an aminophenylboronic acid affinity gel was reduced, 
compared to binding at lower pHs. This group have suggested that the 
results could be explained by the specific effect of TEA on borate 
complexes (Brown & Fletcher, 1951) whereby the buffer complexes with the 
gel and reduces glycated protein binding.
As TEA buffer is structurally similar to bicine (2-hydroxyethyl glycine), it 
is possible that bicine-Dns-PBA interactions could be occurring in the 
fluorescence assay. Any interaction does not appear to be strong enough to
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inhibit Dns-PBA binding to cis-diol groups on glycated proteins, but may 
have a role in preventing the ionisation effects seen in the other buffers with 
changing pH. Investigation of the Dns-PBA assay in TEA buffer would 
certainly be worthwhile.
Following the choice of bicine buffer for use in the DF assay, the optimum 
bicine concentration was determined for analysis of undiluted serum. It was 
preferable not to have to dilute samples prior to analysis as this made the 
assay more time consuming and more susceptable to human error. Hayashi 
and Makino (1985) had diluted serum 1:4 prior to analysis with 0.6 umol/1 
Dns-PBA. It therefore followed that 3.0 jimol/l Dns-PBA would be adequate 
for analysis of undiluted serum and this was confirmed by the results shown 
in Fig. 2.2.10. Any increased interference or spurious fluorescence caused 
by the increased sample volume should be eliminated by the sample blank. 
It was not found necessary to increase the boric acid concentration in 
reagent B for analysis of undiluted serum, as concentrations above 50 
mmol/1 did not decrease the fluorescence emission from analysis of a high 
or a low glycated protein sample. Similarly, when the assay was adapted to 
accomodate the narrower bandwidth emission filter in section 2.2.6.1 and the 
sample volume and Dns-PBA concentration were increased 10-fold, only a 
6-fold increase in boric acid concentration was necessary to prevent specific 
binding. These findings suggest that the boric acid may be capable of 
binding specifically to sites on 2 separate albumin molecules once (he 
albumin concentration reaches a certain level. This would presumably be 
feasible for boric acid in its ionised form when it possesses 4 hydroxyl 
groups, but whether it would be possible for such a small molecule to cross­
link between 2 such large molecules is debatable, particularly if the specific 
binding site on glycated albumin is close to a hydrophobic area wliich is 
unlikely to be exposed on the surface of the molecule. Alternatively, the 
boric acid may be complexing with the buffer whilst the serum
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concentration is low but on increasing the serum content of the assay 
mixture the boric acid may preferentially associate with the glycated 
albumin.
Evaluation of 2 different emission filters for the Cobas Bio in section 2.2.6 
of this chapter was able to demonstrate that a reduction in the bandwidth did 
not confer any advantages to the assay. As the Stokes shift is large (140 nm) 
the 90 nm filter is adequate to discriminate between excitation and emission 
wavelengths, and any spurious fluorescence is accounted for by the reagent 
B blank. Further studies into applications of the 40 nm filter may be 
relevent if any specific interferents are found to affect the fluorescence 
emission of the assay.
In order to maintain the difference between the excitation and emission 
wavelengths well above 100 nm, the excitation wavelength was not adjusted 
to its optimum of 355 nm. This would have reduced the difference to 115 
nm and possibly increased spurious fluorescence. Also, since raising a 
molecule to its excited state is a matter of total energy required, the emitted 
fluorescence band is the same regardless of the wavelength of the absorbed 
energy. Although the best wavelength for raising a compound to an 
activated state is governed by both the absorbance of the compound and the 
intensity of the radiant energy, the Cobas Bio is able to automatically set the 
flash level of its xenon lamp to compensate for any system variation. This 
implies that the change in absorbance wavelength of Dns-PBA in the 
presence of glycated albumin (Table 2.2.6) is due to increased delocalisation 
of pi electrons on binding, which reduces the energy difference between the 
ground state and the 1st excited state of the Dns-PBA. A lower energy 
wavelength is therefore appropriate for excitation.
Results of the assay time course investigation (Fig.2.2.14) indicate that the 
change in Dns-PBA fluorescence occurs rapidly and that binding is virtually
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complete within 2 minutes. This short assay time provides an analytical 
advantage over the ‘Fructosamine’ test which requires a 10 - 15 minute 
incubation time, although both methods are considerably shorter than most. 
As demonstrated in Fig. 2.3.1, the DF assay and the fructosamine test are 
measuring comparable entities on in vitro glycated albumin. The steeper 
slope obtained for the Fructosamine Plus results than for the DF results 
(section 2.3.4) indicates that the Dns-PBA assay is more specific, possibly 
to only one glucose binding site, whereas the fructosamine assay is sensitive 
to a number of different glycation sites. Although it would be desirable to 
express the fluorescence results in (imol/l units in order to give values which 
can be equated to other serum constituents, it is not essential to the useful 
application of the assay. As discussed in the introduction of this thesis, 
many varied ways of expressing glycated protein results have been adopted, 
dependent on the limitations of the methodology involved. Apart from 
adding another calculation to the procedure for determination of results from 
the DF assay, use of such a calibration curve would require that it was re­
established at frequent intervals, under standardised conditions. The 
procedure is therefore not worth considering for routine use but is a useful 
research tool for comparison of the 2 methods.
The fact that interferences in the fluorescence assay are continually 
occurring due to background effects was demonstrated by the dilution curves 
in an aqueous matrix, and the ability of the assay to effectively blank these 
effects was confirmed by the resultant linear DF values. In section 2.3.5 of 
this chapter, the linearity of the optimised fluorometric assay was confirmed. 
The linear response of serum samples made feasible the use of a 3 point 
standardisation and has maintained the simplicity of the assay.
Throughout this study, results obtained from the Cobas Bio were converted 
manually into DF/g/l values. This involved subtraction of reagent B results
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from reagent A results, standardisation of the DF results with respect to the
3 standard values by linear regression , and division of the corrected DF by 
the serum albumin level. Although all 3 stages were simple to perform and 
all were possible using a Casio scientific calculator (fx-115N), a computer 
interface from the Cobas Bio would speed up this step considerably and also 
restrict human error. Unfortunately, funds were not available in this study 
to implement such an interface and it is debatable as to how essential it 
would be if relatively few samples were being routinely analysed.
Having standardised the DF assay between runs, it was possible to assess 
both reagent and sample stability. The Dns-PBA reagent proved to be 
remarkably stable when stored at 4 °C in dark bottles, especially considering 
that APBA affinity gels are prone to degeneration due to oxidation. For 
affinity chromatography using these gels, buffer solutions should be 
degassed prior to use, in order to limit oxidative degeneration. This was not 
found to be necessary with the Dns-PBA solutions which gave consistent 
results throughout a 4 month period whether stored as the 50 jimol/1 stock 
or the 2.5 (imol/l working reagents.
Sample stability is a more complex issue, as different anticoagulants and 
serum components may affect stability in a variety of ways. Results from 
this chapter indicate that storage of serum or lithium heparin plasma is 
inadvisable at room temperature. Serum can be stored for up to 1 month at
4 °C or -20 °C without deterioration, but for up to 3 months at -80 °C. 
Lithium heparin plasma is not stable for over 4 days at 4 °C and the results 
for frozen samples all increased rapidly upon storage. Assuming that the 
heparin anticoagulant (a polymer composed of D-glucosamine, D-glucuronic 
acid and sulphate residues) is stable upon storage and is not broken down 
to produce species capable of glycating proteins, it is possible that the 
lithium heparin is causing structural changes or more subtle environmental 
changes to proteins upon storage. A small change in structure at the specific
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Dns-PBA binding site could increase or decrease the amount of Dns- 
PBA/boric acid binding, and similarly, any environmental change could 
either reduce or enhance fluorescence. Further studies are therefore 
necessary to establish whether the same effect is observed for other glycated 
protein methods. If analysis of lithium heparin plasma is essential, this study 
indicates that it should be performed without delay.
Although 3 freeze-thaw cycles of serum at -20 °C had no significant effects 
on the DF assay results, repeated freezing and thawing of samples should 
be avoided if possible.
As expected, results of the precision studies in section 5 of this chapter 
showed the fluorescence analysis itself to be highly sensitive, with CVs all 
less than 1.5%. Correction of the DF for serum albumin levels made very 
little difference to the level of imprecision, in comparison to the effect of 
subtracting reagent B from reagent A results. Although these percentages are 
relatively high for a fully automated procedure (within-batch CV = 2.9- 
12.1%, between-batch CV = 5.8-11.4%), they are comparable to the 
precision values obtained for measurement of glycated serum proteins by the 
TBA method and for measurement of glycated albumin by affinity 
chromatography with immunoturbidimetry: using the TBA method, Kennedy 
et al (1981) have obtained a within-batch CV of 8% and a between-batch 
CV of 12%, using paired results of duplicate analyses. Reed et al (1986) 
have quoted within-batch CVs of 3.5-9.9% and between-batch CVs of 3.7- 
11.0% for affinity chromatography of glycated albumin. Determination of 
total glycated serum protein by the same technique however, can yield more 
precise results (Gould et al, 1984) with all CVs less than 6.3%.
Schleicher and Wieland (1981) have produced within and between-batch 
CVs of 2.9% and 8.4% respectively, for diabetic samples which they have 
assayed for furosine by HPLC, following stong acid hydrolysis.
The precision of results obtained using the fructosamine method are superior 
to any of these other methods. Within-batch CVs range from 0.5-3.0% and
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between-batch CVs range from 0.9-4.8% (Kruse-Jarres et al, 1989). This is 
due to complete automation and relative simplicity of the reaction.
Data presented in this chapter for the non-diabetic reference range of Dns- 
PBA assay results shows a tightly grouped normal distribution. The diabetic 
data is much more widely spread, especially the insulin-dependent diabetic 
group who are prone to wider fluctuations in blood glucose levels. 
Optimisation of the Dns-PBA method has therefore resulted in an assay 
which gives a 2-fold difference between the mean diabetic and non-diabetic 
results, and is discussed with reference to other glycated protein methods in 
chapter 3 of this thesis.
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CHAPTER 3 
EVALUATION OF TH E DANSYL-PBA ASSAY.
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Introduction.
Prior to the introduction of any new assay into the clinical chemistry 
laboratory, it is important to evaluate the method with respect to other 
established forms of analysis for the relevant analyte. Although the original 
work of Hayashi and Makino (1985) on the Dns-PBA assay included details 
of a positive correlation obtained with affinity chromatography for glycated 
albumin, only 14 samples were included in the analysis. A more extensive 
comparison of the fluorescence assay with this technique has therefore been 
undertaken, and the results of the correlation against glycated serum albumin 
and glycated total protein by affinity chromatography have been compared. 
It has also been necessary to establish whether any commonly encountered 
serum components (interferents or contaminants) will significantly affect the 
assay results (eg. haemolysed or lipaemic serum, presence of anticoagulant), 
before undertaking analysis of samples from a wide range of patients. 
Obviously the effect of certain components will be much more relevant than 
others, depending on the assay in question, so for evaluation of the Dns- 
PBA assay the effect of Schiff base and free glucose in serum samples was 
of high priority. As well as assessing the effects of various serum 
components on the analytical performance of the assay it was also 
appropriate to obtain information on the in vivo effects of relevant 
compounds as this could alter the clinical interpretation of results.
No data has as yet been published concerning possible interferences with the 
Dns-PBA assay. Fluorescence analysis in general is prone to additional 
luminescence signals due to contaminants in the sample, as well as 
quenching or inner filter effects which decrease the emitted light intensity. 
However, the Dns-PBA assay does incorporate its own blank for each 
sample analysed and should therefore be able to keep many of these effects 
to a minimum.
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In addition to assessing the effects of a number of possible interferents 
within the assay, this chapter describes some investigations into the 
specificity of the assay for binding to glycated albumin. The effect of 
borohydride reduction and periodate oxidation of serum albumin have been 
used here with this in mind.
The introduction of thiol groups (as reduced glutathione) and the blocking 
of such groups with p-chloromercuribenzoic acid (PCMB) has been used to 
try and ascertain their involvement in Dns-PBA binding. Similarly, a human 
albumin variant, albumin Redhill (Brand et al, 1984; Brennan et al, 1990) 
has been used in this chapter to determine whether the slight structural 
variations occuting in this albumin variant have an appreciable effect on 
both in vivo and in vitro glycation of the protein.
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M aterials.
Equipm ent:
The Bio-Rad modular diabetes monitoring system was used for high 
performance liquid chromatographic (HPLC) analysis of HbA^g (Bio-Rad 
Laboratories Ltd, Watford, Hertfordshire, UK).
Other equipment was as described in the ‘materials’ section of chapter 2. 
Consumables:
Poly-prep 2ml disposable polypropylene chromatography columns were 
purchased from Bio-Rad Laboratories Ltd (Watford, Hertfordshire, UK). 
Glyco-gel boronate affinity gel was purchased from Pierce and Warriner 
(UK) Ltd (Chester, Cheshire, UK).
Plastic Universal containers and 5ml tubes were purchased from Westerns 
Laboratory Supplies (Aldershot, Hampshire, UK).
Ultrafiltration membranes (10,000 molecular weight cut-off) were obtained 
from Millipore (UK) Ltd, Hertfordshire.
Other consumables were as described in the ‘materials’ section of chapter 
2 .
Reagents:
All reagents were obtained from British Drug Houses Ltd (Poole, Dorset, 
UK) and were of Analar grade, unless stated otherwise.
Oxygen free nitrogen was obtained from BOC Ltd (Guildford, Surrey, UK).
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SECTION 1. COMPARISON OF DANSYL-PBA FLUORESCENCE 
ASSAY RESULTS WITH AFFINITY CHROMATOGRAPHY RESULTS 
FOR GLYCATED ALBUMIN AND GLYCATED TOTAL PROTEIN.
3.1.1. Affinity chromatography procedure.
The following protocol was based on procedures described by Gould et al 
(1984) and John and Jones (1985).
Polypropylene disposable mini-columns (22) were arranged in a suitable 
rack enabling collection of eluates. Glycogel-B boronate affinity gel (100 ml 
gel in a total volume of 200 ml) was mixed well and degassed using oxygen 
free nitrogen. Whilst ensuring constant mixing of the gel, 2 ml aliquots were 
put into each mini-column and allowed to settle, taking care to exclude air 
bubbles. Each column was then equilibrated with 10 ml of wash buffer: 
250 mmol/1 ammonium acetate 
50 mmol/l magnesium chloride 
3 mmol/l sodium azide.
The pH was adjusted to 8.8 using 5M NaOH.
Serum (100 |il) was diluted in 1.5 ml of deionised water. A 150 |Lil aliquot 
of the diluted serum was applied to a 1 ml affinity column at room 
temperature. 1 ml of wash buffer was then added and allowed to soak in, 
followed by a further 8 ml of wash buffer. The entire eluate containing the 
unglycated protein (9.15 ml) was collected in a Universal container. The 
glycated protein fraction was eluted from the column with 3 ml of elution 
buffer:
200 mmol/l sorbitol
50 mmol/l disodium ethyldiaminetetraacetic acid (disodium EDTA)
100 mmol/l tris(hydroxymethyl)methylamine 
3 mmol/l sodium azide.
The pH was adjusted to 8.8 using 5M NaOH.
148
This glycated fraction was collected in 5 ml tubes, then columns were 
washed with 5 ml deionised water followed by 10 ml of 0.01 mol/1 acetic 
acid for regeneration. Columns were stored in the regeneration solution at 
4 °C in the dark.
3.11.1. Glycated albumin measurement by affinity chromatography.
Albumin in the 2 eluates was measured by immunoturbidimetry as described 
by Gerbaut (1987) on a Cobas Bio centrifugal analyser using the DENS plot 
option (Data Evaluation for Non-linear Standard curves). Human protein 
standard SPSOl from the Sheffield Protein Reference Unit (Yorkshire, UK) 
was diluted in wash buffer to produce a range of albumin standards from
1.6-51.9 mg/1. Nephelometric grade goat anti-human albumin antiserum was 
purchased from Atlantic Antibodies (Incstar Ltd, Wokingham, UK) and used 
undiluted, together with a 45 g/1 solution of polyethylene glycol in PBS for 
this assay. The eluates containing unglycated albumin were diluted 1:2 in 
wash buffer prior to analysis.
When the albumin assay was set up as described by Gerbaut (1987), within- 
batch precision ranged from a CV of 1.3% at 47 mg/1 to 2.9% at 21 mg/1 
although the assay was found to be linear down to 2 mg/1.
As demonstrated by Reed, Bhatnagar, Dhar and Winocour (1986), using 
diluted antibody in a similar assay, analysis of albumin standards prepared 
in wash buffer or elution buffer gave superimposable standard curves so 
only one set of standards was required.
Glycated albumin results were expressed as a percentage of the total 
albumin, using the following calculation:
% GA____________ {glycated albumin]__________
6.1 [unglycated albumin]+[glycated albumin]
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3.1.1.2, Glycated total protein measurement by affinity chromatography.
Total protein in the 2 eluates was measured by a modification of the method 
of Bradford (1976) using the Bio-Rad Protein Assay reagent (Bio-Rad 
Laboratories Ltd, Watford, Hertfordshire, UK) as described by Gould et al 
(1984). The reagent was diluted with water and glacial acetic acid in the 
ratio 4:5:1 and the assay was adapted for use on the Cobas Bio centrifugal 
analyser using the following parameters on the DENS plot option:
1. Units mg/1
2. Calculation factor 1000
3. Standard 1 concentration 0.0
3. Standard 2 concentration 3.9
3. Standard 3 concentration 7.8
3. Standard 4 concentration 15.5
3. Standard 5 concentration 31.0
3. Standard 6 concentration 62.0
6. Limit 0
7. Temperature °C 25.0
8. Type of analysis 7.1
9. Wavelength nm 595
10. Sample volume pi 80
11. Diluent volume pi 00
12. Reagent volume pi 80
13. Incubation time sec. 0
14. Start reagent volume pi 0
15. Time of first reading sec. 0.5
16. Time interval sec. 60
17. Number of readings 6
18. Blanking mode 0
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19. Printout mode 6
The human protein standard SPSOl from the Sheffield Protein Reference 
Unit was diluted in wash buffer to produce a range of protein standards 
from 0.0 to 62.0 mg/1. Assay of standards in elution buffer was found to 
increase the results by a constant amount over the whole range, so for 
analysis of the glycated fractions in elution buffer printout mode 6 on the 
Cobas Bio was used to carry out an elution buffer blank. This first calibrator 
was determined within-run and the wash buffer calibration curve was 
automatically corrected by the analyser.
As with the albumin assay, the eluates containing unglycated protein were 
diluted 1:2 in wash buffer prior to analysis.
Within-batch precision for this protein assay ranged from a CV of 1.4% at 
63 mg/1 to 2.7% at 17 mg/1. The assay was linear down to less than 1 mg/1. 
Glycated total protein results were expressed as a percentage of the total 
protein, using the following calculation:
% GTP----------------- \glycatedprotein\__________ ^100
6.1 [unglycated protein]+[glycated protein]
3.1.2. Reference ranges and imprecision of affinity chromatography 
results.
Assay reference ranges were compiled from the samples described in 
Chapter 2 (section 2.5.2) which were used to establish the Dns-PBA 
reference range, although fewer samples were analysed by affinity 
chromatography. For the 52 non-diabetics studied (24 male, 28 female, age
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range 1 8 -9 1  years), the mean ± SD values for % glycated albumin (%GA) 
were 3.35 ± 0.85% with a range of 1.65 - 5.05%. % glycated total protein 
(%GTP) was measured on the same 52 non-diabetics and produced a mean 
± SD of 5.62 ± 0.72% with a range of 4.18 - 7.06%. These results are 
shown graphically as histograms in Figures 3.1.1 and 3.1.2, together with 
the results from the diabetic population (n=86,48 male 38 female, age range 
16 - 82) which gave a mean ± SD %GA of 7.51 ± 3 .11%  and %GTP of 
9.96 ± 3.28%. For the %GA results, the diabetic mean is 2.2 times the non­
diabetic mean and for the %GTP results the diabetic mean is 1.8 times the 
non-diabetic mean.
Pregnant subjects were excluded from these studies.
Assay imprecision was assessed by replicate analyses of patients’ serum 
with low and high levels of glycation. Within-batch CVs ranged from 6.2% 
to 7.6% for %GA, and 5.9% to 6.8% for %GTP. Between-batch CVs ranged 
from 7.8% to 12.9% for %GA, and 7.7% to 8.0% for %GTP.
3.1.3. Correlation of Dns-PBA fluorescence assay results with affinity 
chromatography values.
Least squares regression analysis for the correlation of a wide range of 
DF/g/1 results against %GA and %GTP for the diabetic and non-diabetic 
populations (including pregnant subjects, n = 144) is shown in Figures 3.1.3 
and 3.1.4. Highly significant correlation coefficients were achieved in both 
cases when all results were considered, but the correlation for diabetic 
patients only was reduced slightly and the correlation for non-diabetic 
patients only was negligable.
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FIG. 3.1.1:Diabetic and non-diabetic 
reference ranges for % glycated albumin 
by affinity chromatography.
16-
14-
1 2 -
I
4 -
2 -
1.65 3.05 4.45 5.85 7.25 8.65 10.05 11.45 13.85 15.25 16.65 18.05 19.45
% Glycated Albumin (mean of group) 
—  Non-diabetics —  Diabetics
Assay results were obtained over the course of 1 year, for a total of 52 non­
diabetics and 86 diabetic patients.
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FIG. 3.1.2: Diabetic and non-diabetic 
reference ranges for % glycated total 
protein by affinity chromatography.
22
2 0 -
1 8 -
1 4 -I
4.30 6.70 9.10 11.50 13.90 16.30 18.70 23.5021.10
% Glycated Total Protein (mean of group) 
—  Non-diabetics —  Diabetics
Assay results were obtained over the course of 1 year, for a total of 52 non­
diabetics and 86 diabetic patients.
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FIG. 3.1.3: Correlation of % glycated 
albumin against DF/g/1.
7 -
2 -
% Glycated Albumin
0 Non-diabetics ♦ Diabetics
Standardised DF/g/1 results were correlated against % glycated albumin 
results as measured by affinity chromatography. The line of best fit by least 
squares analysis of the 144 data points is defined by y = 0.32%: + 0.88, and 
r = 0.842. For the diabetic samples (n = 92), y = 027x + 1.34, r = 0.734. 
For the non-diabetic samples (n = 52), y = 0.09% + 1.50, r = 0.184.
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FIG. 3.1.4: Correlation of %glycated
total protein against DF/^1.
8 -
7 -
2 -
0 2 4 6 a 10 12 14 16 18 20 22 24 26
% Glycated Total Protein 
0 Non-diabetics ♦ Diabetics
Standardised DF/g/1 results were correlated against % glycated total protein 
results as measured by affinity chromatography. The line of best fit by least 
squares analysis of the 144 data points is defined by y = 0.31% + 0.18, and 
r  = 0.845. For the diabetic samples (n = 92) y = 0.28% + 0.61, r  = 0.778. For 
the non-diabetic samples (n = 52) y = 0.10% + 1.21, r  = 0.194.
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SECTION 2. THE INVESTIGATION OF POSSIBLE ANALYTICAL 
INTERFERENCES WITH THE DANSYL-PBA ASSAY.
Interference studies were performed as recommended by the International 
Federation of Clinical Chemistry (IFCC, 1984) which suggests that a 
quantity produces an analytical interference if Student’s t-test for paired data 
shows significant differences (p<0.01) between the results obtained in the 
presence and absence of the interfering quantity in the specimens assayed.
3.2.1. The effect of anticoagulant.
Although the Dns-PBA assay has been optimised in the previous chapter for 
analysis of serum samples, several types of plasma are also received in the 
routine clinical chemistry laboratory and it is always possible that incorrect 
specimen types will be presented for analysis. It is therefore helpful to know 
whether other sample types can be assayed to give reliable results. It would 
also be convenient to be able to perform many of the analyses frequently 
required on diabetic patients using one particular specimen type eg. Samples 
collected into potassium ethylenediaminetetraacetic acid (K-EDTA) 
anticoagulant for HbAj^, analysis may also be suitable for the Dns-PBA 
assay.
Paired serum and plasma samples were collected from the routine workload 
within the Chemistry and Haematology departments at Frimley Park 
Hospital and frozen at -20 °C for up to 1 week prior to analysis.
3.2.1.1. Lithium heparin anticoagulant.
Pairs of samples from non-diabetics (n = 23) were assayed in sequence on 
the same run for DF and albumin analysis. Student’s paired t-test showed 
no significant difference between DF, albumin or DF/g/1 results from serum
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or lithium heparin plasma.
3.2.1.2, K-EDTA anticoagulant.
Pairs of samples from diabetics (n = 20) were assayed in sequence on the 
same run for DF and albumin analysis. Student’s paired t-test showed no 
significant difference between DF, albumin or DF/g/1 results from serum or 
K-EDTA plasma.
3.2.1.3. Fluoride oxalate anticoagulant.
Pairs of samples from non-diabetics (n = 21) were assayed in sequence on 
the same run for DF and albumin analysis. Although no significant 
difference was found between DF or DF/g/1 results from serum or fluoride 
oxalate plasma, the albumin results were significantly decreased in the 
plasma samples (p<0.001).
Results of the effects of these 3 anticoagulants are shown in Table 3.2.1.
3.2.2. Schiff base interference.
A patient serum sample with a glucose level of 3.7 mmol/1 was divided into 
2 aliquots of 2 ml. One of these aliquots was placed at 4°C whilst the other 
was dialysed against PBS (pH 7.4) at 37 °C for 24 hours in order to 
dissociate any Schiff s base. Following this incubation, both samples were 
assayed 20 times by the Dns-PBA assay, and also for serum albumin levels 
by the BCG method (Rodkey, 1965). The mean DF/g/1 ± SD result obtained 
for the control sample was 1.84 ± 0.23 and for the sample with dissociated 
Schiff s base was 1.80 ± 0.31. These results were not statistically 
significantly different by Student’s t-test for differences between means,
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Table 3.2.1. Tbe effect of various anticoagulants on tbe Dns-PBA assay 
results.
Anticoagulant n Mean DF/g/1 Mean(serum - plasma)
Serum Plasma DF/g/1 ± SD
Lithium heparin 23 1.67 1.57 0.09 ± 0.33
K-EDTA 20 3.40 3.42 -0.02 ± 0.39
Fluoride oxalate 21 1.39 1.35 0.04 ± 0.31
None of the 3 anticoagulants gave any significant difference in DF/g/1 
results when assessed by Student’s paired t-test (p>0.05).
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which implies that the labile aldimine intermediate does not interfere in this 
assay.
3.2.3. Free glucose interference.
Diabetic and non-diabetic serum samples (20) were selected from the routine 
workload and each divided into 5 aliquots of 200 |il. A stock solution of 
0.88 mol/1 D-glucose was diluted in deionised water to produce 0.44, 0.22 
and 0.11 mol/1 glucose standards. A 20 |xl aliquot of each glucose 
concentration was added to one of the 200 |t1 aliquots of each serum sample. 
This produced 4 test samples containing glucose additions of 10 ,20 ,40  and 
80 mmol/1 plus one control containing the baseline level of glucose within 
the original sample. All samples were mixed well and assayed within 15 
minutes for DF ensuring that each group of 5 samples was assayed together 
on the same run. Results are shown in Table 3.2.2 which indicate that 
glucose levels above 40 mmol/1 will appreciably increase the results, with
p<0.01.
Aqueous dilutions of the glucose standards prepared to produce equivalent 
levels, all gave duplicate DF results well below the assay limit of detection.
3.2.4. Haemoglobin interference.
Haemolysed samples are often received in the laboratory so their suitability 
for DF analysis was investigated.
Haemolysate was prepared as described by Glick et al (1986) to produce a 
final haemoglobin concentration of 181 g /lin  deionised water. Haemoglobin 
solutions containing 90.5, 45.0 and 22.5 g/1 were prepared from 
this haemolysate. Diabetic and non-diabetic serum samples (20) with no 
visible haemolysis were each divided into 4 aliquots of 200 |Lil. A 12 |xl 
aliquot of each haemoglobin concentration (or a 12 jiil water blank) was
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Table 3.2.2. The effects of free glucose, haemolysis and lipaemia on the
Dns-PBA assay results.
Possible Added Mean DF Mean (blank-test)
Interfèrent Concentration D F ±  SD
Glucose 0 mmol/1 97
10 102 -5 ±  15
20 103 -6 + 1 1  *
40 105 -8 + 15 *
80 106 -9 + 11 **
Haemoglobin 0 g/1 73
1.3 71 2 + 1 5
2.5 68 5 ±  13
5.1 63 10 + 16 **
Lipaemia 0 mmol/1 55
(Triglycerides) 3.12 48 Y + 9 **
6.24 45 10 + 9 ***
12.5 46 9 + 1 2  **
25.0 43 12 ± 1 1  ***
n = 20 for all analyses. Data was evaluated using Student’s paired t-test.
* Statistically significant difference, p<0.05. 
Statistically significant difference, p<0.01. 
Statistically significant difference, p<0.001.
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added to one of the 200 |xl aliquots of each serum sample. This produced 
3 test samples containing haemoglobin additions of 5.1, 2.5 or 1.3 g/1 plus 
one non-haemolysed serum control. All samples were mixed well and 
assayed for DF ensuring that each group of 4 samples was assayed together 
on the same run. Results are shown in Table 3.2.2 which indicate that only 
gross haemolysis (haemoglobin > 2.5 g/1) significantly reduced the results 
with p<0.01.
3.2.5. Lipaemia interference.
Intralipid 20% was obtained from KabiVitrum Ltd (Buckinghamshire, UK) 
and used to simulate the turbidity of lipaemia.
Non-lipaemic serum samples (20) were divided as previously described and 
dilutions of intralipid in 0.9% saline were added to produce additional 
triglyceride concentrations of 3.13, 6.25, 12.50 and 25.00 mmol/1. These 
concentrations were verified using a Beckman triglyceride assay kit on the 
Cobas Bio analyser. The mean triglyceride concentration of the 20 baseline 
samples was also determined (1.93 mmol/1). All samples were mixed well 
and assayed for DF ensuring that each group of 5 samples was assayed 
together. Results are shown in Table 3.2.2 which indicate that even a small 
amount of visible lipaemia (triglyceride levels around 3 mmol/1) will 
significantly reduce the DF results (p<0.01).
3.2.6. Bilirubin interference.
Bilirubin and dimethyl sulphoxide (DMSO) were obtained from the Sigma 
Chemical Company Ltd, Poole, Dorset, UK.
Bilirubin (6 mg) was suspended in 100 |iil DMSO (as described by Glick et 
al, 1986) followed by 200 pi of Na2C0 3  (0.1 mol/1). An aliquot of this 
bilirubin solution was added to 4.7 ml of human serum and mixed. HCl (0.1
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mol/1) was added to restore the original pH and the sample was mixed 
again. Equivalent volumes of DMSO, NUiCOj, and HCl were added to an 
identical serum aliquot and the 2 samples were combined to produce final 
bilirubin concentrations of 518, 259, 129 and 32 pmol/1. These dilutions 
were divided and each assayed 20 times. Student’s t-test for the difference 
between means was applied to the data and was able to show that there was 
no significant interference from bilirubin in the Dns-PBA assay below levels 
of 260 pmol/l. There was a significant decrease in mean results from 55 to 
37 DF units in the presence of 518 pmol/1 bilirubin (p<0.001).
3.2.7. Urea interference.
Diabetic and non-diabetic serum samples (20) with urea levels of less than 
6 mmol/1 were divided into aliquots as previously described. A 330 mmol/1 
urea stock solution prepared in deionised water was used to produce final 
serum urea additions of 10, 20 and 30 mmol/1. All samples were mixed well 
and assayed for DF ensuring that each group of 4 samples was assayed 
together. Results are shown in Table 3.2.3 which indicate that urea can 
significantly increase the DF results when levels are above 20 mmol/1.
3.2.8. Salicylate interference.
Non-diabetic serum samples (20) with undetectable amounts of salicylate (as 
assayed by the method of Keller (1947) automated on the Cobas Bio 
analyser) were divided into aliquots as previously described. A 27.5 mmol/1 
stock solution of sodium salicylate was prepared in deionised water and used 
to produce final serum salicylate concentrations of 625, 1250 and 2500 
pmol/1. All samples were mixed well and assayed for DF as before. Results 
are shown in Table 3.2.3 which indicate that salicylate levels above 625 
pmol/1 can significantly increase the DF results (p<0.01). Only 9 paired
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Table 3.2.3. The effects of urea, salicylate and ibuprofen on the Dns-
PBA assay results.
Possible Added 
Interfèrent Concentration
Mean DF Mean (blank-test) 
DF + SD
Urea 0 mmol/1 84
10 83 1 ± 14
20 92 -8 ± 1 4  *
30 90 -6 ± 12 **
Salicylate 0 pmol/1 63
625 65 -2 ±  13
1250 (65) (-12 ±1 4 )  **
2500 72 -9 ± 13 **
Ibuprofen 0 pmol/1 67
61 66 1 ± 10
123 69 -2 ± 13
245 68 -1 ± 15
n = 20 for all analyses except for those values in brackets where n = 9 and 
the corresponding blank DF value is 53. Data was evaluated using Student’s 
paired t-test.
* Statistically significant difference, p<0.05 
Statistically significant difference, p<0.01
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results were available for the addition of 1250 pmol/1 salicylate as the 
remaining samples all gave results with an ‘overflow’ flag for analysis with 
reagent A, indicating fluorescence emission greater than the preset top limit 
for the photomultiplier.
3.2.9. Ibuprofen interference.
Ibuprofen was obtained from the Sigma Chemical Company (Poole, Dorset, 
UK). The compound (0.013 g) was dissolved in 100 pi DMSO, which was 
diluted down in ibuprofen-free serum to produce a 2.7 mmol/1 solution. A 
control serum was prepared using 100 pi DMSO with no added ibuprofen, 
which was used to produce 2 further ibuprofen concentrations of 1.4 and 0.7 
mmol/1 from the 2.7 mmol/1 preparation. This ensured the presence of an 
equivalent amount of DMSO in each dilution.
The serum ibuprofen standards were then used to augment 20 serum 
samples to produce levels of 61, 123 and 245 pmol/1. All samples were 
mixed well and assayed for DF as before. Results are shown in Table 3.2.3 
which indicate that ibuprofen has had no effect on the DF results at any of 
the levels investigated.
3.2.10. Ascorbate interference.
A 2.2 mmol/1 stock solution of L-ascorbate, obtained from the Sigma 
Chemical Company Ltd (Poole, Dorset, UK), was prepared in deionised 
water. Serum samples (20) were augmented with 2.2 or 1.1 mmol/1 
ascorbate (or a water blank) to produce final serum additions of 100 and 200 
pmol/1. All samples were mixed well and assayed immediately for DF as 
before. Results are shown in Table 3.2.4 which indicate that ascorbate does 
not interfere in the assay at levels up to 200 pmol/1.
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3.2.11. Pyridoxal Phosphate interference.
A 440 pmol/1 stock solution of Pyridoxal-5’-phosphate (PLP), obtained from 
the Sigma Chemical Company Ltd (Poole, Dorset, UK), was prepared in 
deionised water. Serum samples (20) were augmented with 44 or 22 pmol/1 
PLP (or a water blank) to produce final serum additions of 4 and 2 pmol/1. 
All solutions and samples were stored in the dark whenever possible, then 
mixed well and assayed for DF as before. Results are shown in Table 3.2.4 
which indicate that PLP does not interfere in the assay at levels up to 4 
pmol/1.
3.2.12. a-Tocopherol interference.
An 880 mg/1 solution of DL-a-tocopherol, obtained from the Sigma 
Chemical Company Ltd (Poole, Dorset, UK), was prepared in 95% ethanol 
as described by Ceriello (1988). A 220 mg/1 solution was prepared from this 
stock and the 2 concentrations were used to augment 20 serum samples to 
produce final a-tocopherol additions of 20 and 80 mg/1. Blanks were 
prepared by the addition of an equivalent volume of 95% ethanol. All 
solutions and samples were stored in the dark whenever possible, then 
mixed well and assayed for DF as before. Results are shown in Table 3.2.4 
which indicate that although DF results increased slightly in the presence of 
80 mg/1 a-tocopherol, this increase was not significant at the 1% level.
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Table 3.2.4. The effects of ascorbate, pyridoxal phosphate and a- 
tocopherol on the Dns-PBA assay results.
Possible Added Mean DF Mean (blank-test)
Interfèrent Concentration D F + S D
Ascorbate 0 pmol/1 91
100 90 1 + 12
200 91 0 + 1 2
Pyridoxal- 0 pmol/l 56
5’-phosphate 2 51 5 ±  11
4 55 1 + 13
a-tocopherol 0 mg/1 57
20 62 -5 ±  18
80 65 -8 + 13 *
n = 20 for all analyses. Data was evaluated using Student’s paired t-test. 
* Statistically significant difference, p<0.05.
167
SECTION 3. THE INVESTIGATION OF POSSIBLE INTERFERING 
FACTORS IN THE BINDING OF GLUCOSE TO SERUM ALBUMIN. AS 
MEASURED BY THE DANSYL-PBA FLUORESCENCE ASSAY.
3.3.1. In vitro studies.
In vitro glycation studies were performed with human serum albumin (HS A) 
solutions (40 g/1) prepared in phosphate buffered saline (PBS: 0.1 mol/1 
KH2PO4, 0.1 mol/1 Na2P 0 4 , pH 7.4) containing 1% sodium azide. HSA was 
obtained from the Sigma Chemical Company Ltd (Poole, Dorset, UK) as 
both the fraction V powder and the fatty acid free fraction V. All 
incubations were performed at 37 °C with either an appropriate blank 
addition or one of two concentrations of the proposed interfèrent (conc.i and 
conc.2), in the presence of 25 mmol/1 D-glucose. Seven separate incubations 
were set up for both the HSA with and without bound fatty acids (450 pi), 
following the protocol outlined in Table 3.3.1. This produced results for 
samples preincubated for 3 days (72 hours) with the interfèrent prior to 
addition of glucose and also for samples exposed to the interfèrent only in 
the presence of glucose for 3 days.
Following incubation, samples 2-7 were dialysed against 0.9% saline (2 
litres) overnight at room temperature. All samples were assayed for DF ( 6  
times per sample), and albumin levels by the BCG method. Student’s t-test 
for assessing the difference between means was applied to the data, for a 
comparison of test results against their respective controls i.e. samples 3  and 
4 were compared to control sample 2 and samples 6  and 7 were compared 
to control sample 5.
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Table 3.3.1. Protocol for in vitro incubations of human serum albumin 
(HSA) with 25 mmol/1 D-glucose and potential interferents.
HSA sample Day 0 Day 3
number (450 pi) additions additions
1 PBS (100 pi) -
2 - PBS (50 pi) + glucose (50 pi)
3 - conc.i (50 pi) + glucose (50 pi)
4 - conc .2 (50 pi) + glucose (50 pi)
5 PBS (50 pi) Glucose (50 pi)
6 conc.i (50 pi) Glucose (50 pi)
7 conc.2 (50 pi) Glucose (50 pi)
Two concentrations of each interfèrent (conc.j and conc.2) were investigated 
with fraction V albumin and fatty acid free fraction V albumin. A stock 
solution of 275 mmol/1 D-glucose was added on day 3 to produce a final 
concentration of 25 mmol/1 in each sample. Dialysis against 0.9% saline was 
performed following a total of 6 days incubation for those samples 
preincubated with glucose.
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3.3.1.1. The in vitro effect of urea on glycation of HSA.
Solutions of urea were prepared in PBS: 
conc.i = 110 mmol/1, conc .2 = 220 mmol/1.
This produced final concentrations of 10 mmol/1 and 20 mmol/1 urea in the 
HSA incubations. Results are shown in Table 3.3.2 which indicate that the 
urea has had no effect on glycation under any of the conditions examined.
3.3.1.2. The in vitro effect of bilirubin on glycation of HSA.
Solutions of bilirubin were prepared in DMSO: 
conc.i = 561 pmol/1, conc .2 = 1122 pmol/1.
This produced final concentrations of 51 pmol/1 and 102 pmol/1 bilirubin in 
the HSA incubations. Control incubations incorporated DMSO in place of 
the PBS blank. Results are shown in Table 3.3.2 which indicate that 
bilirubin can influence the binding of glucose to HSA, particularly when 
pre-incubated with bilirubin in the absence of glucose. This effect was more 
pronounced for the fatty-acid free HSA and appeared to be concentration 
dependent at the levels studied.
3.3.1.3. The in vitro effect of salicylic acid on glycation of HSA.
Solutions of sodium salicylate were prepared in PBS: 
conc.i = 13.75 mmol/1, conc .2 = 27.50 mmol/1.
This produced final concentrations of 1250 pmol/1 and 2500 pmol/1 
salicylate in the HSA incubations. The results shown in Table 3.3.3 indicate 
that salicylate can reduce HSA glycation as measured by the Dns-PBA 
assay, even when in direct competition with glucose. This effect was more 
pronounced for the HSA with bound fatty-acids.
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Table 3.3.2. The effect of bilirubin and urea on HSA glycation as
measured by the Dns-PBA assay.
Sample Mean DF/g/1 + SD
number Bilirubin Urea
HSA:
FAF-HSA:
1 2.68 ± 0.43 2.61 ± 0.36
2 5.36 ± 0.29 4.79 ± 0.29
3 5.38 ± 0.28 4.66 ± 0.34
4 4.64 ± 0.46 * 4.79 ± 0.39
5 5.83 ± 0.24 5.07 ± 0.29
6 5.41 ± 0.14 * 4.75 ± 0.36
7 4.96 ± 0.46 * 4.86 ± 0.25
1 7.00 ± 0.38 6.74 ± 0.43
2 8.71 ± 0.17 8.04 ± 0.65
3 7.88 ± 0.38 ** 8.48 ± 0.65
4 6.33 ± 0.26 ** 8.30 ± 0.61
5 10.19 ± 0.44 8.00 ± 0.36
6 8.63 ± 0.33 ** 8.36 ± 0.28
7 7.71 ± 0.39 *** 7.72 ± 0.28
Sample numbers refer to those described in Table 3.3.1.
* Statistically significant difference from control means, p<0.05.
** Statistically significant difference from control means, p<0.01.
*** Statistically significant difference from control means, p<0.001.
HSA = Human serum albumin.
FAF-HSA = Fatty acid free human serum albumin.
Each sample was analysed 6 times and a comparison between means was 
made using Student’s t-test.
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Table 3.3.3. The effect of salicylate and ibuprofen on HSA glycation as
measured by the Dns-PBA assay.
Sample Mean DF/gA ± SD______
number Salicylate Ibuprofen
HSA:
FAF-HSA:
1 2.69 ± 0.42 4.00 ± 0.09
2 5.26 ± 0.17 8.28 ± 0.24
3 4.83 ± 0.50 7.78 ± 0 .15  *
4 4.68 ± 0.40 * 7.61 ± 0.21  **
5 5.42 ± 0.33 7.45 ± 0.34
6 5.16 ± 0.40 7.03 ± 0 .1 0  *
7 4.59 ± 0 .33  ** 7.31 ± 0.41
1 5.43 ± 0.43 8.41 ± 0.16
2 8.86 ± 0.62 12.69 ± 0.42
3 7.86 ± 0.55 * 12.70 ± 0.22
4 8.00 ± 0.58 12.23 ± 0.46
5 8.52 ± 0.43 12.69 ±0.31
6 8.24 ± 0.68 12.40 ± 0.13
7 8.56 ± 0.36 11.71 ± 0 .23  **
Sample numbers refer to those described in Table 3.3.1,
* Statistically significant difference from control means, p<0.05.
** Statistically significant difference from control means, p<0.01.
HSA = Human serum albumin.
FAF-HSA = Fatty acid free human serum albumin.
Each sample was analysed 6 times and a comparison was made between 
means using Student’s t-test.
172
3.3.1.4. The in vitro effect of ibuprofen on glycation of HSA.
Solutions of ibuprofen were prepared in DMSO: 
conc.i = 1.35 mmol/1, conc .2 = 2.70 mmol/1.
This produced final concentrations of 123 pmol/1 and 245 pmol/1 ibuprofen 
in the HSA incubations. Results are shown in Table 3.3.3 which indicate 
that ibuprofen is also capable of significantly reducing glycation of HSA as 
perceived by the Dns-PBA assay.
3.3.1.5. The in vitro effect of ascorbic acid on glycation of HSA.
Solutions of ascorbic acid were prepared in deionised water (to maintain 
stability at a lower pH than PBS): 
conc.i = 1.1 mmol/1, conc .2 = 2.2 mmol/l.
This produced final concentrations of 100 pmol/1 and 200 pmol/1 ascorbate 
in the HSA incubations. The results shown in Table 3.3.4 indicate that the 
ascorbate has had no significant effect on glycation of HSA with bound 
fatty-acid but has produced a significant decrease in DF results (p<0.05) 
when incubated with fatty-acid free HSA.
3.3.1.6. The in vitro effect of pyridoxal phosphate on glycation of HSA.
Solutions of PLP were prepared in PBS: 
conc.i = 22 pmol/1, conc .2 = 44 pmol/1.
This produced final concentrations of 2 pmol/1 and 4 pmol/1 PLP in the 
HSA incubations. Results are shown in Table 3.3.4 which indicate that the 
highest concentration of PLP (4 pmol/1) has significantly increased the DF 
results obtained for the HSA with bound fatty-acids (p<0.01).
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Table 3.3.4. The effect of in vitro ascorbic acid, pyridoxal phosphate
and alpha-tocopherol on HSA glycation as measured by the Dns-PBA
assay.
number Ascorbate PLP a-tocopherol
HSA: 1 2.65 ± 0.27 2.43 ±0.13 3.90 ± 0.33
2 4.82 ± 0.32 4.10 ± 0.13 7.50 ± 0.25
3 5.08 ± 0.15 4.22 ± 0.16 7.10 ± 0.29 *
4 4.93 ± 0.32 4.42 ± 0.10 ** 7.08 ± 0.29 *
5 4.86 ± 0.18 4.32 ± 0.19 7.19 ± 0.23
6 5.07 + 0.32 4.22 ± 0.13 6.86 ± 0.21 *
7 5.04 ± 0.36 4.77 ± 0.10 ** 7.42 ± 0.42
FAF- 1 7.29 + 0.38 6.40 ± 0.28 8.67 ± 0.20
HSA: 2 8.43 ± 0.26 7.42 ± 0.38 9.05 ± 0.29
3 7.96 ± 0.15 * 7.11 ±0.33 8.50 ±  0.50
4 8.44 ± 0.36 7.50 ± 0.38 9.35 ± 0.35
5 8.28 ± 0.36 7.44 ± 0.48 12.30 ± 0.44
6 8.04 ± 0.27 7.43 ± 0.32 12.50 ±  0.23
7 7.59 + 0.22 * 7.57 ± 0 .14 12.96 ± 0.36 *
Sample numbers refer to those described in Table 3.3.1.
* Statistically significant difference from control means, p<0.05. 
Statistically significant difference from control means, p<0.01.
HSA = Human serum albumin.
FAF-HSA = Fatty acid free human serum albumin.
Each sample was analysed 6 times and a comparison was made between 
means using Student’s t-test.
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3.3.I.7. The in vitro effect of a-tocopherol on HSA glycation.
Solutions of a-tocopherol were prepared in 95% ethanol: 
conc.i = 220 mg/l, conc.j = 880 mg/1.
This produced final concentrations of 20 mg/l and 80 mg/l a-tocopherol in 
the HSA incubations. Control incubations incorporated 95% ethanol in place 
of the PBS blank. Results are shown in Table 3.3.4 which indicate that the 
a-tocopherol has significantly reduced glycation of HSA with bound fatty- 
acids (p<0.05) but significantly increased glycation of the fatty-acid free 
HSA (p<0.05).
3.3.2. In vivo studies»
All individuals recruited to these in vivo studies were non-diabetic according 
to the criteria of the World Health Organisation (1980), and maintained their 
normal lifestyles throughout the study period.
3.3.2.I. The in vivo effect of ascorbic acid on Dns-PBA assay results.
Volunteers for this study (6 male, 6 female, age 19-50 years) were recruited 
at the Department of Biochemistry, Royal East Sussex County Hospital, 
Hastings, and were requested to take 3 tablets of 200 mg ascorbic acid 
(Roche Products Ltd, Welwyn Garden City) first thing in the morning every 
day for a period of 8 weeks. Basal fasting blood samples were taken prior 
to commencing the ascorbate, in addition to fasting samples taken after 2, 
4, 6 and 8 weeks of supplementation. Blood samples were collected into 
fluoride oxalate anticoagulant for glucose analysis, and K-EDTA tubes for 
all other tests. EDTA plasma was stored at -20 °C until batch analysis was 
possible at the end of the study. The results of Dns-PBA assay analysis are 
shown in Table 3.3.5 which suggests that the in vivo ascorbate can cause a
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Table 3.3.5. Tbe effect of in vivo ascorbic acid on plasma protein
glycation as measured by tbe Dns-PBA assay.
Time of sample Mean DF/g/1 + SD Mean (Basal-% weeks)
(weeks) (n=12) DF/g/1 ± SD
Basal 1.55 ± 0.22
2 1.74 ± 0.28 -0.19 ± 0.21 **
4 1.61 ± 0.39 -0.06 ± 0.40
6 1.69 + 0.28 -0.14 + 0.31
8 1.75 + 0.20 -0.20 + 0.29 *
Ascorbic acid (600 mg) was taken daily by 12 individuals over a period of 
8 weeks. Student’s paired t-test was applied to the data.
* Statistically significant difference from basal levels, p<0.05.
** Statistically significant difference from basal levels, p<0.01.
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significant increase in DF/g/1 results. The same samples were also assayed 
for glycated total protein by affinity chromatography and glycated 
haemoglobin both by affinity chromatography and agar gel electrophoresis. 
These assays were performed at the Royal East Sussex County Hospital, as 
described by Marr (1990) and demonstrated no significant change in glucose 
levels throughout the course of the study. Glycated total protein levels were 
found to decrease significantly (p<0.001) after 2 weeks and fall even lower 
as the study progressed. Glycated haemoglobin levels as measured by 
affinity chromatography were decreased significantly at 4 and 6 weeks 
(p<0.01) although no significant difference was observed at 8 weeks. When 
measured by electrophoresis the glycated haemoglobin levels were 
significantly increased at 2 weeks (p<0.05), 4 weeks (p<0.01) and 8 weeks 
(p<0.05).
3.3.2.2. The in vivo effect of pyridoxine hydrochloride on Dns-PBA 
assay results.
Volunteers for this study were recruited from healthy members of laboratory 
staff at Frimley Park Hospital. (3 male, 5 female, age 23-42 years). Subjects 
were required to take one 20 mg tablet of pyridoxine hydrochloride (Roche 
Products, Welwyn Garden City) 3 times a day with meals for a 6 week 
period. Basal blood samples (non-fasting) were taken prior to commencing 
the tablets, in addition to non-fasting samples taken after 2, 4 and 6 weeks 
of supplementation. All serum samples were stored at -20 °C to enable batch 
analysis at the end of the study. Samples were assayed for DF/g/1 and 
fructosamine levels, using the Fructosamine Plus assay. Throughout the 
study, various individuals became unavailable at the required time of 
phlebotomy. This resulted in decreased data for the 4 and 6 week samples. 
Results for these studies are shown in Tables 3.3.6 and 3.3.7 which indicate 
that the pyridoxine hydrochloride has had no significant effect on in vivo
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Table 3.3.6. The effect of in vivo pyridoxine hydrochloride on serum
protein glycation as measured by the Dns-PBA assay.
Time of sample Mean DF/g/1 + SD Mean (Basal-jc weeks)
(weeks) DF/g/1 ± SD
Basal 1.40 + 0.15
2 1.52 ± 0.16 -0.12 + 0.15
4 1.50 + 0.21 -0.10 + 0.28
6 1.43 ± 0.20 -0.01 ± 0.20
Pyridoxine hydrochloride (60 mg) was taken daily by 8 individuals for the 
basal and 2 week samples, 7 individuals for the 4 week samples and 6 
individuals for the 6 week samples. Student’s paired t-test was applied to the 
data, but no significant difference from basal levels was found at any stage.
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Table 3.3.7. The effect of in vivo pyridoxine hydrochloride on serum
protein glycation as measured by the Fructosamine Plus assay.
Time of sample Mean Fructosamine Mean (Basal-% weeks)
(weeks) pmol/1 ± SD p.mol/1 ± SD
Basal 255 ± 15 -
2 251 ± 18 4 + 7
4 255 ± 24 1 ± 13
6 261 ± 18 -6 + 3 **
Pyridoxine hydrochloride (60 mg) was taken daily by 8 individuals for the 
basal and 2 week samples, 7 individuals for the 4 week samples and 6 
individuals for the 6 week samples. Student’s paired t-test was applied to the 
data.
Statistically significant difference from basal levels, p<0.01.
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glycation as perceived by the Dns-PBA assay, but a significant increase in 
results was found for the Fructosamine Plus assay results after 6 weeks.
SECTION 4. INVESTIGATION OF THE SPECIFICITY OF THE 
DANSYL-PBA FLUORESCENCE ASSAY.
3.4.1. Dns-PBA fluorescence analysis of in vitro glycated albumin, a, B 
and y  globulin fraction proteins.
3.4.1.1. Preparation of protein fractions.
Globulin-free albumin, a  and p globulins and y globulins were obtained 
from the Sigma Chemical Company Ltd, Poole, Dorset, UK. A 40 g/1 
solution of each protein fraction was prepared in PBS, pH 7.4 and protein 
electrophoresis was performed on each fraction using the Helena Super Z 
electrophoresis system, in order to determine the purity of the samples. The 
albumin and y globulin fractions appeared to be very pure but a 
considerable amount of albumin was present in with the combined a  and p 
fraction. This albumin was therefore removed as described by Travis and 
Pannell (1973) using a Cibacron blue on glass column, prepared by the 
School of Biological Sciences, University of Surrey, Guildford, UK. Eluates 
were monitored for the presence of albumin or other proteins using the 
methods described in sections 3.1.1.1 and 3.1.1.2. Those fractions found to 
contain proteins other than albumin were pooled and dialysed against 2 
changes of deionised water (2 litres) overnight and then freeze-dried. The 
freeze-dried fraction was reconstituted in 0.9% saline.
180
3.4.1.2. In vitro glycation and sample analysis.
Each of the 3 protein fractions was divided into 3 equal aliquots and D- 
glucose was added to produce final concentrations of 250 mmol/1 and 500 
mmol/1 in 2 of the aliquots. An equivalent addition of PBS was made to the 
third aliquots as a control. All samples were incubated at 37 °C for 28 
hours, then dialysed against deionised water (2 litres) overnight, resulting in 
all glucose levels decreasing to below 1.1 mmol/1. Samples were analysed 
for total protein, albumin, Fructosamine Plus and DF in duplicate. Results 
are shown in Table 3.4.1, indicating that the Dns-PBA assay is not 
recognising the glycated a , P or y fractions. Results obtained with the 
Fructosamine Plus assay confirm that glycation did actually occur for all 3 
protein fractions.
3.4.2. Comparison of affinity chromatographv. Fructosamine Plus and 
Dns-PBA assay specificities.
Equal volumes of in vitro glycated plasma high and low standards (prepared 
in section 2.3.1) were combined to produce a sample giving a %GA result 
of 7.12 and a %GTP result of 10.22 by affinity chromatography. This 
sample was diluted in deionised water and affinity chromatography was 
performed as described in section 3.1.1 of this chapter, using 16 mini­
columns, applying the same diluted sample (approximately 0.7 mg protein) 
to each one.
All wash buffer eluates (containing the unglycated fractions) were combined 
and dialysed against deionised water (2 changes of 5 litres) for 24 hours, 
prior to freeze-drying. The freeze-dried fraction was reconstituted in 200 p.1 
of 0.9% saline and the complete affinity chromatography procedure was 
repeated with a 1:15 dilution of this sample (wash eluate 1) being applied 
to 8 individual columns (approximately 0.5 mg protein load to each
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Table 3.4.1. Results of Dns-PBA and Fructosamine Plus analysis on
glycated serum protein fractions.
Protein
fraction
Glucose
concentration
mmol/1
Mean
DF/TP(g)/l
(n=2)
Fruct Plus/TP 
|Limol/g
Albumin 0
250
500
3.33
19.09
18.46
5.19
23.48
25.83
a ,p
globulins
0
250
500
<L.D.
<L.D.
<L.D.
5.33 
15.00
18.33
Y
globulins
0
250
500
<L.D.
<L.D.
<L.D.
3.32
11.90
16.03
DF/TP(g)/l indicates the DF results divided by the total amount of protein 
in the sample assayed. Fructosamine Plus results were also divided by the 
total protein value.
Results below the limit of detection for the Dns-PBA assay are indicated by 
<L.D.
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column). Wash buffer eluates from this analysis were combined then 
dialysed as above and again freeze-dried. This fraction was reconstituted in 
150 \i\ of 0.9% saline to form wash eluate 2.
The original sample and the 2 wash eluates were assayed for total protein 
and albumin by the methods described in section 3.1.1, by the Fructosamine 
Plus assay and the Dns-PBA assay. Results of these analyses are shown in 
Table 3.4.2 which indicates that species eluting from the affinity columns 
in the unglycated wash fractions are still detectable as glycated species by 
both the Dns-PBA method and the Fructosamine Plus assay. When corrected 
for total protein values, the fructosamine results have actually increased in 
the unglycated wash fraction.
3.4.3. The effect of sorbitol on Dns-PBA binding.
Sorbitol (200 mmol/1) is used for affinity chromatography of glycated serum 
proteins in order to displace these proteins from the phenylboronate group 
on the affinity gel. The effect of sorbitol on the Dns-PBA assay was 
therefore compared to the effect of the boric acid, which is used to displace 
Dns-PBA in the actual assay.
A fresh solution of Dns-PBA reagent A was prepared as described in section 
2.2.8. From this solution reagent B was prepared containing 50 mmol/1 boric 
acid plus 2 further reagents containing either 25 or 50 mmol/1 sorbitol. All 
reagents were adjusted to pH 8.0. A saline blank was assayed in duplicate 
for each reagent, together with a patient sample assayed 5 times with each 
reagent on the Cobas Bio analyser as described in section 2.2.8.
The results shown in Table 3.4.3 indicate that sorbitol is reducing Dns-PBA 
fluorescence to a greater extent than an equivalent concentration of boric 
acid (p<0.001). However, the sorbitol blank values are also significantly 
lower than the boric acid blank.
In order to determine whether the effect of sorbitol on the Dns-PBA
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Table 3.4.2. Analysis of affinity cbromatograpby wasb eluates by tbe 
Dns-PBA assay and tbe Fructosamine Plus assay.
Sample DF Alb DF/g/1 Fruct Plus TP Fruct/TP
(g/l) jimol/1 (g/1) p.mol/g
Original
sample
144 39 3.69 342 59 5.80
Wash 
eluate 1
35 11 3.18 182 15 12.13
Wash 9 4 2.25
eluate 2 (<LD)
80 6 12.70
The original sample was fractionated by application to affinity 
chromatography columns. Wash eluate 1 comprises the unglycated eluates 
from the initial application, wash eluate 2 comprises the unglycated eluates 
from application of wash eluate 1.
Alb = serum albumin 
Fruct Plus = Fructosamine Plus 
TP = total serum protein
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Table 3.4.3. Tbe effect of sorbitol on Dns-PBA binding.
Reagent
Mean fluorescence (arbitrary units)
Saline blank 
(n=2)
Patient sample 
(n=5)
Reagent A 125 824
Reagent A plus 121
50 mM boric acid
725
Reagent A plus 
50 mM sorbitol
96 ** 627 ***
Reagent A plus 
25 mM sorbitol
92 ** 640 ***
Data was evaluated using Student’s t-test for differences between means.
** Statistically significant difference from results obtained with 50 
mmol/1 boric acid, with p<0.05.
*** Statistically significant difference from results obtained with 50 
mmol/1 boric acid, with p<0.001.
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fluorescence assay had a limiting concentration, the same patient serum 
sample was assayed in duplicate with Dns-PBA reagent containing 25, 50, 
100, 150 and 200 mmol/1 sorbitol. This produced a plateau of fluorescence 
results from 100 mmol/1, above which no further decrease in fluorescence 
was observed.
3.4.4. The influence of thiol groups on Dns-PBA binding.
3.4.4.I. Tbe effect of p-cbloromercuribenzoic acid on Dns-PBA binding.
p-Chloromercuribenzoic acid (PCMB) was obtained from the Sigma 
Chemical Company (Poole, Dorset, UK) and was used to block the thiol 
groups present on proteins in human serum.
A stock solution of 33 mmol/1 PCMB was prepared in 0.9% saline. The pH 
was adjusted to 10.5 with 1 mol/1 NaOH and the solution was placed in a 
water bath at 40 °C for 30 minutes. After this time any remaining sediment 
was removed by centrifugation and the stock solution was diluted in 0.9% 
saline to produce 16.5 and 8.25 mmol/l solutions, with the pH adjusted to
10.5. (These concentrations represent approximations due to the relative 
insolubility of PCMB).
Serum samples from the routine workload (200 |nl aliquots from 10 patient 
samples) were augmented with 20 \il of one of the PCMB solutions or a 
saline blank (pH 10.5) to produce final PCMB concentrations of 
approximately 0.75, 1.5 and 3.0 mmol/l. Samples were assayed for DF by 
the Dns-PBA assay ensuring that all 5 aliquots of each individual sample 
were assayed on the same run.
The results are shown in Table 3.4.4 which indicate that the PCMB has 
significantly increased the fluorescence results obtained with reagent A and 
reagent B, and as the increase in reagent A results is greater than that for 
reagent B , most of the DF values have also shown significant increases.
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Table 3.4.4. Tbe effect of PCMB on Dns-PBA binding in buman serum.
PCMB concentration in serum (mmol/l)
0 0.75 1.50
(control)
3.00
Mean fluorescence
Reagent A 802 866 866 871
Reagent B 741 794 799 800
DF 61 72 67 71
Mean (test-control) 
fluorescence 
Reagent A ± SD 
Reagent B ± SD 
DF ±SD
64+15*** 
53+14*** 
11+9 **
64+16***
58+15***
6+16
70+20***
60+20***
10+17***
Saline blank 
fluorescence 
Reagent A 
Reagent B
134
135
135
135
130
132
133
134
Patient serum samples (10) were augmented with PCMB and analysed by 
the Dns-PBA assay. Data was evaluated using Student’s paired t-test.
Fluorescence results are in arbitrary units.
** Statistically significant difference, with p<0.01.
*** Statistically significant difference, with p<0.001.
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Aqueous blank values remained comparable throughout.
3.4.4.2. The effect of glutathione on Dns-PBA binding.
Reduced glutathione (GSH) was obtained from the Sigma Chemical 
Company Ltd (Poole, Dorset, UK) and was used to introduce additional 
thiol groups into the Dns-PBA assay, both by breaking existing disulphide 
bonds in serum proteins and by contributing its own thiol group.
A stock solution of GSH (110 mmol/l) was prepared in bicine buffer and 
used to produce further concentrations of 55 and 11 mmol/l. An aliquot (20 
|xl) of each concentration, plus a bicine blank was added to 200 p,l aliquots 
from 10 patients’ serum samples to produce final GSH concentrations of 1, 
5, and 10 mmol/l. Samples were analysed for DF by the Dns-PBA assay 
ensuring that all 4 aliquots of each sample were assayed on the same run. 
The results are shown in Table 3.4.5 which indicates that the GSH has 
significantly decreased the fluorescence values obtained with reagent A and 
reagent B to a similar extent so that no significant difference occurred in the 
DF results.
3.4.5. In vivo and in vitro glycation studies on albumin Redbill.
Albumin Redhill is an unusual variant of human serum albumin, which has 
been isolated from the bisalbuminaemic sera of a mother and son living in 
the neighbourhood of Redhill, Surrey, UK (Brand et al, 1984). Work by 
Brennan et al (1990) has been able to confirm that albumin Redhill is a 
glycoprotein with an oligosaccharide attachment sequence centered on 
asparagine-318. This attachment sequence of asparagine-tyrosine-threonine 
arises from a mutation in normal human albumin of 320-alanine-+threonine. 
Albumin Redhill also posesses an additional arginine residue at position -1 
due to a mutation in the prepro sequence of albumin which gives rise to an
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Table 3.4.5. Tbe effect of GSH on Dns-PBA binding in buman serum.
GSH concentration in serum (mmol/l)
0 . 1.0 
(control)
5.0 10.0
Mean fluorescence
Reagent A 798 787 784 781
Reagent B 732 722 721 720
DF 66 65 63 61
Mean (test-control) 
fluorescence 
Reagent A ± SD 
Reagent B ± SD 
DF +SD
. 11+8 * *  
. 10+8 * *  
-1+13
-14+10 ** -17±19 * 
-11+8 ** -12+15 *
-3+12 -5+13
Saline blank 
fluorescence 
Reagent A 
Reagent B
134
132
133
131
133
131
131
131
Patient serum samples (10) were augmented with GSH and analysed by the 
Dns-PBA assay. Data was evaluated using Student’s paired t-test.
Fluorescence results are in arbitrary units.
* Statistically significant difference, with p<0.05.
** Statistically significant difference, with p<0.01.
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aberrant signal peptidase cleavage site. The effect of this enzymic 
glycosylation of serum albumin on non-enzymically glycated protein results 
was therefore investigated. A 10 ml blood sample was obtained from the 59 
year old Anglo-Saxon male in question, via the Department of Chemical 
Pathology, East Surrey Hospital, Redhill, Surrey, UK. Blood was divided 
between 2 collection tubes, one with no anticoagulant and one containing K- 
EDTA. The whole blood K-EDTA sample was used for analysis of HbAj^. 
by HPLC using the Bio-Rad modular diabetes monitoring system, as 
described by the manufacturers. A normal result of 4.2% HbA^c was 
obtained.
Serum was removed from the clotted blood sample and divided into 3 
aliquots of 1.5 ml, together with a selected control serum showing a normal 
albumin profile on electrophoresis. A 1.1 mol/1 D-glucose stock solution was 
prepared in PBS (pH 7.4) containing 33 mmol/l sodium azide. A 0.55 mol/1 
glucose solution was prepared from these 2 solutions and 150 |il of either 
PBS, 0.55 mol/1 or 1.1 mol/1 glucose was added to one of each serum 
aliquot to produce final glucose additions of 0, 50 and 100 mmol/l. These 
samples were incubated at 37 °C for 4 days whilst untreated serum samples 
were stored at -80 °C. The incubated samples were then dialysed overnight 
against 1.5 litres of 0.9% saline which reduced all glucose levels to less than 
0.5 mmol/l. All samples (including those stored at -80 °C) were then 
analysed by the Dns-PBA assay, Fructosamine Plus and affinity 
chromatography for %GA and %GTP, in triplicate. Albumin and total 
protein analyses were performed by the BCG (Rodkey, 1965) and biuret 
methods (Gomall et al, 1949). Results of these analyses are shown in Tables 
3.4.6 and 3.4.7. Table 3.4.6 shows that all the glycated serum protein 
results on the untreated albumin Redhill serum sample are within their 
normal reference ranges, with the exception of the DF/g/1 result which is 
just below the 2.5 percentile range of 1.04. The affinity chromatography 
results and the HbAj^. value are all lower than the mean value of their
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Table 3.4.6. In vivo glycated protein results for an albumin Redbill
beterozygote.
Analyte Control serum Albumin Reference range
Redhill
serum
HbAi, (%) 4.2 + 0.1 3.9 - 6.0
DF/g/1 1.48+0.08 1.02+0.07 1.04 - 2.44
Fructosamine plus (p.mol/1) 240 +  7 244 + 3 205 - 285
Fruct plus/TP (timol/g) 3.48+0.07 2.77+0.04 2.66 - 3.70
%GA 2.77+0.46 2.47+0.42 1.65 - 5.05
%GTP 4.47+0.36 4.29+0.18 4.18 - 7.06
Results represent the mean values ± SD of triplicate analyses.
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Table 3.4.7. In vitro glycated serum protein results for an albumin
Redbill beterozygote.
0 mmol/l 50 mmol/l 100 mmol/l
Control
serum : DF/g/1 1.32+0.51 12.71+0.64 21.55+2.57
Fruct/TP
(|Limol/g)
3.73+0.18 15.89+0.29 24.23+1.13
%GA 3.11+0.98 25.80+2.35 42.74+4.01
%GTP 5.49+0.92 33.32+2.30 54.39±5.84
Albumin
Redbill DF/g/1 0.86+0.13 8.00+0.82 17.2111.11
serum : Fruct/TP
(|xmol/g)
3.25+0.11 11.87+0.28 23.01+1.20
%GA 3.58+0.03 22.73+1.69 57.53+3.20
%GTP 6.03+0.24 30.06+2.26 63.09+5.25
Results represent the mean value ± SD of triplicate analyses.
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respective reference ranges although the Fructosamine Plus result is very 
close to the mean of its reference range. However, correction of this 
fructosamine result for total protein content does produce a result towards 
the low end of the range.
In vitro glycation of the variant serum has had a comparable effect to that 
on the control serum (Table 3.4.7) although obviously a direct comparison 
between the 2 individuals is not of any value.
3.4.6. The effect of chemical modification of glvco groups on the Dns- 
PBA assay results.
3.4.6.I. Borohydride reduction.
Several attempts were made at borohydride reduction of ketoamine adducts. 
Two different sources of NaBH^ were used, the Sigma Chemical Co. Ltd 
and BDH Ltd. Borohydride concentrations ranging from 0.4 to 14.0 mg per 
mg protein were used to treat both patient samples or human albumin 
solutions. Borohydride was removed from incubations by dialysis followed 
by freeze-drying of fractions, but in all cases no significant difference was 
found between control and test results when assayed by the Dns-PBA or 
Fructosamine Plus assays. However, a significant effect was observed for the 
following procedure:
A 40 g/1 solution of fatty-acid free HSA was divided into two 1 ml aliquots. 
Sodium borohydride (0.4 mmoles, from BDH Ltd) was dissolved in 1 ml of 
0.1 mol/1 NaHCOg and this was added to one of the HSA aliquots, whilst 
0.1 mol/1 NaHCOj was added to the other as a control. Both samples were 
incubated overnight (19 hours) at room temperature then ultrafiltered (using 
Millipore ultra-free MC membranes with a 10,000 molecular weight cut-off) 
to remove any remaining borohydride. The resulting solutions were assayed 
for DF, Fructosamine Plus and total protein using the Coomassie blue
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method described in section 3.1.1.2. Results of these analyses are shown in 
Table 3.4.8 which indicates that borohydride has caused a significant 
decrease (p<0.001) in both Fructosamine Plus (by 19%) and Dns-PBA (by 
37%) assay results. The effect on fructosamine results is obviously much 
greater.
3.4.6.2. Periodate oxidation.
A 40 g/1 solution of fatty-acid free HSA was prepared in 0.9% saline. A 
solution of sodium periodate (0.1 mol/1) was prepared in deionised water 
and 600 \il of this was added to a 1 ml aliquot of the HSA. A control 
sample was set up with the addition of 600 |xl water. These solutions were 
incubated at room temperature for 30 minutes, after which time 29 p-1 of 
propane diol was added to stop the reaction. Both solutions were 
ultrafiltered and resuspended in 0.1 mol/1 NaHCOg. Glycine (0.4 mmoles) 
was added to both solutions and left to incubate at room temperature for 2 
hours. NaBH^ (0.4 mmoles) was then added to the test sample and incubated 
for a further 1 hour at room temperature. These final solutions were 
ultrafiltrated and assayed for DF, Fructosamine Plus and total protein using 
the Coomassie blue method described in section 3.1.1.2. Aliquots of the 
samples obtained following periodate oxidation alone were also assayed. 
Results of these analyses are shown in Table 3.4.9 which indicates that the 
periodate oxidation has significantly reduced the fructosamine plus results 
by 72% and the Dns-PBA results by 85% (p<0.001 in both cases). As the 
periodate oxidation reaction produces aldehyde groups, these would have 
been capable of reducing the NBT in the fructosamine reaction if not 
completely removed by dialysis. Reduction of these groups was therefore 
performed with NaBH^ which decreased the fructosamine response slightly. 
However, following borohydride reduction of these groups the Dns-PBA 
assay results (DF/TP) increased back up to their original level. Examination
194
Table 3.4.8. The effect of borohydride reduction on Dns-PBA and
Fructosamine Plus assay results.
HSA sample TP (g/1) Fructosamine DF Fruct Plus/TP DF/TP
Plus (p^mol/1) (timol/g)
Control 60.7 286 296 4.71 4.88
Test 73.2
(0.4 mg NaBH^ 
per mg albumin)
72 226 0.98*** 3.09***
Values represent the means obtained for 6 analyses of each sample.
DF results are in arbitrary units.
*** Fructosamine Plus results corrected for total protein (fruct/TP) and 
Dns-PBA results corrected for total protein (DF/TP) were both significantly 
decreased (p<0.001) by borohydride reduction when analysed by Student’s 
t-test for differences between means.
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Table 3.4.9. The effect of periodate oxidation on Fructosamine Plus and
Dns-PBA assay results.
HSA sample TP Fructosamine DF Fruct/TP DF/TP
Plus (p.mol/1) (p.mol/g)
Control 68.7 577 592 8.40 8.62
Test (0.3 mg NalO^ 76.3 
per mg albumin)
180 96 2.36*** 126***
Test (NalO^ / NaBHJ 13.2 21 113 1.59*** 8.56
Values represent the means obtained for 6 analyses of each sample.
DF results are in arbitrary units.
*** Statistically significant difference from control sample, with p<0.001
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of the individual results for reagent A and B indicated that the decrease in 
DF response following periodate oxidation was due to an increase in non­
specific binding (increased reagent B results) with no change in reagent A 
results. The ensuing increase in DF following NaBH^ reduction was 
associated with increases in both total (reagent A) and non-specific (reagent 
B) binding results although the increase in total binding was greater, 
suggesting that specific binding was occurring.
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DISCUSSION
The affinity chromatography procedures used in this study produced 
comparable reference ranges to published data. Gould et al (1984) quote a 
non-diabetic range for glycated total protein of 2.95 -10.27% . The range of 
4.18 - 7.06% obtained in this chapter is possibly narrower due to automation 
of the Coomassie blue protein assay which may have reduced assay 
imprecision. However, the CVs of 5.3 - 6.2% obtained by Gould et al
(1984) are similar to those obtained in this study.
The non-diabetic affinity chromatography reference range for glycated 
albumin measurement obtained by John and Jones (1985) using rocket 
electrophoresis for albumin quantification, was 2.0 - 5.4% and that obtained 
by Reed et al (1986) using immunoturbidimetry for albumin quantification 
was 1.5 - 5.4%. These ranges are both similar to that of 1.65 - 5.05% 
achieved here.
As found with the Dns-PBA assay in Chapter 2 (section 2.5.2.2) the affinity 
chromatography methods produced diabetic ranges of results approximately 
double those of the non-diabetic population. Although good overall 
correlations were obtained between affinity chromatography and DF/g/1 
results, the assay sensitivity of either one or both of the techniques is not 
sufficient to sustain this correlation for the non-diabetic samples alone, 
which cover a relatively narrow range of results. Also, the Dns-PBA assay 
appears to be measuring more than the affinity method for glycated albumin 
as there is a positive intercept on the y axis of Fig. 3.1.3 which represents 
a result of 0.88 DF/g/l when %GA is zero. This intercept is reduced in Fig. 
3.1.4 to 0.18 DF/g/1 for correlation with %GTP results, but this is 
presumably because the unknown DF factor has been off set by the effect 
of protein glycation other than albumin. If, as suggested by Johnson and 
Baker (1988), more than 1 glyco group is required per mole of protein to
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enable binding to the boronate affinity gel, the affinity method would be 
expected to detect less glycation than an assay which is measuring one 
specific glycation site. This may be the case with the Dns-PBA assay as a 
correlation performed by Gould et al (1984) of affinity chromatography 
versus a thiobarbituric acid colo rimetric method for glycated plasma 
proteins also indicates underestimation by the affinity method. Similarly, 
Cruschelli et al (1990) have shown using glycated human serum 
albumin that only 5.3% of the total radioactivity was recovered in the 
glycated fraction following affinity chromatography. The remainder was 
eluted in the wash fraction (44%) or retained on the column (54.7%). 
Alternatively, it is possible that the Dns-PBA assay is responding to an 
additional serum component which is of no relevance to the glycated protein 
levels.
Investigations into the effects of K-EDTA and lithium heparin anticoagulants 
on DF/g/1 results indicated that plasma containing either of these compounds 
could be used to give results comparable to those achieved with serum. 
However, as lithium heparin plasma was shown in Chapter 2 (Table 2.4.4) 
to be unsuitable for analysis following prolonged storage this would not be 
the sample of choice. Similarly, the unsuitability of fluoride oxalate plasma 
for albumin analysis by the BCG method also affects the utility of this type 
of sample. As K-EDTA plasma has not yet been assessed for the effect of 
prolonged storage on Dns-PBA assay results, it can only be proposed as a 
suitable alternative to serum when samples are fresh. All 3 types of 
anticoagulated samples could therefore be accepted for Dns-PBA assay 
analysis if the need arose.
Baynes et al (1984) have shown that following a 24 hour incubation at 37 
°C the dissociation of Schiff s base adducts from albumin is virtually 
complete. The presence of Schiff’s base was therefore shown not to interfere 
in the fluorescence assay as its removal by incubation and dialysis did not
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alter the sample results. This lack of interference is presumably because the 
Schiff’s base, or aldimine adduct, does not possess 2 alcohol groups in a cis 
configuration, either in its straight chain or N-substituted aldosylamine form 
(see Chapter 1, Fig. 1.3.1), to which the Dns-PBA can bind specifically. 
Alternatively, it is always possible that the sensitivity of the Dns-PBA assay 
is just not good enough to be able to distinguish the difference between 
samples with and without the bound aldimine.
Although significant interference of free glucose levels above 40 mmol/i 
was found to occur in the Dns-PBA assay, the actual mean change in DF 
units was only a value of 8 or 9 which is below the assay sensitivity (limit 
of detection = 1 4  DF units) and would have little clinical relevance. This 
interference was not due to glucose alone reacting with the Dns-PBA as 
aqueous dilutions of the glucose standards did not give a concentration 
dependent response. It is therefore possible that glucose is interacting with 
a serum component in some way which slightly influences the assay result. 
Alternatively, in vitro glycation of the proteins could have occurred during 
this investigation, as the labile aldimine can form within 2 hours under 
favourable conditions (Baynes et al, 1984). However, the investigation into 
Schiff’s base interference in this assay would not indicate that this was the 
cause of increased results. Clinically, glycated protein analysis would not be 
of high priority in a patient presenting with such a high blood glucose level. 
The presence of haemoglobin in serum samples did not significantly 
decrease DF results until it became excessive (> 2.5 g/1). Such gross 
haemolysis as this affects not only the colour of the sample but also its 
clarity and would generally be considered as unsuitable for any type of 
automated chemical analysis. The absorption spectrum of haemoglobin 
shows a large peak extending from 500 nm down into the UV region, 
peaking at around 280 nm, so absorbance of both the exciting light for the 
Dns-PBA assay (330 nm) and the emitted light, to a lesser extent (470 nm), 
will be occurring in haemolysed samples. This was apparent in the results
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obtained with reagents A and B which were both reduced in the presence 
of haemoglobin, in a concentration dependent manner.
Lipaemia was found to significantly decrease DF results at all levels tested. 
However, despite the increased incidence of hyperlipidaemia in a diabetic 
population, the clinical relevence of the changes observed is again debatable 
as the mean differences in DF (Table 3.2.2) are all lower than the assay 
limit of detection. Reagent A and B results both decreased as lipaemia 
increased, presumably due to light scattering.
Bilirubin absorbs strongly at 453 nm and can therefore reduce some of the 
emitted light at 470 nm in the Dns-PBA assay. This analytical effect has 
decreased the individual reagent A and B results without having a significant 
effect on DF values until very high bilirubin levels (> 260 p.mol/1).
Unlike haemoglobin, lipids and bilirubin, urea should not have such a direct 
impact on the emitted light in the fiuorometric reaction. As urea levels 
above 20 mmol/1 significantly raised the DF results, it is possible that the 
urea caused a partial unfolding of the protein hereby improving the access 
of Dns-PBA, although none of the concentrations tested significantly 
changed reagent A and B results. The low mean differences obtained upon 
addition of urea (Table 3.2.3) are once again not clinically significant, 
although concentrations of 30 mmol/1 are not unusual in cases of renal 
failure.
Serum samples were assayed in the presence of salicylate ranging from a 
level of 625 p.mol/1 (< 724 p.mol/1 is recommended for analgaesia and 
antipyresis) to a level of 2500 ttmol/l (1086 - 2172 p.mol/1 is recommended 
as an anti-inflammatory; Tietz, 1983). Despite a statistically significant 
difference in results above 1250 p^mol/1, the actual change in mean DF 
values is minimal. The inherent fluorescence of the added salicylate did 
increase the individual reagent A and B results. This effect was great 
enough to cause reagent A results for the 1250 p.mol/1 addition to exceed the 
capacity of the photomultiplier although concentration quenching
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presumably occurred for the samples augmented with 2500 p,mol/l salicylate 
which reduced fluorescence signals. This result could therefore be viewed 
with suspicion and salicylate interference at such high levels may be 
relevant.
No statistically significant differences were obtained for analysis of samples 
in the presence of ibuprofen, for which the therapeutic range is from 48 to 
243 pimol/l (Tietz, 1983).
The internationally recommended reference range for ascorbic acid levels is 
34 to 114 |Limol/l (Tietz, 1983). The same source quotes the recommended 
plasma range for pyridoxal phosphate as 14.6 to 72.8 nmol/1 although 
leakage from blood cells can increase this so raised levels were used to 
assess any analytical interference. Plasma a-tocopherol levels should lie 
within the range of 11.6 to 46.4 p.mol/1 and the results shown in Table 3.2.4 
for inclusion of these vitimins in serum analysis cover ranges exceeding 
those stated here but still do not produce significantly different results for 
p<0.01 (the cut off level suggested by the IFCC, 1984). The presence of a 
cis-diol group on ascorbic acid may have been expected to bind to the Dns- 
PBA and possibly restrict binding to glycated albumin. Although pyridoxal 
phosphate and a-tocopherol are fluorescent compounds themselves, their 
emission maxima are well below the filter window wavelengths used for the 
Dns-PBA assay. These compounds therefore did not alter the magnitude of 
the reagent A and B results.
Haemoglobin carbamylation has been shown to occur in uraemic patients 
whereby urea derived cyanate condenses with N-terminal amino groups of 
haemoglobin (Fliickiger et al, 1981). This carbamylated haemoglobin 
chromatographs with the HhA^ fraction in cation exchange chromatography 
and can therefore result in raised HbA^ levels for patients with renal 
impairment. Although raised levels of glycated serum protein have been 
found in the presence of uraemia (Lamb et al, 1991) this group have also
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suggested that apparently normal levels of glycated serum proteins in 
patients on continuous ambulatory peritoneal dialysis may be due to an 
increased albumin turnover as a result of large losses in the dialysate. In 
vitro carbamylation of serum albumin was therefore attempted in this 
chapter by incubation of HSA with urea. This did not affect results of the 
Dns-PBA assay although it is possible that a 3 day incubation with urea was 
not long enough for carbamylation to occur.
Serum albumin transports a variety of low molecular weight substances 
around the blood stream, such as bilirubin, fatty-acids and drugs. These 
substances are bound reversibly to the albumin molecule and an equilibrium 
is usually established between the bound and free concentrations. The 
average albumin molecule carries more than one ligand and the binding of 
one often interacts with the binding of another. For example, high 
concentrations of fatty-acids have been shown to displace bilirubin very 
efficiently (Heird & Driscoll, 1975) which can have fatal consequences in 
the treatment of the sick neonate. Fatty-acids are found in the blood plasma 
at higher concentrations than any other natural ligands on the albumin 
molecule and can therefore have a significant effect on binding of bilirubin. 
Although bilirubin binds to albumin with high affinity (Brodersen, 1977), 
the results in Table 3.3.2 indicate that there is competition between bilirubin 
and glucose for binding as detected by the Dns-PBA assay. Even though 
glucose binding has been reduced by bilirubin in the presence of fatty-acids, 
this reduction was much greater in their absence, suggesting a common 
binding site for fatty-acid, bilirubin and glucose. Shaklai et al (1984) have 
proposed that lysine-525 of HSA plays a key role in the binding of glucose 
and Other physiologically important ligands (such as bilirubin) to albumin. 
Results of the in vitro bilirubin incubation therefore highlight the problems 
which could arise in interpretation of results from patients with prolonged 
jaundice.
Aspirin (acetylsalicylic acid) is known to inhibit glycation of albumin in
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vitro and in vivo, possibly by acétylation of the protein (Rendell et al, 
1986). In vivo however, the acetylsalicylic acid is rapidly converted to 
salicylic acid which is not an acetylating agent. In vitro incubation of HSA 
with salicylate and glucose did significantly reduce Dns-PBA results despite 
this, and the effect was greater for the HSA containing fatty-acids. Salicylate 
binding studies performed by Mereish et al (1982) have suggested that 
glycated albumin has a decreased capacity to bind salicylate compared to 
unglycated albumin. The higher glycation detected in the control sample of 
fatty-acid free HSA (sample 1, Table 3.3.3) may therefore be preventing 
binding of salicylate during in vitro incubation with glucose. In order to 
determine the full effect of aspirin therapy on the Dns-PBA results, this 
incubation needs to be performed for acetylsalicylic acid, which is thought 
to acetylate serum albumin very rapidly at lysine residue 199 (Walker, 1976) 
with at least 6 other minor acétylation sites (Hawkins et al, 1969). 
Ibuprofen, another anti-inflammatory drug, has been suggested as a putative 
anti-cataract drug by Roberts and Harding (1990) due to its protective effect 
on the lens of the eye in preventing carbamylation and non-enzymic 
glycation. This group propose a different mechanism of action to that of 
aspirin and results shown in Table 3.3.3 of this chapter indicate that like 
salicylate, incubation (and preincubation) with ibuprofen can reduce 
glycation of albumin, particularly in the presence of fatty-acids. It is possible 
that binding of ibuprofen and salicylate to albumin with their hydrophobic 
phenyl groups, is facilitated by the presence of the hydrophobic moieties of 
the fatty-acids, without obscuring the actual binding sites. Salicylate and 
ibuprofen therefore both appear to be able to affect glycation of albumin in 
vitro as determined by the Dns-PBA assay, and may be expected to have an 
effect in vivo when taken over prolonged periods of time.
The covalent modification of proteins by ascorbic acid has been 
demonstrated by Bensch et al (1985) who proposed that this occurred via 
the Maillard reaction. Both in vitro and in vivo glycation of serum proteins
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has been shown to be reduced by the presence of ascorbic acid by Stolba et 
al (1987), using the fructosamine and TEA assays, and by Davie et al 
(1990) using affinity chromatography. During in vitro incubations of 
samples with ascorbic acid, the compound is rapidly oxidised and broken 
down by the following pathway:
L-ascorbic acid -> L-dehydroascorbic acid
:
L-lyxonic acid <— 2,3 diketo-L-gulonic acid —> L-xylonic acid
Oxalic acid + L-threonic acid
Incubation solutions therefore contain a mixture of these compounds which 
possess several hydroxyl and carboxyl groups and could be responsible for 
the observed effects. However, during this study no significant change 
occurred in glycation of HSA with fatty-acids and the decrease observed 
with fatty-acid free HSA was minimal. The effect of ascorbate and its 
metabolites at physiological concentrations therefore does not have an 
appreciable influence on albumin glycation as detected by the Dns-PBA 
assay. Results for the in vivo effect of ascorbic acid on protein glycation 
(Table 3.3.5) shows a reverse trend to that observed by other workers, 
whereby glycation has tended to increase Dns-PBA results although this 
increase was not statistically significant at all stages of the study. It is 
possible that this increase in results reflects the true influence of ascorbic 
acid on the assay results, whereas the in vitro picture has been obscured by 
the rapid oxidation of the compound. An increase in detection of glycated 
haemoglobin for the samples used in this study when measured by agar gel 
electrophoresis coincides with results reported by Davie et al (1992). It is 
therefore possible that the ascorbic acid adduct formed with HSA is actually 
detected by the Dns-PBA assay in the same way as the glucose adduct.
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Observations by Ortwerth and Olesen (1988) suggest that the cis-diol groups 
of ascorbic acid are present on the protein-ascorbate adduct. This could 
explain the increased Dns-PBA response and suggests that the ascorbate 
adduct may well have formed in the same position as glycation in order to 
enhance the fluorescence of the Dns-PBA. Ortwerth and Olesen (1988) have 
also shown that the ascorbate adduct binds strongly to boronate affinity gels 
but that it cannot be eluted by the sorbitol elution buffer. This could 
therefore result in competition for binding of the glycated proteins, a higher 
fraction of which would then be eluted in the wash eluate, effectively 
reducing the final results. Alternatively, the ascorbate adduct may not be 
abundant enough to restrict binding of glycated proteins to the affinity 
matrix and the decreased results could be reflecting a true physiological 
inhibition of glucose binding by ascorbate. However, the use of vitamin C 
as a therapeutic measure for blocking glycation cannot yet be advocated as 
protein-ascorbate adducts are also capable of cross-linking (in vitro) and 
proceeding right through to AGEs (Ortwerth & Olesen, 1988).
Several reports have indicated that patients with diabetes mellitus have lower 
blood levels of vitamin Bg than the non-diabetic population. (Wilson & 
Davis, 1983; Khatami et al, 1988; Solomon & Cohen, 1989). The major 
cofactor form of this vitamin is pyridoxal phosphate, which is capable of 
forming a Schiff’s base with protein amino groups through its reactive 
amino functional group. It should therefore be a competitor with the non- 
enzymic glycation at shared protein reactive sites. It has been proposed 
(Khatami et al, 1988) that increased glycation of lysyl residues on albumin 
(a principal carrier of PLP) may reduce the available binding sites causing 
an increase in the free vitamin which will be more rapidly metabolised than 
the bound. As diabetic patients with nephropathy have significantly lower 
levels of PLP than those diabetics without this complication (Wilson & 
Davis, 1983), vitamin Bg would appear to be assuming a protective role in 
these patients. Dempsey and Christensen (1962) have identified 3 types of
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complexes for PLP with bovine serum albumin in vitro. At pH 7.5, two of 
these were formed at unique sites with a high affinity, whereas the other 
involved numerous non-specific sites. All the complexes seemed to be 
formed on e-amino groups. More recently, Shepard et al (1985) have shown 
that PLP inhibits glycation and galoctosylation of HSA in vitro although 
their observation that inhibition cannot be complete suggests that the PLP 
and sugars have both shared and separate binding sites on HSA. The in vitro 
incubation study with PLP in this chapter produced an increase in Dns-PBA 
assay results at the highest level of PLP used (4 |Limol/l), in the presence of 
bound fatty-acids (Table 3.3.4). The work described by Dempsey and 
Christensen (1962) and Shepard et al (1985) used higher PLP concentrations 
of 330 p-mol/1 and 12 mmol/1 respectively, and may therefore not be 
clinically relevant. The observed increases for the Dns-PBA assay arose due 
to an increase in total binding, not a decrease in non-specific binding. It is 
therefore likely that the PLP has bound at the HSA glycation site, possibly 
facilitated by the presence of the fatty-acids, and is capable of interacting 
with the Dns-PBA in some way so as to orientate the dansyl group into a 
hydrophobic environment. Although the in vivo study of vitamin Bg in this 
chapter produced a statistically significant increase in serum fructosamine 
results after 6 weeks (Table 3.3.7), this change in value of 6 p.mol/1 is 
clinically irrelevant. Neither the Dns-PBA assay or the fructosamine test 
results can therefore be said to have been altered by the supplementation of 
vitamin Bg in vivo.
Vitamin E (a-tocopherol) has been recently shown to inhibit protein 
glycation both in vitro (Ceriello et al, 1988) and in vivo (Ceriello et al, 
1991). This effect was reproduced in vitro for the incubations carried out in 
this chapter (Table 3.3.4) and was more pronounced with HSA in the 
presence of fatty-acids. Ceriello et al (1991) have suggested that a -  
tocopherol interferes with protein glycation at an early step in the Maillard 
reaction, possibly by inhibition of glucose auto-oxidation which reduces the
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covalent linking of glucose to albumin. Glucose auto-oxidation has been 
shown by Wolff and Dean (1987) to contribute to protein modification by 
glucose, and if this was the mechanism by which inhibition occurred (with 
vitamin E being a potent antioxidant), any decrease in glycation should be 
apparent for all methods of analysis. From the results obtained in this thesis 
it would not appear that ascorbate, another strong antioxidant,was affecting 
glycation of HSA by this mechanism.
In section 4 of this chapter, fractionation and in vitro glycation of plasma 
proteins was able to confirm the results obtained by Hayashi and MaMno
(1985), who separated human serum from a non-diabetic into albumin and 
albumin-depleted serum prior to Dns-PBA manual assay analysis. Although 
Hayashi and Makino (1985) were able to show that all their DF response 
was attributable to the albumin fraction, it was possible that the glycated 
protein levels for this subject were not actually high enough to elicit a 
response from the non-albumin fraction. By glycating each plasma fraction 
in vitro and by further dividing the non-albumin proteins into a /p  and y 
globulins, a more reliable indication of the Dns-PBA assay specificity was 
obtained. Although the assay results for the a /p  and y globulin fractions 
were all less than the limit of detection for the fiuorometric assay the raised 
levels of glycation detected by the Fructosamine Plus test have confirmed 
that glycation did actually occur, and at levels which would actually exceed 
those found clinically. It is also interesting to note from Table 3.4.1 that 
glycation as detected by the Dns-PBA assay has not increased with 
increasing glucose concentration, whereas it has for all the Fructosamine 
Plus results. This suggests that a specific binding site for Dns-PBA may 
have been saturated on albumin whereas other available sites are being 
detected by the fructosamine test. Also, the degree of glycation detected by 
the fructosamine test is higher for albumin than for the other proteins, either 
due to more glycation sites being available on albumin or to altered rates of 
glycation for the different proteins, hereby highlighting one of the
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drawbacks of the fructosamine assay.
Results obtained for analysis of the affinity chromatography eluates were 
surprising (Table 3.4.2) as they indicate that a considerable amount of 
material, detectable by the Dns-PBA and fructosamine assays as glycated 
protein, is not retained by the affinity column. The columns were not 
overloaded with protein according to the criteria published by Gould et al, 
1984. The validity of the wash eluate 2 results for the Dns-PBA assay is 
doubtful, as the albumin recovery was low causing a DF result below the 
limit of detection. It is always possible that the affinity method does not 
measure the epitope being detected by the fiuorometric assay at all, as steric 
factors are likely to play a more important part for the affinity technique 
with a fixed gel matrix. A similar phenomenon was observed by Johnson 
and Baker (1988) who, like Cruschelli et al (1990), found that a 
considerable amount of glycated protein labelled with glucose was able 
to pass through boronate affinity gels. Similarly, Talwar et al (1983) found 
that the affinity technique did not measure all glycated forms of 
haemoglobin isolated by ion-exchange chromatography. If the affinity 
technique and the fiuorometric assay are measuring completely different 
aspects of glycated albumin, this could explain some of the wider 
discrepancies observed for correlation of the 2 parameters in Fig. 3.2.3 and 
also the positive intercept on the y axis if glycation of the Dns-PBA site 
occurs more readily than at those sites detected by affinity chromatography. 
When corrected for total protein levels, the Fructosamine Plus results 
increased dramatically following one pass through the affinity columns. As 
this value did not increase appreciably upon a second treatment, it can be 
concluded that this material cannot bind to the affinity gel. It is therefore 
possible that these wash fractions contain appreciable amounts of the non­
specific component described by Schleicher et al (1988) which has not been 
lost by dialysis and freeze-drying (or has even been generated by this
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procedure) but has been multiplied up by correction for total protein.
In section 3.4.3 of this chapter, the effect of the polyol sorbitol on the Dns- 
PBA assay results was compared to the effect of boric acid. As expected, 
the sorbitol did reduce the fluorescence results in the presence of serum, but 
this effect was greater than that observed for the same concentration of boric 
acid. It is therefore possible that the sorbitol, with more hydroxyl groups 
than boric acid, is undergoing several non-specific interactions with serum 
proteins which is reducing the non-specific as well as the specific binding 
of Dns-PBA. Alternatively, as the sorbitol reagent blank values are 
significantly lower than the reagent A blanks, the sorbitol may be reacting 
with the free Dns-PBA (c.f. affinity chromatography) and reducing its 
inherent fluorescence (both the patient sample and the saline blank results 
have been reduced by approximately 25% in the presence of sorbitol). This 
would also reduce the Dns-PBA then available for binding to glycated 
protein and therefore reduce the fluorescence enhancement. It is likely that 
both of these explanations are applicable since a concentration of 100 
mmol/l sorbitol was required before binding sites were saturated. This is a 
vast excess over the Dns-PBA concentration (2.5 p.mol/1) and must therefore 
involve interaction with various serum components.
In order to try and determine whether there is any involvement of thiol 
groups in the binding of Dns-PBA to glycated protein, PCMB was used to 
block these groups. This resulted mainly in increased non-specific binding 
of Dns-PBA to serum components although a small but significant increase 
in specific binding was also apparent. This may have occurred by mutual 
attraction of the bound PCMB and the Dns-PBA as they both possess 
aromatic ring systems. It is also possible that the PCMB itself was 
producing fluorescence when bound within a hydrophobic environment 
although the compound in aqueous solution did not increase the Dns-PBA 
reagent fluorescence. These results are therefore not particularly convincing 
in their suggestion that thiol groups may be reducing specific Dns-PBA
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binding in serum and further information could probably be obtained by 
repeating the experiment with a HSA solution. Not surprisingly, when 
reduced glutathione was used to release extra thiol groups within serum 
samples, the opposite effect to PCMB was observed. Reagent A and B 
fluorescence emissions were both significantly reduced by similar amounts, 
indicating a decrease in non-specific binding of Dns-PBA but no change in 
specific binding. Together, the results of these 2 experiments suggest that 
thiol groups within serum samples are capable of restricting non-specific 
binding of Dns-PBA in human serum. This inhibition could either be due 
to thiols interacting with Dns-PBA resulting in no enhancement of 
fluorescence but reducing the amount of fluorophore available for non­
specific binding, or alternatively, the thiol groups could actually be directly 
preventing the Dns-PBA molecules from non-specific interaction with the 
sample.
Studies in this chapter with albumin Redhill suggest that none of the 
glycated serum protein assays investigated was able to detect the 
carbohydrate moiety in glycosidic linkage to this variant albumin. The 
HbAic result for the patient indicated that his glycaemic control was normal 
so that raised serum glycated protein results would have implied that the 
analysis was measuring more than non-enzymically glycated protein. 
Although the Dns-PBA assay result (DF/g/l) was slightly below the 
reference range determined in section 2.5.2.1, it is likely that storage of the 
blood sample at room temperature during the 24 hours for which it was in 
transit could have reduced the result slightly as found in section 2.4.2. In 
vitro glycation of the albumin Redhill sample produced comparable results 
to the control sample for all the assays. These results were not unexpected 
since affinity chromatography has been shown not to detect glycoproteins 
(Gould & Hall, 1987) and the oligosaccharides of glycoproteins are not 
capable of reducing NBT in the fructosamine assay. The results do however
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indicate that the oligosaccharide attached to asparagine-318 does not appear 
to interfere with non-enzymatic glycation nor its detection by any of these 
assays. This is consistent with the main glycation site for albumin being at 
lysine-525 as suggested by Shaklai et al (1984).
As described in Chapter 1 (section 1.5.2.4), borohydride reduction of 
glycated proteins takes place across the C =  N or C =  O double bond. This 
effectively removes any Schiff’s base and the reactive carbonyl group from 
the glycated protein. For some reason, when borohydride reduction was 
followed by dialysis and freeze-drying of samples, no change in glycated 
protein results could be discerned. However, when samples were ultrafiltered 
for removal of the borohydride, significant changes in glycated protein 
levels were found. Although the ensuing decreases in Fructosamine Plus and 
Dns-PBA assay results were both highly significant, the reduction had a 
greater (but still incomplete) effect on the fructosamine results. This effect 
was also found for the fructosamine assay by Schleicher et al (1988) for 
pooled serum samples but not for a HSA solution. However, the HSA used 
in this chapter was fatty-acid free and may therefore have exposed additional 
epitopes on the protein for reaction with the NBT. Residual fructosamine 
activity found here was 21% of the original total value which is slightly 
lower than that obtained by Schleicher et al (1988) for pooled serum which 
gave values of 25-59%. The Dns-PBA assay results for this study indicate 
that a significant proportion of the DF component (37%) relates to either 
Schiff’s base interactions for analysis of fatty-acid free HSA, or requires 
carbonyl groups to be present. However, periodate oxidation of this albumin, 
which cleaves between adjacent carbons carrying cis-diols/aminols or 
ketoamine groups aswell as C-N bonds (see Chapter 1, section 1.5.2.5), was 
able to reduce the DF response to 15% of its original value. This still 
suggests that the assay is not only measuring the glucose adducts on 
albumin, and could be partly responsible for the positive intercept obtained
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h^ecorrelation with affinity chromatography results in Fig. 3.1.3. After 
periodate oxidation and borohydride reduction, fructosamine results were 
reduced to a similar percentage to that found for borohydride reduction 
alone (19%), again indicating the presence of a non-specific interaction with 
fatty-acid free HSA. Upon treatment with sodium periodate only, the non­
specific binding of Dns-PBA to HSA was found to increase whilst the 
specific binding decreased to a lesser extent. This is consistent with the 
removal of cis-diol groups which supposedly react with the fluorophore. 
Reaction with borohydride then increased the specific and non-specific 
binding to levels which were slightly in excess of their original values 
(when corrected for total protein levels) suggesting that the borohydride is 
producing modifications on the HSA which once again favours binding of 
Dns-PBA, both specifically and non-specifically.
With both the periodate oxidation and borohydride reduction experiments 
performed in this chapter, the use of fatty-acid free HSA should be 
remembered for interpretation of results. It is likely that different results 
would be achieved for HSA incorporating fatty-acids and also for human 
serum samples. These studies therefore warrant further investigation, 
particularly with regard to the fiuorometric assay.
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CHAPTER 4
EXAMINATION OF THE EFFECTS OF METHODOLOGICAL AND 
BIOLOGICAL VARIATION ON GLYCATED PROTEIN VALUES.
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Introduction.
Data on biological variation in clinical chemistry has been shown to have 
several different applications. Fraser and Harris (1989) have used such data 
in order to:
1) establish analytical goals,
2) critically evaluate the significance of changes in serial results,
3) assess the applicability of conventional population based reference ranges,
4) calculate the number of specimens required to determine the true 
homeostatic set point for an individual,
5) determine the optimum mode for reporting numerical results,
6) select the most suitable specimen type,
7) compare available methodologies,
8) assess the clinical utility of tests.
These workers have suggested that data on biological variation should be 
generated early on in the development of any new clinical chemistry test, in 
order to aid the clinical interpretation of results.
In 1987, Howey et al used a modification of the original fructosamine 
method of Johnson et al (1982) to derive data on the biological variation of 
glycated serum proteins. This study monitored healthy non-diabetics over a 
period of 5 weeks and indicated that due to a high ‘Index of Individuality’, 
conventional population based reference ranges were of limited use for this 
test although the results were valuable in monitoring disease with an 
analytical goal for precision (CV) of <2.6%. Howey et al (1989) utilised 
data on biological variation to assess the relative clinical usefulness of 
glycated haemoglobin (as H bA J and serum fructosamine. The study
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involved monitoring stable and newly diagnosed diabetic patients and the 
results indicated that the HbAj measurement was more appropriate for long 
term monitoring of diabetics than the fructosamine test.
As Fliickiger et al (1987) also found considerable differences in 
fructosamine results from samples taken at different times of the day (in 
diabetic patients), data on biological variation using both this original 
fructosamine test and the newer ‘Frucosamine Plus’ test may give some 
information on the specificity of the 2 assays. It is possible that the non­
specific plasma component demonstrated by Schleicher et al (1988) may be 
contributing to the high degree of individuality.
In order to help evaluate the clinical utility of the Dns-PBA fluorescence 
assay, this chapter examines the effects of biological variation on glycated 
protein values, as determined by various methodologies. The effect of 
correcting results for serum protein levels is also investigated.
The statistical evaluation and terminology used within this chapter is that 
recommended by Fraser and Harris (1989).
Materials.
Equipment and reagents were as described previously under ‘materials’ in 
chapters 2 and 3.
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4.1. METHODS.
4.1.1. Patients and specimens
Healthy laboratory staff members (4 male, 6 female, age range 18-38 years) 
were recruited to the study. All subjects were non-diabetic according to the 
criteria of the World Health Organisation (1980) and maintained their usual 
lifestyles throughout the study period, although drug use and consumption 
of alcohol and tobacco products was restricted. Phlebotomy was performed 
by a single individual, whenever possible, in order to minimise variation in 
the amount of tourniquet application. All blood samples were venous and 
were collected in a non-fasting state, from seated subjects.
A weekly profile of results was obtained from 10ml blood samples taken 
twice daily from each subject, at 10am and 3pm over 5 consecutive days. 
A daily profile of results was obtained from 10ml blood samples taken 5 
times over one day, from 5 subjects (1 male, 4 female), at 9am, 11am, 1pm, 
3pm and 5pm. The 1pm sample was pre-prandial.
Blood was divided between tubes containing no anticoagulant or fluoride 
oxalate. Fluoride oxalate plasma was assayed immediately for glucose levels 
using a Beckman glucose oxidase/02 electrode system and the serum 
samples were stored at -20 °C until analysis at the end of the study period. 
On the day of analysis, all samples from one subject were allowed to thaw 
at room temperature mixed thoroughly and centrifuged at 3000 rpm for 5 
minutes. Each set of samples was assayed within the same analytical batch, 
by the following assays: The Dns-PBA assay was performed as described 
in section 2.2.8 , the original fructosamine test and Fructosamine Plus assays 
were purchased as kits from Roche Diagnostics, Welwyn Garden City, 
Herts, UK, and run on a Cobas Fara analyser. Glycated albumin (%GA),
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and glycated total protein (%GTP) were assayed by affinity chromatography 
as described in section 3.1.1. Total protein and albumin measurements were 
also performed on the Cobas Bio analyser using biuret and bromocresol 
green methods of analysis. The assay of total protein and albumin levels 
enabled the fructosamine results to be corrected for both these variables, and 
the DF results of the Dns-PBA assay to be corrected for albumin. As all 
samples were obtained from healthy non-diabetic subjects, the fluorescence 
assay was performed on the Cobas Bio with the PM voltage adjusted using 
a non-diabetic serum sample, hereby heightening the sensitivity of the assay. 
Within-run analytical variance (V^) was estimated for each glycated protein 
assay from replicate analyses of one of the subjects samples (n=10-20). 
This protocol produced a weekly profile of 10 results for each assay, on 
each of 10 subjects (total no. of samples = 100) and a daily profile of 5 
results for each assay, on each of 5 subjects (total no. of samples = 25). All 
sample results were included in the statistical evaluation of the data with the 
exception of 2. These 2 samples were from one individual participating in 
the weekly profile study, and were visibly lipaemic. Results from these 2 
samples were therefore not included in the evaluation of the Dns-PBA assay 
or the original fructosamine assay, where lipaemia is known to interfere with 
the analysis (section 3.2.5 of this thesis; Kruse-Jarres et al, 1989). Results 
from these samples were also omitted whenever total protein or albumin 
values were incorporated into a calculation, for the same reason.
4.1.2. Statistical evaluation of the data.
By correction of the DF fluorescence results for albumin levels and 
correction of fructosamine and Fructosamine Plus results for albumin and 
total protein levels, a total of 13 sets of assay data (including blood glucose
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levels) were available for analysis, for both the weekly and the daily 
profiles. A one-way analysis of variance was performed for each of the 13 
assays, as described by Freund (1988). This analysis produced a mean- 
squares result for both the within-subject and between-subject data which 
were used to produce an F-ratio. A significant F-value for the ratio of 
between-subject to within-subject mean squares implies that the results for 
each subject are part of a subdistribution within the overall distribution and 
that there is significant variation between individuals.
Analytical variance (V^) was derived from within-run precision data for 
each assay, and this component was used to derive the within-individual 
variance (V^) using the formula:
.equation (1)
Vn was then derived from:
Vo-
MSq-MS,
.equation (2)
Where,
MSj = within-subject mean-square 
MSq -  between-subject mean-square 
r = no. of subjects
Hi = total no. of determinations made on the i^ subject 
N  = total no. of determinations 
as advocated by Fraser and Harris (1989).
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The variance results were then used to produce CV^, CVi, and CVq for each 
assay using the following formula:
.................. m"atio»(3)
From the calculated CVs it was possible to derive analytical goals for each 
glycated protein assay using the criterion that the maximum allowable 
analytical variation should be less than or equal to half the average within- 
subject biological variation i.e:
  equation (4)
The obtained as the analytical goal represents an acceptable level of 
imprecision for optimum clinical interpretation of the assay results. 
Although conventional population-based reference values can be used to aid 
diagnosis, these ranges are only of real utility when the between-subject 
variation is smaller than the within-subject variation. An Tndex of 
Individuality’ can be calculated from the data as a ratio of analytical and 
within-subject variation to the between-subject variation:
Index of Individuality =
CV^+Clj
cvl .equation (5)
When this index is less than 0.6 (and said to be high), reference ranges are 
of limited use but they do become valuable when the index of individuality 
is Tow’, exceeding 1.4 (Harris, 1981).
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As glycated protein indices are primarily used to assist in the monitoring of 
diabetic patients, the significance of any observed change between a 
patient’s successive results needs to be quantified for the assay in question. 
In order to apply such a ‘critical difference’ to an assay, it must first be 
established that different individuals will all show a similar amount of 
natural biological variation. The ‘Index of Heterogeneity’ represents the ratio 
of the observed CV of a set of individual variances (including V^) to the 
theoretical CV, [2/(n-l)]^^^, where n is the average number of specimens 
collected per subject, and can be used to show whether the within-subject 
variances show heterogeneity. Significant heterogeneity is said to exist if the 
index differs from 1.00 by more than 2 SDs, defined by 2/(2n)^^ .^ If the 
index of heterogeneity for a particular assay is clearly non-significant, then 
the critical difference, for p<0.05, can be expressed as:
j.
2 .77(C I^+C F^2  equation (6)
These methods of statistical analysis have been applied to the data obtained 
within this chapter.
In addition to these analyses, data for each assay within the daily glycated 
protein profiles was grouped according to the time of day at which the 
sample was taken, and Student’s paired t-tests were performed in order to 
establish any significant diurnal variation in results over the course of 8 
hours.
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4.2. RESULTS.
4.2.1. Weekly glycated protein profiles.
The data obtained for the 10 glycated protein indices is presented 
graphically in Figs 4.2.1 - 4.2.10, which show the mean values obtained for 
each subject and the full range of results in the form of error bars. The y 
axes represent an equivalent range of results for each analysis, enabling a 
direct visual comparison of the assays. The most obvious visual impact of 
these graphs is the wide spread of each individuals Dns-PBA assay results 
(Figs 4.2.1 and 4.2.2), whether corrected for albumin levels or not, in 
comparison to the very small ranges obtained for the uncorrected 
fructosamine and Fructosamine Plus results (Figs 4.2.3 and 4.2.4). 
Correction of results from both fructosamine assays for albumin or total 
protein levels has increased these intra-individual ranges slightly although 
the between-subject variation of the mean values appears to be comparable 
for all the fructosamine and Dns-PBA assays. However, affinity 
chromatography results (Figs 4.2.9 and 4.2.10) show wider between-subject 
variation of the means than the other assays, with variation of within-subject 
results greater than that observed for the fructosamine assays but smaller 
than that found for the Dns-PBA assay.
The F-ratios and mean-squares for all analyses are shown in Table 4.2.1. As 
the mean-squares results vary in their orders of magnitude dependent on the 
units of measurement for each assay, calculation of the F-ratio has enabled 
a more direct comparison. With the exception of blood glucose levels, all 
other assays show a statistically significant difference between the within- 
subject and between-subject ranges obtained in this study. Between-subject
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FIG. 4.2.1: Means and ranges of DF
values for 10 non-diabetic individuals.
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FIG. 4.2.2: Means and ranges of DF/g/l 
values for 10 non-diabetic individuals.
4.0-
2.0 -
Subject noi
Two samples were taken per day from each subject, over the course of 5
days. The 10 results for each individual are shown as the mean value and
full range. (For subject no.4, n=8).
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FIG. 4.2.3: Means and ranges of
Fructosamine values for 10 non-diabetic
individuals.
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FIG. 4.2.4: Means and ranges of 
Fructosamine Plus values for 10 non­
diabetic individuals.
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Two samples were taken per day from each subject, over the course of 5
days. The 10 results for each individual are shown as the mean value and
full range. (For subject no.4, n=8).
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FIG. 4.2.5: Means and ranges of
Fructosamine/Albumin values for 10 non­
diabetic individuals.
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FIG. 4.2.6: Means and ranges of 
Fructosamiue Plus/Albumin values for 10 
non-diabetic individuals.
21 3 4 5 6 7 6 9 10
Subject no.
Two samples were taken per day from each subject, over the course of 5
days. The 10 results for each individual are shown as the mean value and
full range. (For subject no.4, n=8).
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FIG. 4.2.7: Means and ranges of
Fructosamine/Total Protein values for 10
non-diabetic individuals.
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FIG. 4.2.8: Means and ranges of 
Fructosamine Plus/Total Protein values 
for 10 non-diabetic individuals.
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Two samples were taken per day from each subject, over the course of 5
days. The 10 results for each individual are shown as the mean value and
full range. (For subject no.4, n=8).
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FIG. 4.2.9: Means and ranges of %
Glycated Albumin values for 10 non­
diabetic individuals.
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FIG. 4.2.10: Means and ranges of % 
Glycated Total Protein values for 10 
non-diabetic individuals.
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Two samples were taken per day from each subject, over the course of 5
days. The 10 results for each individual are shown as the mean value and
full range. (For subject no.4, n=8).
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Table 4.2.1. One-way analysis of variance results for 13 groups of assay
data, obtained over a 5 day study period.
ASSAY MEAN-SOUARES
Between-subject Within-subject
F
Ratio
Glucose 0.6556 0.4221 1.554
Albumin 75.56 4.694 16.10 **
Total Protein 77.78 8.061 9.649 **
DF 733.0 107.0 6.850 **
DF/g/1 0.2646 0.0556 4.759 *
Fructosamine 0.2937 0.0034 86.19 **
Fruct/Alb 0.8196 0.0491 16.69 **
Fruct/TP 0.4936 0.0173 28.53 **
Fruct Plus 1177 63.58 18.51 **
Fruct Plus/Alb 0.5250 0.0526 9.981 **
Fruct Plus/TP 0.6083 0.0435 13.98 **
% GA 1.127 0.0596 18.91 **
% GTP 3.814 0.0922 41.37 **
Significant difference (increase) in between-subject results compared 
to within-subject results with p<0.05.
Significant difference (increase) in between-subject results compared 
to within-subject results with p<0.01. (Critical value of F=5.35).
Fruct = Fructosamine (mmol/1)
Fruct Plus = Fructosamine Plus (umol/1) 
Alb = Albumin (g/1)
TP = Total Protein (g/1)
Fructosamine results were divided by TP or Alb results and multiplied by 
100. Fructosamine Plus results were divided by TP or Alb results.
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variation is therefore significantly higher than within-subject variation, 
although DF/g/1 results are only significantly different at the 5% level and 
the DF results show the next lowest F  ratio.
Table 4.2.2 shows the calculated analytical, within-subject and between- 
subject variances (V^, V ,^ and Y q ) for each assay. Once again, these values 
are difficult to compare between the different assays so with the use of the 
grand means obtained from all results of every test the various CVs have 
been calculated and presented in Table 4.2.3. Not surprisingly, the within- 
individual CV for blood glucose levels is high, reflecting the constant 
fluctuations about a homeostatic set point in non-fasting subjects. The total 
CV for plasma albumin levels is higher than that for total protein so these 
two variables will be introducing different forms of variation into the assays. 
For the Dns-PBA assay, the analytical CV forms the highest component of 
the total CV, whereas for all other assays the CVq gives the major 
contribution. The CVq is particularly high for the affinity chromatography 
tests which accounts for these assays having the highest total CV. One 
striking difference between the %GA and %GTP results is that the CV^ is 
considerably higher for %GA. The lowest analytical CVs were achieved by 
the fructosamine and Fructosamine Plus assays whether corrected for plasma 
protein levels or not. This in turn has resulted in these assays having the 
lowest total CVs.
As described in section 4.1.2, the index of individuality (equation 5), index 
of heterogeneity, critical difference (equation 6) and analytical goals 
(equation 4) were calculated for each glycated protein assay. These 
components are shown in Table 4.2.4. As the index of individuality for 
every assay except DF/g/1 is less than 1.4, conventional reference ranges are 
generally of limited use. The index of heterogeneity appears to be greatest
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Table 4.2.2. Analytical, within-subject and between-subject variances for
13 groups of assay data, obtained over a 5 day study period.
ASSAY Va Vi Vg GRAND MEAN
Glucose 0.0289 0.3932 0.0234 4.8 (mmol/1)
Albumin 1.690 3.004 7.234 47 (gA)
Total Protein 1.060 7.001 7.117 70 (gA)
DF 100.0 7.000 63.90 126 (arbitrary units)
DF/g/1 0.0529 0.0027 0.0213 2.69 (arbitrary units)
Fructosamine 0.0014 0.0020 0.0296 2.30 (mmol/1)
Fruct/Alb 0.0334 0.0157 0.0787 4.89 (mmol/g)
Fruct/TP 0.0060 0.0113 0.0486 3.31 (mmol/g)
Fruct Plus 34.51 29.07 113.6 250 (p,mol/l)
Fruct Plus/Alb 0.0222 0.0304 0.0482 5.32 (p.molxlOO/g)
Fruct Plus/TP 0.0086 0.0349 0.0577 3.54 ((xmolxlOO/g)
%GA 0.0324 0.0272 0.1067 3.16
%GTP 0.0900 0.0022 0.3722 5.28
The grand mean is the mean result of all data points included in the analysis 
(i.e. n=100, or n=98 when 2 lipaemic samples were omitted as described in 
section 4.1.1).
230
Table 4.2.3. Analytical, within-subject and between-subject CVs for 13 
groups of assay data, obtained over a 5 day study period.
ASSAY CVA% CVi% CVo% CV%
TOTAL
Glucose 3.0 13.1 3.2 19.3
Albumin 2.8 3.7 5.7 12.2
Total Protein 1.5 3.8 3.8 9.1
DF 7.5 2.1 6.3 15.9
DF/g/1 7.7 1.9 5.4 15.0
Fructosamine 1.5 1.9 7.5 10.9
Fruct/Alb 3.1 2.6 5.7 11.4
Fruct/TP 2.2 3.2 6.7 12.1
Fruct Plus 2.8 2.2 4.3 9.3
Fruct Plus/Alb 2.6 3.3 4.1 10.0
Fruct Plus/TP 2.7 5.3 6.8 14.8
%GA 6.2 5.2 10.3 21.7
%GTP 5.9 0.9 11.6 18.4
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Table 4.2.4. Comparison of the Index of Individuality, the Index of 
Heterogeneity, the Critical Differences and the Analytical Goals of 10 
glycated protein indicators, obtained over a 5 day study period.
ASSAY Index of Index of Critical Analytical
Individuality Heterogeneity Difference Goal
(%) < (%)
DF 1.2 1.13 21.6 1.1
DF/g/1 1.5 1.34 22.0 1.0
Fructosamine 0.3 1.10 6.7 1.0
Fruct/Alb 0.7 1.70* (11.2) 1.3
Fruct/TP 0.6 2.18 * (10.8) 1.6
Fruct Plus 0.8 1.40 9.9 1.1
Fruct P/Alb 1.0 1.21 11.6 1.7
Fruct P/TP 0.9 3.92 * (16.5) 2.7
%GA 0.8 1.64 * (22.4) 2.6
%GTP 0.5 2.49 * (16.5) 0.5
Theoretical Index of Heterogeneity (1.00) + 2SD = 1.45
* For results exceeding the Theoretical Index of Heterogeneity by more than 
2 SDs, the Critical Difference is not generally applicable.
The Critical Difference is expressed for p<0.05.
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for those assays incorporating fluctuations in total protein levels. A critical 
difference can be usefully applied to those assays with an index of 
heterogeneity less than the theoretical index of 1.45, which suggests that a 
much larger change in Dns-PBA assay results must be apparent than for 
fructosamine or Fructosamine Plus results in order to state that a significant 
change in glycaemic control has occurred. The analytical goals obtained for 
each assay can be compared to the actual analytical CVs shown in Table 
4.2.3. Only the fructosamine results corrected for total protein levels have 
achieved their analytical goal, due to the relatively high CV%. The affinity 
chromatography and Dns-PBA techniques are a long way from reaching 
their goals although the various other fructosamine assay results come 
appreciably closer.
4.2.2. Daily glycated protein profiles.
The data obtained for the daily profiles of 10 glycated protein indices are 
presented graphically in Figures 4.2.11 - 4.2.20. These graphs give very 
similar information to those from the weekly study in that high within- 
subject variation is apparent for the Dns-PBA assays (Figs 4.2.11 and 
4.2.12) and high between-subject variation is apparent for the affinity 
chromatography results (Figs 4.2.19 and 4.2.20). Once again the 
fructosamine and Fructosamine Plus assays show the lowest amount of 
variability (Figs 4.2.13 and 4.2.14) although this does increase when protein 
corrections are applied (Figs 4.2.15 - 4.2.18).
Statistical analysis of the data was performed as described in section 4.1.2 
to produce Tables 4.2.5 - 4.2.8. With the exception of blood glucose levels, 
the F  ratios produced from this data in Table 4.2.5 are all lower than their 
counterparts in the 5 day study (Table 4.2.1). Again the Dns-PBA assay
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FIG. 4.2.11: Daily means and ranges of
DF values for 5 non-diabetic
individuals.
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FIG. 4.2.12: Daily means and ranges of 
DF/g/1 values for 5 non-diabetic 
individuals.
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2.0 -
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Five samples were taken from each subject over 1 day. The 5 results for 
each individual are shown as the mean value and full range.
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FIG. 4.2.13: Daily means and ranges of
Fructosamine values for 5 non-diabetic
individuals.
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FIG. 4.2.14: Daily means and ranges of 
Fructosamine Plus values for 5 non­
diabetic individuals.
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Five samples were taken from each subject over 1 day. The 5 results for 
each individual are shown as the mean value and full range.
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FIG. 4.2.15: Daily means and ranges of
Fructosamine/Albumin values for 5 non­
diabetic individuals.
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FIG. 4.2.16: Daily means and ranges of 
Fructosamine Plus/Albumin values for 5 
non-diabetic individuals.
=0
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2 3
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1 4 5
Five samples were taken from each subject over 1 day. The 5 results for 
each individual are shown as the mean value and full range.
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FIG. 4.2.17: Daily means and ranges of
Fructosamine/Total Protein values for 5
non-diabetic individuals.
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FIG. 4.2.18: Daily means and ranges of 
Fructosamine Plus/Total Protein values 
for 5 non-diabetic individuals.
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Five samples were taken from each subject over 1 day. The 5 results for 
each individual are shown as the mean value and full range.
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FIG. 4.2.19: Daily means and ranges of %
Glycated Albumin values for 5 non­
diabetic individuals.
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FIG. 4.2.20: Daily means and ranges of % 
Glycated Total Protein values for 5 
non-diabetic individuals.
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Five samples were taken from each subject over 1 day. The 5 results for 
each individual are shown as the mean value and full range.
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Table 4.2.5. One-way analysis of variance results for 13 groups of assay 
data, obtained over the course of 1 day.
ASSAY MEAN-SOUARES F
Between-subject Within-subject Ratio
Glucose 0.5500 0.3042 1.818
Albumin 33.75 2.560 13.18 **
Total Protein 32.50 5.860 5.546 **
DF 197.5 150.42 1.313
DF/g/1 0.1261 0.0625 2.018
Fructosamine 0.1208 0.0039 30.97 **
Fruct/Alb 0.4198 0.0264 15.90 **
Fruct/TP 0.1241 0.0100 12.41 **
Fruct Plus 1272 55.26 23.03 **
Fruct Plus/Alb 0.5975 0.0676 8.839 **
Fruct Plus/TP 0.2158 0.0192 11.24 **
% GA 0.6784 0.0879 7.718 **
% GTP 3.688 0.1004 36.73 **
** Significant difference (increase) in between-subject results compared 
to within-subject results with p<0.01.
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Table 4.2.6. Analytical, within-subject and between-subject variances for 
13 groups of assay data, obtained over the course of 1 day.
ASSAY Va Vi Vg GRAND MEAN
Glucose 0.0289 0.2753 0.0492 5.0 (mmol/1)
Albumin 1.690 0.8700 6.238 45 (gA)
Total Protein 1.060 4.800 5.328 68 (gA)
DF 100.0 50.42 9.416 126 (arbitrary units)
DF/g/1 0.0529 0.0096 0.0127 2.79 (arbitrary units)
Fructosamine 0.0014 0.0025 0.0234 2.23 (mmol/1)
Fruct/Alb 0.0334 0.0000 0.0787 4.93 (mmolxlOO/g)
Fruct/TP 0.0060 0.0040 0.0228 3.28 (mmolxlOO/g)
Fruct Plus 34.51 20.75 243.4 244 (|Limol/l)
Fruct Plus/Alb 0.0222 0.0454 0.1060 5.40 (Umol/g)
Fruct Plus/TP 0.0086 0.0106 0.0393 3.58 (|xmol/g)
%GA 0.0324 0.0555 0.1181 2.97
%GTP 0.0900 0.0104 0.7175 4.75
The grand mean is the mean result of all data points included in the analysis 
(n=25).
240
Table 4.2.7. Analytical, within-subject and between-subject CVs for 13 
groups of assay data, obtained over the course of 1 day.
ASSAY CVa% CVi% CVg% CV%
TOTAL
Glucose 3.0 10.5 4.4 17.9
Albumin 2.8 2.1 5.6 10.5
Total Protein 1.5 3.2 3.4 8.1
DF 7.5 5.6 2.4 15.5
DF/g/1 7.7 3.5 4.0 15.2
Fructosamine 1.5 2.2 6.9 10.6
Fruct/Alb 3.1 0.0 5.7 8.8
Fruct/TP 2.2 1.9 4.6 8.7
Fruct Plus 2.8 1.9 6.4 11.1
Fruct Plus/Alb 2.6 3.9 6.0 12.5
Fruct Plus/TP 2.7 2.9 5.5 11.1
%GA 6.2 7.9 11.6 25.7
%GTP 5.9 2.1 17.8 25.8
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Table 4.2.8. Comparison of the Index of Individuality, the Index of 
Heterogeneity, the Critical Differences and the Analytical Goals of 10 
glycated protein indicators, obtained over the course of 1 day.
ASSAY Index of Index of Critical Analytical
Individuality Heterogeneity Difference Goal
(%) < (%)
DF 4.0 1.15 25.9 2.8
DF/g/1 2.1 0.69 23.4 1.8
Fructosamine 0.4 0.42 7.4 1.1
Fruct/Alb 0.5 1.91 * (8.6) 0.0
Fruct/TP 0.6 2.04 * (8.1) 1.0
Fruct Plus 0.5 0.49 9.4 1.0
Fruct P/Alb 0.8 1.60 13.0 2.0
Fruct P/TP 0.7 1.69 * (11.0) 1.5
%GA 0.9 0.69 27.8 4.0
%GTP 0.4 1.52 17.3 1.1
Theoretical Index of Heterogeneity (1.00) + 2SD = 1.63.
* For results exceeding the Theoretical Index of Heterogeneity by more 
than 2 SDs, the Critical Difference is not generally applicable.
The Critical Difference is expressed for p<0.05.
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results show the lowest F ratios and in this study neither value reaches 
statistical significance. This is therefore the only assay in which there was 
no significant difference between the within-subject and between-subject 
variability over the course of the day.
The variance results and grand means for all the assays are shown in Table 
4.2.6 and this data was used to produce the CVs in Table 4.2.7. The basic 
trends observed for the 5 day study in Table 4.2.3 (described in section 
4.2.1) are also found here. The CV  ^ and CVg values for the various 
fructosamine assays are generally lower than in the 5 day study, resulting 
in slightly lower total CVs. For the affinity chromatography techniques 
these values have both increased whereas for the Dns-PBA assay results, 
CVi has increased and CVq has decreased.
In Table 4.2.8 it can be seen that the index of individuality for the Dns-PBA 
assay exceeds the limit of 1.4, implying that conventional reference ranges 
could be of some use here. For all the other assays this value is very low. 
The index of heterogeneity shows similar trends to the 5 day study results 
but with generally lower values. Critical differences are also very similar to 
those in Table 4.2.4. The analytical goals calculated from this study have 
obviously varied dependent upon the CVj results and would not be as 
applicable to routine use as those values shown in Table 4.2.4 from the 5 
day study.
Results of the paired t-tests for the diurnal variation study showed a 
significant difference for DF and DF/g/1 results which both increased 
significantly from the 9am sample (p<0.05) by 3pm, before falling again by 
the 5pm sample. The 5pm results for DF were still significantly higher than 
those found at 9am (p<0.05) and the results are shown graphically in Figs 
4.2.21 and 4.2.22. %GA results from the 5pm samples were also
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significantly higher than those for the 9am samples (p<0.05) although no 
significant differences were found at any point for the other assays.
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FIG.4.2.21: Variation of DF values from 
5 individuals over an 8 hour period.
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FIG. 4.2.22: Variation of DF/g/1 values 
from 5 individuals over an 8 hour 
period.
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2.0 -
1.5
9.00 11.00 13.00 15.00 17.00
Time of day
Points represent mean values ± standard deviation.
* Statistically significant increase from 9.00am sample with p<0.05.
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DISCUSSION.
The work undertaken in this chapter involved only the study of non-diabetic 
individuals. This was done in order to ensure that any fluctuations in 
glycated protein levels could truly be attributed to biological variation 
around a homeostatic set point, and were not caused by variations in 
glycaemic control. The degree to which blood glucose homeostasis is 
regulated in normal individuals is demonstrated by the low F-ratio produced 
for blood glucose levels, (Tables 4.2.1 and 4.2.5) which indicates that very 
similar glucose values persist, even between these individuals. These 
subjects were studied for the relatively short period of 5 days, based on the 
observations of Fraser and Harris (1989) that very similar results for 
biological variation were generally obtained irrespective of the timescale of 
the study and the number of subjects included. However, the timescale of 
this study was felt to be too short to give a comparable reflection of 
glycated haemoglobin levels due to its longer half life so this analysis was 
not included in the protocol. A previous study by Howey et al (1987) to 
assess components of biological variation with regard to the original 
fructosamine assay, also involved non-diabetic subjects but results may have 
been influenced by the use of an incorrect assay pH and a shorter incubation 
time. In a later paper (Howey et al 1989) this group also quote an analytical 
CV of 7.6% for automated fructosamine analysis, a value which seems 
unusually high, and may have contributed to their finding that HbAi 
measurement was more appropriate than fructosamine.
Having established that the F-ratio for blood glucose levels was statistically 
insignificant for the individuals being studied, it was interesting to note that 
with the exception of DF/g/l results, all other analyses, including albumin 
and total protein levels showed a significant difference in between-subject
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and within-subject results with p<0.01 over the 5 day study period. The 
same general trend was found over the course of 1 day (Table 4.2.5) 
although the various F-ratios tended to be lower. The reason for the lower 
F-ratios obtained with the Dns-PBA assay results can be seen from the 
graphical representations of the data which highlight the wide within-subject 
variation of the DF and DF/g/1 results.
The significant difference in between-subject results for albumin and total 
protein levels does appear to be contributing to between subject variation in 
glycated protein levels, as correction of DF, fructosamine and Fructosamine 
Plus results for plasma albumin or total protein levels consistently decreased 
the F-ratios.
Calculation of the analytical, within-subject and between-subject CVs for all 
the analytes gave very similar information for the 5 day or 1 day study, with 
the exception of the DF results. In the 5 day study the CVj for DF was 
considerably smaller than the CVq, whereas in the 1 day study this trend is 
reversed. This reversal was due to the significant diurnal variation found to 
occur with the DF results which effectively increased the within-individual 
variation over the course of 1 day. The index of individuality for DF results 
was also increased (Table 4.2.8) for the same reason.
There is clearly a large difference in analytical precision (CV^) between the 
fructosamine assays and the Dns-PBA and affinity chromatographies. This 
is due to the reasons stated previously (Chapter 2, discussion) concerning 
the fructosamine and Dns-PBA assays and also to the labour intensive 
manual technique of affinity chromatography.
The highest CVq values were found with affinity chromatography and this 
can be seen graphically in Figures 4.2.9,4.2.10,4.2.19 and 4.2.20 where the 
mean values for each individual are most widely spread out. This effect 
could partly be explained by the between-batch analytical imprecision of the
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assays which is higher than the within-batch analytical CV used in 
calculation for this study. However, this is also the situation for the other 
methods of analysis so it is possible that the high CVq found for affinity 
chromatography is representative of different sub-populations of glycated 
proteins in different individuals, even in the case of glycated albumin. This 
would be possible, if, as suggested by Johnson and Baker (1988) more than 
one glyco group is required per mole of protein to enable binding to the 
boronate affinity gel. The opportunity for glucose to bind non-enzymically 
to albumin, for example, will be restricted by other plasma constituents such 
as long-chain fatty acids, unconjugated bilirubin and hormones. This will 
influence glucose binding to varying degrees in different individuals, and 
become particularly apparent if an assay is not specific for any particular 
glyco group but requires more than one glyco group in a specific orientation 
in order to elicit a response. In this respect, the lower CVq obtained for the 
Dns-PBA assay is indicative of a more specific interaction of the boronate 
with glycated albumin, brought about by the requirements of the dansyl 
group. The fructosamine assay involves determination of individual glyco 
groups (Johnson and Baker, 1986).
Within-subject variation (CVJ of blood glucose levels is high, as all samples 
were random and non-fasting. Other than this, CV  ^ is less than CVq for all 
assays within the 5 day study. The CVj for %GTP is considerably lower 
than for %GA in both the daily and weekly studies despite the similarities 
in the assay procedure. The CV; of 0.9% obtained for %GTP in Table 4.2.3 
is in accordance with the low CVj values obtained for DF, DF/g/1 and the 
uncorrected fructosamine assays. Assuming that the Dns-PBA assay is 
measuring mainly, if not solely, glycated albumin this discrepancy in CVj 
implies some sort of difference between glycated albumin variance within- 
individuals, as measured by the Dns-PBA assay and by affinity
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chromatography. Once again, if more than one glyco group was required to 
be present on the albumin for binding to the boronate gel, only those 
molecules with greater exposure to glucose (either due to increased age of 
the molecule or increased blood glucose levels) would be expected to 
conform. These longer lived molecules would, by definition, have a shorter 
remaining lifespan than the ‘younger’, not so extensively glycated 
molecules, and would therefore show greater variation over a relatively short 
space of time. Similarly, if the Dns-PBA assay is measuring one specific 
glycation site on the albumin, the chances of this being occupied is the same 
throughout the whole lifespan of each molecule, hereby reducing the 
variation within-individuals.
In Tables 4.2.3 and 4.2.7, correction of fructosamine and Fructosamine Plus 
results for albumin or total protein levels has had a variety of different 
effects on the CVi and CVq results with no consistent pattern emerging. 
This could therefore indicate that correction of fructosamine or Fructosamine 
Plus results will generally confer no advantage on the performance of the 
assays.
Whether corrected for plasma protein levels or not, the fructosamine and 
Fructosamine Plus assays have produced the lowest overall CV values (total 
CV) for the glycated protein analysis, mainly due to their low CV^. Use of 
the Fructosamine Plus assay has reduced the between-subject variation 
(C V q) slightly over the original fructosamine assay and may therefore have 
overcome at least some of the effect of the non-specific plasma component 
demonstrated by Schleicher et al (1988).
In general, the index of individuality for most of the glycated protein indices 
is below 1.4 (i.e. ‘high’) so conventional population-based reference ranges 
are of limited use for all the assays (whether corrected for plasma protein 
levels or not) except perhaps the Dns-PBA assay. This finding is in
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accordance with Howey et al (1987) who found a high index of individuality 
for the fructosamine test, and implies that it could be a true phenomenon 
rather than a peculiarity of any particular assay. It has been proposed 
(Johnson et al, 1991) that the variation in turnover rates of glycated albumin 
in non-diabetics may explain this wide between-subject variation. 
Calculation of the index of heterogeneity, as shown in Table 4.2.4 has 
highlighted the greater heterogeneity of within-subject variances for all those 
assays dependent upon the total plasma protein levels of individuals (i.e. the 
highest values are acheived for fructosamine and Fructosamine Plus 
corrected for total protein and %GTP by affinity chromatography). If 
varying degrees of haemoconcentration, due to tourniquet application, could 
have been responsible for the significant between-subject variation in both 
plasma protein levels and glycated protein levels, correction for total protein 
would be expected to reduce the index of heterogeneity. This has clearly not 
occurred and implies that there is genuine heterogeneity of within-subject 
variances for these assays. This is not a surprising finding as individuals’ 
plasma protein profiles will vary considerably, and different rates of 
anabolism, catabolism, glycation and rates of reaction with NET for each 
protein will all combine to produce heterogeneity. This is particularly true 
of the globulin fraction, being composed of a wide diversity of different 
proteins all with different half lives, eg: Plasma fibrinogen (present at a 
concentration of up to 4.5 g/1 in healthy individuals) has a half life of only 
4 days and has been shown to be non-enzymically glycated in-vivo (Lutjens 
et al, 1985).
%GA values and corrected fructosamine and Fructosamine Plus results for 
plasma albumin levels did not produce such a high index of heterogeneity, 
presumably because this one major protein shows more uniform 
characteristics both within and between-individuals. The Dns-PBA assay.
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whether corrected or not for plasma albumin levels, has a low index of 
heterogeneity. This suggests that the DF and the albumin levels are not 
independent of each other, unlike the situation with the fructosamine assays 
where neither total protein nor albumin levels give an accurate reflection of 
what is being measured.
The index of heterogeneity results for the 1 day study show very similar 
trends to those for the 5 day study although values are generally lower, as 
would be expected over a smaller timescale.
Both the fructosamine and Fructosamine Plus assays without any corrections 
applied, show low heterogeneity within-individuals. A critical difference can 
therefore be applied to these results and to the Dns-PBA assay results which 
shows that when monitoring patients, a much higher change in serial results 
is required for significance with the Dns-PBA assay than for the 
fructosamine and Fructosamine Plus tests.
The analytical goals suggested in Table 4.2.4 are clearly unachievable, 
except perhaps in the case of the highly automated fructosamine and 
Fructosamine Plus assays. The analytical goal of <2.6% for the original 
fructosamine assay derived by Howey et al (1987) was obtained from data 
taken over a longer time scale than this study and produced a much higher 
CVi. However, use of glycated plasma protein indices are most 
advantageous over glycated haemoglobin measurements when a more rapid 
response to changing states of glycaemia is required. This study over the 
course of 5 days is therefore not unrepresentative of the clinical use of the 
assay. As these goals do not take into consideration the degree of variation 
that the analytical performance may be introducing into the variability of the 
true result, they are necessarily based on some assumptions. The analytical 
goals obtained also serve to highlight the fact that statistical analyses such 
as these cannot be applied to clinical and analytical situations completely
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inflexibly, and that some general knowledge of the logistics of the actual 
procedures and also of the clinical significance of the results is necessary for 
a useful interpretation, eg: The CVi of 0.0% obtained for fructosamine 
results corrected for albumin in the 1 day study (Table 4.2.7) will clearly not 
remain at this level if more samples are taken or the time course extended. 
In this respect, it is useful to calculate that the CVj plus CVq value for DF 
results in Table 4.2.3 (8.4%) equates to a DF value of 11 from the grand 
mean in Table 4.2.2 (mean DF=126), and is less than the limit of detection 
for the assay (i.e. DF=14) as determined in section 2.3.6 of this thesis. This 
implies that the effects of biological variation on this particular assay are 
going to be negligable in terms of the clinical interpretation of the results.
Results obtained in section 4.2.2 of this chapter indicate that there is some 
diurnal variation occurring in glycated albumin levels during the 8 hours 
studied. This effect was not apparent for those assays measuring glycated 
total protein in this study although previous work on both the original 
fructosamine assay (Flückiger et al, 1987) and the Fructosamine Plus assay 
(Brunnbauer et al, 1989) has recommended that the results should be 
corrected for plasma protein levels due to fluctuating protein values 
throughout the day. However, these investigations were performed with 
diabetic patients, where changes in plasma protein levels will produce larger 
changes in glycated protein levels due to the increased amount of glycation 
initially present.
It is unlikely that the increased DF and DF/g/l results obtained after the 1pm 
sample in this study are reflecting an increase in plasma fatty acid content 
following a meal, as this was shown in section 3.2.5 of this thesis to cause 
a significant decrease in results and the samples were not visibly lipaemic. 
In addition, lipaemia has not been reported to interfere in the affinity
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chromatography technique for glycated albumin. An increase in plasma 
protein levels following a meal could be affecting the Dns-PBA assay by 
increasing light scattering and absorbance but no significant changes in 
protein levels were observed. Again, this would not affect the affinity 
chromatography results.
On the basis of these diurnal variation results, it would be advisable to 
obtain morning samples for glycated albumin analysis, although a study into 
the effects of fasting on glycated albumin levels would be informative.
In conclusion, the results of this study into biological variation have 
indicated that all the glycated plasma protein indices studied show a wide 
degree of between-subject variation (high index of individuality) although 
in this respect the Dns-PBA assay may be slightly better than the others. 
Reference ranges should therefore be referred to with caution when 
comparing glycaemic control between patients. Based on the increased index 
of heterogeneity which occurs upon correction of fructosamine and 
Fructosamine Plus results for plasma protein levels, this procedure cannot 
be recommended when glycaemic control is good. The same effect was also 
found by Howey et al (1989) for well controlled diabetic patients. Affinity 
chromatography for %GA and %GTP has also shown a high index of 
heterogeneity, indicating that these assay results may be more difficult to 
interpret when monitoring patients than the Dns-PBA assay or either 
fructosamine test.
A critical difference can be applied to these latter tests, which is lowest for 
the original fructosamine assay, implying that this test is the most sensitive 
for serial monitoring, closely followed by Fructosamine Plus. These two 
assays are also the ones most likely to ever reach their analytical goals for 
precision.
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CHAPTERS.
APPLICATION OF TH E DANSYL-PBA FLUO ROM ETRIC ASSAY 
TO TH E DIAGNOSIS AND M ONITORING OF DIABETIC
PATIENTS.
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Introduction.
Diabetes is a universal health problem which may occur at any age and is 
particularly prevalent during pregnancy. In overt cases of diabetes patients 
will present with characteristic signs and symptoms, including unequivocally 
high blood glucose concentrations. However, as there is no natural cut off 
point between normal and abnormal glycaemia, there can be considerable 
diagnostic uncertainty as to whether a patient should be classified as diabetic 
or not. In cases where the blood glucose levels and clinical features are 
equivocal it is now usual clinical practice to perform an oral glucose 
tolerance test (OGTT). Despite its common usage this test still has several 
variants in terms of both the glucose load given and the interpretation of 
results. In the USA, a glucose load of lOOg has been advocated whereas in 
Europe a 50g dose is often preferred in order to reduce nausea and 
gastrointestinal disturbance. In 1980 the World Health Organisation (WHO) 
published a report to try and overcome these anomalies by suggesting a 75g 
glucose load as a compromise. This report also introduced the category of 
‘impaired glucose tolerance’ into the classification of results in order to 
cover the borderline region between non-diabetic and diabetic results. This 
category has since been shown to be associated with an increased risk of 
developing coronory heart disease (Fuller et al, 1980; Zammit Maempel, 
1981) as well as a predisposition to diabetes in later life, although the 
cardiovascular effects may be mediated by hyperinsulinaemia or raised 
levels of insulin-like molecules (Yudkin et al, 1990).
Other factors found to influence OGTT results include the patients diet over 
the preceeding 3 days (although this has recently been disputed by Harlass 
et al, 1991), posture throughout the test and the effect of stress on the 
patient. Most of these variables could be eliminated if glycaemic control 
could be established using a single blood sample for analysis of a glycated 
protein. This would be particularly suitable when screening for gestational
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glucose intolerance, as over 50% of the OGTTs performed at the district 
general hospital in this study are for the detection of this condition. 
Although universal screening for gestational glucose intolerance at 24-28 
weeks of pregnancy has had strong support (American Diabetic Association. 
1986), results from the treatment trials of the 1950s and 1960s showed that 
treatment of gestational glucose intolerance decreased the proportion of 
infants weighing > 4.1 kg at birth (O’Sullivan et al, 1966; O ’Sullivan et al, 
1974) but showed no other significant effect on pregnancy outcome. 
Clinicians have therefore not come to any firm decisions as to whether there 
is sufficient justification for universal screening using the OGTT. More 
recently, Santini & Ales (1990) found that this process of screening actually 
failed to decrease the incidence of large infants and also failed to improve 
pregnancy outcome. The more intensive surveillance of the screened patients 
throughout pregnancy also resulted in a significantly higher rate of primary 
Cesarean deliveries. It is possible that a retrospective estimation of the 
patient’s glycaemic state by glycated protein analysis would be more 
physiologically representative than this assessment of an unnatural pure 
glucose load, as it would not be so prone to environmental influences. 
Several workers have investigated the possibility of using glycated 
haemoglobin as an indicator of glucose intolerance. Koenig et al (1976) 
found a good correlation between OGTT results and HbAi^ levels but there 
was a considerable overlap between those classified as non-diabetic and 
diabetic. However, Kesson et al (1982) have since compared the usefulness 
of HbAic to that of HbAj measurement in this respect and were able to show 
that HbAi was raised in 90% of patients with diabetic OGTTs whereas 
HbAjc was raised in only 43%. This group therefore suggested that HbA^ 
estimation is a useful screening test for non-insulin dependent diabetes and 
should be considered when criteria for diagnosis of diabetes are discussed. 
Similarly, Forrest et al (1988) who assessed four different methodologies for 
glycated haemoglobin as screening tests, concluded that the measurement
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was as accurate as that of the fasting blood glucose levels in predicting 
glucose tolerance abnormalities if methods specific for the stable ketoamine 
adduct were used.
Comparisons of HbAi and fructosamine in the diagnosis of glucose tolerance 
abnormalities have also been made using an OGTT as the reference method. 
Guillausseau et al (1990) found an optimum sensitivity and specificity of 
75% for HbAi and 55% for the fructosamine assay, concluding that neither 
test was suitable for diagnosis of mild abnormalities in glucose tolerance. In 
1987, Salemans et al performed a similar comparison and found that the 
fructosamine test was slightly more sensitive than HbAj (52% vs 44%) for 
detection of impaired glucose tolerance although both parameters had a 
sensitivity of 67% for detection of those classified as diabetic.
Although Baker et al (1983) have suggested from their results that 
fructosamine is a reliable index when screening for diabetes mellitus, 
patients with frank fasting hyperglycaemia and clinical signs of diabetes 
were included in their analysis which may have biased the results.
The use of glycated protein indices for detection of gestational diabetes has 
generally been shown to bè even less effective than the examples above. 
Vermes et al (1988) found that fructosamine and HbAi^ had similar 
diagnostic values for non-pregnant adults but that neither could replace 
OGTT for diagnosis of gestational diabetes. Cefalu et al (1990) and Roberts 
et al (1990) also concluded that the fructosamine assay was not a useful 
screening test for gestational diabetes. This chapter therefore investigates the 
use of the Dns-PBA assay for detection of impaired glucose tolerance in 
both pregnant and non-pregnant subjects in relation to results of OGTTs.
Direct comparisons have also been made in this chapter between the ability 
of the Dns-PBA assay, Fructosamine Plus, affinity chromatography and 
HbAjc analysis by HPLC, to detect both chronic and acute changes in 
glycaemic control in diabetics. Since the turnover of serum proteins is
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considerably faster than that of haemoglobin, a more rapid response of 
glycated serum protein assays for both acute and chronic changes in 
glycaemic control would be expected, providing the assay in question is 
sufficiently sensitive to change. Dolhofer and Wieland (1980) were able to 
demonstrate this phenomenon in an insulin treated patient, whereby the 
temporal relationship of HbA^ and glycated albumin levels was monitored. 
After 20 days of therapy the glycated albumin levels (as measured by a 
HMF-TBA method) had dropped by over 50% whereas HbAj levels had 
decreased by only 15%. Similar results have been shown by Kennedy et al 
(1981).
In 1989, Winocour et al compared the relative clinical usefulness of glycated 
serum albumin (as measured by affinity chromatography) to that of the 
fructosamine assay and HbA^ (by ion exchange), during changes in 
glycaemic control of insulin dependent diabetics. This group concluded that 
glycated serum albumin was a more sensitive indicator of short term 
improvement in glycaemic control than either of the other assays. Glycated 
fibrinogen has also been shown to be a rapid indicator of changing 
glycaemic control (Hammer et al, 1989) as this plasma protein has an even 
shorter half life than albumin. It is possible that the decreased sensitivity of 
the fructosamine test to changes in glycaemic control observed by Winocour 
et al (1989) is due to the non-specific component of this assay described by 
Schleicher et al (1988). In this chapter the sensitivity of various glycated 
protein analyses were therefore compared by monitoring the recovery of 
patients admitted to hospital in diabetic ketoacidosis and also by monitoring 
the progress of a newly diagnosed diabetic on insulin therapy.
Materials.
Equipment and reagents were as described previously under ‘materials’ in 
chapters 2 and 3.
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SECTION 1. APPLICATION OF THE DANSYL-PBA ASSAY TO 
SCREENING FOR IMPAIRED GLUCOSE TOLERANCE AND 
DIABETES.
5.1.1. Methods.
Fasting serum samples were obtained from 123 patients attending Frimley 
Park Hospital for an OGTT over the course of 1 year. The majority of these 
patients (74) were pregnant women, who were referred for an OGTT at 
various stages during pregnancy due to development of glycosuria, previous 
delivery of a large baby, the presence of hydramnios or a strong family 
history of diabetes. The remaining patient group (49) consisted of 26 males 
and 23 females, referred for OGTT due to a finding of glycosuria, a 
previous raised fasting blood glucose level, a history of recurrent infections 
or other clinical indications of possible diabetes.
The OGTTs were performed according to the following protocol:
Patients were requested to follow an unrestricted diet for 3 days, then to fast 
for 10-16 hours prior to the test. A fasting venous blood sample was taken 
on arrival at 9.00 am for glucose and Dns-PBA assay analysis, together with 
a mid-stream urine sample for glucose testing. Providing the blood glucose 
level was <7.8 mmol/1 a 75g glucose load was given as the monosaccharide 
in the form of 116 mis Hycal (Beecham Products, Brentford, UK) and 
further blood samples were taken at 30, 60, 90, and 120 minutes. Urine 
samples were collected with the 60 and 120 minute bloods. Samples for 
blood glucose analysis were collected into fluoride oxalate tubes and plasma 
was assayed by a glucose dehydrogenase method on the Cobas Bio analyser. 
Urine was tested for the presence or absence of glucose using Ames 
‘Diastix’ (Miles Ltd, Ames division, Slough, UK). Dns-PBA assay analysis 
was performed on serum from the fasting sample only.
Subjects remained seated throughout the test and were not permitted to
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smoke.
Individuals were classified as having normal glucose tolerance when fasting 
and 2 hour post load plasma glucose values were <7.8 mmol/1. Impaired 
glucose tolerance was defined as fasting plasma glucose <7.8 mmol/1 and 
2 hour plasma glucose >7.8 mmol/1 but <11.1 mmol/1. Fasting plasma 
glucose >7.8 mmol/1 and/or 2 hour post load plasma glucose >11.1 mmol/1 
was considered diagnostic for diabetes mellitus. A finding of glycosuria in 
the absence of plasma glucose levels >10.0 mmol/1 classified a patient as 
having a low renal threshold for glucose (renal glycosuria). The additional 
blood samples at 30, 60 and 90 minutes facilitated this diagnosis.
Patients from the pregnant and non-pregnant groups were therefore classified 
according to one of the following responses: normal, renal glycosuria, 
impaired glucose tolerance or diabetic.
5.1.2. Results.
Table 5.1.1 shows the Dns-PBA assay results for the pregnant and non­
pregnant OGTT groups as means ± SD. In the non-pregnant group, only the 
patients diagnosed as diabetic by the OGTT showed DF/g/l results 
significantly higher than those for normal OGTT patients (p<0.05). None of 
the other pregnant groups gave DF/g/l results significantly different from the 
pregnant normals but the pregnant normals and renal glycosurie patients had 
DF/g/l results significantly lower than their non-pregnant counterparts.
5.I.2.I. Use of receiver operating characteristic (ROC) curves.
ROC curves were produced as described by Robertson and Zweig (1981). 
Each DF/g/l result as classified in Table 5.1.1 by OGTT was categorised as 
a true positive (TP), true negative (TN), false positive (FP) or false negative
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Table 5.1.1. Dns-PBA assay results for patients classified by an oral 
glucose tolerance test.
Mean DF/g/l ± SD
OGTT
classification n Non-pregnant n Pregnant
Normal 16 1.64 ± 0.32 21 1.10 ± 0.46 ***
Renal glycosuria 15 1.59 ± 0.46 43 1.17 ± 0.47 **
Impaired glucose 
tolerance 4 1.75 ± 0.77 8 1.35 ± 0.61
Diabetic 14 2.26 ± 1.05 t 2 1.71 ± 0.14
t  Statistically significant difference from normal non-pregnant group
with p<0.05.
* * Statistically significant difference from respective non-pregnant group
with p<0.01.
*** Statistically significant difference from respective non-pregnant group
with p<0.001.
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(FN) according to whether each result was less than, or greater than or equal 
to various DF/g/l cut off values. Using these definitions, the specificity and 
sensitivity of the Dns-PBA assay at each cut off level was determined using 
the following formulae:
TP
Sensitivity
TP + FN
TMSpecificity
TN + FP
The predictive value of a positive (PVP) or a negative (PVN) test result was 
also calculated, assuming that the prevalence of disease in the population at 
large undergoing OGTT is equivalent to the prevalence observed in this 
study.
pyp  ,  iPrevalence){TP)
(Prevalence)(TP) + (FP)(1-Prevalence)
p y ^ ___________ (1 -Prevalence)(l -FP)_________
(l-Prevalence)(l-FP) + {Prevalence)(l-TP)
These calculations were performed on the pregnant and non-pregnant OGTT 
groups in order to assess the utility of the Dns-PBA assay at discriminating 
the diabetic patients from all others, as well as its ability to discriminate 
those with impaired glucose tolerance or diabetes from all others. Results 
are shown in Tables 5.1.2 - 5.1.5, which were used to produce the ROC
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Table 5.1.2. Dns-PBA assay ROC curve data for detection of diabetes
in a non-pregnant OGTT group.
Cut off level Sensitivity Specificity PVP PVN
DF/g/l % % % %
1.0 100 9
1.5 64 26 - -
1.8 57 60 - -
1.9 57 74 47 80
2.0 50 83 55 80
2.1 43 91 66 80
2.3 43 94 74 79
2.5 36 100 100 78
3.0 29 100 100 78
Table 5.1.3. Dns-PBA assay ROC curve data  for detection of 
diabetes/im paired glucose tolerance in a non-pregnant group.
Cut off level Sensitivity Specificity PVP PVN
DF/g/l % % % %
1.0 94 6
1.5 61 26 -
1.8 56 65 - -
1.9 56 77 59 75
2.0 50 87 69 75
2.1 44 97 90 75
2.3 44 100 100 75
2.5 28 100 100 70
3.0 22 100 100 69
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Table 5.1.4. Dns-PBA assay ROC curve data for detection of diabetes
in a pregnant OGTT group.
Cut off level 
DF/g/l
Sensitivity
%
Specificity
%
PVP
%
PVN
%
1.0 100 39 5 100
1.5 100 67 9 100
1.6 100 82 14 100
1.7 50 90 14 98
1.8 50 93 18 98
1.9 0 96 - -
2.0 0 96 - -
2.1 0 99 - -
2.3 0 100 - -
Table 5.1.5. Dns-PBA assay ROC curve data for del
diabetes/impaired glucose tolerance in a pregnant OGTT gr
Cut off level Sensitivity Specificity PVP PVN
DF/g/l % % % %
0.2 100 2
1.0 70 34 15 87
1.5 60 69 24 91
1.6 60 86 41 91
1.7 40 94 52 91
1.8 40 97 68 91
1.9 10 97 - -
2.0 10 97 - -
2.1 0 97 - -
2.3 0 100 - -
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curves in Figures 5.1.1 and 5.1.2.
The optimum portion of the ROC curves shown is in the upper left hand 
comer of the graph. The closer the curve comes to this point the more 
effective the test. Using a cut off value of 1.9 DF/g/l for the non-pregnant 
group, sensitivities of 57% and 56% were produced for detection of diabetes 
and diabetes/impaired glucose tolerance respectively. These are the points 
closest to the top left comer in Fig. 5.1.1 and correspond to a PVP of 47% 
and a PVN of 80% for detection of diabetes (ie, 80% of patients with results 
<1.9 DF/g/l will not have diabetes, 47% of patients with results >1.9 DF/g/l 
will have diabetes) and a PVP of 59% with a PVN of 75% for detection of 
impaired glucose tolerance or diabetes.
For the pregnant group in Fig. 5.1.2, optimum sensitivities were achieved 
at a cut off level of 1.6 DF/g/l with a sensitivity for detection of diabetes of 
100% {PVP = 14%, PVN = 100%) and a sensitivity of 60% for detection of 
impaired glucose tolerance/diabetes {PVP = 41%, PVN = 91%).
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FIG. 5.1.1: Dns-PBA assay ROC curves for
the prediction of impaired and/or
diabetic OGTTs.
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Various cut off levels for DF/g/l results from 49 non-pregnant patients are 
shown for the detection of diabetes ( # )  or diabetes/impaired glucose 
tolerance (O). Points marked with an arrow indicate the optimum cut off 
value of 1.9 DF/g/l.
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FIG. 5.1.2: Dns-PBA assay ROC curves for
the prediction of impaired and/or
diabetic OGTTs in pregnant women.
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Various cut off levels for DF/g/l results from 74 pregnant women are shown 
for the detection of diabetes ( # )  or diabetes/impaired glucose tolerance (O). 
Points marked with an arrow indicate the optimum cut off value of 1.6 
DF/g/l.
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SECTION 2. COMPARISON OF GLYCATED PROTEIN METHODS FOR 
MONITORING ACUTE AND CHRONIC CHANGES IN GLYCAEMIC 
CONTROL.
5.2.1. Monitoring chronic changes in glycaemia.
Although it is necessary to bring a patient with poor glycaemic control back 
to normoglycaemia as soon as possible, when stabilising a newly diagnosed 
insulin dependent diabetic, achievement of good blood glucose control can 
actually take several weeks or months. This is because following the initial 
diagnosis of diabetes, much of the responsibility then lies with the patient 
to get used to a particular regime of diet and insulin administration. This, 
together with familiarisation with home blood glucose monitoring techniques 
will involve a certain amount of trial and error on the part of both the 
patient and the clinician until satisfactory control is established. Subtle 
reductions in glycated protein levels will therefore be occurring following 
the initial onset of insulin therapy so that useful monitoring of the patient’s 
progress, in terms of reduction of glycated protein levels, requires a 
sufficiently sensitive assay.
5.2.1.1. Methods
A 58 year old female patient was admitted to hospital as an emergency with 
hyperventilation attacks, shortly after being diagnosed as suffering from 
diabetes mellitus. This patient had a blood glucose level of 21.3 mmol/1 but 
was not ketoacidotic as demonstrated by arterial blood gas results. Blood 
glucose levels were reduced initially by oral administration of metformin but 
as this failed to reduce levels below 10 mmol/1, insulin therapy was 
commenced on day 10. The patient was discharged within 2 weeks under 
the care of the district nursing staff and instructed in the technique of home
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blood glucose monitoring using Ames glucostix (Miles Ltd, Ames Division, 
Sluogh, UK). An average of 4 blood glucose results per day were obtained 
by the patient over the period of study.
Venous blood samples (10) were obtained from this patient over a period of 
3 months, with her informed consent, whilst her diabetes was brought under 
control. These samples were assayed in the laboratory for blood glucose 
levels (using a glucose dehydrogenase method on the Cobas Bio analyser), 
DF/g/l using the standardised Dns-PBA assay described in this thesis and 
fructosamine using a ‘Fructosamine Plus’ kit from Roche Diagnostics on the 
Cobas Bio analyser. The affinity chromatography techniques described in 
section 3.1 were used to measure glycated albumin (%GA) and glycated 
total protein (%GTP) levels. Glycated haemoglobin was measured as HbAi^ 
using the automated HPLC modular diabetes monitoring system from Bio- 
Rad (Bio-Rad Laboratories Ltd, Watford, Hartfordshire, UK). All analyses 
were performed on serum with the exception of plasma glucose and HbAjc 
which were performed on blood collected into fluoride oxalate. Samples 
were analysed as soon as possible following their arrival in the laboratory 
and were not batched for analysis. This approach was taken in order to 
simulate the conditions under which patients would normally be monitored 
and also to enable useful results to be reported back to the clinicians.
5.2.I.2. Results
The glycated protein and blood glucose profiles obtained over the 3 month 
study of this one patient are shown in Figs 5.2.1 to 5.2.4 which compare the 
performance of the Dns-PBA assay to the other techniques. The blood 
glucose results include both those obtained in the laboratory and the daily 
means of those obtained by the patient at home. All glycated protein results 
are expressed as a percentage of their highest value achieved, in order to 
enable a direct visual comparison of the methodologies. The actual results
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FIG. 5.2.1: The temporal relationship of 
DF/g/l and glycated Hb to chronic 
decreases in blood glucose levels.
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FIG. 5.2.2: The temporal relationship of 
DF/g/l and%GA to chronic decreases in 
blood glucose levels.
Time (days) 
Glucose DF/g/l GA
Results were obtained from a newly diagnosed diabetic who commenced 
insulin therapy on day 10.
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FIG. 5.2.3: The temporal relationship of 
DF/g/l and%GTP to chronic decreases 
in blood glucose levels.
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FIG. 5.2.4: The temporal relationship of 
DF/g/l and fructosamine to chronic 
decreases in blood glucose levels.
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Results were obtained from a newly diagnosed diabetic who commenced 
insulin therapy on day 10.
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for each glycated protein assay are shown in Table 5.2.1 (unfortunately, a 
fluoride oxalate sample was not received to enable HbAj^ analysis on day 
64).
The comparison of DF/g/l results to HbAjj. results in Fig 5.2.1 shows that 
the initial rate of decrease in HbAjj. is not far behind that for the DF/g/l 
results. A relatively large drop in DF/g/l values occurring for the 
fluorometric assay between days 21 and 26 appears to be reflected in the 
HbAjc results approximately 22 days later (days 43-48). By day 57 it would 
appear that both types of analysis are giving similar clinical information. 
One notable feature about the %GA affinity chromatography profile in Fig 
5.2.2 is that values do not reach a peak until day 7. This is also the case for 
the %GTP results in Fig 5.2.3. There appears to be a greater similarity in 
%GTP results to DF/g/l than for %GA, with the %GA values showing a 
more marked decrease than the other two after day 48. The absolute values 
for the various glycated protein analyses given in Table 5.2.1 show that 
similar maximum levels of glycation were achieved for HbAjc %GA and 
%GTP (14.0%, 14.02% and 15.33% respectively). By day 98 the DF/g/l and 
%GA results had shown the highest percentage decreases from their 
maximum observed values (60% and 63% decreases respectively) and the 
final DF/g/l result was within the non-diabetic reference range for the assay. 
HbAic %GA and %GTP results were reduced to levels just above those 
observed for a non-diabetic population whereas the Fructosamine Plus 
results remained appreciably higher and showed the lowest percentage 
decrease (40%) of all the assays.
5.2.2. Monitoring acute changes in glycaemia.
Acute changes in glycaemia may be expected to occur in out of control 
insulin dependent diabetics, whereby lack of insulin administration will lead 
to hyperglycaemia and ketoacidosis or alternatively, excess administration
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Table 5.2.1. Glycated protein results during stabilisation of a newly 
diagnosed insulin dependent diabetic.
Day DF/g/1 %HbAi, %GA %GTP Fructosamine 
Plus (p.mol/1)
1 4.55 14.0 13.2 14.51 580
5 4.41 13.9 13.28 15.19 563
7 4.29 13.6 14.02 15.33 534
21 3.79 12.2 10.85 11.88 433
26 3.16 12.0 12.08 11.17 414
43 2.95 10.7 8.68 9.32 374
48 2.70 9.1 7.15 8.75 361
57 2.87 8.7 6.20 8.96 360
64 2.90 - 5.68 7.53 324
98 1.81 6.7 5.17 7.14 348
Non-■diabetic reference ranges: DF/g/l 1.04 -2 .4 4
HbAi, 3 .9 - 6.0
%GA 1.65 - 5.05
%GTP 4.18 -7 .06
Fructosamine 205 - 285 
Plus
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of insulin will lead to the onset of hypoglycaemia. As prolonged severe 
hypoglycaemia is incompatible with life and short episodes will have little 
effect on glycated protein levels, the effect of severe acute changes in blood 
glucose levels on glycated proteins were studied in patients admitted to 
hospital in diabetic ketoacidosis.
5 2.2.1. Investigation of possible analytical interferences in ketoacidotic 
serum.
During an episode of diabetic ketoacidosis, the levels of certain serum 
constituents other than glucose can change dramatically. The most notable 
of these with regard to this study include triglycerides, p-hydroxybutyrate 
and acetoacetate. As visual lipaemia was shown to interfere with the Dns- 
PBA assay in section 3.2.5, patients with lipaemic serum were not included 
in the study. Preliminary investigations were therefore performed regarding 
the effect of glucose, p-hydroxybutyrate and acetoacetate on the 
Fructosamine Plus and affinity chromatography assay results together with 
the effect of p-hydroxybutyrate and acetoacetate on the Dns-PBA assay 
results. Investigations in section 3.2.3 have shown that the small increase in 
DF/g/l results occurring in the presence of over 80 mmol/1 glucose is 
minimal (approximately a 9% increase on a non-diabetic result and a 5% 
increase on a diabetic result) considering the precision profile of the assay 
(CV = 5.6% - 12.1%).
Normal fasting levels of p-hydroxybutyrate and acetoacetate can vary from 
30 - 300 p.mol/1 and levels in disease can rise to as high as 300 mmol/1, 
p-hydroxybutyrate was obtained from the Sigma Chemical Company (Poole, 
Dorset, UK) and used diluted in PBS (pH 7.4) to augment aliquots of a 
serum sample giving final concentrations of between 0.03 and 300 mmol/1. 
Following analysis of these samples (5 times each) by all the above
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methodologies, no significant differences were obtained between the means 
of the augmented samples and those with the addition of a PBS blank. 
Samples were reassayed following a 24 hour incubation at 37 °C but any 
differences remained statistically insignificant for all the assays. This 
protocol was then repeated using acetoacetic acid (lithium salt, obtained 
from the Sigma Chemical Company) in the same concentrations which also 
had no effect on any of the assays. However, the addition of 10, 20, 40 or 
80 mmol/1 D-glucose to 2 non-diabetic patient samples reduced the mean 
affinity chromatography results by between 4% (20 mmol/1 glucose) and 
10% (80 mmol/1 glucose) for %GA, and by between 2% and 9% for %GTP. 
This did not appear to be a strictly linear relationship dependent on the 
glucose level.
The Fructosamine Plus assay did show a linear response to increasing 
glucose concentrations for analysis of 3 non-diabetic serum samples when 
augmented with 10, 20, 40 and 80 mmol/1 (r=0.996, y = 0.6% + 208). This 
was paralleled by aqueous glucose solution results (r=0.990, y = 0.6% + 3.2) 
with the difference in intercepts reflecting the sample matrix. The results 
obtained for 80 mol/1 glucose additions gave a 44 p,mol/l increase in 
fructosamine values which is equivalent to approximately 17% of a non­
diabetic result or 11% of a typical diabetic result. A glucose correction was 
therefore applied to fructosamine results when blood glucose levels were 
>15.0 mmol/1 in studies throughout the remainder of this section (5.2.2) by 
applying the following formula:
Corrected Fructosamine = Fructosamine (p.mol/1) - 0.6 Glucose (mmol/l) 
(p.mol/1)
Fructosamine results corrected and uncorrected for glucose have also been 
expressed as a l%mol/g value when divided by serum albumin levels in this 
section.
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S.2.2.2. Patients and methods.
Patients admitted to Frimley Park Hospital in diabetic ketoacidosis were 
recruited to this trial. The informed consent of the patient was obtained once 
their condition was stabilised and when their discharge was within 3 days, 
the patient was requested to return for further blood samples on 2 
convenient occasions over the following 2 weeks. After exclusion of patients 
presenting with lipaemic serum and those which were not prepared to attend 
for additional blood samples, 3 patients were available for study. Two of 
these patients had an extended stay in hospital due to complicating factors 
so samples were more readily available. However, on occasions the correct 
sample type was not taken for a particular analysis so a small number of 
specific data points have been missed in some of the following figures. 
Whenever possible, samples were analysed for glucose, DF/g/l, HbA^c 
%GA, %GTP and Fructosamine Plus.
Patient no. 1.
This 44 year old male insulin dependent diabetic was admitted to hospital 
with a blood glucose level of 30.0 mmol/l. Prior to this ketoacidotic episode 
he had been reasonably well controlled (recent HbA^g results were <7.0%) 
and thought that a blockage in his insulin syringe may have been to blame 
for his condition. Following intravenous administration of fluids and insulin 
therapy this patient made a rapid recovery and was discharged within 3 
days.
Patient no. 2.
This 64 year old female non-insulin dependent diabetic was admitted to 
hospital with a blood glucose level of 53.4 mmol/l and clinical signs of 
dehydration. She gave a history of nausea, vomiting and hyperventilation, 
together with excessive thirst on the day of admission. On the following day
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a cardio-respiratory arrest necessitated intubation and ventilation of this 
patient with prolonged ionotropic support. Despite the onset of a chest 
infection this patient made a good recovery and continued to control her 
diabetes on diet alone.
Patient no. 3.
This 72 year old female insulin dependent diabetic was admitted to hospital 
in diabetic ketoacidosis with a blood glucose level of 76.0 mmol/l. This 
patient had been using continuous ambulatory peritoneal dialysis (CAPD) 
for the previous year due to chronic renal failure and on admission she had 
a serum urea concentration of 26.6 mmol/l. This patient also had a chronic 
anaemia with a haemoglobin of 8.9 g/dl and her blood glucose levels proved 
to be difficult to stabilise due to the presence of glucose in her dialysis 
fluid.
During her stay in hospital, this patient’s blood urea levels ranged between 
14.6 and 26.6 mmol/l.
S.2.2.3. Results.
Patient no. 1.
Glycated protein and glucose profiles for this patient are shown in Figs 5.2.5 
- 5.2.7. Apart from a lapse in glycaemic control on day 3, this patient’s 
blood glucose levels were brought back to normal within a week of 
admission. In Fig 5.2.5 the uncorrected Fructosamine Plus results follow the 
pattern of the changing blood glucose results. When corrected for albumin 
or albumin and glucose levels the profile is similar but the initial percentage 
drop in results from admission to day 1 is not as dramatic as for the 
uncorrected results. Also, a slight increase is apparent between the first 2 
corrected results which was not found for the uncorrected results. When 
corrected for glucose and albumin levels there is a maximum decrease of
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FIG 5.2.5: Fructosamine Plus profiles
for diabetic patient no. 1 following
admission on day 0.
100 r-40
a 90-g
80-  
S 70 -
-3 5
-3 0
'o
I
-2 5  -g60 -
50- -2 0
40- -1 5  3
30-
-1 0I 2 0 -I - 5
0 2 4 6 a 1610 12 14
Time (days)
Blood glucose results (♦) and Fructosamine Plus results (0) are shown as the 
percentage of the maximum value achieved for a patient recovering from 
diabetic ketoacidosis. Correction of these results for serum albumin (O ) or 
serum albumin and glucose levels (□ ) as described in section 5.2.2.1 is also 
shown.
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FIG. 5.2.6: Glycated Hb and DF/g/l
profiles for diabetic patient no. 1
following admission on day 0.
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Glycated Hb Glucose
FIG. 5.2.7: GA and GTP profiles for 
diabetic patient no. 1 following 
admission on day 0.
«
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Glycated protein results are shown as the percentage of the maximum value 
achieved for each assay.
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24% at day 14.
In Fig 5.2.6 the glycated haemoglobin (HbAiJ results are still increasing 
over the period of study. The DF/g/l results are maximal for the second 
sample after admission but do not appear to respond to the increased blood 
glucose level at day 3. These results show a maximum decrease of 33% at 
day 14.
In Fig 5.2.7 the %GA and %GTP profiles are very similar to one another 
and follow the changes in blood glucose levels. A maximum decrease of 
22% occurred for %GA and 27% for %GTP on day 14.
Patient no. 2.
Glycated protein and glucose profiles for this patient are shown in Figs 5.2.8 
- 5.2.10. Although blood glucose levels fell rapidly over the first day, they 
were gradually increasing again by day 5, presumably due to the onset of 
the chest infection. In Fig 5.2.8 the uncorrected Fructosamine Plus results 
show the most dramatic reduction over the study period and as observed 
with patient 1, correction of these results for albumin or glucose and 
albumin resulted in maximum results for the second sample instead of the 
first. All 3 profiles followed the pattern of the blood glucose levels with a 
reduction of 40% for the glucose and albumin corrected results on day 8. 
HbAic results in Fig 5.2.9 remained fairly consistent until day 8 when they 
decreased. The DF/g/l results rise to their maximum before being reduced, 
and then follow the blood glucose profile with a reduction of 42% on day 
8 .
In Fig 5.2.10 %GA and %GTP profiles are very similar although the 
reduction in %GTP results is slightly greater with a decrease of 50% on day 
8 compared to 42% for %GA. The highest results for both of these assays 
were achieved on admission.
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FIG.5.2.8: Fructosamine Plus profiles
for diabetic patient no. 2 following
admission on day 0.
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Blood glucose results (♦) and Fructosamine Plus results (0) are shown as the 
percentage of the maximum value achieved for a patient recovering from 
diabetic ketoacidosis. Correction of these results for serum albumin (O ) or 
serum albumin and glucose levels (□ ) as described in section 5.2.2.1 is also 
shown.
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FIG. 5.2.9: Glycated Hb and DF/g/l
profiles for diabetic patient no. 2
following admission on day 0.
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FIG. 5.2.10: GA and GTP profiles for 
diabetic patient no. 2 following 
admission on day 0.
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Glycated protein results are shown as the percentage of the maximum value 
achieved for each assay.
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Patient no. 3.
Glycated protein and glucose profilés for this patient are shown in Figs 
5.2.11 - 5.2.13. In Fig 5.2.11 correction of the Fructosamine Plus results has 
once again resulted in the highest value changing from the first to the 
second sample. Profiles are otherwise similar to the blood glucose levels, 
with a decrease of 26% at day 21.
HbAjj. results (Fig 5.2.12) appear to fluctuate around a steady level over the 
study period showing more within-subject variation than either of the other 
2 patients.
DF/g/l results also shown in Fig 5.2.12 show a peak value 1 day after 
admission then closely follow the blood glucose profile with a large 
reduction in magnitude of 73% by day 21.
In Fig 5.2.13, %GA and %GTP results reached their peak on day 2, then as 
observed for patient no. 2 the %GTP results decreased slightly more than 
the %GA results with a day 21 value reduced by 31% of the maximum 
compared to 22% for %GA.
In Fig 5.2.14, the effect on the actual assay results of correcting this 
patient’s Fructosamine Plus values for albumin or albumin and glucose 
levels is demonstrated. It can clearly be seen that the time of the peak 
fructosamine response is altered by both corrections.
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FIG. 5.2.11: Fructosamine Plus profiles
for diabetic patient no. 3 following
admission on day 0.
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Blood glucose results (♦) and Fructosamine Plus results (0) are shown as the 
percentage of the maximum value achieved for a patient recovering from 
diabetic ketoacidosis. Correction of these results for serum albumin (O ) or 
serum albumin and glucose levels (□ ) as described in section 5.2.2.1 is also 
shown.
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FIG. 5.2.12: Glycated Hb and DF/g/l
profiles for diabetic patient no. 3
following admission on day 0.
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FIG.5.2.13: GA and GTP profiles for 
diabetic patient no. 3 following 
admission on day 0.
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Glycated protein results are shown as the percentage of the maximum value 
achieved for each assay.
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FIG. 5.2.14: The effect of applying
corrections for albumin and glucose
levels on Fructosamine Plus results.
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Fructosamine Plus results are those obtained during stabilisation of patient 
no.3. Values are shown uncorrected and corrected for either albumin only 
or albumin and glucose levels as described in section 5.2.2.1.
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DISCUSSION.
Results from section 1 of this chapter have highlighted the importance of 
considering pregnant and non-pregnant subjects as 2 distinct groups, as far 
as glycated proteins are concerned. The significance of the lower glycated 
protein (DF/g/l) results obtained for the pregnant group is discussed more 
fully in Chapter 6 of this thesis. Although the mean difference between 
those with normal OGTT response and a diabetic response is very similar 
for the pregnant and non-pregnant groups (0.61 and 0.62 DF/g/l 
respectively) the small number of pregnant patients falling into this category 
(n=2) has reduced the significance of the difference for this group. The 
presence of renal glycosuria does not appear to have made any difference 
to the Dns-PBA assay results for either group as may well have been 
expected, since the ability of the kidneys to reabsorb glucose would not be 
expected to have any impact on blood glucose homeostasis in non-diabetics. 
Even though the pregnant group results for impaired glucose tolerance and 
diabetic classifications are still lower than their corresponding non-pregnant 
groups, the results fail to reach statistical significance due to the smaller 
number of patients within these categories.
The use of ROC curves to determine the effectiveness of the Dns-PBA 
assay as a screening test for impaired glucose tolerance or diabetes, has 
enabled this assay to be compared to other glycated protein techniques 
which have been previously assessed. For the non-pregnant group, the 
optimum sensitivity (for detection of impaired glucose tolerance / diabetes) 
of 56% with a specificity of 77% compares favourably with the optimum 
values of 55% for each component obtained by Guillausseau et al using the 
fructosamine assay. Salemans et al (1987) who also assessed the 
fructosamine assay in this way found a sensitivity of 52% combined with 
a specificity of 98%, a PVP of 93% and a PVN of 84%. These values are
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better than those acheived here for the Dns-PBA assay.
For detection of diabetes only, in non-pregnant subjects, these workers found 
an optimum sensitivity of 67% with 96% specificity, a PVP of 82% and a 
PVN of 97%. This is also better than the 57% sensitivity, 74% specificity, 
PVP of 47% and PVN of 80% found for the Dns-PBA assay, and could be 
attributed to the much lower imprecision of the fructosamine test. However, 
results for the detection of gestational glucose intolerance produced by these 
workers using the fructosamine test were disappointing, producing only 17% 
sensitivity with 98% specificity {PVP = 25%, PVN = 96%) compared to 
60% sensitivity and 86% specificity {PVP = 41%, PVN = 91%) for the Dns- 
PBA assay in this study. It is likely that these more favourable Dns-PBA 
assay results are merely due to there being so few pregnant patients 
classified with impaired glucose tolerance / diabetes, and it is possible that 
if larger numbers were studied this dicrepancy would disappear. However, 
if the DF/g/l results are representative of a single glycated species on serum 
albumin, this assay could give more reliable results during pregnancy than 
the fructosamine test when it is not corrected for serum protein levels, as 
these are generally reduced to various degrees due to the increased volume 
of distribution. It could therefore be concluded that the Dns-PBA assay may 
be of some value in providing supplementary information to that obtained 
by oral glucose tolerance testing, particularly when screening for gestational 
diabetes, although in common with glycated haemoglobin and the 
fructosamine test, this analysis alone cannot replace the current system. In 
borderline cases of diabetes or impaired glucose tolerance, any of these 
assays could provide useful additional information, as the work described in 
this chapter and by other workers on this subject has assumed that oral 
glucose tolerance testing has a sensitivity and specificity of 100%, which is 
clearly debatable.
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The study of a newly diagnosed diabetic patient in this chapter has given an 
indication of the clinical utility of 5 different glycated protein 
methodologies. Although the HbAjj. results do not show such a steep initial 
drop as the serum protein assays, this technique is still useful for weekly 
monitoring of the patient’s control, albeit with slightly less sensitivity in the 
initial stages. The different responses of the Dns-PBA assay and HbAi^ 
analysis are most marked for the 20 days following the onset of insulin 
therapy, hereby reflecting the shorter half-life of serum albumin with the 
same trend emerging 3 weeks later for HbAi^. Surprisingly, the %GA results 
show an increase at day 26 which could be reflecting the trend towards 
higher mean blood glucose levels over the preceeding 2 days (suggesting 
that this is the most sensitive assay), or could merely be due to random 
biological/analytical variation. The deviation between the Dns-PBA assay 
and %GA results from day 48 (Figure 5.2.2) could also be attributed to 
random variation, because the Dns-PBA assay results compare very well to 
those obtained for %GTP and the Fructosamine Plus assay over the whole 
period of study. One consistent discrepancy between the flourometric assay 
results and both affinity chromatography measurements is the pattern 
emerging over the first 7 days monitoring of this patient. %GA and %GTP 
results continued to rise slightly until day 7 whereas DF/g/l, HbAi^ and 
Fructosamine Plus values all showed their peak values on admission. This 
effect is unlikely to be due to the influence of raised glucose levels on the 
affinity chromatography results as the blood glucose values actually changed 
very little in these 3 samples. It is therefore possible that the affinity 
technique is responding to changing glycaemic control at a slightly slower 
rate than the fluorometric assay, which could also account for the continuing 
decrease in %GA results once the DF/g/l values appear to have stabilised 
around day 48. The closer relationship found for DF/g/l and %GTP could 
then be attributed to those glycated proteins with a shorter half-life than 
serum albumin which would accelerate the decrease in %GTP levels to a
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rate more comparable to that of the Dns-PBA assay, assuming that this 
technique is measuring only glycated albumin. Once again this seems to 
indicate a possible requirement for more than one glyco group on the 
protein to enable detection by affinity chromatography.
It is tempting to speculate that the failure of the Fructosamine Plus results 
to decrease by as much as the other assays by day 98 (Figure 5.2.4) is due 
to the effect of non-specific reducing activity being detected by this method. 
However, up until this final point the Fructosamine Plus profile was very 
similar to the other assays and it would not be reasonable to condemn the 
fructosamine method on the basis of this one final result.
In general, this study has confirmed the findings of other workers (Dolhofer 
& Wieland, 1980; Kennedy et al, 1981) in demonstrating the slower 
response of glycated Hb to changing blood sugar levels, although the effect 
was not nearly as marked in this study. This could be due to the 
measurement of HbA^c here using a precise automated analysis compared to 
measurement of HbA^ by the other workers using manual micro-columns. 
All the glycated protein methodologies assessed in the monitoring of this 
one patient have shown themselves to be effective, with a particularly 
dramatic response from the %GA values.
The effect of glucose on the affinity chromatography and Fructosamine Plus 
techniques was only examined briefly in this thesis, although the results do 
support data from Rendell et al (1984) who found that glycated albumin 
estimation by affinity chromatography was decreased with increasing 
glucose levels, and Lehmann (1988) who demonstrated that Fructosamine 
Plus results increased with increasing glucose levels. The decrease in affinity 
chromatography results can be explained by the excess glucose restricting 
interactions of the cis-diol groups with the boronate gel, hereby resulting in 
less binding of the glycated protein fraction, although this is in contrast to 
the positive interference found for glucose with the Dns-PBA assay which
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relies on a similar interaction. In the Fructosamine Plus assay glucose 
appears to be capable of reducing the NET to a certain extent, even after the 
10 minute incubation period which serves to eliminate most of the other 
non-specific reductions. Although glucose concentrations in the general 
diabetic out-patient population would not normally reach levels high enough 
for this interference to be of a major concern, the effect is worth considering 
as an additional factor for the fructosamine assay which, when combined 
with a raised serum albumin level (in a hyperglycaemic, dehydrated patient) 
could have a cumulative effect in falsely elevating the serum fructosamine 
value.
For the patients admitted to hospital in diabetic ketoacidosis, correction of 
Fructosamine Plus results for serum albumin levels has generally had a 
much more dramatic effect on the fructosamine profiles than the correction 
for glucose levels, although this is obviously most relevent for the initial 
samples on each patient. For all 3 patients studied, application of the 
albumin or albumin/glucose correction factor has resulted in the maximum 
Fructosamine Plus values appearing later on within the first 24 hours of 
hospitalisation. For patient no. 1 this coincides with the DF/g/l results which 
peaked at day 1 although %GA and %GTP values did not reach their 
maxima until day 3. As Baynes et al (1984) have suggested that the Schiffs 
base formed upon glycation of proteins has a dissociation half-life of 
approximately 2 hours at 37 °C, most ketoamine formation must occur 
within this period so the maximum formation of the ketoamine within 24 
hours of the peak glucose levels would seem to be the most realistic. As 
found for the monitoring of a newly diagnosed diabetic, the affinity 
chromatography results therefore appear to respond slightly later than the 
other 2 glycated serum protein assays to changes in blood glucose levels. 
There is a much bigger contrast between the HbAj,, results and the glycated 
serum protein results in the study of these acute patients compared to the
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newly diagnosed diabetic. HbAjj. values for patient no. 1 are actually still 
increasing on day 14 by which time glycaemic control had been fully 
regained.
Patient no. 2 was a non-insulin dependent diabetic, and as such her blood 
glucose levels may well have been gradually increasing over a number of 
days prior to the development of ketoacidosis. Although the corrected 
Fructosamine Plus and Dns-PBA analyses on this patient showed a 
maximum response within the first 24 hours of admission the %GA and 
%GTP values were at their highest for the first sample taken. This could 
therefore indicate that the initial affinity chromatography results are more 
representative of the patient’s glycaemic state prior to admission. HbAi^ 
values for patient no. 2 did not alter significantly until day 8 when a fairly 
sharp decrease was observed. Such a sudden decrease over the course of 1 
day for this assay is not feasible for a patient with no abnormalities of the 
red blood cells and is therefore most likely to be due to an analytical effect. 
Patient no. 3 was an interesting case for monitoring various glycated protein 
levels, due to the presence of chronic uraemia which would have modified 
the haemoglobin and plasma proteins by carbamylation. Renal failure had 
occurred as a consequence of this patient’s diabetes, which had been 
diagnosed approximately 20 years previously. Determination of HbAj^ in 
patients with chronic renal failure can be complicated by 2 factors. Firstly 
the life span of the erythrocytes is shortened, with or without impairment of 
erythropoiesis. Patients undergoing haemodialysis will also lose blood during 
this procedure, so the reference interval for interpretation of results can be 
variable. Secondly, as also applies to plasma proteins, the cyanate formed 
spontaneously from urea reacts with the a-amino groups of protein and 
when measured by ion-exchange chromatography this carbamylated 
haemoglobin co-chromatographs with HbAi^, falsely elevating the results. 
Lamb et al (1991) have compared levels of glycated albumin (by affinity 
chromatography) and fructosamine in patients on haemodialysis and CAPD.
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Both constituents were found to be elevated in haemodialysis patients but 
not those on CAPD. However, when corrected for albumin or total protein 
the fructosamine results for CAPD patients were also significantly raised 
over the control group. Large losses of albumin are known to occur in the 
dialysate with CAPD which can result in increased albumin turnover in 
these patients, giving falsely decreased glycated albumin values.
Kiienburg et al (1990) found HbAjj. values to be unaltered by haemodialysis, 
whereas Fructosamine Plus results were significantly increased by the 
resulting haemoconcentration and required correction for serum protein 
levels in order to compare pre and post-dialysis results. Increased values 
from glycated protein assays have also been reported by several other groups 
when non-diabetic patients in renal failure have been compared to healthy 
subjects (Peheim et al, 1990; Tsang et al, 1991; Engbaek et al, 1989) 
although it is uncertain whether these effects were due to the glucose 
intolerance found to occur in chronic renal failure or due to analytical 
detection of carbamylated haemoglobin. Using an enzyme immunoassay 
specific for HbAj^ Engbaek et al (1989) have suggested that the increased 
levels seen for other methods are due to detection of carbamylated 
haemoglobin as the enzyme immunoassay gives significantly lower results 
than the ion-exchange HPLC method. Lamb and Dawnay (1992) have 
proposed that reduced erythrocyte survival would be expected to result in 
a decreased level of glycation rather than an increase, but if there is a 
concurrent deficiency of erythropoietin affecting the production of red blood 
cells this could be obscured. A study by Bruns et al (1984) has indicated 
that affinity chromatographic measurement of glycated haemoglobin is not 
interfered with by carbamylated haemoglobin in patients on CAPD so it is 
reasonable to assume that measurement of %GA and %GTP by this method 
is similarly unaffected analytically.
For patient no. 3, red cell production/survival has been affected by renal 
failure, as represented by her low haemoglobin level. Over the 10 days of
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study this patient’s HbAi^ values did not show any real change, despite 
fluctuating about a mean value to a much greater extent than the other 2 
patients’ results for this analysis (see Figure 5.2.12). This increased within- 
subject variation could therefore be attributed to interference from 
carbamylated haemoglobin as well as fluctuations in red blood cell survival 
times, hereby reducing the clinical utility of this analyte in cases of renal 
failure. Correction of Fructosamine Plus results for this patient has again 
resulted in the maximum response moving away from the first sample. The 
overall decrease in these results of 26% at day 21 (Figure 5.2.11) is in line 
with those for affinity chromatography (31% reduction for %GTP, 22% 
reduction for %GA) whereas the DF/g/l results have shown a much larger 
decrease (73%). This discrepancy was not observed for the other 2 patients 
and could therefore be a consequence of the impaired renal function. It is 
questionable as to whether the renal failure has artificially lowered the Dns- 
PBA assay results or raised the other assay levels although in vitro studies 
in Chapter 3 of this thesis (section 3.3.1.1) have suggested that the Dns- 
PBA assay is not affected by uraemia. Also, when it is considered that 
patient no. 1 had an initial blood glucose level of 30.0 mmol/l and glycated 
serum protein levels decreased by approximately 25% 14 days later, patient 
no. 2 had an initial blood glucose level of 53.4% and glycated serum protein 
levels decreased by approximately 45% 8 days later, it would appear to be 
more reasonable that glycated serum protein levels for patient no. 3 
(admitted with a blood glucose level of 76.0 mmol/l) might decrease by 
nearer 73% than 22-31% 21 days later. The increase in albumin turnover for 
a patient on CAPD would also be expected to accelerate the decrease in 
glycated albumin levels following stabilisation of glycaemic control. This 
therefore suggests that the Fructosamine Plus and affinity chromatography 
results have been artificially raised as a consequence of the renal failure and 
that the Dns-PBA assay is more appropriate for use in such situations.
As shown in Figure 5.2.14, correction of Fructosamine Plus results for blood
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glucose levels has had an appreciable effect on the results when glucose 
concentrations were very high. Obviously this is a very extreme example 
and although the correction could not be advocated for general use, it has 
proved to be relevent in this particular study.
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CHAPTER 6.
GLYCATED PROTEIN LEVELS IN DIABETIC AND NON­
DIABETIC PREGNANCY.
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Introduction.
Before the introduction of insulin in 1922, infertility was common amongst 
diabetics, maternal death was a wcry real threat during pregnancy and 
perinatal survival was less than 40%. Today maternal mortality has been 
virtually eliminated and infant mortality rates have steadily declined, 
approaching that of non-diabetic women for well controlled diabetic 
pregnancies. As normal pregnancy in itself modifies every aspect of fuel 
economy (Freinkel, 1980) it is not surprising that the medical care of 
pregnant women with pregestational insulin-treated diabetes mellitus can 
necessitate considerable specialised care of the patient, with close liahon 
between the diabetic and obstetric specialists. The metabolic and obstetric 
problems encountered with diabetic pregnancy have been reviewed by 
Brudenell and Doddridge (1989).
During normal pregnancy there is significant hypertrophy of the p-islet cells 
of the pancreas, probably as a result of increased oestrogen and progesterone 
levels (Heilman, 1960; Aerts and Van Asshe, 1975). It has been shown that 
the sensitivity of the p-cells to the stimulating effects of glucose is enhanced 
during pregnancy (Green & Taylor, 1972) so insulin production is increased. 
This effect is likely to be mediated by raised levels of oestrogen, 
progesterone and human placental lactogen and is accompanied by 
diminished responsiveness to insulin action in the periphery. This resistance 
appears to be mediated at the post-receptor level (Tsibris et al, 1980) by 
factors which may be linked to the intracellular changes in fuel economy. 
In normal pregnancy, the slow increase in plasma insulin levels has been 
reported to reach a peak at 32 weeks gestation and then to gradually decline 
to non-pregnant levels post-partum (Baird, 1986). It is therefore necesary to 
try and match these changes in the pregnant insulin dependent diabetic, 
necessitating a continually changing regime of insulin therapy throughout
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pregnancy. Baird (1986) also found a small but significant rise in fasting 
blood glucose levels between 16 and 32 weeks which fell back down to 
non-pregnant control levels at term. However, Lind et al (1973) and Victor 
(1974) reported that fasting blood glucose levels were significantly lower 
than normal from the tenth week onwards. There is obviously still some 
controversy in this area, which could arise from the different populations 
studied, as the ability of each individual’s pancreas to respond to the 
challenge of pregnancy will obviously vary, hence the common occurrence 
of gestational diabetes whereby increased demand for insulin cannot be fully 
met by a slightly failing pancreas. Gestational diabetes is most commonly 
seen in the second half of pregnancy, especially during the third trimester 
when there is an increase in insulin antagonism with a slight deterioration 
in glucose tolerance, and the hypoglycaemic effect of intravenous insulin is 
less (Burt, 1956). At this stage, peak levels of blood glucose following a 
carbohydrate load are higher than normal so for the insulin dependent 
diabetic more liberal administration of short acting insulin may be necessary 
to counteract these peaks.
During pregnancy, the fetus disposes of a substantial proportion of the 
maternal blood glucose as it passes across the placenta by facilitated 
diffusion. The fetus will continually extract glucose from the maternal 
circulation until this system is saturated at approximately 10-15 mmol/l, 
hereby maintaining its own blood glucose levels slightly below those 
prevailing in the mother due to some consumption by the placenta. The fetus 
can utilise glucose 2-3 times faster than an adult (Page, 1969) hereby acting 
as a continual drain on the maternal supply, although insulin has been 
shown not to pass across the placenta in either direction.
It has been proposed by Metzger and Freinkel (1975) that the net increase 
in insulin action in early human pregnancy conserves energy (‘facilitated 
anabolism’) whereas later it is reduced in order to provide ample glucose to 
the fetus at a time when its growth is maximal and its preferential utilization
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of glucose reaches a peak.
Glycosuria is common during normal pregnancy, with a great deal of diurnal 
and day to day variation in the glucose excretion rate. This phenomenon is 
mainly due to an increased glomerular filtration rate and a diminished ability 
of the proximal renal tubules to reabsorb glucose, but it does mean that 
monitoring of urinary glucose by pregnant diabetics will not always produce 
results which reflect their glycaemic control.
As well as these alterations in carbohydrate metabolism, every aspect of 
lipid metabolism is affected by pregnancy, particularly the free fatty acids, 
triglycerides, phospholipids and cholesterol. The first 2 trimesters are 
anabolic, whereby plasma free fatty acid and glycerol levels fall as body fat 
accumulates. In the third trimester increased catabolism occurs causing 
raised free fatty acid and glycerol levels which are then available as fuel to 
the maternal tissues to offset the increasing diversion of glucose and amino 
acids to the rapidly growing fetus. Plasma levels of cholesterol and 
phospholipid are also increased during pregnancy although the significance 
of this hormonally induced change is still not clear.
In order to try and establish whether intensive glycaemic control in diabetic 
pregnancies results in normalisation of these other metabolic fuels, Reece 
et al (1991) studied insulin dependent diabetics with strict control, and non­
diabetics throughout pregnancy by comparing their plasma levels of insulin, 
amino acids, triglycerides, free fatty acids and ketones. Despite the presence 
of plasma insulin profiles which differed substantially between the 2 groups 
(with the diabetics showing hyperinsulinaemia), there was very near 
normalisation of the other insulin-sensitive metabolites in the diabetic 
subjects.
The value of ‘tight’ blood glucose control in the 2nd and 3rd trimesters of 
pregnancy was established in the human by Karlsson and Kjellmer (1972) 
who found a perinatal mortality rate of 3.8% when pre-prandial maternal
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glucose in the 3rd trimester was below 5.5 mmol/1 and a rate of 23.6% 
when mean blood glucose exceeded 8.3 mmol/1. However, there is still some 
uncertainty over how tight control needs to be and what degree of control 
can actually be achieved in practice..
Whether IDDM increases a woman’s risk of having a spontaneous abortion 
has been contraversial. Most of the earlier studies in this area found no 
increased risk for diabetics but it has recently been disputed that these 
studies were not systematically performed, as several groups now have 
evidence to show that the risk of fetal loss is increased in poorly controlled 
diabetics (Mills et al, 1988). There is no dispute however, over the 
association of fetal macrosomia with diabetic pregnancy and the infants of 
diabetic mothers are traditionally portrayed as being big. The increase in 
fetal size is due to an increase in both weight and length, with increased size 
and weight of most internal organs, showing both hypertrophy and 
hyperplasia. Adipose tissue is prominent in the subcutaneous tissues and 
contributes to the round face and neck and the large chest and abdomen. 
Fetal hyperglycaemia (as a result of maternal hyperglycaemia) is generally 
held to be responsible for this condition, whereby the fetus becomes 
hyperinsulinaemic in order to cope with its increased glucose supply. 
Although the human p-cell is recognisable from the 10th week of gestation, 
and insulin is found in fetal blood from about the 12th week onwards, 
amino acids are important in early islet development and insulin secretion, 
hence the importance of normalising all metabolic fuels in the mother. 
Secretion of insulin by the fetus does not become responsive to glucose until 
about 28 weeks gestation, by which time insulin secreted under amino acid 
stimulation will already have caused a wide variety of cells to secrete 
growth stimulating peptides. Later on in pregnancy, insulin promotes the 
laying down of fat in response to increased blood glucose levels, which will 
occur to excess if the fetal pancreas is being overstimulated. 
Hyperglycaemia cannot be the only cause of macrosomia, because although
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the incidence of diabetes is increased among mothers of macrosomie infants, 
only a small minority of all women giving birth to such babies show any 
abnormality of carbohydrate metabolism (Madanlon et al, 1980). It is 
therefore likely that other hormones also significantly influence the levels 
of fetal glucose and insulin, hence the development of macrosomia. If the 
fetus becomes hypoxic and is also hyperglycaemic, there is increased 
metabolism of glucose through the hexose monophosphate shunt pathway, 
resulting in an exaggerated synthesis of triglycerides in fetal adipose tissue 
so increasing the macrosomia (MacFarlane & Tsakalos, 1983). No consistent 
relationship has been found between maternal blood glucose levels or 
glycated haemoglobin during pregnancy, and birthweight. Once again this 
highlights the likelihood of a combination of factors being responsible for 
macrosomia and that although good control of maternal blood glucose levels 
may lower the overall incidence, it can also be associated with individual 
cases of macrosomie babies and their inherent problems of delivery.
As a consequence of hyperinsulinaemia induced whilst in-utero, neonates 
from diabetic mothers often become hypoglycaemic within the first 24 hours 
of life, although current awareness of this phenomenon is now such that it 
should not contribute to perinatal mortality.
‘Unexplained’ perinatal mortality was also, until fairly recently, a cause for 
great concern with diabetic pregnencies and led to the precaution of 
premature delivery. However, babies that were delivered by Caesarean 
section at 35-36 weeks then often died in the neonatal period as a result of 
respiratory distress. This syndrome is more prevalent in infants of diabetic 
mothers anyway, possibly because a state of hyperinsulinaemia can reduce 
glycerol-3-phosphate and dihydroxyacetone phosphate production, hereby 
impairing phospholipid synthesis and surfactant production in the fetal lung 
(Stubbs & Stubbs, 1978). Preterm delivery is therefore no longer advocated 
unless there is fetal macrosomia or other complications, in which case the 
risk of unexplained uterine death is higher and delivery at 37-38 weeks is
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usually indicated.
It is now commonly thought that the cause of such ‘unexplained’ 
intrauterine deaths is fetal anoxia. This has been suggested to occur due to 
a reduction in blood flow through the intervillus space of the placenta 
(Rekonen et al, 1976) as a result of morphological changes in the diabetic 
placenta, particularly villous oedema and increased branching of the villi, 
which hinder oxygen transfer to the fetus from the maternal blood. In 
addition to this, HbAi^ has an increased affinity for oxygen compared to 
non-glycated HbA and releases it much less readily. Raised HbAi^ levels can 
decrease oxygen levels by as much as 10% in this way (Madsden & Ditzel, 
1982,1984) and oxygen consumption by the diabetic fetus and placenta can 
also be increased by hyperinsulinaemia (Milley et al, 1984) thereby 
compounding the problem. The situation is further exacerbated in the 
presence of maternal vascular disease, hypertension or pre-eclampsia and 
maternal ketoacidosis will be particularly harmful due to its effect on the 
oxygen dissociation curve. Relative hypoxia in the fetus leads to an 
increased incidence of fetal distress during labour and is responsible for the 
polycythaemia and subsequent jaundice often seen in the infants of diabetic 
mothers. It is possible that a certain degree of hypoxia exists even in well 
controlled diabetic pregnancies (Brudenell, 1987) and may well be the cause 
of intrauterine death, particularly when the pregnancy is complicated or 
badly controlled and the fetus macrosomie.
Although it has long been recognised that ketoacidosis in pregnant diabetics 
causes intrauterine death of the fetus, the severity of acidosis required to 
cause death can vary considerably. Fortunately this scenario is not 
commonly found, as pregnant diabetics are generally well motivated and 
tend to succumb to hypoglycaemic episodes more frequently than severe 
hyperglycaemia. It has been shown that the presence of hypoglycaemia 
during critical stages of development in rat embryos causes congenital 
abnormalities (Akazawa et al, 1989) but there is as yet no evidence to
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support this in humans.
Due to the steady decline of most of the factors contributing to perinatal 
mortality and morbidity in diabetic pregnancy, congenital abnormality is 
now the most prevalent. It is now accepted that a diabetic woman is 3-4 
times more likely to have a congenitally malformed baby than her non­
diabetic counterpart and the most important time for good diabetic control 
during organogenesis is over the first 7 weeks of intrauterine life (Mills et 
al, 1979). In order to minimise the effects of maternal diabetes on 
organogenesis the patient should be well controlled before conception as 
well as throughout the first trimester. Tight control of maternal blood 
glucose concentration in these early weeks of pregnancy can be achieved by 
preconceptional counciling and has been associated with a highly significant 
reduction in the risk of serious congenital abnormalities in the offspring 
(Steel et al, 1990). Similarly, preconception management has also been 
shown to reduce the risk of spontaneous abortion in diabetics (Dicker et al, 
1988; Rosenn et al, 1991).
In the light of this evidence, it is not surprising that these trends are also 
reflected in levels of glycated haemoglobin throughout pregnancy. In 1987, 
Stubbs et al reported on a multicentre trial carried out in the UK in which, 
out of 230 diabetic pregnancies in 196 different women, 3% had offspring 
with major and 9% with minor malformations. The median HbAj of those 
with major malformations (12.9%) was significantly higher than that of 
those with no malformations (10.8%) although the median HbA^ of those 
with minor malformations (10.5%) was not significantly different from the 
group with no malformations. Studies performed since this one have 
particularly highlighted raised HbA^c levels during the first trimester as 
being associated with an increased incidence of major malformations (miller 
et al, 1981; Ylinen et al, 1984) and although work by Greene et al (1989) 
confirms this observation, together with an increased risk of spontaneous 
abortion, this group found that there was a broad range of glycaemic control
303
over which the risks for both adverse outcomes were not substantially 
elevated. Similar results were obtained by Lucas et al (1989) who also found 
evidence to suggest that hyperglycaemia increases the relative risk of fetal 
malformations when associated with maternal diabetes of long duration 
and/or with vascular complications. There have been conflicting reports 
about the correlation of maternal glycated haemoglobin with birthweight. 
Miller et al (1981), as well as several other groups found no such correlation 
but Widness et al (1978) and Ylinen et al (1981) did find a link between 
third trimester HbAi and relative birthweight. To add to the controversy, 
Knight (1983) and Russell et al (1984) have both found near normal HbAi 
levels throughout macrosomie pregnancies hereby supporting the concept 
that it is not hyperglycaemia alone which is responsible for this 
consequence. It is also interesting to note that Peck et al (1991) found a 
direct correlation between first trimester HbAj levels and birthweight. A 
possible explanation for this effect has been based on the fact that during the 
first and second trimesters fetal growth is mainly by an increase in cell 
number whereas in the third trimester growth is due to an increase in cell 
size. Hyperglycaemia in early pregnancy may therefore influence cell 
numbers in adipose and other tissue with later development of macrosomia. 
Glycated haemoglobin and glycated serum protein levels have also been able 
to demonstrate the gradient of blood glucose levels occurring between 
mother and fetus by measuring these entities in maternal and cord blood at 
delivery. Studies by Hall et al (1983) and John et al (1984) have both shown 
that glycated protein levels in cord blood are generally lower than those in 
the mother, for both diabetic and non-diabetic pregnancies.
Apart from being a useful research tool, glycated protein analysis is ideally 
suited to the monitoring of glycaemic control in pregnant diabetic patients, 
particularly if glycated plasma proteins are monitored as they respond much 
more rapidly than glycated haemoglobin to changes in control (Leiper et al, 
1985).
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Although high glycated protein levels in pregnant diabetic patients will 
signify that glycaemic control must be rapidly improved, it is important to 
establish the effect that pregnancy itself has on particular glycated protein 
values, either directly through alterations in carbohydrate metabolism or 
indirectly due to changes in the life-span or concentration of the protein 
concerned. However, by monitoring glycated haemoglobin values throughout 
non-diabetic pregnancy some conflicting results originally occurred, whereby 
some authors reported an increase in HbA^g due to pregnancy (Schwartz et 
al, 1979) and others a decrease (Lind & Cheyne, 1979; Leslie et al, 1978; 
Fadel et al, 1979; Staley & Murray-Arthur, 1988). It is now generally 
accepted that those studies showing increased glycated haemoglobin results 
were more likely to be unreliable, due to a limited number of data, and it 
has also become apparent that different methodologies can be the cause of 
variability; Van Dieijen-Visser et al (1986) found a significant decrease in 
HbAj as measured by ion-exchange chromatography during pregnancy but 
no change in results as measured by an electrophoresis technique. As the red 
cell volume increases progressively throughout pregnancy, the influx of new 
young erythrocytes presumably has a diluting effect on the percentage of 
glycated haemoglobin present and could therefore explain the decreases 
observed in HbA^ levels. Also, if as suggested by Lind et al (1973), fasting 
blood glucose levels are lowered in pregnancy after the tenth week of 
gestation, this could be a contributing factor. Although Lind and Cheyne 
(1979) using ion-exchange found HbAj to remain significantly decreased 
from 20 weeks gestation onwards, Staley and Murray-Arthur (1988) using 
the same technique found a significant decrease at 20-24 weeks followed by 
a gradual increase in results back up to their original levels again at term. 
This effect was also found by Hall (1985) using affinity chromatography 
whereby glycated haemoglobin levels were significantly lower in the second 
and third trimesters although the third trimester values were slightly higher 
than the second, possibly reflecting glycation of the red cell influx earlier
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on in pregnancy. This study by Hall also involved the measurement of 
glycated plasma proteins by affinity chromatography which, despite a steady 
decrease throughout the course of pregnancy, showed no statistically 
significant change. Leiper et al (1985) made similar observations using 
affinity chromatography to measure glycated haemoglobin, glycated plasma 
proteins and glycated albumin, the mean values of which were also 
insignificantly lower for pregnant non-diabetics when compared to controls. 
Monitoring of glycated plasma proteins throughout pregnancy naturally 
incorporates different problems to those associated with glycated 
haemoglobin. It is well documented that plasma protein and albumin 
concentrations can fall by up to 30% during pregnancy even though some 
protein levels do actually increase (eg. caeruloplasmin and other binding 
proteins). This effect is mainly due to the increased circulatory volume 
associated with pregnancy and does necessitate the correction of glycated 
plasma protein results for the given level of protein concerned, or its 
expression as a percentage of the total protein concentration. These effects 
make the fructosamine assay unsuitable for monitoring glycaemic control 
during pregnancy, even when corrected for plasma total protein levels as 
results could be reflecting changes in protein profile as well as their 
glycation. Also, as the fructosamine reaction is likely to be mediated by 
formation of free radicals (Jones et al, 1987) the increased concentration of 
caeruloplasmin, a known scavenger of free radicals, could cause a reduction 
in response of the glycated proteins to NET. However, when corrected for 
total protein levels, plasma fructosamine results have been shown to increase 
significantly (p<0.01) in the third trimester when compared to the first 
(Staley & Murray-Arthur, 1988), a finding which the authors suggest may 
be due to altered protein synthesis/catabolism or increases in proteins with 
a high affinity for glucose. It is also possible that increasing levels of uric 
acid throughout pregnancy could have caused the effect as the study was 
performed with the original fructosamine reagents which did not contain
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uricase. Another study of uncorrected fructosamine values throughout 
pregnancy (Van Dieijen-Visser et al, 1986) demonstrated a progressive 
decrease in results due to a significant drop in mean protein and albumin 
levels.
It is difficult to speculate as to whether glycated albumin levels would be 
expected to change during pregnancy, and if so, in what direction they 
would go, as reports of reduced fasting blood glucose levels (Lind et al, 
1973) combined with increasing glucose intolerance towards the third 
trimester (Burt, 1956) would suggest that a variety of effects could be 
possible.
It was therefore the intention of this chapter to monitor non-diabetic 
pregnancies using affinity chromatography techniques for glycated albumin 
and glycated total serum protein, and to see how well a profile of Dns-PBA 
assay results for the same samples fitted the overall picture. Application of 
these techniques to monitoring a small number of insulin-dependent diabetic 
pregnancies was performed in order to establish whether the Dns-PBA assay 
could be usefully implemented in this way.
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Materials.
Equipment and reagents were as described previously under ‘materials’ in 
Chapters 2, 3 and 5.
6.1. METHODS.
6.1.1. Monitoring non-diabetic pregnancy.
Volunteers for this study were recruited from a General Practitioners 
Surgery upon attendance for routine antenatal blood tests at approximately 
12 weeks gestation between November 1990 and January 1991. Each 
volunteer gave their informed consent to participate and had no family 
history of diabetes mellitus or gestational diabetes in previous pregnancies. 
A total of 21 women were originally recruited to the study, 3 of whom 
spontaneously aborted within 16 weeks gestation and 2 who failed to attend 
for further blood samples. This resulted in a final study group of 16 women 
with a mean age (± SD) of 28 ± 4 years; 3 subjects were primigravidas, 10 
were primiparous and 3 were multiparous. Although 2 volunteers were 
normally cigarette smokers, only 1 continued to do so throughout pregnancy. 
The alcohol intake of all participants was minimal, if any and no prescribed 
medicines were being taken. During the course of the study one subject 
underwent an oral glucose tolerance test at 32 weeks gestation due to the 
presence of glycosuria, which was shown to be renal glycosuria, as her 
glucose tolerance was normal.
Blood samples were obtained from these 16 volunteers at approximately 12, 
23 and 34 weeks gestation. The samples taken at 12 and 34 weeks coincided 
with routine antenatal blood tests, hereby necessitating only one additional 
venepuncture at 23 weeks. On each occasion the serum from 10 ml of blood 
collected into plain glass tubes containing no anticoagulant was used for 
analysis of glycated albumin (%GA) and glycated total protein (%GTP) by
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affinity chromatography (see section 3.1.1), as well as Dns-PBA assay (see 
section 2.2.8) including serum albumin analysis. Plasma from 5 ml of blood 
collected into fluoride oxalate tubes was assayed for random glucose levels 
using a glucose dehydrogenase method on the Cobas Bio analyser (Banauch 
et al, 1974). Glucose analysis was performed on the day of venepuncture 
whereas serum for glycated protein analysis was frozen at -20 °C for up to 
one month prior to analysis. Serum samples from each individual were not 
saved for batch analysis due to the instability of samples upon prolonged 
storage. The groups in which samples were assayed were randomised as 
much as possible by including samples from different stages of pregnancy 
within each analytical run.
To enable a direct comparison of glycated protein results to those obtained 
for non-pregnant subjects, the results from 14 non-pregnant, non-diabetic 
women incorporated within the reference ranges determined in sections 3.1.2 
and 2.5.2.1 of this thesis, age matched as closely as possible to give a mean 
± SD of 26 ± 5 years, were used as a reference.
6.1.2. Monitoring insulin-dependent diabetic pregnancy.
This study was concerned only with the monitoring of progestational insulin- 
dependent diabetics and not those developing diabetes as a consequence of 
pregnancy. Pregnant insulin-dependent diabetic women were identified in 
collaboration with the diabetic liaison nurse at Frimley Park Hospital 
between the months of August 1990 and March 1991. As a total of only 5 
diabetic women attending this District General Hospital were pregnant 
within this period, all 5 were recruited to the study, with their informed 
consent, regardless of how far advanced their pregnancy was. This final 
study group had a mean age (± SD) of 27 ± 3 years; 3 subjects were 
primigravidas, 1 was primiparous and 1 was multiparous. None of the 
individuals were smokers and no alcohol was consumed by any of them
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throughout pregnancy. Three individuals were taking iron and vitamin 
supplements and one was on antibiotics both prior to and during pregnancy 
for a history of urinary tract infections. Each patient’s diabetes was being 
treated with human insulin and the individuals were encouraged to alter their 
daily dosages depending upon home blood glucose results, by additional 
administration of short acting insulin preparations whenever necessary. The 
progress of each patient was initially assessed monthly by the diabetic and 
obstetric specialists, incorporating blood tests for HbAi^ analysis on each 
occasion. This analysis was performed by ion-exchange HPLC on 2.5 ml of 
blood collected into K-EDTA tubes. During venepuncture additional samples 
(as described in section 6.1.1) were taken for analysis of %GA, %GTP and 
Dns-PBA assay (including serum albumin analysis) as well as for random 
blood glucose levels.
For the 5 patients studied, the mean duration of diabetes prior to this 
pregnancy (± SD) was 11.6 ± 6.0 years.
6.2. RESULTS.
6.2.1. Monitoring non-diabetic pregnancy.
Results of blood tests from the 16 pregnant non-diabetics were divided into 
3 groups which represented mean ± SD results obtained at 10 ± 2, 22 ± 1 
and 34 ± 2 weeks gestation. These results of random glucose, albumin, 
DF/g/1, %GA and %GTP analysis are shown in Table 6.2.1 which 
demonstrates a general trend for decreasing albumin and glycated serum 
protein levels during normal pregnancy. There was no significant change in 
random blood glucose levels throughout pregnancy but serum albumin fell 
significantly from 10 to 22 weeks gestation by 11%. This decrease was 16% 
by 34 weeks with the 5% drop from 22 to 34 weeks also being statistically 
significant. Dns-PBA assay results (DF/g/1) also fell significantly between
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Table 6.2.1. The effect of pregnancy on random  blood glucose, serum  
album in and glycated serum  protein levels in non-diabetics.
WEEKS GESTATION (MEAN ± SD) 
10 ± 2  2 2 +  1 34 ±2
Glucose (mmol/1) 4.8 ± 0.7
Albumin (g/1) 
DF/g/1 
%GA 
%GTP
45 + 2 
1.46+0.24 
3.00+0.47 
4.73+0.55
4.9 ± 0.9 
40 + 2 *** 
1. 10+ 0.20 * * *  
3.01+0.41 
4.24+0.42 **
4.9 ± 0.8 
38 + 1 ***c 
1.17+0.38 ** 
2.50+0.35 **b 
4.66+0.44 a
Non-diabetic women (n=16) were studied at 3 time points during their 
pregnancy. Comparisons of results between trimesters were made using 
Student’s paired t-test.
a
b
c
Significant difference from results at 10 + 2 weeks with p<0.01.
Significant difference from results at 10 + 2 weeks with p<0.001.
Significant difference from results at 22 + 1 weeks with p<0.05.
Significant difference from results at 22 + 1 weeks with p<0.01.
Significant difference from results at 22 + 1 weeks with p<0.001.
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10 and 22 weeks and remained low at 34 weeks. Although the %GTP values 
also showed a significant decrease between 10 and 22 weeks this was not 
found for %GA where there was no significant change until later in 
pregnancy. At 34 weeks when the %GA results were significantly lower 
than their 10 week values the %GTP levels had risen back up to a value 
comparable to that at 10 weeks gestation.
The mean ± SD results for the group of 14 non-pregnant age matched non­
diabetic women were 1.91 ± 0.25 for DF/g/1, 2.84 ± 0.65 for %GA and 5.32 
± 0.59 for %GTP. A comparison of these values against those obtained for 
10 weeks gestation using Student’s t-test for differences between means 
shows that DF/g/1 results are significantly reduced between 10 and 34 weeks 
of pregnancy with p<0.001 and %GTP results are also significantly reduced. 
However, %GA results in this study are not significantly different to their 
non-pregnant counterparts at any stage. This effect is shown graphically in 
Figure 6.2.1, where the y axes represent an equivalent range of results for 
each analysis, enabling a direct visual comparison of the assays. All 16 
women gave birth to live babies with no detectable abnormalities, at a mean 
(± SD) gestational age of 40 ± 1 weeks. An elective Caesarean section was 
performed for one subject due to the presence of a small birth canal but the 
remaining 15 all had normal vaginal deliveries. The mean birthweight (± 
SD) of the infants was 3.615 ± 0.485 kg and none of the babies became 
jaundiced.
6.2.2. Monitoring insulin-dependent diabetic pregnancy.
By grouping the available glycated protein results from all 5 diabetic 
patients to represent the 3 trimesters of pregnancy, the statistical significance 
of any changes could be assessed by using Student’s t-test for differences 
between means. This produced mean ± SD glycated protein results for 10
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Figure 6.2.1. The effect of normal pregnancy on glycated serum protein 
levels compared to non-pregnant subjects.
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Glycated protein results (means ± SD) at means of 10, 22 and 34 weeks 
gestation in 16 non-diabetic pregnancies compared to a group of age 
matched non-pregnant female controls (0 weeks gestation, n=14).
** Significant difference from non-pregnant controls with p<0.01.
*** Significant difference from non-pregnant controls with p<0.001.
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+ 2, 21 ± 4 and 33 ± 3 weeks gestation which are shown in Table 6.2.2. 
The values obtained for 10 + 2 weeks were calculated from 4 observations 
on 3 patients, the values for 21 ± 4  weeks were from 6 observations on 4 
patients and the values for 33 ± 3 weeks were from 12 observations on 5 
patients. All the glycated protein values showed a decrease as pregnancy 
progressed although only the DF/g/1 results were not significantly reduced 
at 21 ± 4 weeks when compared to the 10 + 2 weeks value. All 4 glycated 
protein assay results were significantly reduced by 33 ± 3 weeks compared 
to 10 + 2 weeks but this value was only significantly lower than the 21 ± 
4 weeks result for %GA. The mean random blood glucose levels are 
generally uninformative due to only a small number of results being 
available for this analyte, which can fluctuate widely in insulin-dependent 
diabetics.
As these results have been compiled from different numbers of patients and 
samples in each trimester they are not necessarily directly comparable 
between the trimesters. In order to obtain a more accurate picture of how 
well each glycated protein assay can be used to monitor diabetic pregnancy, 
the results obtained over 3 trimesters for 2 individual diabetic pregnancies 
are shown in Figures 6.2.2 and 6.2.3.
All 5 women gave birth to live babies with no detectable abnormalities, at 
a mean (± SD) gestational age of 38 + 1 weeks. Only one subject had a 
normal vaginal delivery; one had an elective Caesarean section performed 
due to raised blood pressure and renal complications, whilst 3 subjects had 
emergency Ceasarean sections. These were performed due to cephalo-pelvic 
disproportion in one patient, fetal distress during the first stage of labour in 
another and ineffective contractions during the second stage of labour in the 
third patient. One baby was admitted to the special care baby unit with 
unstable blood glucose levels for 3 days following delivery and 2 babies 
required phototherapy for neonatal jaundice. The mean birthweight (± SD) 
was 3.282 ± 0.564 kg.
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Table 6.2.2. M onitoring insulin-dependent diabetic pregnancy with 
various glycated protein techniques.
WEEKS GESTATION (MEAN ± SD)
10 ± 2  21 + 4 33 ± 3
Glucose (mmol/1) 6.5 ± 2.8 10.0 + 5.8 9.7 ± 3.1
% HbAi, 8.7 ± 1.1 6.0 ± 0.9 ** 6.4 + 1.0 **
DF/g/1 3.40+0.99 2.34+0.61 1.77+0.57 ***
%GA 8.09+1.60 4.86+1.51 * 3.66+0.74
%GTP 9.56+2.45 6.55+1.29 * 5.96+0.54 ***
Results were compiled from samples taken at various time points throughout 
5 diabetic pregnancies. Comparisons were made using Student’s t-test for 
differences between means.
* Significant difference from results at 10 + 2 weeks with p<0.05.
** Significant difference from results at 10 + 2 weeks with p<0.01.
*** Significant difference from results at 10 + 2 weeks with p<0.001.
t  Significant difference from results at 21 + 4  weeks with p<0.05.
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Figure 6.2.2. Glycated protein profiles during pregnancy for patient
number 1.
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Glycated protein profiles shown are for %BbAi^ (♦), DF/g/1 (0), %GA (O ) 
and %GTP (□ ) results. These are expressed as a percentage of their 
maximum value achieved.
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Figure 6.2.3. Glycated protein profiles during pregnancy for patient
number 2.
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Glycated protein profiles shown are for %HbAic (♦), DF/g/1 (0), %GA (O ) 
and %GTP (□ ) results. These are expressed as a percentage of their 
maximum value achieved.
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DISCUSSION.
The patients monitored for glycated protein levels throughout this chapter 
have been studied at approximately monthly or 3 monthly intervals. As 
glycated haemoglobin results are representative of the preceeding 4-6 weeks 
blood glucose control and glycated albumin results represent the preceeding 
2-3 weeks, by sampling patients at intervals of greater than or equal to one 
month, the 2 different analytes should give overlapping information, as 
demonstrated in Chapter 5 when a newly diagnosed diabetic was monitored 
over a period of 3 months (section 5.2.1.2). Based on this assumption and 
the work of Lind and Cheyne (1979), Staley and Murray-Arthur (1988) and 
Hall (1985) who found glycated haemoglobin levels to be decreased after 
20 weeks gestation, results obtained for glycated serum proteins should be 
able to elucidate whether this effect is due solely to an increase in red cell 
volume or due to changes in carbohydrate metabolism. However, the results 
presented in Figure 6.2.1 of this chapter give an indication of how different 
conclusions can be drawn depending upon which method of analysis is used. 
The overall indication from the information in Figure 6.2.1 is that glycation 
of plasma proteins is decreased as a result of pregnancy, which suggests that 
the decreases in second trimester glycated haemoglobin levels observed by 
other workers are at least partially reflecting a change in carbohydrate 
metabolism. The most marked effect was observed in the fluorometdc Dns- 
PBA assay results which showed highly significant reductions at 10 weeks 
of pregnancy that levelled out after 22 weeks, by which time DF/g/1 results 
had been reduced by 42%. This is in accordance with data from Lind et al 
(1973) who demonstrated that fasting blood glucose concentration is about 
0.3 mmol/1 lower in pregnant women by 10 weeks gestation, and that this 
lower level is maintained for the rest of pregnancy. Although the %GTP 
results follow the same general pattern, the maximum decrease at 22 weeks 
is only 20% below the non-pregnant value and %GTP levels actually rise
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significantly between 22 and 34 weeks.
By comparing the %GTP results to those obtained for %GA, it is apparent 
that when measured by affinity chromatography, the changing plasma 
protein profile occurring throughout pregnancy causes these 2 variables to 
give conflicting results. Very little data is available on longitudinal changes 
in glycated albumin during pregnancy, although a study by Rai et al (1988) 
using the method of Kumar et al (1988), based on the differential reduction 
of free and bound glucose by sodium borohydride (see section 1.5.2.4 of 
Chapter 1) has suggested that glycated albumin values progressively increase 
with gestation, hereby reflecting the decreased glucose tolerance associated 
with this condition. This effect was clearly not observed for any of the 
assays used in this chapter where the lack of significant change in %GA 
results conflicts with the other 2 assays. There is no obvious explanation for 
this finding as the Dns-PBA assay has been shown not to detect plasma 
globulin proteins (see section 3.4.1) and yet if the effect of the %GA profile 
is subtracted from the %GTP profile (assuming that equal amounts of 
albumin and globulin are present in a typical sample), results very similar 
to those for DF/g/1 would be produced, suggesting that DF/g/1 is reflecting 
changes in glycation of protein other than albumin.
Alternatively, if the 2 different types of methodology are the cause of the 
discrepancy (fluorometric vs affinity chromatography) better agreement 
between %GA and %GTP might have been expected, whereas these results 
imply that glycated albumin levels do not change until a decrease at the 
third trimester despite rapidly declining glycation of plasma globulins from 
early on in pregnancy. One possible explanation could involve the increased 
binding of steroid hormones to albumin during pregnancy, possibly 
restricting access of Dns-PBA to a particular glycation site recognised by 
this assay, but not affecting binding to a boronate affinity matrix.
One other point of note in Figure 6.2.1 is the between individual variation
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for the 3 assays, as represented by the SD error bars. DF/g/1 and %GA 
results show a similar degree of variation between pregnant individuals 
whereas %GTP results show much less variation. This is not in accord with 
the results shown in Table 4.2.3 of Chapter 4 where %GTP for non-pregnant 
subjects has a between subject plus analytical CV (CVq+CV^) of 17.5%, 
%GA has a value of 16.5% and DF/g/1 has the lowest CVg+CV^ of 13.1%, 
which indicates that plasma total protein profiles become more comparable 
between individuals throughout the various stages of pregnancy, possibly as 
a consequence of the decreased serum albumin levels or increased 
concentrations of other binding proteins.
Despite the differences observed between the glycated serum protein assays 
in this longitudinal study of non-diabetic pregnancy, the clinical utility of all 
the assays has been demonstrated for monitoring diabetic pregnancy. For the 
cross-sectional study summarised in Table 6.2.2, DF/g/1, %GA and %GTP 
results decreased by 31%, 40% and 38% respectively between the first and 
second trimesters, and by a further 24%, 25% and 9% respectively between 
the second and third trimesters. The differences observed for the glycated 
protein profiles in non-diabetic pregnancy are therefore not apparent for 
these insulin dependent diabetics where the %GA assay results have 
decreased by the greatest amount. However, the relatively small decrease in 
%GTP results between the second and third trimesters could be reflecting 
the upward trend observed for this measurement in the non-diabetics.
The individual diabetic patient profiles shown in Figures 6.2.2 and 6.2.3 
include HbA^g analysis which in both cases (and also in the cross-sectional 
study) decreases from the first to the second trimester then increases again 
into the third. This coincides with results from Staley and Murray-Arthur 
(1988), Hall (1985) and Rai et al (1988) for studies with non-diabetics, with 
the raised third trimester glycated haemoglobin levels being attributable to 
glycation of the new red cell influx earlier on in pregnancy, as well as to 
possible impaired glucose tolerance occurring towards term. However, the
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glycated plasma protein results in this study do not support the latter 
suggestion as the profiles shown in Figures 6.2.2 and 6.2.3 remain steady 
or continue to decrease for all the assays even after the glycated 
haemoglobin results have started to increase. From the 2 complete profiles 
shown, the Dns-PBA assay and %GA results show a greater percentage 
decrease by the third trimester than the %GTP results. A similar effect was 
observed in Chapter 5 of this thesis (section 5.2.1.2) for the stabilisation of 
glycaemic control in a newly diagnosed diabetic over a period of 3 months, 
whose %GTP levels did not decrease by as much as %GA or DF/g/l, which 
therefore suggests that this phenomenon may be due to differences in 
glycation rates of the different proteins rather than anything occurring as a 
consequence of pregnancy. This cannot however, explain the decreasing 
%GTP results for non-diabetic pregnancy in the face of unchanging %GA 
values.
Although glycated plasma protein levels are going to be unaffected by the 
increased red cell volume occurring during pregnancy, there is a possible 
analogy for serum albumin levels. Olufemi et al (1991) have shown that 
despite the actual decrease in serum albumin concentration secondary to the 
increased plasma volume, there is an increase in albumin synthesis such that 
total intravascular albumin is raised in late pregnancy. Although the situation 
was not studied in earlier pregnancy, it could explain the decreased %GA 
results found in this study at 34 weeks in non-diabetics, and could possibly 
contribute to the divergence of the glycated haemoglobin and glycated 
serum protein results for the 2 diabetics during late pregnancy as 
demonstrated in Figures 6.2.2 and 6.2.3.
The Dns-PBA assay therefore appears to be a useful adjunct, or alternative 
to glycated haemoglobin analysis for monitoring glycaemic control during 
diabetic pregnancy, with the advantage of being able to detect deteriorating 
or improving control more quickly than glycated haemoglobin, by virtue of 
its shorter half-life. This effect can only be taken advantage of if blood
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samples are assayed at less than monthly intervals, a procedure which is 
therefore only likely to be performed throughout pregnancy for those 
patients considered to be at very high risk. By performing both glycated 
haemoglobin and glycated plasma protein analysis, particularly towards the 
end of pregnancy when opposing effects are coming into action, a more 
informed picture of glycaemic control could be obtained.
Although all the diabetic patients included in this study managed to decrease 
their HbAi^ results considerably during pregnancy, down to levels less than 
7%, it is interesting to note the high incidence of Caesarean sections 
performed amongst this group compared to the non-diabetics, despite there 
being no cases of macrosomia amongst the off-spring. The mean birthweight 
of the infants of diabetic mothers was less than that for the non-diabetics, 
possibly reflecting the lower mean gestational age of this group. The 
presence of jaundice in 2 of the 5 babies was indicative of a degree of 
hypoxia during pregnancy leading to polycythaemia, and the unstable blood 
glucose levels for the baby of patient number 1 in Figure 6.2.2 occurred 
despite apparently good or even improving glycaemic control towards the 
end of pregnancy, as judged by the glycated plasma protein analyses.
It is therefore clear that monitoring of glycated proteins throughout diabetic 
pregnancy can provide useful and encouraging information to both the 
clinician and the patient, but it should not be assumed that attainment of 
near normal or normal glycated protein levels will necessarily lead to an 
absence of the complications commonly associated with diabetic pregnancy.
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CHAPTER 7. 
FINAL DISCUSSION.
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7.1. THE DANSYL-PBA ASSAY.
The measurement of glycated blood proteins for assessment of retrospective 
glycaemic control has now been well documented for monitoring diabetic 
patients. With the exception of the fructosamine assay, none of the currently 
available glycated protein methodologies are ideally suited to routine 
laboratory analysis of large numbers of samples, in terms of both cost and 
throughput times. Those methods which can be automated, such as HbA^g 
analysis by HPLC, can reduce the required technician time but also involve 
appreciable financial investment in dedicated analytical equipment, hereby 
maintaining a relatively high cost assay.
Despite its recent gain in popularity, the fructosamine assay is by no means 
an ideal method for measuring glycated serum protein, for the reasons 
discussed in section 1.5.2.6. Nevertheless, when the Roche ‘Fructosamine 
Plus’ kit is automated on a Cobas Bio centrifugal analyser, the consumable 
cost per sample is relatively cheap at 49 pence. With this system a 
maximum of 23 samples can be assayed in approximately 20 minutes, 
assuming that no correction for albumin or total protein levels is being 
made, and the between-batch assay CVs are less than 5% (Kruse-Jarres et 
al, 1989). In comparison to the fructosamine test, the Dns-PBA assay 
investigated in this thesis could be used to assay 20 patient samples in 
approximately 20 minutes, at a consumable cost per sample of 21 pence, or 
approximately 25 pence including serum albumin analysis (these are 
reagent and consumable costs for April 1992, excluding standards and 
controls but inclusive of VAT at 17.5%). Although between-batch CVs can 
be as high as 11.4% for non-diabetic samples (with correction for serum 
albumin) this level of imprecision is comparable to those obtained for the 
specific measurement of glycated albumin by affinity chromatography both 
in this thesis (section 3.1.2; between-batch CV of 7.8-12.9%) and by other 
workers (Reed et al, 1986; between-batch CV of 3.7-11.0%). Results from
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studies in section 3.4.1 indicate that the Dns-PBA method specifically 
detects glycated albumin as opposed to other glycated serum proteins, and 
other than cost, this would appear to be its main advantage over the 
fructosamine method. The specificity of the Dns-PBA assay for glycated 
albumin obviously facilitates correction of the DF results for serum albumin 
levels. Even if fructosamine results are corrected for serum total protein 
levels, this cannot accurately compensate for different protein profiles 
whereby individual proteins show different glycation rates and different 
numbers of possible glycation sites. It has been clearly shown in vitro 
(Lamb et al, 1991; Baynes et al, 1984) that production of glycated albumin 
is in first order relation to albumin concentration, despite the vast excess of 
available lysine residues over reactive open chain glucose molecules, so 
correction of results for serum albumin levels would appear to be 
appropriate. Any abnormalities in albumin metabolism would affect both 
corrected and uncorrected results.
In view of the lack of response from a , p and y globulin proteins to the 
Dns-PBA assay analysis (see section 3.4.1) it would appear that the assay 
does not detect glycoproteins. The a-globulin fraction in particular is rich 
in these compounds eg. acid glycoprotein, which has a total carbohydrate 
content of approximately 41% (Schultze and Heremans, 1966).
In Chapter 2 of this thesis the Dns-PBA assay has been automated, 
optimised and adapted from the original procedure described by Hayashi and 
Makino (1985) to enable analysis of undiluted serum samples. In the 
protocol described by Hayashi and Makino the final reaction mixture 
contained a 1:500 serum dilution and 0.59 pimol/1 Dns-PBA. When adapted 
in this thesis for sampling of undiluted serum the final reaction mixture 
contained a 1:130 serum dilution and 2.48 jiimol/l Dns-PBA, hereby 
maintaining a similar ratio of Dns-PBA concentration to serum volume. 
However, it is not possible to calculate the specific molar ratios for binding
325
of Dns-PBA to albumin since the majority of Dns-PBA binding is non­
specific.
In 1990, Hayashi et al used their manual Dns-PBA fluorometric assay to 
measure glycated albumin in urine samples. Although this group found that 
urinalysis was sometimes hindered by intense fluorescence in the samples, 
further research with the automated Dns-PBA assay as optimised in this 
thesis could include its assessment for detection of glycated albumin in 
urine, as Hayashi et al (1990) found that the percentage of glycation of 
urinary albumin when measured by fluorometry was approximately the same 
as that of serum albumin.
In section 2.4.2, sample stability was investigated in order to determine the 
best way of storing patient samples prior to analysis. Unfortunately, for this 
investigation it was not possible to obtain reasonable numbers of fresh 
samples from diabetic patients on any one particular day so non-diabetic 
samples had to be used. This may therefore have resulted in an 
underestimation of any in vitro glycation, which may occur more readily 
upon storage of diabetic samples with higher blood glucose levels. As the 
general trend found in this section was for an increase in DF results upon 
frozen storage, particularly at -20 °C, it would be informative to extend the 
study with diabetic samples or alternatively by adding variable amounts of 
glucose to non-diabetic samples. However, use of diabetic sera would also 
give higher baseline DF values, which would reduce the relative magnitude 
of the SDs obtained for baseline-stored results (see Table 2.4.3) which can 
influence whether statistical significance is achieved between pairs of 
results.
The non-diabetic reference range established in section 2.5.2.1 for the 
fluorometric assay was derived from approximately equal numbers of males 
and females. As this reference range (shown in Fig 2.5.1) obviously follows 
a normal distribution and is clearly not bimodal, it would appear to be 
unlikely that males and females have different distributions of results.
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However, following collection of more non-diabetic data it will be possible 
to establish whether there is in fact any difference. Similarly, if the Dns- 
PBA assay is to be used routinely a paediatric reference range would be 
required, as other studies have indicated that both fructosamine and glycated 
albumin levels are lower in children’s sera than adults (Abe et al, 1989; De 
Schepper et al, 1988). Analysis of glycated serum protein is particularly 
advantageous for monitoring children’s glycaemic control as HbF is often 
still present, which can interfere with some forms of glycated haemoglobin 
analysis.
7.2. COMPARISON OF DANSYL-PB A ASSAY RESULTS TO AFFINITY 
CHROMATOGRAPHY.
In Chapter 3 of this thesis, DF/g/1 results from the Dns-PBA assay have 
been compared to affinity chromatographic analysis of the same samples, for 
%GA and %GTP. The clinical utility of the affinity chromatography 
technique has been well documented and it is now an established method for 
measuring glycated proteins. Due to the similarities of the APBA affinity gel 
and the fluorometric Dns-PBA ligand, combined with the lack of specialised 
equipment needed in order to perform the chromatographic analysis, the 
affinity method seemed an obvious choice for a direct comparison of results. 
However, it became apparent as the work for this thesis progressed, that the 
interaction of the dansyl group on Dns-PBA with glycated albumin is 
fundamental to the specificity of the fluorometric assay, and appears to 
introduce an additional factor which is not applicable to the affinity 
technique. It is therefore very likely that the different binding requirements 
for detection by these 2 different forms of analysis is the cause of the 
positive intercept for the DF/g/l versus %GA correlation in Fig 3.1.3 and 
also the much higher between-individual variation in %GA and %GTP 
results compared to the other assays in Chapter 4 (see Table 4.2.3). In view
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of these discrepancies, comparisons of the Dns-PBA assay results to 
established chemical methods of analysis, as described in section 1.5.2, 
would be very informative, as a negative intercept on the DF/g/1 axis would 
also be suggestive of a very specific albumin binding site for Dns-PBA in 
the fluorometric assay.
The study described in section 3.4.2 confirmed that the Dns-PBA assay 
could detect species that were not retained by an APBA affinity column. As 
this study was originally performed with the intention of producing a sample 
containing no glycated protein, which was then to be subjected to 
fluorometric analysis, the elution buffer eluates containing glycated protein 
were not saved for analysis. It would therefore be useful to repeat this 
experiment with the analysis of all the chromatography eluates by the 
fluorometric procedure in order to calculate recoveries in each fraction. 
These recoveries could then be compared to those obtained by other workers 
using glucose labelled glycated proteins (Cruschelli et al, 1990; 
Johnson and Baker, 1988) in order to establish whether it is only glycated 
protein that the Dns-PBA assay has detected in these ‘unglycated’ 
chromatography fractions.
Analysis of samples for both %GA and %GTP by affinity chromatography 
in Chapter 3 has produced reference ranges for both analytes, with a mean 
%GTP value 1.7-fold higher than the mean %GA value for the non-diabetic 
population. As both these mean values are in accordance with those 
achieved by other groups (Gould et al, 1984; Reed et al, 1986) they do 
suggest that some of the serum globulin proteins are more susceptible to 
glycation than albumin. This effect may be due to detection of glycated 
immunoglobulins, as Austin et al (1987) found these proteins to show the 
greatest proportion of glycation in vivo, with a half-life in plasma not 
dissimilar to that of albumin.
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7.3. DANSYL-PBA ASSAY INTERFERENCES.
In section 3.2.2 of Chapter 3, the effect of Schiffs base interference on the 
Dns-PBA assay was investigated. Although it was concluded that Schiffs 
base was not detected by this assay, the serum sample used for analysis had 
a glucose level of only 3.7 mmol/1. It is therefore possible that any 
dissociation of the labile aldimine was negligible for this sample and that 
the assay may not be sufficiently sensitive to detect any change. As high 
blood glucose levels were shown to significantly increase DF/g/1 results in 
section 3.2.3, and the correlation of DF/g/1 results versus %GA did give a 
positive intercept (which could be interpreted as being due to Schiffs base 
detection by the Dns-PBA assay) this experiment needs to be repeated, 
ideally with diabetic serum samples showing a range of baseline glycated 
protein and blood glucose levels, before detection of this aldimine by the 
Dns-PBA assay can be conclusively ruled out.
Chapter 3 of this thesis also investigated the in vitro effect of several 
possible interferents on the fluorometric assay (sections 3.2.3 - 3.2.12). As 
the assay incorporates a blank reading with reagent B for every sample 
assayed, it can be assumed that in order for a component to actually affect 
the DF results, it must be exerting different effects upon the reagent A and 
reagent B analyses. In this respect it is possible that positive interferences 
with the assay may be due to the interfèrent itself fluorescing at a binding 
site where it can be displaced by boric acid (eg. salicylate), and that 
negative interferences may be due to steric hind ranee which could restrict 
specific binding of boric acid thereby raising the blank results (eg. bilirubin). 
Although the effects of sodium salicylate were investigated in sections 3.2.8 
and 3.3.1.3 for possible interference in the assay analysis and also on in 
vitro glycation of albumin as detected by this method, investigation of the 
effect of acetylsalicylate was omitted. Although upon ingestion, 
acetylsalicylic acid (aspirin) is rapidly converted to salicylic acid, the
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relatively short exposure to the acetyl compound has been shown to be 
sufficient to acetylate albumin, particularly in those patients on long term 
aspirin therapy. The dose dependent inhibition of plasma protein glycation 
by acetylsalicylate has been demonstrated by Day et al (1979) and Kennedy 
et al (1982) using the TBA-HMF method. It would therefore be interesting 
to establish whether acetylsalicylate is capable of reducing the Dns-PBA 
assay results to a greater extent than salicylate, which did reduce the assay 
response at therapeutic levels.
Other studies in Chapter 3 which warrant further investigation are those 
described in sections 3.4.4 and 3.4.6 where the effect of thiol groups on the 
fluorometric assay was performed by adding PCMB or GSH to serum 
samples. Due to the complex mixture of proteins present in serum, this may 
well have obscured any more definite results which could have been 
apparent if human albumin solutions had been employed instead. Similarly, 
the use of fatty-acid free HSA for the borohydride experiments was not ideal 
as this does not represent the true compound of analysis in patient samples. 
In this respect it is interesting to note from Table 3.3.2, for example, that 
the fatty-acid free HSA obtained from the Sigma Chemical Company, which 
was claimed to be a fatty-acid free preparation of the ordinary HSA also 
used in this study, appeared to show a much higher level of glycation than 
the HSA with bound fatty-acids. This discrepancy was also observed for 
fructosamine and affinity chromatographic analysis, which suggests that 
either very different plasma pools were used for purification of each 
albumin, or that at some stage in the procedure for fatty-acid removal 
glycation of the albumin occurred. Alternatively, all 3 assays could be 
detecting a contaminant which although unlikely, would help to explain the 
surprisingly high DF response which remained after borohydride reduction. 
It would therefore be informative to pursue this area of research with 
alternative albumin preparations as well as with serum samples.
Although the results from Chapter 3 are not inconsistent with the existence
330
of a specific glycation site on albumin which is recognised by Dns-PBA, 
very little has been elucidated about the actual position of the binding site, 
other than that it is likely to be shared with compounds such as bilirubin and 
salicylate. Further investigations into the specific interaction of Dns-PBA 
would necessitate separation of the bound and free Dns-PBA, followed by 
characterisation of the Dns-PBA-albumin complex.
7.4. CLINICAL STUDIES.
In Chapter 4 the various glycated serum protein methodologies have been 
compared in terms of biological variation. Although the most striking visual 
impact of the different methods is that of the much smaller within-individual 
variation for the fructosamine assays in Figures 4.2.1 - 4.2.10 compared to 
the others, the statistical analysis undertaken was able to separately identify 
the analytical variance and hereby compare the assays in terms of true 
biological variation. For this study data were subjected to a one-way 
analysis of variance, which assumes that each assay has a set level of 
analytical imprecision which does not change with the slightly differing 
glycated protein results found between individuals. In practice this is not 
strictly true as those patient samples with the higher glycated protein results 
will generally produce lower CVs than samples with lower levels of analyte. 
Although financial restraints prevented it in this study, it is possible to 
correct for this situation by assaying each sample in duplicate for every 
method studied, in order to assess analytical precision, and then applying a 
two-way analysis of variance to the results. It is doubtful as to whether this 
would actually have affected the final outcome for this particular study as 
all the individuals were non-diabetic and as such had a relatively narrow 
range of glycated protein values.
In Tables 4.2.3 and 4.2.7, high between-individual CV values were derived 
for the affinity chromatography methods. This resulted in high indices of
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individuality and heterogeneity for the technique (Table 4.2.4), suggesting 
that this form of analysis is likely to be the one most difficult to interpret 
when monitoring patients. In general, this chapter has indicated that there 
is a high index of individuality for glycated proteins with all 3 forms of 
analysis, suggesting that it is likely to be a true biological phenomenon. As 
glycated albumin (%GA) in particular has one of the highest between- 
individual CVs it is possible that the variation is due to changes in the 
vascular and non-vascular distribution of proteins, with albumin being 
particularly vulnerable to redistribution due to its small size. Approximately 
60% of the total exchangable body albumin pool is extravascular (Whicher 
and Spence, 1987) and present in lower concentration than the intravascular 
albumin. It therefore follows that the rate of extravascular albumin glycation 
is reduced and the degree of exchange occurring between these 2 pools 
could affect glycated serum albumin levels. Additional factors could also 
come into play if glycated proteins are not exchanged at the same rate as 
their non-glycated counterparts, due to alterations in their overall charge. 
Different individuals will obviously show some variation in the amount of 
protein present in their intra and extravascular compartments which may 
therefore be contributing to the high between-subject variation of glycated 
albumin in particular. This phenomenon may also be relevant to the diurnal 
variation seen to occur for the %GA and Dns-PBA assay results whereby 
glycated albumin levels in this groiip of laboratory staff were increased 
towards the end of the day. It is possible that this could be reflecting 
expansion of the intravascular compartment overnight upon recumbency, 
with an influx of the less glycated extravascular albumin towards early 
morning. Throughout the day, orthostatic pressure would reduce the 
intravascular compartment, and glycated albumin levels could increase 
slightly as glycation then occurred at the higher intravascular rate. It would 
therefore be interesting to monitor glycated albumin levels over a 24 hour 
period in recumbant non-diabetic subjects, in order to establish whether
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these results occurred by chance or whether the effect can be eliminated by 
restricting albumin exchange between the intra and extravascular pools. 
The results for biological variation in Chapter 4 do not support correction 
of fructosamine test values for serum albumin or total protein levels, but this 
study was performed with a healthy group of non-diabetic individuals whose 
variation in serum proteins would have been minimal over the period of 
study. This conclusion is therefore in contrast to that found in Chapter 5 
(section 5.2.2.3) where correction of fructosamine results for serum proteins 
was essential in order to interpret results in the face of rapidly changing 
states of hydration.
In Chapter 5 the clinical utility of the Dns-PBA assay for both acute and 
chronic monitoring of changes in glycaemic control was established. 
Although the method was shown not to be a particularly valuable screening 
test for diabetes or impaired glucose tolerance this was not surprising as no 
glycated protein method has yet been advocated to replace the oral glucose 
tolerance test. However, like other methodologies the Dns-PBA assay could 
provide supplementary information to OGTTs, particularly if OGTT and 
clinical indications are equivocal.
The investigation of glycated protein levels during pregnancy, as described 
in Chapter 6, gave an insight into the complexities of interpreting both 
glycated haemoglobin and glycated serum protein levels during this 
condition. As it is desirable to detect deterioration in glycaemic control as 
soon as possible in pregnant diabetics, it is preferable to measure the 
glycated protein with the shorter half-life i.e. albumin. Although the half-life 
of the normal red blood cell is 60 days, the Amadori product reaches 
equilibrium in 21-28 days so subject to changes in blood glucose 
concentration, the amount of Amadori product present once equilibrium is 
attained will remain constant after this time, whatever the half-life of the 
protein (Cerami, 1985). This fact has been frequently overlooked in the 
literature and does indicate that the difference in the timescales represented
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by glycated albumin and glycated haemoglobin is not as large as often 
suggested, with glycated albumin levels being representative of the previous 
2-3 weeks blood glucose control and glycated haemoglobin being 
representative of possibly as little as the previous 3-4 weeks control. This 
could explain the similar rates of decreasing glycated serum protein and 
glycated haemoglobin levels observed for the newly diagnosed diabetic 
shown in Figures 5.2.1 and 5.2.2 as well as in Figures 6.2.2 and 6.2.3 for 
the diabetic pregnancies.
Although DF/g/1 results throughout normal pregnancy showed the same 
trend as previous reports for glycated haemoglobin levels (Staley and 
Murray-Arthur, 1988; Hall, 1985) i.e. a significant decrease in the second 
trimester increasing back up again by the third, different methodologies in 
this thesis produced different pictures. Bearing in mind the quite dramatic 
divergence of HbA^g and glycated albumin (%GA and DF/g/1) results 
observed in the third trimester of the diabetic pregnancies shown in Figures 
6.2.2 and 6.2.3, it would be wise to assay both quantities at this stage of 
pregnancy. From the study described in Chapter 6 of this thesis it is not 
possible to comment on these profiles with regard to the diabetic patients’ 
blood glucose control throughout pregnancy as unfortunately reliable 
documentation of home blood glucose monitoring results was not available. 
A knowledge of actual blood glucose levels would have been particularly 
useful for interpretation of these conflicting results.
7.5. THE IDEAL ROUTINE METHOD FOR GLYCATED PROTEIN.
There are several points to consider for a glycated protein method which is 
ideally suited to the routine laboratory. Such a method should:
1) be automated, hereby reducing hands-on time and improving 
precision,
2) be capable of discriminating one specific glycated protein, rather than
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a variety of different ones,
3) not be too expensive in terms of capital costs, consumables and 
labour,
4) be accurate, precise and not subject to any common interferences,
5) have a recognised method of standardisation enabling comparisons of 
serial results over a long time span,
6) be quality controlled by reliable, stable preparations.
Expression of assay results in terms of a percentage or an absolute amount 
of the compound in question would also be desirable, if only to facilitate a 
greater understanding of the analyte being assayed. The possibility of 
developing a portable automated system, adapted for analysis of smaller 
numbers of samples (such as those from surgeries or clinics) would be 
provided by the most flexible assay and the ability to analyse filter paper 
blood spot samples would also be advantageous.
The most obvious assay currently available which fulfills most of these 
criteria is HbAjj. analysis by immunoassay. However, this technique is not 
yet completely automated for the handling of large numbers of samples and 
it is still relatively expensive. Also, as the antibodies involved generally 
recognise the glycated N-terminal heptapeptide of the haemoglobin p-chain, 
those haemoglobin variants with alterations at p6 (eg HbS, HbC) will not 
be detected, which can result in falsely low percentage HbAj^ results.
The Dns-PBA assay, as automated and optimised in this thesis has been 
shown to satisfy points l)-3) above. The actual accuracy of the method can 
currently only be established by performing correlations with other 
methodologies, which is why it is now particularly relevont to assess the 
method with regard to chemical forms of analysis, although good 
discrimination between diabetic and non-diabetic populations has been 
demonstrated. There is clearly room for improvement in the precision of the 
Dns-PBA assay, although at its current level this does not preclude the
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clinical application of the test. The. fluorometric analysis has been well 
standardised and controlled throughout the course of this thesis but 
preparation of standards and controls on a more commercial basis would be 
required in order to make the assay more attractive to routine laboratories. 
Due to the nature of the standardisation procedure adopted in this study (i.e. 
the photomultiplier voltage of the fluorometer is determined by an in vitro 
glycated preparation of human plasma, which is then used as one of the 
assay standards) it would be necessary for individual laboratories to establish 
their own reference ranges relèvent to the particular analyser in use. As this 
is common laboratory practice for most new analytes, it can be concluded 
that the automated Dns-PBA assay can be usefully implemented at very 
little cost in those laboratories already possessing automated 
spectrofluorometric equipment.
The other main contender for routine automated analysis of glycated serum 
proteins is the fructosamine test which has its own inherent disadvantages, 
different to those encountered for the fluorometric assay. For the specific 
detection of glycated albumin however, affinity chromatography followed 
by immunoturbidimetric detection of albumin is probably the method most 
often employed for routine analysis of relatively large numbers of samples. 
As this affinity technique is approximately 10-times more expensive than the 
Dns-PBA assay in terms of consumable costs alone, the novel fluorometric 
form of analysis should definitely be able to find a place in the routine 
clinical chemistry laboratory.
336
BIBLIOGRAPHY.
Abe F, Yano M, Minami Y, Ueda T, Chikakiyo H, Miyamoto N, Shirakawa 
N, Shima K. Alterations in fructosamine and glycated albumin levels during 
childhood.
Ann. Clin. Biochem. 1989;26:328-331.
Abraham FC, Perry RE, Stallings M. Application of affinity chromatography 
for separation and quantitation of glycosylated hemoglobins.
J. Lab. Clin. Med. 1983;102:187-197.
Acharya AS, Manning JM. Amadori rearrangement of glyceraldehyde­
hemoglobin Schiff base adducts, a new procedure for the determination of 
ketoamine adducts in proteins.
J. Biol. Chem. 1980;255:7218-7224.
Aerts L, Van Asshe FA. Ultrastructural changes of the endocrine pancreas 
in pregnant rats.
Diabetologia, 1975;11:285-289.
Akazawa M, Akazawa S, Hashimoto M, Akashi M, Yamazaki H, Tahara D, 
Yamamoto H, Yamaguchi Y, Nakanishi T, Nagataki S. Effects of brief 
exposure to insulin-induced hypoglycemic serum during organogenesis in rat 
embryo culture.
Diabetes, 1989;1573-1578.
Allen DW, Schroeder WA, Balog J. Observations on the chromatographic 
heterogeneity of normal adult and fetal hemoglobin.
J. Am. Chem. Soc. 1958;80:1628-1634.
Allgrove J, Cockrill BL. Fructosamine or glycated haemoglobin as a 
measure of diabetic control?
Arch. Dis. Child. 1988;63:418-422.
American Diabetes Association, Inc. Gestational diabetes mellitus. 
Diabetes, 1985;34:123-126.
Armbruster DA. Fructosamine: Structure, analysis, and clinical usefulness 
(review).
Clin. Chem. 1987;33:2153-2163.
337
Austin GE, Mullins RH, Morin LG. Non-enzymatic glycation of individual 
plasma proteins in normoglycaemic and hyperglycaemic patients.
Clin. Chem. 1987;33:2220-2224.
Baird JD. Some aspects of metabolism and hormonal adaptation to 
pregnancy.
Acta Endocrinologica Suppl. 1986;277:11-18.
Baker J, Johnson RN. Serum fructosamine - the pH factor.
BMJ. 1985;291:1050.
Baker JR, Metcalf PA, Johnson RN, Newman D, Rietz P. Use of protein 
based standards in automated colorimetric determinations of fructosamine 
in serum.
Clin. Chem. 1985;31:1550-1554.
Baker JR, O’Connor JP, Metcalf PA, Lawson MR, Johnson RN. Clinical 
usefulness of estimation of serum fructosamine as a screening test for 
diabetes mellitus.
BMJ. 1983;287:863-7.
Banauch D, Rindfrey H, Heiger R. A glucose determination on mechanized 
analysers using glucose dehydrogenase.
Z. Klin. Chem. Klin. Biochem. 1974;12:265-266
Banting EG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic 
extracts in the treatment of diabetes mellitus.
Canad. Med. Assoc. J. 1922;12:141-6.
Baynes JW, Thorpe SR, Murtiashaw MH. Nonenzymatic glucosylation of 
lysine residues in albumin.
Methods Enzymol. 1984;106:88-98.
Bensch KG, Fleming JE, Lohmann W. The role of ascorbic acid in senile 
cataract.
Proc. Nat. Acad. Sci. USA. 1985;82;7193-7196.
Blair SC, Schier GM, Gan lET. More on serum fructosamine assay (letter). 
Clin. Chem. 1987;33:446-447.
Bookchin RM, Gallop PM. Structure of haemoglobin A^ p: nature of the N- 
terminal p chain blocking group.
Biochem. Biophys. Res. Commun. 1968;32:86-93.
338
Bradford MM. A rapid and sensitive method for the quantitation of 
microgram quantities of protein using the principle of dye binding.
Anal. Biochem. 1976;72:248-254.
Brand S, Hutchinson DW, Donaldson D. Albumin Redhill, a human albumin 
variant.
Clin. Chim. Acta, 1984;136:197-202.
Brennan SO, Myles T, Peach RJ, Donaldson D, George PM. Albumin 
Redhill (-1 Arg, 320 Ala—>Thr): a glycoprotein variant of human serum 
albumin whose precursor has an aberrant signal peptidase cleavege site. 
Proc. Natl. Acad. Sci. USA. 1990;87:26-30.
Brodersen R. Binding of bilirubin and other ligands to human serum 
albumin.
In: Peters T, Sjoholm I, editors. Albumin: structure, biosynthesis, function. 
FEBS 11th meeting Copenhagen; 1977;50:61-70.
Broughton PMG. Quality Control. In: Williams D, Nunn R, Marks V, eds. 
Scientific Foundations of Clinical Biochemistry. Volume 1, Analytical 
Aspects. (First edition).
London :Heinemann, 1978:pp459-480.
Brownlee M. Glycosylation products as toxic mediators of diabetic 
complications.
Annu. Rev. Med. 1991;42:159-66.
Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end-products 
in tissue and the biochemical basis of diabetic complications.
N. Engl. J. Med. 1988;318:1315-1321.
Brownlee M, Vlassara H, Cerami A. Measurement of glycosylated amino 
acids and peptides from urine of diabetic patients using affinity 
chromatography.
Diabetes, 29; 1980:1044-1047.
Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the 
pathogenesis of diabetic complications.
Ann. Int. Med. 1984;101:527-537.
Brudenell JM. Observations on fetal cord blood PO2 in diabetic pregnancy. 
William Meredith Retcher Shaw Memorial Lecture.
Royal College of Obstetricians and Gynecologists, 1987.
339
Brudenell JM, Doddridge MC. Diabetic pregnancy. In: Current reviews in 
obstetrics and gynaecology. No. 13. Lind T, series editor. Churchill 
Livingstone, 1989.
Brunnbauer M, Kuenburg E, Winter P, Muller MM, Prager R. Circadian 
variations of fructosamine in patients with type-II diabetes mellitus.
In: Kraupp O, Sinzinger H, editors. Wiener Klinische Wochenschrift. 
European Fructosamine Workshop; 1989;Oct 26-28; Vienna:pp70-71.
Bruns DE, Lobo PI, Savory J, Wills MR. Specific affinity-chromatographic 
measurement of glycated haemoglobins in uremic patients.
Clin. Chem. 1984;30:569-571.
Bunn HE. Evaluation of glycosylated hemoglobin in diabetic patients. 
Diabetes, 1981;30:613-617.
Bunn HE, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis 
of human hemoglobin Slow glycosylation of hemoglobin in vivo.
J. Clin. Invest. 1976;57:1652-1659.
Bunn HF, Higgins PJ. Reaction of monosaccharides with proteins: possible 
evolutionary significance.
Science 1981;213:222-224.
Burnett TJ, Peebles HC, Hageman JH. Synthesis of a fluorescent boronic 
acid which reversibly binds to cell walls and a diboronic acid which 
agglutinates erythrocytes.
Biochem. Biophys. Res. Commun. 1980;96:157-162.
Burt RL. Peripheral utilisation of insulin in pregnancy and the puerperium. 
Obstet. Gynecol. 1956;2:658-664.
Cardell BS. Pathology of diabetes.
In: Oakley WG, Pyke DA, Taylor KW, editors. Clinical diabetes and its 
biochemical basis. Blackwell, 1968:ppl47-180.
Cefalu WT, Bell-Farrow AD, Petty M, Izlar C, Smith JA. Clinical validation 
of a 2nd generation fructosamine assay.
Clin. Chem. 1991;37:1252-1256.
Cefalu WT, Prather KL, Chester DL, Wheeler CJ, Biswas M, Pemoll ML. 
Total serum glycosylated proteins in detection and monitoring of gestational 
diabetes.
Diabetes Care, 1990;13:872-5.
340
Cerami A. Accumulation of advanced glycosylation endproducts on proteins 
and nucleic acids: role in ageing.
Prog. Clin. Biol. Res. 1985;195:79-88.
Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. A 
preliminary note on inhibiting effect of a-tocopherol (vitamin E) on protein 
glycation.
Diabete Metab. 1988;14:40-42.
Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. 
Vitamin E reduction of protein glycosylation in diabetes. New prospect for 
prevention of diabetic complications?
Diabetes Care, 1991;14:68-72.
Cohen MP, Hud E. Production and characterisation of monoclonal 
antibodies against human glycoalbumin.
J. Immunol. Methods, 1989;117:121-129.
Cole RA, Soeldner JS, Dunn PJ, Bunn HF. A rapid method for the 
determination of glycosylated hemoglobins using high pressure liquid 
chromatography.
Metabolism, 1978;27:289-301.
Court S. Diabetes mellitus: a perspective.
Rec. Adv. Paed. 1991;9:75-91.
Cruschelli L, Clerico A, Penno G, Navalesi R, Giampietro O. Colorimetric 
versus radioimmunological measurement of glycated and non-glycated semm 
albumin after affinity chromatigraphy.
Acta Diabetologia Latina, 1990;27:349-356.
Davidson S. Endocrine and metabolic diseases.
In: Macleod J, editor. Davidson’s principles and practice of medicine. 14th 
edition. New York: Churchill Livingstone, 1984:pp417-487.
Davie S, Gould B, Yudkin J. Effect of vitamin C on glycosylation of 
proteins.
Diabetes, 1992;41:167-173.
Day JF, Thorpe SR, Baynes JW. Non-enzymically glucosylated albumin. In 
vitro preparation and isolation from normal human serum.
J. Biol. Chem. 1979;254:595-597.
341
De Feo P, Gaisano MG, Raymond MW. Differential effects of insulin 
deficiency on albumin and fibrinogen synthesis in humans.
J. Clin. Invest. 1991;88:833-840.
De Schepper J, Derde MP, Goubert P, Gorus F. Reference values for 
fructosamine concentrations in children’s sera: influence of protein 
concentration, age, and sex.
Clin. Chem. 1988;34:2444-2447.
De Meyer J. Action de la sécrétion interne du pancréas sur différents 
organes et en particular la sécrétion rénale.
Arch. Fisiol. 1909;7:96-99.
Dempsey WB, Christiansen HN. The specific binding of pyridoxal-5’- 
phosphate to bovine plasma albumin.
J. Biol. Chem. 1962;237:1113-1120.
Dicker D, Feldberg D, Samual N, Yeshaya A, Karp M, Goldman JA. 
Spontaneous abortion in patients with insulin-dependent diabetes 
mellitus :The effect of preconceptional diabetic control.
Am. J. Obstet. Gynecol. 1988;158:1161-1164.
Dolhofer R, Wieland OH. Increased glycosylation of serum albumin in 
diabetes mellitus.
Diabetes, 1980;29:417-422.
Dolhofer R, Wieland OH. Improvement of the thiobarbituric acid assay for 
serum glycosylprotein determination.
Clin. Chim. Acta, 1981;112:197-204.
Dolhofer-Bliesener R, Gerbitz KD. Impairment by glycation of 
immunoglobulin G F  ^fragment function.
Scand. J. Clin. Lab. Invest. 1990;50:739-746.
Dominiczak MH. The significance of the products of the Maillard 
(browning) reaction in diabetes.
Diabetic Med. 1991;8:505-516.
Dominiczak MH, Macrury SM, Orrell JM, Paterson KR. Long-term 
performance of the fructosamine assay.
Ann. Clin. Biochem. 1988;25:627-633.
342
Drexel H, Klocker H, Patsch JR, Breier C, Braunsteiner H. Measurement of 
glycated protein by a rapid and specific method for absolute quantification 
of lysine bound glucose.
Clin. Chem. 1987;33:1656-1659.
Engbaek F, Christiansen SE, Jespersen B. Enzyme immunoassay of HbAi^: 
analytical characteristics and clinical performance for patients with diabetes 
mellitus with and without uraemia.
Clin. Chem. 1989;35:93-7.
Engbaek F, Sprensen GH, MacIntyre B, Clausen I, Lund HT, Jastrup B. 
Interference of abnormal hemoglobins on the measurement of hemoglobin 
Ale by ion-exchange chromatography.
Clin. Chim. Acta, 1990;191:239-244.
Eberhardt MS, Wagener DK, Orchard TJ. HLA heterogeneity of insulin 
dependent diabetes at diagnosis: the Pittsburg IDDM study.
Diabetes, 1985;34:1247-1252.
Fadel HE, Hammond SD, Huff TA, Harp RJ. Glycosylated haemoglobins 
in normal pregnancy and gestational diabetes.
Obstet. Gynaecol. 1979;54:322-326. •
Feeney RE, Blankenhom G, Dixon HB. Carbonyl-amine reactions in protein 
chemistry.
Adv. Prot. Chem. 1975;29:135-203.
Fisken RA, Chan AW, Hanlon A, MacFarlane lA. Longitudinal changes in 
serum fructosamine do not parallel those in glycated haemoglobin in young 
adults with insulin-dependent diabetes.
Clin. Chim. Acta, 1990;191:79-86.
Fliickiger R, Gallop PM.
In: Wold F, Moldave K, editors. Methods in enzymology.
Academic Press: New York. 1984; 106:pp77-87.
Fliickiger R, Harman M, Meier W, Loo S, Gabbay KH. Haemoglobin 
carbamylation in uraemia.
N. Eng. J. Med. 1981;304:823-827.
Fliickiger R, Winterhalter KH. In vitro synthesis of haemoglobin Aj^. 
FEBS Lett. 1976;71:356-360.
343
Fliickiger R, Woodtli T, Berger W. Evaluation of the fructosamine test for 
the measurement of plasma protein glycation.
Diabetologia, 1987;30:648-652.
Forrest RD, Jackson CA, Gould BJ, Casbum-Budd M, Taylor JE, Yudkin 
JS. Four assay methods for glycated hemoglobin compared as screening tests 
for diabetes mellitus: The Islington diabetes survey.
Clin. Chem. 1988;34:145-148.
Foster AB. Zone electrophoresis of carbohydrates.
Adv. Carbohydr. Chem. 1957;12:81-115.
Fraser CG, Harris EK. Generation and application of data on biological 
variation in clinical chemistry.
Grit. Rev. Clin. Lab. Sci. 1989;27:409-437.
Freinkel N. The Banting Lecture 1980: of pregnancy and progeny. 
Diabetes, 1980;29:1023-1035.
Freund JE. Modem elementary statistics.
7th rev ed. London: Prentice-Hall International, 1988:pp386-391.
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease 
risk and impaired glucose tolerance. The Whitehall Study.
Lancet, 1980;1:1373-1376.
Furth AJ. Methods for assaying nonenzymatic glycosylation (review). 
Analyt. Biochem. 1988;175:347-360.
Gallop PM, Fliickiger R, Hanneken A, Mininsohn MM, Gabbay KH. 
Chemical quantitation of hemoglobin glycosylation: fluorometric detection 
of formaldehyde released upon periodate oxidation of glycoglobin.
Analyt. Biochem. 1981;117:427-432.
Garlick RL, Mazer J. The principal site of non-enzymic glycosylation of 
human semm albumin in vivo.
J. Biol. Chem. 1983;258:6142-6146.
Garlick RL, Mazer JS, Higgins PJ, Bunn HF. Characterisation of 
glycosylated haemoglobins. Relevance to monitoring of diabetic control and 
analysis of other proteins.
J. Clin. Invest. 1983;71:1062-1072.
344
Gerbaut L. Immunoturbidimetry of albumin in serum, cerebrospinal fluid, 
and urine with a unique calibration curve.
Clin. Chem. 1987;33:1260-1261.
Ghiggeri GM, Candiano G, Delfino G, Queirolo C. Characterisation of the 
phenylhydrazone derivatives of ‘glycated albumin’ purified from diabetic 
sera.
Carbohydr. Res. 1986;153:314-317.
Ghosh PB, Whitehouse MW. 7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole: a 
new fluorigenic reagent for amino acids and other amines.
Biochem. J. 1968;108:155-156.
Glick MR, Ryder KW, Jackson S. Graphical comparisons of interferences 
in clinical chemistry instrumentation,
Clin. Chem. 1986;32:470-475.
Goldstein DE, Little RR, Wiedmeyer HM, England J, McKenzie EM. 
Glycated hemoglobin methodologies and clinical applications.
Clin. Chem. 1986;32:B64-B70.
Gomall AG, Bardawill CJ, David MM. Determination of serum proteins by 
means of the biuret reaction.
J. Biol. Chem. 1949;177:751-766.
Gottschalk A. Some biochemically relevant properties of N-substituted 
fructosamines derived from amino-acids and N-arylglucosylamines. 
Biochem. J. 1952;52:455-460.
Gould BJ, Hall PM. m-Aminophenylboronate affinity ligands distinguish 
between non-enzymically glycosylated proteins and glycoproteins.
Clin. Chim. Acta, 1987;163:225-230.
Gould BJ, Hall PM, Cook JGH. Measurement of glycosylated haemoglobins 
using an affinity chromatography method.
Clin. Chim. Acta, 1982;125:41-48.
Gould BJ, Hall PM, Cook JGH. A sensitive method for the measurement of 
glycosylated plasma proteins using affinity chromatography.
Ann. Clin. Biochem. 1984;21:16-21.
Green IC, Taylor KW. Effects of pregnancy in the rat on the size and 
insulin secretory response of the islets of Langerhan.
J. Endocrinol. 1972;54:317-325.
345
Greene MF, Hare JW, Cloherty JP, Benacerraf BR, Soeldner JS. First- 
trimester hemoglobin and risk for major malformation and spontaneous 
abortion in diabetic pregnancy.
Teratology 1989;39:225-231.
Guillausseau PJ, Charles MA, Paolaggi F, Timsit J, Chanson P, Peynet J, 
Godard V, Eschwege E, Rousselet F, Lubetzki J. Comparison of HbAj and 
fructosamine in diagnosis of glucose tolerance abnormalities.
Diabetes Care, 1990;13:898-900.
Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes JW. Enhanced 
nonenzymatic glucosylation of human serum albumin in diabetes mellitus. 
Proc. Natl. Acad. Sci. USA. 1979;76:4258-4261.
Hall P. The study of glycosylated proteins in diabetes mellitus.
PhD Thesis. University of Surrey, 1985.
Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RDG. Glycated 
fibrinogen: A new index of short term diabetic control.
Ann. Clin. Biochem. 1989;26:58-62.
Harlass FE, McClure GB, Read JA, Brady K. Use of a standard preparatory 
diet for the oral glucose tolerance test. Is it necessary?
J. Reprod. Med. 1991;147-50.
Harris EK. Statistical aspects of reference values in clinical pathology. 
Prog. Clin. Pathol. 1981;8:45-66.
Haughland RP. Molecular Probes: Handbook of fluorescent probes and 
research chemicals. April 1985. Cambridge Bioscience, Cambridge. UK.
Hawkins D, Pinckard RN, Crawford IP, Farr RS. Structural changes in 
human serum albumin induced by ingestion of acetylsalicylic acid.
J. Clin. Invest. 1969;48:536-542.
Hayashi Y, Makino M. Fluorometric measurement of glycosylated albumin 
in human serum.
Clin. Chim. Acta, 1985;149:13-19.
Hayashi Y, Morikawa A, Makino M. Heterogeneity of urinary albumin from 
diabetic patients.
Clin. Chim. Acta, 1990;190:93-104.
346
Hayes EJ, Gleason RE, Soeldner JS, Wacks M, Blankstein L. Measurement 
of hemoglobin by liquid chromatography and by agar gel electrophoresis 
compared.
Clin. Chem. 1981;27:476-479
Heird WC, Driscoll JM. Use of intravenously administered lipid in neonates. 
Paediatrics, 1975;56:5.
Heilman B. The islets of Langerhans in the rat during pregnancy and 
lactation with special reference to the changes in the B/A ratio.
Acta Obstet. Gynecol. Scand. 1960;39:331-349.
Hill RP. The effect of calibration on the between-laboratory variation of 
serum fructosamine.
Ann. Clin. Biochem. 1988;25:435-439.
Hill RP. Semi-automated colorimetric method for measuring 
glycohemoglobin, with reduction of nitroblue tétrazolium, evaluated.
Clin. Chem. 1990;36:2131-2133.
Hindle EJ, Rostron GM, Clark SA, Gatt JA. Serum fructosamine and 
glycated haemoglobin measurements in diabetic control.
Arc. Dis. Child. 1986;61:113-117.
Hindle EJ, Rostron GM, Gatt JA. The estimation of serum fructosamine: an 
alternative measurement to glycated haemoglobin.
Ann. Clin. Biochem. 1985;22:84-89.
Howey JEA, Bennet WM, Browning MCK, Jung RT, Fraser CG. Clinical 
utility of assays of glycosylated haemoglobin and serum fructosamine 
compared: use of data on biological variation.
Diab. Med. 1989;6:793-796.
Howey EA, Browning MCK, Fraser CG. Assay of serum fructosamine that 
minimises standardisation and matrix problems: use to assess components 
of biological variation.
Clin. Chem. 1987;33:269-272.
Hud E, Cohen MP. Evaluation and performance characteristics of a novel 
ELISA using monoclonal antibody to glycated albumin.
Clin. Chim. Acta, 1989;185:157-164.
347
Igaki N, Sakai M, Hata H, Oimomi M, Baba S, Kato H. Effects of 3- 
deoxyglucosone on the Maillard reaction.
Clin. Chem. 1990;36:631-634.
International Federation of Clinical Chemistry. Drug effects in clinical 
chemistry. Part 2. Guidelines for evaluation of analytical interference.
J. Clin. Chem. Clin. Biochem. 1984;22:275-279.
Isbell HS, Frush HL. Mutarotation, hydrolysis, and rearrangement reactions 
of glycosylamines.
J. Org. Chem. 1958;23:1309-1319.
Javid J, Pettis, Koenig RJ, Cerami A. Immunologic characterisation and 
quantification of haemoglobin Ale.
Br. J. Haematol. 1978;38:329-337.
Jemtorp P, Sundkvist G, Fex G, Jeppson JD. Clinical utility of serum 
fructosamine in diabetes mellitus compared with haemoglobin Aj^. 
Clin.Chim. Acta, 1988;175:135-142.
John WG, Jones AE. Affinity chromatography: a precise method for 
glycosylated albumin estimation.
Ann. Clin. Biochem. 1985;22:79-83.
Johnson RN, Baker JR. The alkaline reducing activity of glycated serum 
proteins and its relevence to diabetes mellitus.
Clin. Chem. 1986;32:368-370.
Johnson RN, Baker JR. Inaccuracy in measuring glycated albumin 
concentration by thiobarbituric acid colorimetry and by boronate 
chromatography.
Clin. Chem. 1988;34:1456-1459.
Johnson RN, Easdale RW, Tatnell M, Baker JR. Significance of variation 
in turnover of glycated albumin on indices of diabetic control.
Clin. Chim. Acta, 1991;198:229-238.
Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the 
estimation of serum glycosylprotein. An index of diabetic control.
Clin. Chim. Acta, 1982;127:87-95.
Johnson RN, Metcalf PA, Baker JR. Relationship between albumin and 
fructosamine concentration in diabetic and non-diabetic sera.
Clin. Chim. Acta, 1987;164:151-162.
348
Jones AF, Winkles JW, Thomalley PJ, Lunec J, Jennings PE, Bamett AH. 
Inhibitory effect of superoxide dismiitase on fructosamine assay.
Clin. Chem. 1987;33:147-149.
Kallner A. Detergent enhances interference of urate in determinations of 
fructosamine.
Clin. Chem. 1989;35:1803-1804.
Kallner A. Elimination of ^"^C-glycated albumin from serum of rabbit. 
Scand. J. Clin. Lab. Invest. 1990;50:763-768.
Karlsson K, Kjellmer I. The outcome of diabetic pregnancies in relation to 
the mothers blood sugar level.
Am. J. Obstet. Gynecol. 1972;112:213-220.
Kawauchi H, Tuzimura K, Maeda H, Ishida N. Reaction of fluorescein- 
isothiocyanate with proteins and amino acids.
J. Biochem. 1969;66:783-789.
Keen H, Jarrett J, Editors. Complications of diabetes. 2nd edition. Edward 
Arnold Ltd, 1982.
Keller WS. A rapid method for the determination of salicylate in serum or 
plasma.
Am. Clin. Pathol. 1947;17:415-417.
Kennedy L, Mehl T, Elder E, Varghese M, Merimee T. Nonenzymatic 
glycosylation of serum and plasma proteins.
Diabetes, 1982;31 ;Suppl.3:52-56.
Kennedy L, Mehl TD, Riley WJ, Merimee TJ. Non-enzymically 
glycosylated serum protein in diabetes mellitus: an index of short-term 
glycaemia.
Diabetologia, 1981;21:94-98.
Kesson CM, Young RE, Talwar D, Whitelaw JW, Robb DA. Glycosylated 
haemoglobin in the diagnosis of nonrinsulin dependent diabetes mellitus. 
Diabetes Care, 1982;5:395-8.
Khatami M, Suldan Z, David I, Li W, Rockey JH. Inhibitory effects of 
pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic 
glycosylation.
Life Sciences, 1988;43:1725-1731.
349
Klenk DC, Hermanson GT, Krohn RI, Fujimoto EK, Mallia AK, Smith PK, 
England JD, Wiedmeyer HM, Little RR, Goldstein DE. Determination of 
glycosylated hemoglobin by affinity chromatography: comparison with 
colorimetric and ion-exchange methods, and effects of common 
interferences.
Clin. Chem. 1982;28:2088-2094.
Knight A. Concerning macrosomy in diabetic pregnancy.
Lancet, 1983 ;ii: 1431.
Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. 
Correlation of glucose regulation and haemoglobin Aj^ in diabetes mellitus. 
N. Engl. J. Med. 1976;295:417-420.
Kricka LJ, Grégoire T, Dumont L, Wilding P. Interference-free method for 
glycated proteins in serum and whole blood, based on a boronate reagent. 
Clin. Chem. 1991;37:1520-1523.
Kumar A, Rao P, Pattabiraman TN. A colorimetric method for the 
estimation of serum glycated proteins based on differential reduction of free 
and bound glucose by sodium borohydride.
Biochem. Med. Met. Biol. 1988;39:296-304.
Kruse-Jarres JD, Jarausch J, Lehmann P, Vogt BW, Rietz P.
A new colorimetric method for the determination of fructosamine.
Lab. Med. 1989;13:245-253.
Kiienburg E, Brunnbauer M, Watzinger U, Winter P, Müller MM, Graf H, 
Prager R. Fructosamine in haemodialysis patients.
In: Kraupp O, Sinzinger H, editors. Wiener Klinische Wochenschrift. 
European Fructosamine Workshop; 1989 Oct 26-28; V ienna:ppll-13.
Laguesse E. Sur la formation des ilots de Langerhans dans le pancréas.
C R soc. Biol. 1893;Paris 9 série 5:819.
Lamb E, Dawnay A. Glycated haemoglobin measurement in uraemic 
patients (letter).
Ann. Clin. Biochem. 1992;29:118-119.
Lamb E, Mainwaring-Burton R, Dawnay A. Effect of protein concentration 
on the formation of glycated albumin and fructosamine.
Clin. Chem 1991;37:2138-2139.
350
Lamb E, Venton TR, Cattell WR, Dawnay A. Glycated albumin and 
fructosamine levels in patients on haemodialysis and continuous ambulatory 
peritoneal dialysis (CARD).
Proc. ACB Nat. Met. 1991;C93:123.
Langerhans PE. Beitrage zur mikroscopischen anatomie der 
bauchspeicheldinse.
Medical dissertation, 1869. Friedrich Wilhelms University. Berlin.
Larsen ML, Hprder M, Mogensen EF. Effect of long-term monitoring of 
glycosylated hemoglobin levels in insulin-dependent diabetes mellitus.
N. Engl. J. Med. 1990;323:1021-1025.
Lee WK, Dominiczak MH. Fast glycation of albumin generates fluorescence 
which reflects the accumulation of advanced glycosylation end-products 
(abstract).
Proc. ACB Nat. Met. 1990;41:(A33).
Lehmann P. Investigation of interfering factors.
In: Fructosamine Workshop Report. Boehringer Mannheim GmBH 
1988;Wiesbaden:39-45.
Leiper JM, Talwar D, Robb DA, Lunan CB, MacCuish AC. Glycosylated 
albumin and glycosylated proteins: rapidly changing indices of glycaemia 
in diabetic pregnancy.
Q. J. Med. 1985;218:225-231.
Leslie RDG, Pyke DA, John PN, White JM. Haemoglobin A  ^ in diabetic 
pregnancy.
Lancet, 1978;ii:958-959.
Lind T, Billewicz WZ, Brown G. A serial study of changes in oral glucose 
tolerance in pregnancy.
J. Obstet. Gynecol. Brit. Comm. 1973;80:1033-1039.
Lind T, Cheyne GA. Effect of normal pregnancy upon the glycosylated 
haemoglobins.
Brit. J. Obstet. Gynaecol.l979;86:210-213.
Lloyd D, Marples J. Simple colorimetry of glycated serum protein in a 
centrifugal analyser.
Clin. Chem. 1984;30:1686-1688.
351
Lucas MJ, Leveno KJ, Williams ML, Raskin P, Whalley PJ. Early 
pregnancy glycosylated hemoglobin, severity of diabetes, and fetal 
malformations.
Am. J. Obstet. Gynecol. 1989;161:426-431.
Lutjens A, te Velde AA, Veen EA vd, Meer J vd. Glycosylation of human 
fibrobrinogen in vivo.
Diabetologia, 1985;28:87-9.
MacFarlane CM, Tsakalakos N. Relative fetal hypoxia as a contributing 
factor to fetal macrosomia in diabetic pregnancy.
Medical Hypothesis, 1983;11:365-374.
Madanlon HD, Dorchester WL, Thorosian A, Freeman RK. Macrosomia - 
maternal, fetal and neonatal implications.
Obstet. Gynecol. 1980;55:420.
Madsden H, Ditzel J. Changes in red cell oxygen transport in diabetic 
pregnancy.
Am. J. Obstet. Gynecol. 1982;143:421-424.
Madsden H, Ditzel J. Blood oxygen transport in the first trimester of 
diabetic pregnancy.
Acta Obstet. Gynecol. Scand. 1984;63:312-320.
Maillard LC. Action des acides amines sur les sucres: formation des 
melanoidines par voie méthodique.
C R Seances Acad Sci [III], 1912;154:66-68.
Makita Z, Nakayama H, Taneda S, Kato M, Kuroda Y, Aoki S, Misawa K, 
Nakagawa S. Radioimmunoassay for the determination of glycated 
haemoglobin.
Diabetologia, 1991;34:40-45.
Makita Z, Radoff S, Rayfield EJ, Young Z, Skolnik E, Delaney V, Friedman 
EA, Cerami A, Vlassara H. Advanced glycosylation end-products in patients 
with diabetic nephropathy.
N. Engl. J. Med. 1991;325:836-842.
Malins J. Definition and aetiology of diabetes mellitus.
In: Clinical diabetes mellitus. London: Eyre and Spottiswoode, 1968:ppl-41.
352
Mallia AK, Hermanson GT, Krohn RI, Fujimoto EK, Smith PK. Preparation 
and use of a boronic acid affinity support for separation and quantitation of 
glycosylated hemoglobins.
Analyt. Lett. 1981;14:649-661.
Man* S. An investigation into the effect of vitamin C on the glycation of 
proteins in vivo.
MSc. Thesis. University of Surrey, 1990.
McCance DR, Coulter D, Smye M, Kennedy L. Effect of fluctuations in 
albumin on serum fructosamine assay.
Diab. Med. 1987;4:434-436.
McFarland KF, Catalano EW, Day IF, Thorpe SR, Baynes JW. 
Nonenzymatic glucosylation of serum proteins in diabetes mellitus. 
Diabetes, 1979;28:1011-1014.
Miller E, Hare JW, Cloherty JP et al. Elevated maternal haemoglobin A^ g 
in early pregnancy and major congenital abnormalities in infants of diabetic 
mothers.
N. Engl. J. Med. 1981;304:1331-1334.
Milley JR, Rosenberg AA, Phillips AF, Molteni RA, Jones MD, Simmons 
MA. The effect of insulin on fetal oxygen exchange.
Am. J. Obstet. Gynecol. 1984;149:673-678.
Mills JL, Baker L, Goldman AS. Malformations in infants of diabetic 
mothers occur before the 7th gestational week. Implications for treatment. 
Diabetes, 1979;28:292-273.
Mills JL, Simpson JL, Driscoll SG et al. Incidence of spontaneous abortion 
among normal women and insulin-dependent diabetic women whose 
pregnancies were identified within 21 days of conception.
N. Engl. J. Med. 1988;319:1617-1623.
Mereish KA, Rosenberg H, Cobby J. Glucosylated albumin and its influence 
on salicylate binding.
J. Pharm. Science, 1982;71:235-238.
Metzger BE, Freinkel N. Regulation of protein metabolism and 
gluconeogenesis in the fasted state.
In: Comerini-Davalos RA, Cole HS (eds). Early diabetes in early life. 
Academic Press, New York, pp 303-312.
353
Miedema K, Casparie T. Glycosylated haemoglobins: biochemical evaluation 
and clinical utility.
Ann. Clin. Biochem. 1984;21:2-15.
Mortensen HB, Christophersen C. Glycosylation of human haemoglobin in 
red blood cells studied in vitro. Kinetics of the formation and dissociation 
of haemoglobin A^ .^
Clin. Chim. Acta, 1983;134:317-326.
Mosca A, Carenini A, Zoppi F, Carpinelli A, Banfi G, Ceriotti F, Bonini P, 
Pozza G. Plasma protein glycation as measured by fructosamine assay. 
Clin. Chem. 1987;33:1141-1146.
Myohanen TA, Bouriotis V, Dean DG. Affinity chromatography of yeast 
alpha-glucosidase using ligand-mediated chromatography on immobilized 
phenyl boronic acids.
Biochem. J. 1981;197:683-688.
Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information 
value of the glycosylated hemoglobin assay.
N. Engl. J. Med. 1984;310:341-346.
National Diabetes Data Group: Classification and diagnoses of diabetes 
mellitus and other categories of glucose intolerance.
Diabetes, 1979;28:1039-57.
Ney KA, Colley KJ, Pizzo S V. The standardisation of the thiobarbituric acid 
assay for nonenzymic glucosylation of human serum albumin.
Analyt. Biochem. 1981;118:294-300.
Nicholls K, Mandel TE. Advanced glycosylation end-products in 
experimental murine diabetic nephropathy: effect of islet isografting and 
aminoguanidine.
Lab. Invest. 1989;60:486-93.
Ghe Y, Matsuura M, Nakajima Y, Shin S, Hashimoto F, Hirota M, Shima 
K. Radioimmunoassay of glycosylated albumin with monoclonal antibody 
to glucitol-lysine.
Clin. Chim. Acta, 1987;169:229-238.
Olufemi S, Talwar D, Robb DA. The relative extent of glycation of 
haemoglobin and albumin.
Clin. Chim. Acta, 1987;163:125-136.
354
Olufemi OS, Whittaker PG, Halliday D, Lind T. Albumin metabolism in 
fasted subjects during late pregnancy.
Clin. Sci. 1991;81:161-168.
Ortwerth BJ, Olesen PR. Ascorbic acid induced crosslinking of lens 
proteins:evidence supporting a Maillard reaction.
Biochim. Biophys. Acta, 1988;956:10-22.
O ’Sullivan JB, Gellis SS, Dandrow RV, Tenney BO. The potential diabetic 
and her treatment during pregnancy.
Obstet. Gynecol. 1966;27:683-689.
O’Sullivan JB, Mahan CM, Charles D, Dandrow RV. Medical treatment of 
the gestational diabetic.
Obstet. Gynecol. 1974;43:817-821.
Page EW. Human fetal nutrition and. growth.
Am. J. Obstet. Gynecol. 1969;104:378-387.
Peck RW, Price DE, Lang GD, MacVicar J, Heamshaw JR. Birthweight of 
babies bom to mothers with type I diabetes: is it related to blood glucose 
control in the first trimester?
Diabetic Med. 1991;8:258-262.
Peheim E, Descoeudres C, Diem P, Colombo JP, Vorberg E. Fructosamine 
determination in chronic renal disease (hemodialysis patients).
In: Kraupp O, Sinzinger H, editors. Wiener Klinische Wochenschrift. 
European Fmctosamine Workshop; 1989 Oct 26-28; Vienna:ppl3-20.
Phillipou G, Seaborn CJ, Phillips PJ. Re-evaluation of the fructosamine 
reaction.
Clin. Chem. 1988;34:1561-1564.
Rahbar S. An abnormal hemoglobin in red cells of diabetics.
Clin. Chim. Acta, 1968;22:296-298. •
Rai KB, Kumar A, Pattabiraman TN. Glycated albumin and glycated 
haemoglobin levels in normal pregnancy.
Biochem. Med. Met. Biol. 1988;39:5-10.
Reece AE, Coustan DR, Sherwin RS, Tuck S, Bates S, O’Connor T, 
Tamborlane WV. Does intensive glycaemic control in diabetic pregnancies 
result in normalization of other metabolic fuels?
Am. J. Obstet. Gynecol. 1991;165:126-130.
355
Reed P, Bhatnagar D, Dhar H, Winocour PH. Precise measurement of 
glycated serum albumin by column affinity chromatography and 
immunoturbidimetry.
Clin. Chim. Acta, 1986;161:191-199.
Rekonen A, Luotola H, Pitkanen M, Kinkka J, Pyorala J. Measurement of 
intervillous and myométrial blood flow by an intravenous ^^^ Xe method. 
Brit. J. Obstet. Gynaecol. 1976;83:723-728.
Rendell M, Nierenberg J, Brannan C, Valentine JL, Stephen PM, Dodds S, 
Mercer P, Smith PK, Walder J. Inhibition of glycation of albumin and 
hemoglobin by acétylation in vitro and in vivo.
J. Lab. Clin. Med. 1986;108:286-293.
Robb DA, Olufemi OS, Williams DA, Midgley JM. Identification of 
glycation at the N-terminus of albumin by gas chromatography-mass 
spectrometry.
Biochem. J. 1989;261:871-878.
Roberts AB, Baker JR, Metcalf P, Mullard C. Fructosamine compared with 
a glucose load as a screening test for gestational diabetes.
Obstet. Gynecol. 1990;76:773-5.
Roberts KA, Harding JJ. Ibuprofen, a putative anti-cataract drug, protects the 
lens against cyanate and galactose.
Exp. Eye Res. 1990;50:157-164.
Robertson EA, Zweig MH. Use of receiver operating characteristic curves 
to evaluate the clinical performance of analytical systems.
Clin. Chem. 1981;27:1569-1574.
Rodkey FL. Direct spectrophotometric determination of albumin in human 
serum.
Clin. Chem. 1965;11:478-487.
Rodriguez-Segade S, Lojo S, Camina MF, Paz JM, Del Rio R. Effects of 
various serum proteins on quantification of fructosamine.
Clin. Chem. 1989;35:134-138.
Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA. Pre-conception 
management of insulin-dependent diabetes - improvement of pregnancy 
outcome.
Obstet. Gynecol. 1991;77:846-849.
356
Rowbury D, Farrance I, Fitzgerald A. Effect of measurement wavelength on 
fructosamine results (letter).
Clin. Chem. 1989;35:1552-1553.
Russell G, Farmer G, Lloyd et al. Macrosomia deapite well-controlled 
diabetic pregnancy.
Lancet, 1984;i:283-284.
Sakurai T, Tsuchiya S. Superoxide production from nonenzymically glycated 
protein.
FEES Lett. 1988;236:406-410.
Sakurai T, Tsuchiya S. Binding of nitroblue tétrazolium to human serum 
albumin in a fructosamine test.
Clin. Chim. Acta, 1989;185:213-214.
Salemans THE, van Dieijen-Visser MP, Brombacher PJ. The value of HbAi 
and fructosamine in predicting impaired glucose tolerance - an alternative 
to OGTT to detect diabetes mellitus or gestational diabetes.
Ann. Clin. Biochem. 1987;24:447-452.
San-Gil F, Schier GM, Moses RG, Gan JET. Improved estimation of 
fructosamine, as a measure of glycated serum protein, with the Technicon 
RA-1000 analyser.
Clin. Chem. 1985;31:2005-2006.
Santini DL, Ales KL. The impact of universal screening for gestational 
glucose intolerance on outcome of pregnancy.
Surg. Gynecol. Obstet. 1990;170:427-36.
Schafer EA. The endocrine organs; an introduction to the study of internal 
secretion.
London: Longmans, Green & Co. 1916. pl28.
Schleicher E, Denfel T, Wieland OH. Non-enzymatic glycosylation of 
human serum lipoproteins: elevated epsilon-lysine glycosylated low density 
lipoprotein in diabetic patients.
FEES Lett. 1981;129:1-4.
Schleicher ED, Mayer R, Wagner EM, Gerbitz K. Is serum fructosamine 
assay specific for determination of glycated serum protein?
Clin. Chem. 1988;34:320-323.
357
Schleicher E, Olgermôller B, Schôn J, Dürst T, Wieland OH. Limited 
nonenzymatic glucosylation of low-density lipoprotein does not alter its 
catabolism in tissue culture.
Biochim. Biophys. Acta, 1985;846:226-233.
Schleicher E, Wieland OH. Specific quantitation by HPLC of protein 
(lysine) bound glucose in human serum albumin and other glycosylated 
proteins.
J. Clin. Chem. Clin. Biochem. 1981;19:81-87.
Schleicher E, Wieland OH. Protein glycation: measurement and clinical 
relevance.
J. Clin. Chem. Clin. Biochem. 1989;27:577-587.
Schultze HE, Heremans JF. Molecular biology of human proteins, with 
special reference to plasma proteins. Vol. 1. Amsterdam: Elsevier, 1966.
Schwartz HC, King KC, Schwartz AL, Edmunds D, Schwartz R. Effects of 
pregnancy on haemoglobin Aj^ in normal, gestational diabetic and diabetic 
women.
Diabetes, 1979;25:1118-1122.
Shaklai N, Garlick R, Bunn F. Non-enzymatic glycosylation of human 
serum albumin alters its conformation and function.
J. Biol. Chem. 1984;259:3812-3817.
Shapiro R, McManus MJ, Zalut C, Bunn HF. Sites of nonenzymatic 
glycosylation of human hemoglobin A.
A. J. Biol. Chem. 1980;255:3120-3127.
Shepard DC, Hitz JB, Dain JA. Pyridoxal-5’-phosphate inhibits 
nonenzymatic glycosylation of proteins.
Biochem. Arch. 1985;1:143-151.
Shima K, Ito N, Abe F, Hirota M, Yano M, Yamamoto Y, Uchida T, 
Noguchi K. High performance liquid chromatographic assay of serum 
glycated albumin.
Diabetologia, 1988;31:627-631.
Shimojo N, Hirai M, Naka K, Yoshikawa C, Okuda K, Aono S, Isshiki G, 
Fujii S. Plasma fructosamine assay in children with insulin dependent 
diabetes mellitus.
Clin. Chim. Acta, 1988;176:101-106
358
Simpson I. Labeling of small molecules with fluorescein.
Analytical Biochem. 1978;89:304-305.
Sims EAH, Calles-Escandon J. Classification of diabetes. A fresh look for 
the 1990s?
Diabetes Care, 1990;13:1123-1128.
Soini E, Hemmila I. Fluoroimmunoassay: present status and key problems. 
Clin. Chem. 1979;25:353-361.
Solomon LR, Cohen K. Erythrocyte O2 transport and metabolism and effects 
of vitamin Bg therapy in type II diabetes mellitus.
Diabetes, 1989;38:881-886.
Somani BL, Sinha R, Gupta MM. Fructosamine assay modified for the 
estimation of glycated hemoglobin.
Clin. Chem. 1989;35:497.
Staley MJ. Fructosamine and protein concentrations in serum.
Clin. Chem. 1987;33:2326-7.
Staley MJ, Murray-Arthur F. Plasma fructosamine in non-diabetic 
pregnancy.
Brit. J. Obstet. Gynaecol. 1988;95:265-270.
Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care 
of diabetic women reduce the risk of abnormal babies?
BMJ. 1990;301:1070-1074.
Stolba P, Hatle K, Krnakova A, Stfeda M, Starka L. Effects of ascorbic acid 
on nonenzymatic glycation of serum proteins in vitro and in vivo (abstract). 
Diabetologia, 1987;30:585A.
Stubbs SM, Doddridge M, John PN, Steel JM, Wright AD. Haemoglobin Aj 
and congenital malformations.
Diabetic Med. 1987;4:156-159.
Stubbs WA, Stubbs SM. Hyperinsulinism, diabetes mellitus, and respiratory 
distress of the newborn:a common link?
Lancet, 1978;2:308-309.
Talwar D, Barr BB, Kesson CM, Robb DA. Determination of glycosylated 
adult and foetal haemoglobins by affinity chromatography.
Clin. Chim. Acta, 1983;128:61-67.
359
Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces 
expansion of the molecular packing of collagen.
J. Mol. Biol. 1988;203:495-505.
Tietz NW, editor. Clinical guide to laboratory tests.
W.B.Saunders Company, 1983.
Travis J, Pannell R. Selective removal of albumin from plasma by affinity 
chromatography.
Clin. Chim. Acta, 1973;49:49-52.
Tsang WM, Priyakumar P, Grenfell A. Glycated haemoglobin measurement 
in uraemic patients.
Ann. Clin. Biochem. 1991;28:414-416.
Tsibris JCM, Raynor LG, Buhi WC, Buggie J, Spellacy WN. Insulin 
receptors in circulating erythrocytes and monocytes from women on oral 
contraceptives or pregnant women near term.
J. Clin. Endocrinol. Metab. 1980;51:711-717.
Van Dieijen-Visser MP, Salemans T, Van Wersch JWJ, Schellekens LA, 
Brombacher PJ. Glycosylated serum proteins and glycosylated haemoglobin 
in normal pregnancy.
Ann. Clin. Biochem. 1986;23:661-666.
Van Diejen-Visser MP, Seynaeve C, Brombacher PJ. Influence of variation 
in albumin or total protein concentration on serum fructosamine 
concentration (letter).
Clin. Chem. 1986;32:1610.
Vardi P, Dibella EE, Pasquarello TJ, Srikanta S. Islet cell autoantibodies: 
pathology and clinical applications.
Diabetes Care, 1987;10:645-653.
Vermes I, Zeyen L, van Roon E, Brandts H. The role of serum fructosamine 
as a screening test for gestational diabetes mellitus.
Horm. Metab. Res. 1989;21:73-6.
Victor A. Normal blood sugar variation during pregnancy.
Acta Obstet. Gynecol. Scand. 1974;53:37-40.
Von Mering J, Minowski O. Diabetes mellitus nach pankreasextirpation. 
Arch. Exp. Path. Pharmak. 1889:26;371-387.
360
Walker JE. Lysine residue 199 of human serum albumin is modified by 
acetylsalicylic acid.
FEES Lett. 1976;66:173-175.
Watts GF, Macleod AF, Benn JJ, Slavin BM, Morris RW, Williams CD, 
Kearney EM, Lowy C, Sonksen PH. Comparison of the real-time use of 
glycosylated haemoglobin and plasma fructosamine in the diabetic clinic. 
Diabetic Med. 1991;8:573-579.
W est KM. Hyperglycaemia as a cause of long-term complications. In:Keen 
H, Jarrett J, editors. Complications of diabetes (2nd edition).
Arnold, 1975:13-18
Wilson RG, Davis RE. Clinical chemistry of vitamin Bg.
Adv. Clin. Chem. 1983:23:1-68.
Winocour PH, Bhatnagar D, Kalsi P, Hillier VF, Anderson DC. Relative 
clinical usefulness of glycosylated serum albumin and fructosamine during 
short term changes in glycaemic control in insulin dependent diabetes 
mellitus.
Diabetes Care, 1989;12:665-72.
W olff SP, Dean RT. Glucose autoxidation and protein modification: the 
potential role of ‘autoxidative glycosylation’ in diabetes.
Biochem. J. 1987;245:243-250.
Whicher J, Spence C. When is serum albumin worth measuring?
Ann. Clin. Biochem. 1987;24:572-580.
WHO expert committee on diabetes mellitus. Second report. Geneva. 
WHO, Tech. Rep. Ser. 1980;646.
Widness JA, Schwartz HC, Thompson D et al. Haemoglobin Aj^ 
(glycohaemoglobin) in diabetic pregnancy: an indicator of glucose control 
and fetal size.
Brit. J. Obstet. Gynaecol. 1978;85:812-817.
Winocour PH, Bhatnagar D, Reed P, Dhar H. Does the measurement of 
serum fructosamine accurately reflect levels of glycated albumin in insulin 
dependent diabetes?
Ann. Clin. Biochem. 1987;24:47-52.
361
Woo J, Weinstock RS, Ozark C, Sunderji S. Glyacted albumin by affinity 
chromatography and radioimmunoassay in the management of diabetes 
mellitus.
J. Clin. Lab. Anal. 1987;1:163-169.
Ylinen K, Aula P, Stenman UH et al. Risk of minor and major fetal 
malformations in diabetics with high haemoglobin A^  ^ values in early 
pregnancy.
BMJ. 1984;289:345-346.
Ylinen K, Hekali R, Teramo K. Haemoglobin Aj^ during pregnancy of 
insulin dependent diabetics and healthy controls.
J. Obstet. Gynecol. 1981;1:223-228.
Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM. Impaired glucose 
tolerance. Is it a risk factor for diabetes or a diagnostic ragbag?
B.M.J. 1990;301:397-402.
Zammit Maempel JV. Impaired glucose tolerance and diabetes - WHO 
criteria.
B.M.J. 1981;282:481.
Ziel FH, Davidson MB. The role of glucosylated serum albumin in 
monitoring glycémie control in stable insulin-requiring diabetic out-patients. 
J. Clin. Endocrinol. Metab. 1987;64:269-73.
Zoppi F, Mosca A, Granata S, Montalbetti N. Glycated proteins in serum: 
Effect of their relative proportions on their alkaline reducing activity in the 
fructosamine test.
Clin. Chem. 1987;33:1895-1897.
:i^iVERSiTY O F SURREY LIBRARY
362
